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Rett syndrome is a debilitating autistic spectrum disorder affecting one in ten 
thousand girls. Patients develop normally for up to eighteen months before a period 
of regression involving stagnation in head growth, loss of speech, hand use and 
mobility. It is almost exclusively caused by mutation in Methyl CpG binding Protein 
2 (MeCP2). MeCP2 has traditionally been thought of as a transcriptional repressor, 
although its exact function remains unknown and it has recently been shown that the 
protein can also bind to hydroxymethylation and non-CpG methylation, which occurs 
predominantly at CAC sites in the mature nervous system. Genotype-phenotype 
studies of the most common Rett-causing mutations in affected patients revealed that 
a missense mutation, R133C results in a milder form of Rett syndrome. The reasons 
for this are unclear, as the mutation lies right in the heart of the methylated DNA 
binding domain. Previous in vitro studies of R133C showed a severe deficit in 
binding to methylated cytosine. A subsequent study found that R133C binding to 
hydroxymethylated cytosine was specifically impaired, whereas binding to 
methylated cytosine was indistinguishable from wildtype. Defining the DNA binding 
impairment of MeCP2R133C would yield important insights into Rett disease 
pathophysiology and provide an explanation for the phenotypic spectrum seen in 
patients. To shed light on these matters, a novel mouse model of the R133C mutation 
was created. The R133C mouse had a phenotype that was less severe than other 
missense mutant mice, in terms of survival, growth, Rett-like phenotypic score and 
some behavioural paradigms thus recapitulating the patient data. At the molecular 
level in adult mouse brain, MeCP2R133C protein abundance was reduced. 
Immunohistochemistry showed that MeCP2R133C had an abnormal pattern of 
localisation in the nucleus of neurons. In vitro electrophoretic mobility shift assays 
suggested that MeCP2R133C binding to (hydroxy)methyl-CAC may be reduced to a 
greater extent than binding to mCpG. Chromatin immunoprecipitation experiments 
confirmed the deficit in binding to methylated sites and supported a disproportionate 
reduction in binding to methylation in a CAC sequence context. Analysis of adult 
mouse cerebellar gene expression revealed a subtle upregulation of long genes and 
downregulation of short genes. Based on these data, it is proposed that Rett 
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syndrome caused by the R133C mutation results from a combination of protein 
instability and defective binding to methylated DNA. Methyl-CAC binding is 
potentially abolished. The downstream biological consequence of this is a length-
dependent deregulation of gene expression in the brain.  
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Lay Summary 
Rett syndrome is an autistic spectrum disorder affecting one in ten thousand girls that 
results in severe disability. Affected patients develop normally for up to eighteen 
months before losing hand and language skills they had already achieved. Their 
mobility and growth are also reduced. It is almost exclusively caused by mutation in 
a protein called MeCP2 on the X chromosome. This protein binds to methylation in 
DNA and the result is thought to be that fewer genes are expressed. Recently it has 
been shown that MeCP2 can also bind to bits of DNA that would result in more 
genes being expressed (hydroxymethylation). If the clinical severity of Rett 
syndrome and the mutation causing it are assessed in large numbers of patients, the 
R133C mutation is reproducibly associated with milder clinical features. For 
example, patients may still be able to use their hands. This is unexpected as the 
mutation lies in a key part of the protein, which it uses to bind DNA. Previous 
studies have shown that MeCP2R133C can’t bind methylated DNA. A subsequent 
study found that only binding to hydroxymethylated DNA and not methylated DNA 
was affected. If the MeCP2R133C binding deficit can be understood, the differences 
that we see between patients and the reason they get Rett syndrome can be 
disentangled. In order to answer this question, a mouse model of MeCP2R133C was 
made. Like the patients, the mice showed milder symptoms compared to other 
mutant mice. Reduced levels of mutant protein and an abnormal binding pattern in 
neurons were found by examining brain tissue. Binding to known methylated target 
sequences was impaired in the brain. Analysis of gene expression in a specific area 
of the brain – the cerebellum – showed that genes of long length were slightly more 
abundant in the mutant and genes of short length were slightly less abundant. The 
outcome of this study is that Rett syndrome caused by the R133C mutation is milder 
than Rett syndrome caused by other mutations because the protein is modestly 
reduced and it binds abnormally to methylated DNA leading to a subtle length 
dependent change in gene expression. 
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L1 LINE1  L1 long interspersed nuclear elements 
m   Methylated 
Maj sat  Major satellite DNA 
MBD   Methylated DNA binding domain 
Mecp2  Methyl CpG binding protein 2 (mouse gene) 
MECP2  Methyl CpG binding protein 2 (human gene) 
MeCP2  Methyl CpG binding protein 2 (mouse and human protein) 
miRNA  micro RNA 
NCoR   Nuclear receptor co-repressor 
NEB   New England Biolabs 
NEO cassette  Neomycin resistance cassette 
NID   NCoR interaction domain 
NLS   Nuclear localisation signal 
NMR   Nuclear magnetic resonance 
NP   Neuronal precursor 
N-terminus  Amino-terminus 
OD   Optical density 
PAC   P1-derived artificial chromosome 
PAGE   Polyacrylamide gel electrophoresis 
PBS   Phosphate-buffered saline 
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PBST   Phosphate-buffered saline with Tween-20 
PCR   Polymerase chain reaction 
PMD   Partially methylated domain 
qPCR   Quantitative PCR 
R133C-GFP  MeCP2R133CEGFP  
R133C-GFP  Mecp2R133CEGFP 
R306C-GFP  MeCP2R306CEGFP  
R306C-GFP Mecp2R306CEGFP 
RNA   Ribonucleic acid 
RNAse  Ribonuclease 
RNA-seq  High throughput sequencing of cDNA derived from RNA 
RPM   Revolutions per minute 
RTT   Rett-like phenotype in the mouse 
SILAC  Stable isotope labelling with amino acids in culture 
T   Thymine 
T158M-GFP  MeCP2T158MEGFP  
T158M-GFP  Mecp2T158MEGFP 
TAB-seq  High throughput sequencing of DNA following Tet-assisted bisulfite 
treatment 
TAE   Tris-acetate EDTA 
TBE   Tris-borate EDTA 
TBS   Tris-buffered saline 
TBST   Tris-buffered saline with Tween-20 
TEMED  Tetramethylethylenediamine 
Tet enzyme  Ten-eleven translocation dioxygenase 
TRD   Transcriptional repression domain 
Tris   Tris(hydroxymethyl)aminomethane 
WT-GFP  MeCP2EGFP 
WT-GFP  Mecp2EGFP 
XCI   X chromosome inactivation  
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1. Introduction 
1.1 Rett syndrome 
Rett syndrome is a debilitating autistic spectrum disorder affecting 1 in 10,000 girls, 
making it one of the leading causes of genetic intellectual disability in females 
(Laurvick et al, 2006). Rett syndrome was first described in 1966 by Dr Andreas 
Rett, an Austrian paediatric neurologist. Although later to become his eponym, he 
referred to the characteristic constellation of symptoms and signs as “cerebral 
atrophy and hyperammonaemia in infancy” in his original publication in German. 
The syndrome only became internationally recognised in the 1980’s when Dr Bengt 
Hagberg published a seminal paper in English describing the syndrome in 35 females 
and named it “Rett syndrome” (Hagberg et al, 1983). With the observation that Rett 
syndrome affected girls, a hunt for a genetic cause ensued. Exclusion mapping using 
rare familial cases identified Xq28 as the responsible region. Candidate genes were 
investigated and a landmark finding in Rett syndrome research came in 1999 when it 
was discovered that mutation in the MECP2 gene, encoding Methyl-CpG binding 
protein 2, was responsible, thus making Rett syndrome one of an exclusive subset of 
complex neuropsychiatric disorders that is caused by mutation of one gene (Amir et 
al, 1999). Therefore it is anticipated that modelling the disorder in vitro and in vivo 
will make a molecular understanding possible. 
1.1.1 Clinical Features 
Rett syndrome is characterised by a period of generally unremarkable development 
for 6 to 18 months. However, with retrospective assessment, there may be some 
hypotonia and subtle abnormality of hand-eye coordination during this time 
(Einspieler et al, 2005). Classically, the syndrome then unfolds in four clinical 
stages, although there is wide variability in the particular features presented by 
individual females (Kerr & Engerström, 2001; Smeets et al, 2011).  
 
Stage I: The Early Onset Stagnation Period (between 6 and 18 months). There is an 
alteration in interaction that can be abrupt, for example infants may become irritable 
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or less demanding. Speech and motor development begin to show signs of delay 
however there can be babbling, single words and sitting.  
 
Stage II: The Rapid Developmental Regression Period (between 18 months and 4 
years). This phase may be heralded by days to weeks of general malaise and distress 
and is characterised by a loss of acquired skills. Autistic features become apparent, 
such as reduced communication and diminished interest in surroundings although 
eye contact is preserved. Speech and hand use regress and the child begins to self 
stimulate instead of interacting with her environment, for example by head-tapping. 
Vacant spells, blinking, panting, spitting, hypersalivation, hyperventilation, facial 
grimacing and twitching indicate brain stem immaturity. Head growth typically 
decelerates, resulting ultimately in microcephaly with head size around three 
standard deviations below the mean.  
 
The Pseudo-Stationary Stage III. Characteristic hand stereotypies emerge with 
repetitive movements in the midline such as hand wringing, clapping or washing. 
Motor dysfunction is apparent in apraxia, ataxia, gait abnormality and muscle 
dystonia resulting in a progressive neurogenic scoliosis. Respiratory dysfunction 
occurs during wakefulness with hyperventilation, hypoventilation, breath holding, 
apnoeas, apneustic breathing, or Valsalva manoeuvre breathing which frequently 
leads to air swallowing. Seizures ensue and affect up to 80% of girls (Steffenburg et 
al, 2001). Somatic growth is reduced, ultimately falling to two standard deviations 
below the mean. Symptoms and signs of autonomic dysfunction manifest, such as 
cold, small feet, decreased intestinal motility and abnormalities of the 
electrocardiogram. Other frequent features are an uncoordinated swallow, gastro-
oesophageal reflux, bruxism, impaired nociception and sleep disturbance. There may 
be some recovery of skills and character traits acquired prior to Stage II. The child 
appears happy and interested and will communicate needs with intense eye-pointing. 
Inattention, hyperactivity, periods of agitation and unexplained night laughing are 
common. Although severely intellectually disabled, girls are still able to learn and 
experience new things.  
 
 23 
The Late Motor Deterioration Stage IV is prolonged and commences when mobility 
decreases with muscle wasting and rigidity. Girls ultimately become wheelchair 
dependent.  
 
Each stage is associated with a characteristic pattern on electroencephalography 
(EEG): in Stage I the EEG is normal with focal spikes emerging in Stage II. Stage 
III-IV EEG’s are more variable with pseudoperiodic delta pattern and generalised 
periodic spike activity (Hagne et al, 1989). Abnormalities have also been found in 
event related potentials with reduced amplitude and longer latency (Stauder et al, 
2006).  
1.1.2 Rett syndrome in males 
Males only carry one copy of the MECP2 gene as they only have one X 
chromosome. Rett syndrome was previously thought to be lethal prior to birth, 
however male infants have been reported with mutations in the MECP2 gene that 
cause typical Rett syndrome in females (Kankirawatana et al, 2006). The clinical 
course is severe with a progressive neonatal encephalopathy, failure to thrive, 
respiratory insufficiency, microcephaly, intractable seizures, hypotonia leading to 
progressive rigidity and abnormal motor movements. Affected patients die in early 
infancy (Schüle et al, 2008). Alternatively, males can display signs of typical Rett 
syndrome in the context of an abnormal karyotype (Maiwald et al, 2002) or somatic 
mosaicism, where an MECP2 mutation arises during development of the embryo and 
is not present in all cells (Down, 2000). 
1.1.3 Diagnostic Criteria 
Rett syndrome remains a clinical diagnosis, due to the association of MECP2 
mutations with other clinical presentations (described in 1.6.1). Criteria for 
diagnosing Rett syndrome were established in 1985 for females (Hagberg et al, 
1985) and revised to include males in 1988 (The Rett Syndrome Diagnostic Work 
Group 1988), variant presentations in 1994 (Hagberg & Skjeldal, 1994) (see 1.1.4), 
and to broaden the diagnosis so that deceleration of head growth and a period of 
normal development were no longer mandatory in 2002 (Hagberg et al, 2002). In 
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2010, the RettSearch Consortium, an international network of clinically orientated 
Rett syndrome researchers, produced revised, simplified diagnostic criteria that 
emphasised the importance of the regressive phase with subsequent stabilisation and 
clarified the requirement for supportive criteria (see table 1) (Neul et al, 2010). There 
was good concordance with the 2002 criteria in a large population of patients (Percy 
et al, 2010). The goal was to streamline and unify the study of Rett syndrome, 
removing any ambiguity in making a diagnosis.  
1.1.4 Phenotypically Similar Presentations 
There are three common related disorders that present in a similar fashion to classical 
Rett syndrome. Historically they have been referred to as: the Preserved Speech 
Variant (Zapella, 1992), the Early Seizure Variant (Hanefeld, 1985) and the 
Congenital Variant (Rolando, 1985). 
 
In the Preserved Speech Variant, the clinical picture is milder with a later regressive 
phase and prolonged pseudostationary phase. Patients tend to recover their language 
following the regressive phase and can use single words or phrases. Girls have an 
intelligence quotient (IQ) of up to 50 and some retention in hand use. Although 
autistic behaviours are common, epilepsy, autonomic dysfunction and reduced head 
circumference are rare. In addition, girls can have normal height and weight with 
milder spinal deformities (Neul et al, 2010). 
 
The Early Seizure Variant does not present with as many features of typical Rett 
syndrome, but instead is characterised by onset of infantile spasms and refractory 
myoclonic epilepsy within the first five months of life and prior to the regressive 
phase (Neul et al, 2010). This variant is associated with mutation in the CDKL5 gene 
on the X chromosome, which encodes cyclin-dependent kinase-like 5 (Tao et al, 
2004; Bahi-Buisson et al, 2008). This protein shares homology with members of the 
mitogen-activated protein (MAP) kinase and cyclin-dependent kinase (CDK) 
families and has been proposed to phosphorylate MeCP2 in vitro (Mari et al, 2005). 
Interestingly, this activity is abolished with CDKL5 mutations (Bertani et al, 2006). 
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Consider Rett syndrome diagnosis when postnatal deceleration of head growth is observed. 
Required for typical or classic Rett syndrome 
A period of regression followed by recovery or stabilisation 
1. All main and all exclusion criteria 
2. Supportive criteria are not required, although often present in typical Rett syndrome 
Required for atypical or variant Rett syndrome 
1. A period of regression followed by recovery or stabilisation 
2. At least 2 of the 4 main criteria 
3. 5 of 11 supportive criteria 
Main criteria 
1. Partial or complete loss of acquired purposeful hand skills 
2. Partial or complete loss of acquired spoken language 
3. Gait abnormalities: impaired (dyspraxia) or absence of ability (apraxia) 
4. Stereotypic hand movements such as hand wringing/squeezing, clapping/tapping, 
mouthing and washing/rubbing automatisms 
Exclusion criteria for typical Rett syndrome 
1. Brain injury secondary to trauma (peri- or postnatally), neurometabolic disease or severe 
infection that cause neurological problems 
2. Grossly abnormal psychomotor development in the first 6 months of life 
Supportive criteria for atypical Rett syndrome 
1. Breathing disturbances when awake 
2. Bruxism when awake 
3. Impaired sleep pattern 
4. Abnormal muscle tone 
5. Peripheral vasomotor disturbances 
6. Scoliosis/kyphosis 
7. Growth retardation 
8. Small cold hands and feet 
9. Inappropriate laughing/screaming spells 
10. Diminished sensitivity to pain 
11. Intense eye communication – “eye-pointing”  
 
Table 1. Rett syndrome diagnostic criteria (Neul et al 2010) 
 
The Congenital Variant runs a severe course and is characterised by grossly 
abnormal early development with hypotonia, early postnatal microcephaly, 
regression within five months of life, frequent autonomic abnormalities as well as 
tongue stereotypies and specific jerky movements of the limbs. Girls rarely have the 
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intense Rett eye gaze (Neul et al, 2010). This variant has been associated with 
mutations in the autosomal FOXG1 gene, encoding forkhead box protein G1, a brain-
specific transcriptional repressor essential for telencephalon development (Ariani et 
al, 2008). 
1.1.5 Clinical severity rating scales 
There has been significant disparity in the means different Rett syndrome researchers 
have chosen to measure clinical severity, which has impacted on meaningful 
comparison of results between studies. Four commonly used scales will be briefly 
described as they are referenced repeatedly in later sections.  
 
The Kerr scale was developed by an international group in 2001 in order to define a 
minimal data collection set for Rett syndrome researchers investigating genotype-
phenotype correlation (Kerr et al, 2001). The scale contains twenty items, scored 
from 0–2 (maximum 40). A higher score indicates greater severity. Clinical features 
considered are: head circumference during the first year, developmental progress in 
the first year, present head circumference, weight, height, muscle tone, spine posture, 
joint contractures, gross motor function, hand stereotypy, other involuntary 
movements, voluntary hand use, oro-motor difficulty, intellectual disability, speech, 
epilepsy, awake breathing rhythm, peripheral circulation, mood disturbance and 
sleep disturbance.  
 
The Percy scale contains fifteen items scored up to five, with a maximum score of 50 
(Colvin et al, 2003; adapted from Amir et al, 2000). A higher score denotes a more 
severe phenotype. Clinical features considered are age at onset of regression, 
ambulation, respiratory dysfunction, head growth, somatic growth, sitting, crawling, 
hand use, non-verbal communication, language, seizures, feeding, onset of 
stereotypies, autonomic dysfunction and scoliosis. 
 
The Pineda scale contains ten items scored up to four, with a maximum of 30 (Colvin 
et al, 2003; adapted from Monrós et al, 2001). A higher score denotes a more severe 
phenotype. Clinical features considered are age at loss of social interaction, head 
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growth, sitting alone, ambulation, language, epilepsy, respiratory function, hand use, 
air swallowing/bloating and onset of stereotypies. 
 
The WeeFIM is a functional independence measure for children and measures 
independent functioning with a maximum composite score of 126. Subscales for self-
care, mobility and cognition are scored out of 56, 35 and 35, respectively (Msall et 
al, 1994). A lower score denotes greater impairment and dependence. 
1.1.6 Neuropathology 
People with Rett syndrome have small brains (Casanova et al, 1991) with no sign of 
gross malformation, degeneration, demyelination or inflammation (Armstrong et al, 
2002). The brain is the only organ that is disproportionately small in relation to the 
patient’s height and this relative reduction in weight does not progress with age 
(Armstrong et al, 2005). There is a reduction of grey matter throughout the cortex, 
most so in prefrontal, posterior frontal and anterior temporal regions (Subramaniam 
et al, 1997). This is related to significantly reduced dendritic arborisation of frontal, 
motor and subicular cortical pyramidal neurons (Armstrong et al, 1998), dendritic 
spine loss in the frontal cortex (Belichenko & Dahlström, 1995), decreased neuronal 
size in the cortex, thalamus, basal ganglia, amygdala and hippocampus with 
increased packing density in the hippocampus (Bauman et al, 1995). The neurons of 
the pars compacta in the substantia nigra contain less melanin than age matched 
controls (Jellinger & Seitelberger, 1986) and a recent study documented significantly 
reduced levels of a dopamine metabolite, homovanillic acid and serotonin 
metabolite, 5-hydroxyindoleacetic acid (5-HIAA) in cerebrospinal fluid of 64 
patients with Rett syndrome compared to 200 controls (Samaco et al, 2009). 
However, generally there have not been consistent differences found in 
neurotransmitter profiles in Rett syndrome patients (Armstrong, 2002). The 
neuropathological findings are consistent with a failure of normal brain development, 
rather than a degenerative process. 
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1.1.7 Prognosis 
There is currently no cure for Rett syndrome and the management principally focuses 
on individualised rehabilitation programs led by a multidisciplinary team, as well as 
control of seizures. Mortality risk is increased, with sudden unexplained death 
mainly attributed to defective cardiorespiratory dysfunction. A database study of 332 
Australian females with Rett syndrome revealed that in those that had died by the 
time of study, the average age of death was 16 years and 7 months (Freilinger et al, 
2010). The majority of these early deaths were related to respiratory causes 
(infection, failure or aspiration) or seizures. The survival rate from this analysis was 
64.9% at the age of 32. This corroborated well with a survival estimate of 70% at 35 
years in North America (Kirby et al, 2010). Therefore Rett syndrome represents a 
severe, debilitating disease resulting in reduced quality of life and lifespan for those 
afflicted.  
1.2 The methylation landscape of the brain 
Since the discovery in 1999 that the gene responsible for Rett syndrome was MECP2 
(Amir et al, 1999), there have been significant advances in understanding the 
function of Methyl CpG binding Protein 2 (MeCP2) and the manner in which it 
interacts with the unique genomic environment of the brain, generating potential 
hypotheses for the molecular basis of Rett syndrome. Ultimately the goal of this 
research is to further understanding of neurodevelopmental disease and generate 
effective therapies to alleviate suffering in patients with Rett syndrome. Rett is a 
neuropsychiatric syndrome and MeCP2 is most highly expressed in neurons 
(Shabazian et al, 2002; Kishi et al, 2004), so in order to review the function of 
MeCP2, first the genomic epigenetic environment in which the protein operates will 
be considered. 
 
Epigenetic mechanisms add an extra layer of complexity to the biological 
information stored in the deoxyribonucleic acid (DNA) sequence comprised of four 
bases – adenine (A), thymine (T), cytosine (C) and guanine (G). One such 
mechanism is methylation of cytosine (Figure 1.2), which has been referred to as the 
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“fifth base” (Lister et al, 2009). In mammals this predominantly occurs at cytosines 
when followed by guanines, forming self-complementary, symmetrical CpG pairs 
(Sinsheimer, 1955). The mark is established by the coordinated activity of three 
DNA (cytosine-5)-methyltransferase (Dnmt) enzymes. Dnmt3a and Dnmt3b place 
methylation de novo and Dnmt1 maintains methylation following DNA replication 
(Bestor, 1988; Okano et al, 1998). CpG methylation (mCpG) is established during 
embryogenesis in 70-80% of CpG’s, widely distributed at low frequency and the 
genome is globally methylated. Unmethylated CpG’s are generally clustered into 
discrete regions known as CpG islands, which are associated with gene promoters in 
approximately two thirds of cases (Antequera & Bird, 1999). When a CpG island 
gains methylation during development, the associated promoter is switched off. 
Thus, DNA methylation plays critical roles in genomic imprinting, X-chromosome 




Figure 1.2 Cytosine methylation 
 
Cytosine can be methylated at the carbon-5 position by Dnmt enzymes to form 5-
methylcytosine (mC). Spontaneous deamination results in thymine. Adapted from 
sigmaaldrich.com. 
 
The location of mCpG can be determined at single base pair resolution by bisulfite 
sequencing (Frommer et al, 1992). When DNA is treated with sodium bisulfite, 
unmethylated cytosines are converted to uracil, whereas mC’s are not. Following 
amplification and sequencing, any remaining C’s can be identified as methylated in 
the original material. Bisulfite treatment followed by high throughput sequencing 
(bisulfite-seq) has uncovered the mCpG landscape genome wide. The mCpG level is 
high over genes, intergenic regions and repetitive DNA and relatively low over 
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promoters and distal regulatory regions. Methylation frequency of individual CpG’s 
is high (80-100%) with a separate low frequency population corresponding to CpG 
islands, so-called “low methylation regions” or LMRs and “partially methylated 
domains” or PMDs, which are dynamically methylated. This results in a bimodal 
distribution of mCpG (Lister et al, 2009; Stadler et al, 2011; Ziller et al, 2011). 
Interestingly there is little contribution of PMD regions in the neuronal methylome, 
suggesting alternative mechanisms of gene expression regulation (Lister et al, 2013). 
 
In keeping with this, in recent years it has become apparent that the methylome of 
the brain is more complex than other terminally differentiated tissues. In addition to 
mCpG, the brain harbours significant proportions of cytosine that are alternatively 
modified, thus expanding the repertoire of methylated sites. 
 
Non-CpG methylation, or CH methylation (mCH), is methylation occurring at 
cytosines followed by bases other than guanine, where H can be A, C or T. 
Previously thought to be an artefact, its existence was confirmed in mice 
(Ramsahoye et al, 2000) and humans (Lister et al, 2009) within the last twenty years. 
mCH is different from mCpG for a number of reasons. Firstly, the level of mCH is 
very low in most somatic tissues but high in neurons with appreciable amounts in 
embryonic stem (ES) cells, glia and oocytes (Ziller et al, 2013; Guo et al, 2014; He 
& Ecker, 2015). Secondly, for each CH site, only a small proportion of alleles is 
methylated, so the methylation level of each mCH site is approximately 20% (Lister 
et al, 2013). Thirdly, the signal is widely distributed with no obvious clustering of 
sites into island-like structures. mCH appears to correlate with the distribution of 
mCpG and is relatively depleted over highly expressed genes although it seems to be 
individually excluded from inaccessible regions of chromatin (Ziller et al, 2013; 
Lister et al, 2013). Fourthly, it accumulates with maturation of the nervous system, 
predominantly in neurons and most rapidly in the early postnatal brain corresponding 
to the primary phase of synaptogenesis in human and mouse (Lister et al, 2013). 
Finally, in brain the mark is established solely through de novo methylation with 
Dnmt3a being the likely writer. Dnmt3a expression in brain increases in the postnatal 
period in concert with the accumulation of mCH and knock down of Dnmt3a results 
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in the loss of mCH, but not mCpG (Ziller et al, 2013; Guo et al, 2014; Gabel et al, 
2015). Interestingly disruption of Dnmt3a expression before this time results in a 
neurological phenotype (Nguyen et al, 2007; Tatton-Brown et al, 2014) whereas 
disruption following this developmental phase does not (Feng et al, 2010) indicating 
that this may be a critical period of mCH establishment. 
 
Only 1.3-1.5% of CH is methylated in adult mouse and human brain (Lister et al, 
2013). However, given the abundance of CH and the underrepresentation of CpG in 
the genome (Bird et al, 1980), this is still an appreciable proportion of the 
methylome. In a pure neuronal population mCH represents half of the human and 
over a third of the mouse methylome (Lister et al, 2013). In cells of the nervous 
system mCH occurs mainly in a CAC context whereas in ES cells it occurs mainly in 
a CAG context (Lister et al, 2009; Xie et al, 2012; Guo et al, 2014; Varley et al, 
2013) implying a reconfiguration of the mark with differentiation of cells. This may 
be through passive dilution via cell division, followed by accumulation in 
differentiated non-dividing cells or through active and specific mechanisms in a non-
random fashion. In favour of the latter, there is evidence that mCH placement can 
correlate between biological or sample replicates and is depleted in “mCH deserts” 
over olfactory receptor and immunoglobin genes. Furthermore, there appears to be a 
cell type-specific distribution in that glial-specific genes are CH hypermethylated in 
neurons and vice versa (Lister et al, 2013).  
 
The function of mCH is yet to be determined, but it has been associated with 
repression of gene expression in vivo in mouse frontal cortex (Xie et al, 2012) and 
mouse dentate gyrus (Guo et al, 2014) and in vitro using methylated reporter 
constructs transfected into cultured neurons (Guo et al, 2014). Interestingly, when 
mCH occurs in a CAG context in pluripotent cells, it is not associated with 
repression of genes (Lister et al, 2009; Ziller et al, 2011). Therefore there may be 
two distinct functions of mCH depending on its sequence context and resulting 
binding partners. In either case, this potentially revises opinion on regulation of gene 




In addition to mCH, hydroxymethylation (hm) of cytosines accumulates with 
maturation of the nervous system. HmC is formed when mC is oxidised by Ten-
eleven translocation (Tet) dioxygenases (Tahiliani et al, 2009). This may be part of a 
demethylation pathway with subsequent oxidation steps or hmC may exist in the 
steady state as an epigenetic regulator in its own right (Kinde et al, 2015). The 
abundance of hmC has been overlooked, as traditional methods of identifying mC 
using sodium bisulfite treatment cannot distinguish the two marks. Its importance in 
mammals was brought to the forefront when it was identified in high abundance in 
cerebellar tissue using a combination of thin layer chromatography, high 
performance liquid chromatography and mass spectrometry (Kriaucionis et al, 2009). 
With the advent of Tet-assisted bisulfite (TAB) sequencing, where a glucosylation 
step prior to treatment with Tet enzymes protects hmC from further oxidation, the 
modification could be mapped at single base pair resolution across the genome (Yu 
et al, 2012). In neurons, hmC is enriched over distal regulatory elements and gene 
bodies, depleted at transcription start sites and correlates with gene activity (Song et 
al, 2011; Szulwach et al, 2011; Mellen et al, 2012). 
 
Levels of hmC accumulate with postnatal development of the nervous system and are 
eventually 5-10 fold higher in the brain than in any other tissue, constituting 
approximately 40% of all modified CpG’s in cerebellum and nearly 25% in mouse 
cortex: almost a fifth of the methylome (Kriaucionis et al, 2009; Lister et al, 2013). 
Nearly 100% of hmC is in a CpG context in mouse cortex (Lister et al, 2013) and 
human brain (Wen et al, 2014) suggesting that hmCH may not be a biologically 
relevant signal. These figures may be a product of biased Tet enzyme conversion in 
TAB-seq and it will be interesting to see if advances in technology revise these 
estimates. 
  
The significant postnatal revision of the (hydroxy)methylome in neurons, with build-
up of mCH and hmCpG establishes a unique cellular environment. The significance 
is unknown and linking its importance to the processes of neurodevelopment will be 
a future challenge. Deficiency of “writers” of this methylation lead to neurological 
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impairment (Nguyen et al, 2007; Zhang et al, 2013) Understanding “readers” of this 
(hydroxy)methylome will be key and in this regard, the study of MECP2 and Rett 
syndrome may yield some insights. 
1.3 Methyl CpG binding Protein 2 
Methyl CpG binding protein 2 (MeCP2) was first characterised in 1992 in a search 
for proteins that might be candidates for interpretation of cytosine methylation 
(Lewis et al, 1992). It is one of a family of proteins able to bind methylated DNA, 
although mutation of the other members does not result in similar neurological 
phenotypes (Hendrich & Tweedie, 2003). MeCP2 is an abundant nuclear protein that 
is 5-10 times more highly expressed in post-mitotic neurons than other tissues with 
appreciable amounts also in glia, lung and spleen (Shabazian et al, 2002; Kishi et al, 
2004). The number of molecules per neuronal nucleus in the adult mouse was 
estimated by quantitative western blotting to be approximately 16 million, which 
would be sufficient to nearly saturate the 40 million predicted mCpG sites in the 
neuronal genome (Skene et al, 2010). Expression of MeCP2 increases postnatally 
until adulthood. This closely parallels the remodelling of the neuronal methylome 
(see 1.2) and corresponds to a time of intense synaptogenesis, suggesting a linked 
function.  
 
MeCP2 is present in all vertebrates and is well conserved in mammals with 95% 
identity between human and mouse (Guy et al, 2011). The protein has three main 
functional domains: the methylated DNA binding domain (MBD), nuclear 
localisation signal (NLS) and transcriptional repression domain (TRD). The MBD 
(amino acids 78-162) is the minimal domain required for binding to a mCpG 
dinucleotide in vitro (Nan et al, 1993). The NLS (amino acids 255-271) is the 
minimum polypeptide fragment with nuclear subcellular localisation of MeCP2 when 
transfected into murine fibroblasts (Nan et al, 1996). The TRD (amino acids 207-
310) is the minimal polypeptide fragment able to repress transcription of reporter 
constructs using a GAL4 binding system in murine fibroblasts (Nan et al, 1997). This 
was later refined by exclusion mapping to pinpoint the minimum region required to 
repress transcription in vitro and interact with the nuclear receptor co-repressor 
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complex (NCoR) - the NCoR interaction domain (NID) (amino acids 285-309) (Lyst 




Figure 1.3 Methyl CpG binding Protein 2 (MeCP2) 
Schematic representation of MeCP2 protein, isoform e2 (486 amino acids). The major 
functional domains are shown: the methylated DNA binding domain (MBD, blue), the nuclear 
localisation signal (NLS, shaded) and the NCoR Interaction Domain (NID, pink), along with 
three putative AT hooks (grey). The location of the originally defined transcriptional 
repression domain (TRD) is indicated with arrows and a dotted line. Regulatory 
phosphorylation sites are plotted in blue (adapted from Lyst & Bird, 2015). 
 
The MECP2 gene contains four exons and there are two possible protein isoforms, 
variant in their N-termini and inclusion of exon 2. MeCP2α/e1 contains exon 1, 
which is spliced directly to exon 3. MeCP2β/e2 contains exons 2-4. MeCP2α/e1 is 
the more ancestral form, is more efficiently translated and is approximately ten times 
more abundant in mouse brain than MeCP2β/e2 (Kraukionis et al, 2004). There are 
three possible MECP2 transcripts from alternative use of polyadenylation sites in the 
3’ untranslated region (1.9, 7.5 and 10kb) (D’Esposito et al, 1996), which may allow 
regulation of MeCP2 by micro-RNA binding (Klein et al, 2007; Han et al, 2013). 
Additionally, MeCP2 contains multiple phosphorylation sites (Figure 1.3) and there 
is evidence that these may serve as a means of regulation in response to neuronal 
activity (Chen et al, 2003; Zhou et al, 2006; Tao et al, 2009; Ebert et al, 2013). 
1.3.1 Binding Properties of MeCP2 
MeCP2 expression correlates with evolution of the neuronal (hydroxy)methylome, 
but what is the evidence that it can interact with the various forms of cytosine 
modification? 
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1.3.2 Binding to mCpG 
MeCP2 was identified by virtue of its ability to selectively bind a single symmetrical 
mCpG pair, independent of sequence context, in a southwestern assay (Lewis et al, 
1992). This was confirmed with definition of the minimal fragment required for this 
function, the MBD (amino acids 78-162) using an electrophoretic mobility shift 
assay (EMSA) (Nan et al, 1993). In the mouse, major satellite DNA makes up 7% of 
the genome and is comprised of a 234 base pair repeat containing eight mCpG sites 
(Horz & Altenburger, 1981). Therefore the satellite DNA represents almost half of 
mouse genomic mCpG. MeCP2 bound with high affinity to fully methylated major 
satellite DNA probes by southwestern assay (Lewis et al, 1992). Following these 
early studies, mCpG binding specificity has been extensively replicated in vitro 
(Meehan et al, 1992; Hendrich & Bird, 1998; Ballestar et al, 2000; Yusufzai et al, 
2000; Free et al, 2001; Valinuck et al, 2004; Galvao & Thomas, 2005).  
 
Structural analysis of MeCP2 has reinforced this evidence and explained it in atomic 
detail. The solution structure of the MBD was predicted using nuclear magnetic 
resonance (NMR) spectroscopy (Wakefield et al, 1999). It appeared to form a novel 
wedge shape with a four-stranded antiparallel β-sheet comprising one face and a 
three-turn α-helix comprising the other. The wedge was asymmetrical, which was 
surprising given the symmetry of the mCpG dyad binding site. The authors predicted 
that aspartate at position 121 interacted with the flexible side chains of either 
arginine 111 or arginine 133 and buttressed them into an ordered conformation, in a 
manner similar to zinc finger motifs. Subsequently, and in agreement, the crystal X-
ray structure of the MBD in complex with double-stranded DNA containing a single 
mCpG dyad was solved (Ho et al, 2008). MBD residues made multiple close 
contacts with the methylated cytosines. Two hydrophobic arginine fingers – arginine 
111 and arginine 133 – projected in to the major groove of the DNA, making contact 
with the guanine residues. This structure was stabilised by several water molecules 




Therefore there was convincing evidence in vitro that MeCP2 could associate with 
fragments of methylated DNA. In eukaryotic cells DNA is further organised by 
wrapping 147bp stretches around histone protein octamers, forming nucleosomes. 
Nucleosomes are then spaced by linker DNA as chromatin with a “beads on a string” 
appearance (Luger et al, 1997). There is substantial evidence that MeCP2 associates 
with DNA in the context of chromatin and that in this respect also, there is a 
preference for mCpG. 
 
MeCP2 initially appeared chromatin-associated in vitro, being more readily extracted 
from rat brain nuclei in the presence of increasing concentrations of micrococcal 
nuclease (Meehan et al, 1992). Murine major satellite DNA is concentrated in the 
pericentromeric heterochromatin and can be visualised easily using 4’,6 diamidino-2-
phenylindole (DAPI) or Hoechst 33258 staining by microscopy (Miller et al, 1974). 
MeCP2 was observed to be associated with this pericentromeric heterochromatin in 
murine fibroblasts and murine ES cells with a characteristic punctate binding pattern 
(Lewis et al, 1992; Nan et al, 1996). When methylation was reduced to 5% by 
homozygous mutation of a methyltransferase gene in ES cells, this binding pattern 
was abolished and MeCP2 appeared dispersed (Nan et al, 1996).  
 
Association with methylated DNA has been confirmed by chromatin 
immunoprecipitation (ChIP) experiments at single genomic loci, such as the 
methylated maternal allele of imprinted genes (Gregory et al, 2001) or the brain 
derived neurotrophic factor (BDNF) locus (Chen et al, 2003). By utilising MeCP2 
ChIP followed by high throughput sequencing (ChIP-seq), association with 
chromatin can be visualised genome-wide. One such study in mouse brain indicated 
that MeCP2 coated the genome and binding coincided with the occurrence of mCpG 
(Skene et al, 2010). This broad binding profile was corroborated in mouse brain 
(Baker et al, 2013) and cultured neurons (Cohen et al, 2011). Methylation-dependent 
binding was confirmed by ChIP-seq in mouse ES cells and derived neurons where 
MeCP2 preferentially bound mCpG rich sequences and linearly tracked local 
methylation density, regardless of the underlying genomic features (Baubec et al, 
2013). Therefore relative enrichment was found over exons, promoters with 
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intermediate CpG content, and some classes of repetitive DNA, which contain the 
highest density of mCpG. The distribution of MeCP2 altered dramatically with 
depletion of methylation in ES cells to regions of accessible chromatin, marked by 
DNAse hypersensitivity and histone modifications representing actively transcribed 
chromatin (H3K4me1 and H3K27ac). Therefore genome wide assessment of binding 
in cultured neurons and brain indicates that MeCP2 tracks mCpG density.  
1.3.3 MeCP2 binding to unmethylated DNA 
In addition to binding with high specificity to methylated cytosines, there has been 
some evidence that MeCP2 can also bind non-specifically to unmethylated DNA. 
Early experimental evidence during the characterisation of MeCP2 detected lower 
affinity binding to unmethylated probes by southwestern assays and EMSA’s (Lewis 
et al, 1992; Meehan et al, 1992). There was also evidence that the MBD alone could 
bind to unmethylated probes by EMSA with a dissociation constant that was 100-
fold higher than for methylated probes (Valinuck et al, 2004). This binding has not 
just been reported for oligonucleotide probes, as in addition human MeCP2 could 
compact unmethylated reconstituted nucleosomal arrays in vitro into large ellipsoidal 
structures (Georgel et al, 2003). Interestingly, although an earlier study indicated a 
dependence on methylation for association with mouse pericentromeric 
heterochromatin (Nan et al, 1996), this finding was not replicated in ES cells that 
were triple knock-out for Dnmt genes. In fact, the characteristic punctate pattern of 
binding was unperturbed (Baubec et al, 2013). An association with unmethylated 
DNA has also been replicated by ChIP experiments at single genomic loci, for 
example the imprinted H19 locus, where MeCP2 bound preferentially to the 
unmethylated maternal allele (Kemohan et al, 2010) and genome wide: MeCP2 ChIP 
followed by a custom microarray analysis in a human neuronal cell line revealed that 
the majority of promoters bound by MeCP2 were of expressed genes and the vast 
majority (>90%) were not highly methylated (Yasui et al, 2007). However, an 
important caveat to this finding was that the MeCP2 antibody the authors used for 
ChIP was shown to discriminate poorly between protein extracts from wildtype mice 
and Mecp2-null mice, so these may not have been genuine MeCP2 binding sites 
(Guy et al, 2011). 
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The fact that binding to methylated DNA was preserved in the presence of an excess 
of unmethylated competitor DNA led to the speculation that binding to methylated 
DNA and unmethylated DNA was achieved with different regions of the protein. To 
this end, MeCP2 contains (R)GRP(K) motifs, or AT hooks, a feature of high 
mobility group (HMG) proteins that bind to AT rich DNA (Johnson et al, 1989) and 
it was suggested that this may be the basis of non-specific association with DNA. In 
keeping with this, MeCP2 required the presence of at least four AT bases adjacent to 
the mCpG dyad to bind to DNA probes with high affinity in vitro and in vivo, for 
example at the brain derived neurotrophic factor (BDNF) locus (Klose et al, 2005). 
However, the same study indicated that mutating an AT hook did not alter binding 
selectivity. The importance of the AT hook motifs has been investigated using mouse 
models and is discussed in section 1.7.1. 
 
Structural studies have lent support to non-specific binding, indicating that the 
thermal stability of MeCP2 was increased on association with unmethylated DNA 
(Ghosh et al, 2008). Furthermore, by using hydrogen-deuterium exchange mass 
spectrometry it was shown that the MBD recognises methylated and unmethylated 
DNA in a similar manner (Hansen et al, 2011). Moreover there has been some 
evidence that additional regions of MeCP2 downstream of the MBD can 
independently bind DNA and compact chromatin (Adams et al, 2007; Nikitina et al, 
2007; Kumar et al, 2008; Ghosh et al, 2010). 
 
Therefore although there is a wealth of evidence to suggest that MeCP2 specifically 
binds to DNA methylated in a CpG context, this abundant protein can also associate 
with relatively unmethylated sites in the genome, perhaps utilising AT hook motifs 
and regions other than the MBD. This non-specific binding may be a mechanism for 
immediate association with DNA, in order to then migrate towards methylated 
binding sites (Hansen et al, 2010). 
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1.3.4 MeCP2 binding to hmC 
Following the discovery of moderate levels of hydroxymethylation in the mature 
nervous system (Kriaucionis et al, 2009), one group searched for protein binders that 
may interpret this DNA moiety. A protein species was pulled down from rodent 
brain nuclear extracts using a hydroxymethylated probe, resolved by SDS-PAGE and 
identified by mass spectrometry as MeCP2. This species was not pulled down in 
Mecp2-null brain extracts. Interaction was also demonstrated by surface plasmon 
resonance and EMSA, which was sensitive to glycosylation of hmC (Mellen et al, 
2012). No other hmC binders were identified in this study. MeCP2 was also 
identified as an hmC reader in mouse ES cell nuclear extracts (but not differentiated 
neuronal precursors or neurons) by quantitative mass spectrometry (Spruijt et al, 
2013).  
 
On the contrary, earlier work had suggested that MBD binding to a symmetrical 
hmCpG dyad was almost equivalent to binding unmodified cytosine by EMSA i.e. 
affinity was reduced 100-fold (Valinuck et al, 2004). Similar results were found 
using fluorescence polarisation and amino acids 77-205 of MeCP2 (Hashimoto et al, 
2012). Furthermore, data from MeCP2 ChIP-seq combined with TAB-seq in mouse 
brain, suggests that MeCP2 does not bind to hmCpG in vivo. A relative depletion of 
MeCP2 was detected at gene bodies enriched for hmCpG (Gabel et al, 2015) and no 
correlation was found between MeCP2 binding and hmCpG content across genes 
(Chen et al, 2015). 
 
These conflicting results can perhaps be explained when the probes used to bind 
MeCP2 are considered. The probe used by Spruijt et al contained four consecutively 
modified CpG dinucleotides in a 27 base pair oligonucleotide. This artificial 
concentration of the moiety may have captured low affinity binding. Additionally, 
their experimental protocol changed from ES cells (where they utilised stable isotope 
labelling with amino acids in culture (SILAC) medium to label cellular proteins) to 
neuronal precursors and brain extracts (as there was no SILAC-compatible 
neurobasal medium, so label-free quantification was employed instead). Binding was 
only detected in ES cells and so may have been an artefact of the protocol. The 
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binding probes used by Mellen et al contained hydroxymethylation in a CpG and CA 
context at multiple sites, with hmCpG being relatively underrepresented. This raises 
the possibility that MeCP2 was binding to hmCA in these experiments. Indeed a 
double-stranded oligonucleotide probe containing hmCA was found to be a superior 
competitor species to one with hmCpG by EMSA for both the MBD and full length 
MeCP2, indicating binding in vitro (Gabel et al, 2015). Moreover, MeCP2 binding 
was correlated with genes containing higher levels of hmCA in vivo in mouse brain 
(Gabel et al, 2015). Therefore overall, it seems unlikely that MeCP2 binds to the vast 
majority of hmC in the brain. 
1.3.5 MeCP2 binding to mCH 
Early work showed that MeCP2 could bind probes with multiple cytosines 
methylated in a CH context very weakly by southwestern assay (Meehan et al, 1992). 
In comparison to a single mCpG pair, the methyl group on thymine (see Figure 1.2) 
when placed opposite a methylated cytosine in a CA context did not present an 
adequate substitute. The probes used in this study contained CA methylation in a 
CAG and CAT context. A subsequent study showed that the MBD could bind to a 
single mCpG paired with a mismatched TG with comparable affinity to a 
symmetrically methylated CpG pair by EMSA, indicating that the methyl group on 
the thymine may act as a suitable substitute for cytosine methylation in the right 
sequence context (Valinuck et al, 2004). 
 
A recent study investigated the distribution of mCH in adult mouse hippocampus 
(Guo et al, 2014). The authors noticed using published MeCP2 ChIP-seq data from 
sorted neurons that CH was hypermethylated near MeCP2 binding sites. MeCP2 
ChIP was repeated and the DNA pulled down was bisulfite sequenced at individual 
loci. Notably the MeCP2-bound DNA was enriched for mCH over input DNA in the 
absence of any mCpG. This association was supported in vitro using the MBD in 
EMSA’s. The MBD was shown to associate with probes methylated both in a CT and 
CAC context with lower affinity than to mCpG probes. Both modifications present 
on the same probe enhanced binding (Guo et al, 2014). 
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mCH binding has been replicated in two separate laboratories using MeCP2 ChIP-
seq combined with high-resolution methylation maps in mouse brain tissues (Gabel 
et al, 2015; Chen et al, 2015). In vitro EMSA work using the MBD and full-length 
protein refined the “H” and showed that MeCP2 has high affinity for mCA probes, 
but not mCC or mCT (Gabel et al, 2015). Binding of full-length protein to mCA by 
EMSA has been replicated (Chen et al, 2015) and a preference for C as the third base 
has been determined (J Connelly unpublished data). This fits neatly with the most 
abundant form of mCH being mCAC in the brain (Guo et al, 2014) and explains why 
earlier studies using CAT or CAG probes did not detect this high affinity binding. 
Furthermore, it implies some requirement for symmetry in MeCP2 binding sites as 
mCAC also presents a methyl group on the thymine of the opposite complementary 
strand. 
 
Thus, MeCP2 can bind to and interpret the unique pattern of cytosine methylation in 
the neuronal methylome. Exclusion at regions of hmCpG may also be functionally 
relevant. This leads to the questions: where do you need MeCP2 and what does it do 
there? In order to answer these questions, mouse modelling has been extensively 
employed. 
1.4 Mouse models of MECP2 
Mouse models have been widely utilised in biomedical science. The mouse is similar 
to the human in terms of anatomy, physiology and genetics and harbours a genome 
that is readily manipulated. In addition, mice are small, have a short reproductive 
cycle and lifespan, making them an efficient organism in which to study the effects 
of disease (research.jax.org). 
 
Male mice that are Mecp2-null recapitulate the phenotype of Rett syndrome. Mecp2-
null male mice appear normal at birth. However, their growth is restricted and they 
developed a stiff, uncoordinated gait from three weeks of age. There is a progressive 
phenotype of reduced spontaneous movement, tremor, hind-limb clasping, irregular 
breathing and bruxism. This is followed by rapid weight loss and death at around 
eight weeks. Affected females, heterozygous for Mecp2, develop symptoms from 
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three months onwards but have a normal lifespan (Guy et al, 2001). As in patients, 
subtle abnormalities of behaviour and vocalisation are detectable during the grossly 
normal, pre-symptomatic phase (De Filippis et al, 2010). Mecp2-null mice have 
reduced brain weight and small, tightly packed neurons in the hippocampus, cortex 
and cerebellum (Chen et al, 2001). The size of these regions is reduced by 
approximately 10% (Belichenko et al, 2008) and there is evidence of reduced 
dendritic spine density in the cortex and hippocampus (Belichenko et al, 2009). The 
period of unremarkable development, progressive neurological phenotype and 
neuropathology are all reminiscent of Rett syndrome in humans. Mice have therefore 
been widely accepted as an excellent tool in which to study Rett syndrome. 
1.4.1 Global, life-long requirement for MeCP2 
Mouse models have been used to try and disentangle the requirement for MeCP2 in 
specific tissues, cell types or stages of development in order to learn more about 
protein function and the pathogenesis of Rett syndrome. 
 
The importance of MeCP2 function in the brain was emphasised by the observation 
that the mouse Rett-like phenotype (RTT) was grossly indistinguishable when a 
floxed Mecp2 gene was knocked out in neurons and glia using Cre recombinase 
(Cre) expressed under the Nestin promoter (Nestin-Cre) (Guy et al, 2001; Chen et al, 
2001). A landmark finding came in Rett syndrome research when it was proven that 
re-expression of Mecp2 on a null background (using tamoxifen-inducible Cre to 
excise a floxed STOP cassette upstream of the Mecp2 gene) could effectively reverse 
RTT (Guy et al, 2007), including neuronal soma size, dendritic complexity and 
length (Robinson et al, 2012). This exciting research raised the question of whether 
therapeutic strategies in Rett syndrome might be curative. It also highlighted that the 
nervous system appeared to develop sufficiently for full functioning to be restored at 
a later time point. It is remarkable that the emergence of RTT in female Mecp2 
heterozygous mice occurs not at the same developmental time as human patients, but 
the same chronological time, as if neuronal function can continue in the face of 
MeCP2 deficiency for a limited period. Rett syndrome appears to be a problem of 
neuronal maintenance, rather than gross abnormality of neurodevelopment with 
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studies failing to detect abnormalities of neuronal differentiation or proliferation in 
the absence of Mecp2 (Kishi et al, 2004). In support of this statement, deletion of 
Mecp2 in adult males results in emergence of a RTT phenotype and death after ten 
weeks (McGraw et al, 2011). This also occurs if Mecp2 is deleted at a juvenile stage 
(Nguyen et al, 2012), although the onset of symptoms is slightly delayed with very 
early inactivation, indicating that there may be critical periods for MeCP2 function: 
postnatally when RTT symptoms would develop and in adulthood when animals 
would fail to survive, therefore MeCP2 is required throughout the lifespan (Cheval et 
al, 2012). To complicate matters, the level of MeCP2 expression appears to be 
critical. Mouse models have recapitulated the MeCP2 duplication syndrome in 
patients, where MeCP2 expression at higher than endogenous levels also causes a 
neurodevelopmental phenotype and reduced lifespan (Collins et al, 2004; Luikenhuis 
et al, 2004; Samaco et al, 2012). Furthermore a 50% reduction in MeCP2 expression 
caused by floxing the gene, resulted in abnormality of respiration, motor function, 
memory and social interaction (Samaco et al, 2008; Kerr et al, 2008). The level of 
MeCP2 expression must be just so. 
 
Numerous studies have suggested that neuronal dysfunction in Rett syndrome is 
centred on the synapse, although this is unlikely to be the only manifestation of 
neuropathology. Reduced spontaneous activity related to smaller miniature excitatory 
post-synaptic currents (EPSC’s), was detected using whole cell patch clamp 
recording in cortical pyramidal neurons (Dani et al, 2005). Reduced magnitude of 
evoked EPSC’s and reduced frequency of spontaneous EPSC’s were observed in 
hippocampal glutamatergic neurons (Chao et al, 2007). This was thought to be the 
result of a reduction in the presynaptic pool of readily-releasable neurotransmitter 
and related to a reduced number of glutamatergic synapses in the pre-symptomatic 
period. A further study demonstrated unimpaired hippocampal neurogenesis, but a 
reduction in synapse number in the dentate gyrus, related to reduced dendritic spine 
density and apparent immaturity of post-mitotic neurons (Smrt et al, 2007). 
Abnormalities in synaptic inhibitory/excitatory balance have been replicated in 
cortex (Wood et al, 2010), hippocampus (Nelson et al, 2006) and induced pluripotent 
stem cell-derived neurons from mouse (Farra et al, 2012) and human (Marchetto et 
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al, 2010). Moreover, synaptic dysfunction is evident from impaired long-term 
potentiation (LTP) in Mecp2 heterozygous females (Guy et al, 2007) and impaired 
LTP and long-term depression (LTD) in mice expressing a truncated form of 
MeCP2, which was compatible with learning and memory deficits uncovered in 
these mice (Moretti et al, 2006). Thus Rett syndrome is at least in part related to 
synaptopathy. 
 
Although studies are united in reporting abnormal synapse formation and function in 
Rett models, it is difficult to reconcile the paradoxical reduction in spontaneous 
excitation and excitatory synapse number observed in cortex and hippocampus with 
the high incidence of seizures and apparent hyperexcitability of the Rett brain. One 
possibility is that although reduced excitatory activity is observed at individual 
synapses, in the complexity of the developing brain, the overall network effect is 
different – for example reduced excitation of inhibitory interneurons. Indeed, Zhang 
and colleagues demonstrated diminished basal inhibitory rhythmic activity in Mecp2-
null hippocampal slices, with the authors concluding that this rendered the tissue 
prone to hyperexcitability due to heightened synchronisation of cells (Zhang et al, 
2008). Furthermore, re-examination of electrical activity in cultured hippocampal 
neurons from Mecp2-null animals revealed an increase in evoked excitatory 
transmission following short trains of action potentials and an increase in presynaptic 
release probability (inferred from reduced paired pulse ratios), consistent with 
hyperexcitability of the cells (Nelson et al, 2011). A third explanation is that the 
synaptic effects in various brain regions and cell types are diverse or that MeCP2 
function is crucial in just a few cell types or regions.  
 
Although the phenotype of Rett syndrome does not intuitively map to one region of 
the brain, as the brain functions in a network the impairment of one “node” could 
cause widespread dysfunction. Mouse models have been used to try and disentangle 
the issue of whether Rett syndrome is a global brain disorder or a disorder of specific 
brain regions or neuronal subtypes. This is possible by using a Cre expression under 
the control of region or cell-specific promoters to remove a floxed Mecp2 gene. In 
this fashion several tissue-specific knock-outs have been studied allowing the 
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breakdown of the RTT phenotype into component parts. Mecp2 knock-out in 
forebrain using calcium/calmodulin-dependent kinase II (CamKII)-Cre resulted in 
impaired motor coordination and social behaviour with increased anxiety, however 
mice had a normal lifespan (Chen et al, 2001). Knock-out in the hypothalamus using 
single-minded homolog 1 (Sim1)-Cre resulted in aggression, hyperphagia, obesity, 
and altered response to stress (Fyffe et al, 2008; Wang et al, 2014). Mecp2 knock-out 
in the basolateral amygdala using stereotactic injection of adeno-associated virus 
packaged with Cre, caused heightened anxiety and deficits in cue-dependent fear 
learning (Adachi et al, 2009). Mecp2 knock-out in caudal pons, medulla and spinal 
cord with homeobox B1 (HoxB1)-Cre reduced lifespan to around 13 weeks and 
caused abnormal heart rate and respiratory response to hypoxia, underscoring the 
importance of hindbrain in RTT (Ward et al, 2014). Although contributory to the 
phenotype, these studies reveal that Mecp2 knock-out in solitary brain regions does 
not recapitulate RTT, but simply results in dysfunction of that region. Different cell 
types have been interrogated for Mecp2 dependence in a similar fashion. 
 
Mice with Mecp2 knocked out in dopaminergic and noradrenergic neurons using 
tyrosine hydroxylase (TH)-Cre were hypoactive and had reduced levels of TH, 
dopamine and noradrenaline. Knock-out in serotonergic neurons using PC12 ets 
factor 1 (Pet1)-Cre resulted in aggression, hyperactivity, reduced tyrosine 
hydroxylase 2 (TH2) and serotonin levels (Samaco et al, 2009). In contrast to these 
mild phenotypes, mice lacking Mecp2 in GABA-ergic neurons due to vesicular 
inhibitory amino acid transporter (Viaat)-Cre, displayed most of the features of RTT 
with some subtle variations such as slightly longer lifespan (26 weeks), excessive 
grooming, forepaw stereotyped movements and increased sociability, making the 
major inhibitory neurotransmitter in the brain a key player in Rett syndrome 
pathology (Chao et al, 2010). However, deletion of Mecp2 in GABAergic neurons 
may simply be a more direct way of causing the excitatory/inhibitory imbalance that 
Mecp2 deletion in whole brain achieves and so mirrors the phenotype, rather than 
recapitulates it.  
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Co-culture experiments indicated a non-cell autonomous role for glia in the 
pathogenesis of Rett syndrome. Culturing wildtype hippocampal neurons with 
Mecp2-null astrocytes resulted in abnormalities of the neurons, which grew at lower 
density and had fewer and shorter dendrites (Ballas et al, 2009). This effect was 
replicated with only the conditioned medium from astrocytic culture, indicating that 
an unknown secreted factor was responsible. This result was not replicated in a 
subsequent study, but instead the authors suggested a role for microglia in the 
pathogenesis of Rett syndrome when they observed detrimental effects with culture 
of wildtype neurons in conditioned medium from Mecp2-null microglia. They 
identified the toxic secreted factor as glutamate, which was five times the normal 
secreted level (Maezawa & Jin, 2010). Knock-out of Mecp2 in astrocytes using glial 
fibrillary acidic protein (GFAP)-Cre resulted in small mice with hindlimb clasping 
and irregular breathing but normal lifespan, mobility and hippocampal dendritic 
arborisation (Lioy et al, 2011). Knock-out exclusively in oligodendrocytes using 
neural-glial antigen 2 (NG2)-Cre resulted in a very mild phenotype of hindlimb 
clasping and hyperactivity (Nguyen et al, 2013). A role for glial cells in pathogenesis 
was convincing, but could not account for the entire RTT phenotype. 
 
Therefore deletion of Mecp2 in specific brain regions and cell types indicates that 
MeCP2 is required throughout the whole brain, however dysfunction of GABAergic 
neurons and glial cells seem particularly influential for expression of the phenotype. 
An important question was whether these conclusions would be supported by 
complimentary rescue experiments when MeCP2 is re-expressed in particular regions 
or cell types on a null background.  
 
The reversibility of the syndrome had been shown using re-expression from the 
endogenous locus in all cells (Guy et al, 2007), furthermore expression in all cells 
using a randomly integrated P1-derived artificial chromosome (PAC) (Collins et al, 
2004) or expression in post-mitotic neurons using Mecp2 knocked in to the 
endogenous Tau locus prevented onset of symptoms in null mice (Luikenhuis et al, 
2004). On the contrary, incomplete improvement of symptoms and lifespan was 
found by reactivating a rescue Mecp2 transgene with a floxed STOP cassette in brain 
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during embryogenesis (Nestin-Cre), post-mitotic neurons during embryogenesis 
(Tau-Cre) or forebrain in the postnatal period (CamKII-Cre) (Giacometti 2007). 
Other region-specific rescues have been unsuccessful such as striatum and 
cerebellum (Alvarez-Saavedra et al, 2007) and caudal pons, medulla and spinal cord 
(Ward et al, 2014). However rescue of respiratory response to hypoxia and abnormal 
heart rate – two key causes of lethality in Rett syndrome – were demonstrated in the 
latter, identifying the hindbrain as a potential therapeutic target.  
 
Re-expression of MeCP2 in specific cell types has not resulted in complete rescue 
either. Astrocyte re-expression only extended lifespan by around four months, 
although weight and mobility improved and respiration, hippocampal neuronal soma 
size, dendritic complexity and expression of a glutamatergic transporter were all 
normalised (Lioy et al, 2011). Re-expression in oligodendrocytes lengthened lifespan 
by just 3 weeks, but increased weight, improved hindlimb clasping and motor 
function (Nguyen et al, 2013). One promising study reported a near reversal of RTT 
in Mecp2-null mice that received bone marrow transplantation following whole body 
irradiation, which allowed recolonisation of the brain’s microglia population with 
wildtype cells (Derecki et al, 2012). This study also reported a dramatic 
improvement in symptoms with re-expression in myeloid cells using lysozyme 2 
(LysM)-Cre. Mice had normal survival, increased weight, improved mobility and 
fewer apnoeas. The mechanism was proposed to be dependent on microglial 
phagocytosis. However, these findings were not replicated using three different 
mouse lines in independent laboratories and it was shown that the LysM-Cre rescue 
resulted in MeCP2 expression in only a quarter of microglia, but also in some 
neurons. Repeating the rescue with a more specific microglial Cre did not improve 
RTT (Wang et al, 2015). 
 
These disappointing rescue efforts may indicate that to rescue a phenotype that has 
already manifested, MeCP2 function must be restored in all cells. Prevention of onset 
by expression of MeCP2 exclusively in neuronal cells as demonstrated by 
Luikenhuis and colleagues may be achievable prior to the development of the mature 
nervous system when compensatory strategies are still possible. An alternative 
 48 
explanation is that there was also MeCP2 expression in glial cells under the Tau 
promoter in this study and so a pure neuronal rescue may not be possible. In 
summary, MeCP2 is required in all cells of the brain to prevent features of Rett 
syndrome. 
1.4.2 Mouse modelling & therapeutics  
There have been significant and rewarding advances in the Rett field from the use of 
mouse models. One important limitation of this line of investigation is whether the 
findings in the mouse can really be extrapolated to the human. For example, how can 
the effects of cognitive impairment and absence of speech be modelled in this 
organism? Is this disorder truly recapitulated when male mice survive into adulthood 
and human males die in infancy? Furthermore, much of the research has focused on 
male mice when Mecp2 heterozygous females more realistically model the disorder. 
These aspects are tested when potential therapies identified in the mouse progress to 
clinical trials.  
 
There have been a number of possible therapeutic avenues generated from mouse 
model experiments (Pozzo-Miller et al, 2015). Perhaps the most promising is insulin-
derived growth factor 1 (IGF1) treatment, which was attempted following the 
observation that there are increased levels of IGF-binding protein 3 in patients and 
Mecp2-null mice and the RTT phenotype improved with IGF-1 treatment (Tropea et 
al, 2009). A safety trial was completed (Pini et al, 2012) and phase II trials are 
underway.  
 
In addition, the expression of BDNF (an autocrine factor that supports differentiation 
and plasticity of neurons and promotes their survival) is reduced in Mecp2-null mice 
and replacing this with ectopic expression from a transgene ameliorated RTT (Chang 
et al, 2006). A subsequent study showed that a small molecule ligand (7,8-
dihydroxyflavone) of the BDNF receptor, tropomyosin receptor kinase B (TrKB) 
improved symptoms in Mecp2-null mice (Johnson et al, 2011) and there are currently 
two clinical trials assessing the efficacy of BDNF-related compounds in patients 
(Pozzo-miller et al, 2015).  
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An alternative way of treating Rett syndrome would be to replace wildtype MeCP2 
using gene therapy where the gene can be packaged into a non-pathogenic virus that 
can infect the central nervous system and be delivered intravenously, intrathecally or 
intracranially. Extended survival and symptom improvement was demonstrated in 
Mecp2-null male mice that had gene therapy in the postnatal period by intracranial 
injection (Gadalla et al, 2012). Another group delivered Mecp2 to heterozygous 
female mice via tail vein injection and observed a reduction in phenotypic score, 
absence of seizures and improvement on behavioural tests (Garb et al, 2013). There 
are currently no gene therapy trials in patients with Rett syndrome. 
 
Hopefully at some point the field will be in a position to test the reversibility of Rett 
syndrome in a patient group. 
 
1.5 The functions of MeCP2 
The key to understanding the molecular basis of Rett syndrome is to elucidate the 
function of MeCP2 and how its binding properties and global expression requirement 
can be translated into meaningful biological consequences in the brain. There have 
been a number of proposed functions, which are discussed in the following sections 
but after more than twenty years of research the true function of MeCP2 has not been 
indisputably demonstrated. 
1.5.1 Transcriptional repression 
MeCP2 has traditionally been thought of as a transcriptional repressor, given the 
association with cytosine methylation and the ability of the 207-310 amino acid (aa) 
fragment to repress transcription of reporter constructs in vitro (Nan et al, 1997). 
Early work showed that rat MeCP2 could repress transcription of the α-globin gene 
when it was both methylated and unmethylated in histone free rat liver nuclear 
extracts (Meehan et al, 1992). Later experiments using transient transfection of 
affinity purified rat MeCP2 revealed that transcription of a reporter construct was 
selectively repressed in HeLa cell nuclear extracts when from a methylated promoter 
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(Nan et al, 1997). This transcriptional repression was partially dependent on 
deacetylation of histones and subsequently, MeCP2 was found to interact with Sin3a, 
which recruits histone deacetylases (HDACs), in vivo (Jones et al, 1998; Nan et al, 
1998). In addition to Sin3a, MeCP2 has also been shown to bind to other co-
repressors, namely cSki, the NCoR complex, co-repressor for element-1-silencing 
transcription factor (CoREST) and Brahma (Guy et al, 2011). Recently, it was 
demonstrated that in vitro transcriptional repression of a reporter construct is 
dependent on interaction with NCoR and HDAC activity, thus refining the TRD to 
the NID (Lyst et al, 2013). Histone hyperacetylation has been observed in the brain 
of Mecp2 deficient mouse models (Shabazian et al, 2002; Skene et al, 2010) and 
treatment with a histone decetylase inhibitor, Trichostatin A, recreates synaptic 
defects seen in Mecp2 deficient neurons (Nelson et al, 2006). By binding methylated 
DNA in chromatin and linking this signal to chromatin modifiers, MeCP2 can 
therefore function as an epigenetic effector in the organisation and interpretation of 
information contained within the genetic code, ultimately resulting in repression of 
gene transcription. This hypothesis has been hampered by the lack of a consistently 
detectable subset of genes that are upregulated in Mecp2-null cells and tissues. This 
is discussed in detail in the following section. 
1.5.2 Gene expression in Mecp2 models 
The search for a subset of deregulated genes in Mecp2-null brain led to 
glucocorticoid response genes (Nuber et al, 2005) and mitochondrial respiratory 
chain genes (Kraukionis et al, 2006), however alterations in expression were not 
consistent across studies or disease stages. Imprinted genes would be candidates for 
MeCP2 regulation, given that they are allele-specifically methylated. Their 
deregulation in the context of MeCP2 deficiency has been controversial and 
inconsistent (Lawson-Yuen et al, 2007). These potential subsets did not seem to 
encapsulate the entire Rett phenotype and were not universally altered across studies. 
 
Several region-specific gene expression studies comparing Mecp2-null brain tissue to 
wildtype have been conducted in the search for patterns of gene misregulation. An 
initial report using cortical and hippocampal tissue from both pre- and symptomatic 
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mice found no significant alterations in global gene expression, but that genes were 
subtly up- and downregulated in comparison to wildtype brain (Tudor et al, 2002). 
Several hundred genes were deregulated in cerebellum, however gene expression in 
littermates was more similar than in mice of the same genotype and genes were not 
consistently altered across different time points (Jordan et al, 2007). There were no 
significant differences in gene expression found between cortex, midbrain and 
cerebellum and no genes that were significantly altered in all three regions in 
symptomatic males (Urdinguio et al, 2008). Subtle alteration in gene expression was 
found in just over 100 genes in striatum in symptomatic mice and by combining gene 
expression data from previous studies, the authors noted that the misregulated genes 
in different brain regions had a more distinctive transcriptional signature than that of 
the different genotypes (Zhao et al, 2013). 
 
A new hypothesis arose, when gene expression patterns were compared in 6 week 
Mecp2-null and Mecp2 overexpresser mice (where MeCP2 was expressed at 2-3 
times the endogenous level). It was observed that several hundred genes were altered 
commonly in cerebellum and hypothalamus with the majority of genes being 
downregulated in the Mecp2-null and up-regulated in the Mecp2 overexpresser 
tissue, leading to speculation that MeCP2 was acting as a transcriptional activator 
(Charhour et al, 2008; Ben-Shachar et al, 2009). These findings were replicated in 
amygdala (Samaco et al, 2012). This is discussed further in 1.5.4. 
 
Most regions of the brain are collages of different cell types, each potentially with 
their own gene expression signature. MeCP2 may have different target genes 
depending on the neuronal cell type and this may have resulted in the mixed up- and 
downregulation and lack of consistent targets seen with analysis of whole regions. 
An alternative approach to investigation has been using gene expression analyses in 
MeCP2 deficient cultured cells and clonal cells derived from patient material. 
Analysis of dentate gyrus granule cells in symptomatic mice revealed 13 
differentially expressed genes (12 of which were upregulated) including genes 
involved in cytoskeleton formation and synaptogenesis (Smrt et al, 2007). It has been 
shown that cultured astrocytes from neonatal mice express higher levels of astroglial 
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markers, glial fibrillary acidic protein (GFAP) and S100β (Okabe et al, 2012). Li et 
al analysed an isogenic population of neuronal cells differentiated from MeCP2 
deficient human ES cells in vitro. Their microarray data was normalised for the total 
number of input cells and so corrected for reduced total RNA in the MeCP2 deficient 
cells. With this correction, they found that ten times more genes were downregulated 
than upregulated in the absence of MECP2. They related the downregulated set to 
high levels of hmC content and high expression level and concluded that MeCP2 
acted as a transcriptional activator in their cultured neurons. They did not see the 
same effects in neuronal precursors (Li et al, 2013). This reduction in total RNA in 
cultured cells has been reported previously in neurons differentiated from Mecp2-
null ES cells (Yazdani et al, 2012), but not been replicated in animal models and 
raises the question of whether these were primary effects of MeCP2 deficiency or 
secondary to the culture of “sick” cells.  
 
Although initial efforts to examine gene expression patterns in clonal cell lines 
derived from patient material yielded inconsistent results (Traynor et al, 2002; 
Delgado et al, 2006) or revealed only a handful of significant expression changes in 
cell types not known to be affected in Rett syndrome (Nectoux et al, 2010), studies 
using induced pluripotent stem cells (iPSC) derived from Rett syndrome patient 
material have also suggested that Mecp2 deficiency results in the alteration of 
transcription of many genes. Using RNA-seq, Tanaka and colleagues were able to 
distinguish the global gene expression pattern in induced pluripotent stem cells 
(iPSC’s) with mutant MECP2 from iPSC’s with wildtype MECP2 derived from 
female patient fibroblasts and found thousands of both up- and downregulated genes 
in the mutant cells. The authors suggested that there were different patterns of gene 
expression in iPSC’s derived from patients carrying different MECP2 mutations 
(Tanaka et al, 2014). One important limitation of this study is that the gene 
expression was analysed in stem cells, which have a different methylome and 
MeCP2 expression level to mature neuronal tissue. However the use of matched 
mutant and wildtype material derived from one patient provides a unique opportunity 
to control for the variable genetic background in different people.  
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An alternative view is that the lack of clearly distinguishable and consistent patterns 
of gene deregulation in these studies is not due to cell type-specific effects, but 
because genes are only regulated by MeCP2 in response to neuronal activity. 
Neurons are dependent on efficient interpretation of transient stimuli in order to store 
network information in the long term and so deregulation at this level could lead to 
neuropsychiatric disability. There is evidence to suggest that MeCP2 constitutively 
binds to the BDNF promoter region in cultured neurons, but with calcium influx 
coincident with neuronal activity, MeCP2 is phosphorylated at serine 421 and is 
released from the promoter, relieving the repression on BDNF transcription with a 
subsequent increase in histone acetylation (Chen et al, 2003; Martinowich et al, 
2003). This precise mechanism may underlie the exclusive importance of MeCP2 in 
the nervous system and explain the emergence of the Rett phenotype at the time of 
intense synaptogenesis. Abnormalities of dendritic complexity in cultured 
hippocampal neurons overexpressing Mecp2 were found to be dependent on 
phosphorylation of serine 421 (Zhou et al, 2006). A serine 421 phosphomutant 
mouse showed abnormalities of dendritic arborisation and abnormal responses to 
novel experiences however there were no differences detectable in MeCP2 ChIP and 
gene expression profiles in the resting state or in response to depolarisation (Cohen et 
al, 2011). The mechanism may depend on phosphorylation of serine 424 in concert, 
as a double phosphomutant mouse had enhanced long-term potentiation, context-
dependent fear conditioning and spatial memory with an increased number of 
excitatory synapses in the cortex and hippocampus. MeCP2 was more tightly bound 
to target gene promoters (Li et al, 2011). Additionally, a small number of genes were 
deregulated in a serine 80 phosphomutant mouse that had abnormal locomotor 
activity and reduced association of MeCP2 with DNA, which is in keeping with 
serine 80 becoming dephosphorylated on neuronal stimulation (Tao et al, 2009). Due 
to these mild phenotypes and effects on MeCP2 binding and gene expression, it 
seems unlikely that phosphorylation of MeCP2 is the principal determinant of 
MeCP2 transcriptional regulation. 
 
A fresh perspective on gene expression was offered when it was observed that genes 
of greater than 100kb in length were disproportionately represented in neuronal 
 54 
specific processes and mutated in autistic spectrum disorders (King et al, 2013). A 
recent study analysed gene expression profiles using microarrays in four distinct cell 
types (motor cortical pyramidal cells, motor cortical interneurons, noradrenergic cells 
from the locus coeruleus and cerebellar purkinje cells) derived from symptomatic 
Mecp2-null mice and wildtype littermates (Sugino et al, 2014). Across all cell types 
there were over 800 misregulated genes: a small majority (56.2%) were upregulated 
in the absence of MeCP2 and only two genes were misregulated reproducibly in all 
four cell types underlining the importance of analysing individual cell types when 
searching for subsets of regulated genes. The authors observed that genes related to 
cell adhesion processes (which are long as a class) were over-represented in the 
group of altered genes. Misregulated genes were plotted according to length and a 
specific upregulation of genes greater than 100kb in length was noted in the Mecp2-
null cells. This length dependent relationship did not hold for genes that were 
downregulated in the absence of MeCP2, indicating that MeCP2 was a repressor of 
long gene transcription (Sugino et al, 2014). 
 
This finding was reproduced by another group, which analysed multiple previous 
studies with new data derived from combinations of microarrays, qPCR, RNA-seq 
and nCounter analysis in Mecp2-null mice, ES cell-derived neurons, Mecp2R306C/y 
brain and cortical tissue from a patient with Rett syndrome (Gabel et al, 2015). The 
authors found that the magnitude of long gene upregulation correlated with disease 
progression and severity. Using MeCP2 ChIP-seq data combined with published high 
resolution methylation maps, the authors proposed the mechanism of MeCP2 long 
gene regulation involved binding to mCA, as they observed that only long genes with 
high mCA content were upregulated in the absence of MeCP2. There was no effect 
of mCA content on the expression of short genes. Furthermore, reducing mCA by 
excising a floxed Dnmt3a gene in mouse brain using Nestin-Cre recapitulated the 
upregulation of long genes seen with a lack of functional MeCP2.  
 
Support for a mCH mechanistic theory came from a third recent study that combined 
high coverage GFP ChIP-seq in hypothalamus of an enhanced green fluorescent 
protein (EGFP) tagged Mecp2 transgenic mouse line with published methylation 
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maps and RNA-seq analysis of gene expression in Mecp2-null and overexpresser 
mouse hypothalamus (Chen et al, 2015). The authors found that over one thousand 
reciprocally misregulated genes in both the Mecp2-null and overexpresser mice had 
increased levels of MeCP2 binding and higher mCH, but not higher mCpG content in 
the gene body in comparison to genes that were unchanged. Genes that were 
uniquely misregulated in the overexpresser model had intermediate mCH content, 
perhaps indicating that extra MeCP2 had spilled over to lower affinity sites. 
Interestingly, MeCP2 appeared to bind to high mCH genes that were downregulated 
in the Mecp2-null hypothalamus, indicating that there may be separate gene-specific 
mechanisms for regulation by mCH (Chen et al, 2015).  
 
To sum up, the only consistent subset of genes upregulated in the absence of MeCP2 
are long. The gene length effect in Rett models is small, but global. This exciting 
new theory of MeCP2 function needs further investigation and leads to the question 
of whether manipulation of long gene expression in Mecp2-null mice would be a 
viable therapeutic strategy. 
1.5.3 Regulation of transcriptional noise  
Given (1) the abundance of MeCP2 in neurons, (2) the abundance of methylated 
cytosines, (3) the global binding pattern of MeCP2, (4) the increase in repetitive 
element RNA in Mecp2-null brain nuclei (Skene et al, 2010) and (5) the increase in 
L1 long interspersed nuclear element (LINE1) retrotransposition in Mecp2-null 
mouse brain and induced pluripotent stem cells derived from a Rett syndrome 
patient’s fibroblasts (Muotri et al, 2010), one possibility is that MeCP2 acts to reduce 
transcriptional noise, preventing aberrant transcription on a genome-wide scale. 
Therefore in the absence of MeCP2, transcription of unessential repetitive material is 
prioritised with variable impact on individual genes. One line of evidence against this 
hypothesis is that no increase in variance of gene expression (which would be 
predicted with increased stochastic gene expression) was found in striatum, 
cerebellum or hypothalamus of Mecp2-null animals in comparison to wildtype (Zhao 
et al, 2013). The authors of this study suggested that MeCP2 was performing a 
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coordinated role in regulation of transcription, which is compatible with the long 
gene hypothesis described in the previous section. 
1.5.4 Activation of transcription 
It has been proposed that MeCP2 acts as a transcriptional activator, given that the 
majority of genes are downregulated in its absence (see 1.5.2) and the finding of 
reduced RNA synthesis in Mecp2 deficient neurons in culture (Yazdani et al, 2012; 
Li et al, 2013). A plausible mechanism for this regulation would be recruitment of 
transcription factor, cyclic AMP-responsive element-binding protein 1 (CREB1), 
which has been reported (Charhour et al, 2008) and/or association with hmCpG, 
which has been linked to actively transcribed genes (Mellen et al, 2012). However, it 
is now known that MeCP2 does not bind to hmCpG in vivo (see 1.3.4) and by current 
estimates the amount of hmCA is too low to be biologically significant. Reduced 
transcription has not been replicated in mouse models and may be a secondary effect 
of unhealthy cells in culture. Another possibility is that in the absence of MeCP2, 
aberrant transcription of material that is not accounted for by microarray analysis and 
is filtered out in RNA-seq experiments, such as repetitive elements, results in a 
homeostatic downregulation of transcribed genes. Therefore the various 
transcriptional hypotheses are not mutually exclusive. It may be that MeCP2 exerts 
different effects depending on mode of interaction with DNA, cell type or 
developmental stage. 
1.5.5 Regulation of chromatin 
Another proposed function of MeCP2 that is related to transcriptional repression is 
the regulation of chromatin structure. It has been shown that the amount of histone 1 
(H1) is doubled in the Mecp2-null brain (Skene et al, 2010) and given that injection 
of H1 accelerated the fluorescence recovery after photobleaching (FRAP) kinetics of 
MeCP2 in mouse fibroblasts, the two proteins may compete for binding sites in vivo 
(Ghosh et al, 2010). The ability of MeCP2 to assemble reconstituted nucleosomal 
arrays has been demonstrated in vitro (Georgel et al, 2003) and at the cellular level 
MeCP2 induced the formation of large chromocentre clusters when transfected into 
myoblasts (Brero et al, 2005). Chromatin looping was lost at an imprinted locus in 
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Mecp2-null brain indicating that the conformation of the chromatin had altered and 
previously juxtaposed sites had become separate (Horike et al, 2005). Together these 
data present convincing evidence that MeCP2 may be able to induce the formation of 
higher order chromatin structures, perhaps by displacing H1. This could potentially 
be the mechanism by which MeCP2 regulates gene expression. 
1.5.6 Post-transcriptional regulation 
Post-transcriptional roles have been proposed for MeCP2. An association with a Y-
box transcription factor, YB1 that regulates alternative splicing has been 
demonstrated. In the same study, ectopic expression of MeCP2 in HeLa cells altered 
the splicing pattern of a co-transfected reporter minigene (Young et al, 2005). More 
recently, MeCP2 has been implicated in micro-RNA (miRNA) processing. When 
phosphorylated at serine 80, MeCP2 associated with DiGeorge syndrome critical 
region 8 (DGCR8), a component of the miRNA processing machinery. On neuronal 
firing, MeCP2 was dephosphorylated, dissociated from the complex and miRNA 
processing proceeded (Cheng et al, 2014). This suggests that there would be an 
upregulation of miRNA in the absence of MeCP2, however microarray analysis of 
whole brain from post-symptomatic Mecp2-null animals revealed that 70% of 
annotated miRNA’s were downregulated (Urdinguio et al, 2010). A second study 
using high throughput sequencing of small RNAs contradicted this finding, reporting 
that the majority of miRNAs were upregulated in Mecp2-null cerebellum (Wu et al, 
2010). The differing results may be the result of using a specific brain region, a 
different method of expression analysis or slightly younger mice in the second study. 
1.5.7 A multifunctional protein 
MeCP2 has a plethora of proposed interacting partners and consequently could be 
related to a number of cellular processes and functions (Lyst & Bird, 2015). Circular 
dichroism (CD) studies have indicated that MeCP2 is 60-65% unstructured and 
therefore intrinsically disordered (Ghosh et al, 2008). This conformational plasticity 
has been related to multifunctionality and the ability to bind multiple different 
protein partners (Hansen et al, 2010). It is possible that the function of MeCP2 is 
highly dependent on interaction with other protein complexes and the abundance of 
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these will vary between cell types. This leads to a complex hypothesis where the 
function of MeCP2 would be entirely cell type and state dependent, which would be 
difficult to disentangle. 
1.6 Mutations in MECP2 that cause Rett syndrome 
Study of Rett-causing mutations is a way of highlighting key regions of MeCP2 that 
are necessary for function and in turn understanding the molecular basis of the 
syndrome. Mutations in MECP2 have been identified in over 95% of cases of 
classical Rett syndrome (Moretti & Zoghbi, 2006) and in around 75% of atypical 
cases (Cuddapah et al, 2014). They almost always arise de novo, which means that 
Rett syndrome is very unlikely to run in families, especially as affected females 
usually do not reproduce. In fact recurrence risk with a negative family history is less 
than 0.1% (Smeets et al, 2011). The majority of mutations are of paternal origin, 
which explains the rarity in males (Trappe et al, 2001). Most are likely the result of 
the high mutability of mC, which can undergo spontaneous deamination to thymine 
(see Figure 1.2). The X chromosome is highly methylated in the male germ cells, but 
not in oocytes, hence the preponderance of paternal transmission (Wan et al, 1999).  
 
More than 800 different mutations are described on the RettSyndrome.org Variation 
Database – a valuable resource of collated mutation information contributed by 
researchers and clinicians. Despite this vast number, eight common point mutations 
resulting from C to T transition account for approximately half. In descending order 
of frequency, these are p.Thr158Met (T158M, 8.8%), p.Arg168X (R168X, 7.3%), 
p.Arg255X (R225X, 6.4%), p.Arg270X (R270X, 5.8%), p.Arg294X (R294X, 4.9%), 
p.Arg306Cys (R306C, 4.8%), p.Arg133Cys (R133C, 4.24%) and p.Arg106Trp 
(R106W, 2.8%) (Christodoulou et al, 2003). Another common mutation class is 
carboxy-terminal deletions, accounting for approximately 10% of cases.  
 
Around half of cases caused by common mutations occur in the MBD of MECP2 and 
this region is completely conserved between human and mouse. Furthermore, if all 
causative missense mutations (where one amino acid is substituted for another) are 
plotted along the length of the protein, it can be seen that the mutations cluster over 
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the MBD and the NID (Figure 1.6). Plotting all polymorphisms recorded in 
unaffected controls (derived from the Exome Aggregation Consortium) excludes 
these domains. This indicates that the integrity of these regions is crucial and led to 
the hypothesis that a functional MBD and NID were all that was required to prevent 
Rett syndrome (Lyst & Bird, 2015). There are, however three known missense 
mutations that lie outwith these domains (A2V, P225R and P322L) and the sizeable 
group of C-terminal deletions, that require further investigation and are not 




Figure 1.6 Rett syndrome mutation analysis of MeCP2 
 
Schematic representation of MeCP2 protein, isoform e2 (486 amino acids) with major 
functional domains and putative AT hooks indicated. The locations of the Rett missense 
mutations are plotted in red and underline the importance of the MBD and NID. The locations 
of the R133C, T158M and R306C mutations pertinent to this study have been highlighted. 
Neutral amino acid variants from the Exome Aggregation Consortium are plotted in black 
and tend to lie outwith the MBD and the NID. Phosphorylation sites are shown in blue. 
Adapted from Lyst & Bird, 2015. 
 
1.6.1 Mutations in MECP2 with other consequences 
As well as resulting in Rett syndrome, mutations in MECP2 have been associated 
with X-linked mental retardation (Meloni et al, 2000; Orrico et al, 2000; Couvert et 
al, 2001; Yntema et al, 2002), non-progressive encephalopathy in males 
(Imessaoudene et al, 2001), Angelman syndrome-like phenotype (Watson et al, 
2001), psychosis, pyramidal signs and macro-orchidism (PPM-X) (Klauck et al, 
2002), early onset schizophrenia (Cohen et al, 2002) and infantile autism (Carney et 
al, 2003). In addition, there is a neurodevelopmental syndrome caused by duplication 
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of the MECP2 gene (Peters et al, 2013). Therefore the relevance of research into 
MeCP2 is potentially widespread and will have significant impact further afield. 
1.7 Study of Rett-causing mutations 
The complete phenotype of Rett syndrome cannot be attributed to single regions or 
cell types and the function of MeCP2 is still unclear, although promising research 
implicates the regulation of long genes. It is now important to study patient groups 
and mouse models with commonly occurring mutations in MECP2 in order to learn 
more about protein function and disease pathogenesis, to yield prognostic 
information and better inform recruitment to clinical trials There has already been 
some progress in this field, which is discussed in the following sections. 
1.7.1 Mouse models of Rett-causing mutations 
A mouse model of the rarely occurring T158A mutation revealed that instability of 
the protein was a major contributory factor to the RTT phenotype with mutation of 
this residue (Goffin et al, 2011). Using a mouse model, it was confirmed that MeCP2 
with the R306C mutation failed to associate with the NCoR complex in vivo, which 
resulted in definition of the NID of the protein (Lyst et al, 2013). Modelling a 
mutation affecting a translation start site in exon 1 of Mecp2 implicated this more 
abundant isoform in the RTT phenotype (Yasui et al, 2014), however this is likely 
the result of reduced protein abundance rather than isoform-specific effects, as rescue 
of an Mecp2-null phenotype using a transgene expressing the e2 isoform has been 
demonstrated (Collins et al, 2004). 
 
It seems unlikely that disrupting regulatory phosphorylation of MeCP2 causes Rett 
syndrome as mouse models of MeCP2 phospho-mutants display very mild 
phenotypes (Tao et al, 2009; Cohen et al, 2011; Ebert et al, 2013) and there are no 
known missense mutations of phosphorylation sites. However, their disruption will 
be additive. It is possible that phosphorylation sites interact and their functioning is 
impaired by other Rett mutations, for example phosphorylation of threonine 308 is 
abolished in mice with the R306C mutation and was shown to be important for 
dissociation from NCoR in response to neuronal activity (Ebert et al, 2013). 
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Furthermore, phosphorylation sites will be disrupted in early truncation and some C-
terminal deletion mutations. Another possibility is that the sort of phenotype caused 
by phosphomutants is not possible to measure in the mouse but has significant 
impact on the functioning of a human. 
 
An observation made in patients indicated that a frameshift occurring at G273 results 
in a milder neuropsychiatric phenotype than frameshift at R270. Modelling these two 
mutations in transgenic mice recapitulated this severity with average survival of 
approximately 29 weeks and 12 weeks, respectively. Investigation revealed the 
importance of a putative AT hook domain in MeCP2 that was disrupted in R270X 
protein and resulted in subtle deficits in DNA binding, chromatin association, alpha 
thalassemia/mental retardation syndrome X-linked protein (ATRX) co-localisation 
and nucleosomal array assembly (Baker et al, 2013). It may also be possible that the 
earlier truncation disrupts the NLS (amino acids 255-271) however the protein 
appeared nuclear. One further caveat to this study is that there are no known Rett-
causing missense mutations that disrupt the AT hook.  
 
The same group later proposed that an intact MBD and TRD are required to produce 
toxic effects of MeCP2 overexpression, as transgenes with R111G or R306C did not 
produce a phenotype on a wild type background (Heckman et al, 2014). However, 
there was no wild type overexpresser presented in parallel for comparison. 
Interestingly, the authors noted that the phenotype of the R306C transgene on the 
Mecp2-null background was more severe than their previous G273X model where 
the C-terminal portion of the protein is lost, with the R306C mice only surviving for 
18 weeks. They proposed a dominant negative effect of this mutation and attributed 
it to a deficit in DNA binding with the R306C mutation (shown by ChIP and EMSA) 
due to disruption of a “basic patch” of amino acids, presumably used to associate 
non-specifically with DNA. These results require further investigation, as some of 




Thus, mouse models of Rett-causing mutations have helped to underline the 
importance of different domains of MeCP2 in Rett pathogenesis. The advantage to 
mouse modelling is that male mice with Mecp2 mutations survive into adulthood and 
the effects of mutant protein can be studied without the complicating factor of 
skewed XCI. This is discussed in the following section. 
1.7.2 X Chromosome Inactivation (XCI) 
There is significant clinical heterogeneity in Rett syndrome, despite the classical 
course of development. Refining this heterogeneity by analysing subgroups of 
patients can aid in understanding the pathogenesis and this task has been addressed 
by dividing patients into categories based on their particular mutation in MECP2. 
Before moving on to review the study of Rett-causing MECP2 mutations in humans, 
it is important to note another potential source of clinical variability. 
 
As MECP2 is located at Xq28, it is subject to XCI in females. This is the process by 
which one X is inactivated at random in every cell to compensate for the presence of 
two copies (Lyon, 1961). Usually the XCI pattern is considered skewed if more than 
75-80% of cells express one allele and is typically calculated by analysing the 
methylation pattern of the androgen receptor in leukocytes. The pattern of XCI has 
been reported as random and non-random in Rett patients (Amir et al, 2000). It is 
potentially influential in determining phenotypic severity because it regulates the 
load of mutant protein in the brain. Convincing evidence of this phenomenon comes 
from rare examples of unaffected mothers with highly skewed XCI transmitting the 
mutant copy of the MECP2 gene to their offspring, who then manifest the disease 
(Schanen et al, 1997; Masuyama et al, 2005) or cases of monozygotic twins with 
markedly different phenotypic severity and corresponding variance in XCI (Ishii et 
al, 2001). Additionally, studies focusing on particular mutations have statistically 
related skewing to phenotypic severity (Archer et al, 2007). Two caveats to the 
interpretation of this measure are (1) that skewing in XCI has been shown to increase 
with age, so may not correlate with retrospectively reported clinical features (Sharp 
et al, 2000) and (2) the pattern in leukocytes may not reflect that in the brain, 
furthermore inactivation in the brain may be region-specific, so it may be impossible 
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to know the true pattern of XCI in an individual with Rett syndrome in life (Gibson 
et al, 2005). 
1.7.3 Clinical studies of genotype-phenotype correlation 
There has been a wealth of work linking particular types of MECP2 mutation to 
clinical severity in Rett syndrome. This is reviewed in the following section. 
 
An early study found that patients with truncation mutations (n=30) were more likely 
to have lower homovanillic acid and patients with missense mutations (n=18) were 
more likely to have scoliosis (Amir et al, 2000). There was no difference in clinical 
severity between the two groups when 13 variables were considered. Patients with 
skewed XCI were excluded. Cheadle et al performed this analysis and detected 
significantly reduced clinical severity in the missense group (n=20) compared to the 
truncation group (n=24) when hand use, speech and walking were considered. 
Additionally, subdividing the truncation group revealed lower clinical severity in late 
truncations (n=16) compared to truncations upstream of the TRD (n=10). XCI was 
not considered (Cheadle et al, 2000).  
 
There was a flurry of interest in genotype-phenotype correlation over the next four 
years, although investigating groups could not come to a consensus regarding which 
set of mutations predicted increased severity. Monros et al reported that truncation 
mutations were associated with greater clinical severity than missense mutations 
using an early version of the Pineda scale (Monrós et al, 2001). In contrast, Hoffbur 
et al reported that cases with MBD missense mutations or early truncations were 
clinically more severe than cases with mutations occurring within or downstream of 
the TRD when assessing individuals with random XCI using five clinical features. 
The authors suggested that the pattern of XCI could affect clinical outcome (Hoffbur 
et al, 2001). Huppke et al contradicted these findings and reported lower severity in 
patients with missense mutations and C-terminal deletions than truncations using six 
clinical features (Huppke et al, 2002). Smeets et al found no correlation between 
skewing of XCI and milder phenotype. They corroborated that early truncation 
mutations resulted in a more severe clinical phenotype than missense mutation cases 
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using the Kerr scale and a simplified six-point version (Smeets et al, 2003). Schanen 
et al stated that patients with missense mutations had lower overall severity scores 
and better language performance than those with nonsense mutations, however 
particular MBD and TRD mutations could not be separated by clinical severity in 
their study (Schanen et al, 2004). Three further studies did not find any influence of 
mutation type or XCI on clinical severity (Auranen et al, 2001; Nielsen et al, 2001; 
Weaving et al, 2003). These conflicting findings from many different countries were 
likely related to the small sample sizes (n≤123), meaning that diverse mutations were 
being grouped together on the basis of similar location within MECP2. Later, using 
alternative approaches to genotype-phenotype correlation and with the growth of 
patient databases and international collaboration, the frequency of common 
mutations was appreciated and it was possible to further refine mutation groups. A 
reproducible spectrum of phenotypic severity emerged. 
1.7.4 The R133C mutation in vivo 
Yamashita et al took a different approach to the question of phenotype-genotype 
correlation by focusing on cases with a specific clinical feature: preserved speech 
(Yamashita et al, 2001). At the time, there was diagnostic uncertainty over these 
children who met criteria for autistic spectrum disorder and Rett syndrome. The 
authors analysed MECP2 mutations in 30 Japanese patients, five of whom had 
preserved speech. XCI was not assessed. They discovered that all of the five 
preserved speech cases had mutation in the MECP2 gene and two of the five had the 
R133C mutation. None of the patients without preserved speech had the R133C 
mutation. The two patients with R133C appeared to have the mildest clinical 
presentations. For example, the first of these patients developed normally for three 
years prior to regression, she had normal growth, was able to walk and in-line skate, 
but was clumsy. She could still eat with a spoon and regained social interest at five 
years of age. The second patient had preserved ambulation. The authors speculated 
that the R133C mutation might result in a milder form of Rett syndrome.  
 
With a similar approach, Leonard and colleagues asked whether there was evidence 
of a milder Rett syndrome phenotype in patients with the R133C mutation (Leonard 
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et al, 2003). This group analysed clinical data for 24 international patients with the 
R133C mutation and compared them to 98 Rett syndrome patients with other 
mutations from an Australian Rett syndrome database. The comparison mutations 
were distributed throughout the length of MECP2 and different categories of 
mutation were equally represented. XCI patterns were assessed in 85 cases, however 
patients with skewing were not excluded. Clinical severity was assessed using the 
Kerr, Percy, Pineda and WeeFIM scales. They found that patients with the R133C 
mutation were significantly less likely to be in the severe category for voluntary hand 
use, speech, gross motor function and ambulation, age at losing social interaction, 
sleep disturbance, respiratory dysfunction, awake breathing rhythm, onset of and 
frequency of hand stereotypies, or scoliosis. This reduction in severity over a wide 
spectrum of clinical parameters translated into significantly lower composite severity 
scores in the R133C group than the comparison group according to all four clinical 
scales. The authors concluded that there was evidence of a milder clinical syndrome 
with the R133C mutation.  
 
In a slightly larger follow up study with 147 cases, the same group distinguished two 
truncation mutations within a similar region of MECP2 that would have been 
grouped together in previous studies. The authors found that R270X was 
significantly more severe than R294X on all of their four severity scales. They also 
noted that the T158M cases were conspicuously mid-range in severity, could not be 
distinguished from other mutations, and that the R306C cases were at the milder end 
of the spectrum with significantly later onset of regression (Colvin et al, 2004). 
 
A UK study of 135 cases confirmed that patients with early truncating mutations had 
a more severe phenotype than missense or late truncating mutations using a 
dimensional approach to assessment that took into account typicality, severity (using 
a five-point scale) and clinical course. Analysis of individual mutations revealed that 
patients with the R133C mutation (n=9) had a significantly lower severity score than 
P255X and T158M patients (Charman et al, 2005). 
 
 66 
The reduced severity of patients with the R133C mutation was corroborated by an 
American study, which considered 245 Rett syndrome patients for phenotype-
genotype correlation (Neul et al, 2008). The authors excluded patients with atypical 
Rett syndrome from this study, which may have led to disproportionate exclusion of 
those with the R133C mutation and preserved speech. There were 12 patients with 
the R133C mutation and the other mutations were classified as one of the other most 
common point mutations, C-terminal truncations, large deletions, other or no MECP2 
mutation. Clinical severity was assessed using 13 traits. There was a significant 
difference in the overall clinical severity scores between the groups, with the R133C 
mutation group achieving the lowest severity score of all the groups studied 
(significantly lower than R168X and large deletions by pairwise analysis). This 
observation stood up when the R133C group was compared to the R168X group and 
participants with skewed XCI had been removed. Under these circumstances, the 
R168X group was also significantly more severely affected than R306C patients. 
Ambulation, hand use and language distinguished the mutation groups. R133C 
patients were significantly more likely to have preserved hand use and language and 
there was a trend towards lower severity for ambulation when compared to the 
R168X group (50% of the R133C group used words, 92% used hands and 75% could 
walk alone). This study also highlighted reduced severity in the C-terminal deletion 
category and reported the interesting observation that only a small proportion of 
patients with the R306C mutation could use words. 
 
Bebbington et al studied 272 Rett syndrome patients, using InterRett, the 
international Rett syndrome database (Bebbington et al, 2008). Patients were 
assessed using the Kerr, Percy and Pineda scales and grouped by mutation: the eight 
most common point mutations, along with C-terminal deletions. The study did not 
take the pattern of XCI into account but excluded Australian cases from the Leonard 
et al study, to allow valid comparison. In addition, the Kerr scores were age-
corrected to prevent any skewing towards increased severity for the older patients. 
There were 27 patients with the R133C mutation in the study. The R133C patients 
had the lowest severity score on all three scales with statistically significant 
comparisons to R168X, R255X and T158M on every scale. They were more likely to 
 67 
have a delayed onset of regression and hand stereotypies and around two thirds had 
preserved hand function, compared to less than one third over the whole cohort. They 
were less likely to have severe feeding difficulties. All R133C cases learnt to walk 
and 21% of this group were able to use phrases in speech, compared to 2% of the rest 
of the group. Bebbington et al did not find any significant differences between the 
mutation groups in any other features indicating that R133C Rett syndrome is still a 
severe and debilitating condition. They were able to segregate R133C, R294X, 
R306C and C-terminal deletions as a generally milder group, R106W, R168X and 
T158M as an intermediate group, with R270X and R255X conferring the most severe 
phenotype. A spectrum of severity was beginning to form. In addition, the authors 
were able to demonstrate a good correlation of clinical severity scores for individual 
mutations with the earlier Australian Study (Leonard et al, 2003) and recommended 
routine genetic testing for individuals where a diagnosis of Rett syndrome was being 
considered. 
 
The same group reported 832 Rett syndrome cases from the Australian Rett 
syndrome database and the InterRett database with a focus on C-terminal deletions 
(Bebbington et al, 2010). There were 56 patients with the R133C mutation included 
in their study. By direct comparison with the C-terminal deletion group (79 patients) 
the authors showed that the R133C cases had significantly lower severity scores on 
the Pineda and Percy scales, were more likely to learn and be able to walk, and were 
more likely to currently have speech. Although not the focus of this study, this data 
lends further weight to the conclusion that the R133C mutation causes the mildest 
form of Rett syndrome. 
 
A Dutch group analysed 137 Rett syndrome patients from their Maastricht-Leuven 
Rett syndrome database using the Kerr scale (Halbach et al, 2012). The participants 
included girls with typical and atypical Rett syndrome. There was data on XCI 
pattern for 22 patients, but they were not excluded. Mutations were classified 
according to position in the MECP2 gene: MBD, TRD, C-terminal and other. If a 
mutation occurred in more than five patients, it was analysed separately. There were 
10 patients with the R133C mutation and this group achieved the lowest overall score 
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for clinical severity when compared to all other recurrent mutations (including C-
terminal deletions). There was a statistically significant difference in the proportion 
of R133C patients who had normal development in the first year of life (80%) 
compared to patients with the R168X mutation (13%). The proportion of R133C 
patients with oro-motor difficulties (30%) was significantly lower than patients with 
the P152R mutation (60%). The authors noted that patients with the R133C mutation 
had consistently low scores in all domains, however they advised caution with 
emphasis on prognostic power, given the clinical heterogeneity observed in patients 
with the same mutation. 
 
Urbanowicz et al looked specifically at language abilities in 766 Rett syndrome 
patients that were 15 years or younger at the time of enrolment to the Australian Rett 
syndrome database and the InterRett database (Urbanowicz et al, 2014). There were 
55 patients with the R133C mutation in this study. Using enrolment questionnaire 
speech information, the authors categorised speech ability into no speech, use of 
babble or use of words. Mutation categories were the eight most common point 
mutations, early truncation, large deletion, C-terminal deletions or other. The R133C 
group were more likely to be able to say words before their regression than patients 
with large deletions and the most likely to say words following their regression of all 
the mutation groups. This study called into question the utility of distinguishing a 
preserved speech variant of Rett syndrome from classical cases, given that 185 of the 
766 patients in the study did not experience a regression in their speech and 
language, which is a requirement for the diagnosis of classical Rett syndrome. 
 
Finally, Cuddapah et al analysed a database of nearly 1000 American Rett syndrome 
patients for genotype-phenotype correlation, including 51 patients with the R133C 
mutation (Cuddapah et al, 2014). They divided patients into typical (n=815) and 
atypical (n=148) Rett syndrome (including 40 and 11 R133C cases, respectively) and 
used data gathered by experienced clinicians over several clinic visits. In this way, 
they were able to observe progression of disease over time. The study used 16 
mutation groups: in addition to the eight most common point mutations, they had 
3’truncations, deletions, exon 1 mutations, insertions, large deletions, other point 
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mutations, splice sites and no mutation. XCI was not recorded. They assessed clinical 
severity using thirteen separate traits. In the typical Rett category, the R133C patients 
had the lowest average severity score, except for the exon 1 mutation group. The 
score was significantly lower than twelve of the other mutation categories. This 
relationship persisted when individual clinical abilities were examined and the 
mutation was ranked similarly for the atypical Rett cases. The authors noted that the 
difference in phenotypic severity between the least severe mutations (exon 1 
mutations, R133C, R306C, R294X, 3’ truncations) and the most severe mutations 
(R168X, insertions, large deletions, R270X) widened in the atypical Rett syndrome 
analysis, which perhaps was an indication that these should not be considered 
separately and may have produced more robust differences in phenotypic severity if 
grouped together. Overall the authors concluded that (1) severity worsens with age, 
(2) hand use and age of onset of stereotypies predict disease severity for both groups, 
(3) ambulation and age of independent sitting predict severity in the typical cases and 
(4) language predicts severity in the atypical group (though this is not surprising, 
given that this includes the preserved speech variant of Rett). The interpretation of 
the R133C patient data was certainly influenced by over a quarter of patients being 
allocated to the atypical category. In this large study, R255X, R106W and T158M 
mutations were associated with Rett syndrome of intermediate severity.  
 
The general consensus of these genotype-phenotype studies that the R133C mutation 
results in a milder form of Rett syndrome is supported by the existence of a male 
patient with the mutation. A case report of a Japanese boy with classical Rett 
syndrome, who was found to have the R133C mutation, was published (Masuyama et 
al, 2005). The patient had a history of developmental delay, autistic features, 
stereotypic hand movements, seizures, abnormal respiration in wakefulness, loss of 
purposeful hand use, growth retardation and was bed bound by the age of eight, due 
to motor impairment. The patient’s sister also had Rett syndrome caused by the 
R133C mutation: their mother was a carrier with skewed XCI and mild intellectual 
disability. The authors were able to rule out somatic mosaicism in the boy. 
Additionally, a case of a male patient with classical Rett syndrome and the R133H 
mutation has also been reported (Monrós et al, 2001). Normally, males with MECP2 
 70 
mutations that cause typical Rett in females and a normal karyotype die in the 
neonatal period with severe encephalopathy (Kankirawatana et al, 2006). Therefore 
the survival of a male into childhood underlines the reduced severity conferred by the 
R133C mutation.  
 
There is wide phenotypic variability between individuals with the same mutation and 
although the R133C mutation is associated with preserved speech, not all patients 
with R133C have preserved speech. Equally, there don’t seem to be abilities that are 
always lost in individuals with the R133C mutation, which would point towards a 
specific deficit in MeCP2 function conferred by this mutation. A recent study looked 
at 114 Italian patients, including 7 patients with the R133C mutation, using the Rett 
Assessment Rating Scale (RARS) (Fabio et al, 2014). This novel instrument assessed 
thirty clinical symptoms that were rated from 0-7 with the aim of achieving finer 
grain resolution of clinical profiles. The authors observed that patients with the 
R133C mutation deviated from a “mild” scoring profile most in the cognitive 
domain, which included visual and auditory perception, attention, spatial orientation, 
temporal orientation, memory, eye contact, gestures and, rather confusingly, verbal 
skills. Although this was a small study, it will be interesting to see if it’s possible to 
elucidate any specific deficits conferred by the mutation using more detailed clinical 
analysis in the future. This would yield further clues towards understanding the 
molecular basis of MeCP2 dysfunction in these patients. 
 
There are a number of important limitations to these clinical studies. Firstly, XCI 
status is rarely taken into account and it has been shown that skewing (at least from 
blood profiles) seems to affect phenotypic expression in some cases. Secondly, some 
of the data analysed is derived from voluntary and retrospective parent reporting, 
which is subject to ascertainment bias and recall bias. Thirdly, there was disparity in 
which clinical severity scale was used to rate patients between the studies and so 
different aspects of Rett syndrome were captured. Finally, separating the R133C 
participants into typical and atypical Rett syndrome in the largest study may have 
hampered the ability to detect subtle variation in phenotype caused by this mutation 
by reducing statistical power. Nevertheless, clinical studies from different countries 
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involving patients of different ages, using different means of assessment come to the 
same convincing conclusion that the R133C mutation is associated with a less severe 
form of Rett syndrome in patients. 
1.8 The R133C mutation in vitro 
The reduced clinical severity observed in patients with the R133C mutation is clear. 
This is surprising, as R133 is one of two arginine fingers proposed to confer binding 
specificity to MeCP2 (see 1.3.2). In the following sections, in vitro studies of 
MeCP2R133C are reviewed. 
1.8.1 Binding to mCpG 
DNA binding of Xenopus laevis MeCP2 was assessed by EMSA, using 42 base pair 
duplex oligomers with either one or twelve mCpG pairs. Binding of MeCP2R133C to 
the multiply methylated probe was virtually abolished, to the extent that saturation of 
the probe could not be achieved with increasing amounts of protein. By 
Southwestern assay with the same probes, MeCP2R133C binding to the singly and 
multiply methylated duplexes was 20% and 10% of wildtype protein binding, 
respectively (Ballestar et al, 2000). The same group revisited the Southwestern 
experiment with human MeCP2. They found that MeCP2R133C binding to the 
multiply methylated duplex was abolished (Yusufzai et al, 2000). Binding of an 
MBD fragment of human MeCP2 to a 28 base pair DNA duplex with a single mCpG 
pair was measured by EMSA. The wildtype MBD shifted 99% of the probe at the 
maximum peptide concentration assayed. MBDR133C shifted 18% of the probe at an 
equivalent peptide concentration, which was in agreement with Ballestar et al (Free 
et al, 2001). However in an identical experiment (except the duplex was 17 base 
pairs) rat MBDR133C binding to a single mCpG dyad was abolished by EMSA 
(Galavao & Thomas 2005). The focus of this study was to investigate MBD binding 
to unmethylated Holliday junction DNA, which may mimic MeCP2 binding to 
nucleosomes in order to compact chromatin. The authors observed that MBDR133C 
had just a 2-fold reduction in binding the four-way junction DNA. 
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EMSA’s were revisited in another study using human MeCP2 and a 208 base pair 
probe that was methylated at twelve CpG sites. At equivalent protein concentrations, 
there was 25-30% more unshifted probe with MeCP2R133C compared to wildtype, 
indicating that binding was not abolished. This experiment was repeated with twelve 
ligated 208bp probes, presenting 144 CpG sites. They found no impairment in the 
ability of MeCP2R133C to shift the unmethylated tandem, however there was only a 
minor enhancement of the shift when this large, complex probe was methylated. 
Wildtype protein showed a substantial enhancement of binding when the probe was 
methylated. The authors’ interpretation was that MeCP2R133C was binding by 
methylation-independent mechanisms (Nikitina et al, 2007). This same experiment 
using MBDR133C produced a very weak methylation-dependent enhancement of the 
shift, suggesting that the smaller segment also bound with low affinity in the 
presence of the R133C mutation (Ghosh et al, 2008). 
 
Although MeCP2 is well conserved, these results collectively highlight the 
importance of species, protein fragment, and target probe in measuring DNA binding 
in vitro. To sum up, the R133C mutation significantly impairs specific binding to 
DNA probes methylated in a CpG context, but largely retained non-specific binding 
to unmethylated DNA. 
1.8.2 Structural impact 
Interestingly, despite the significant reduction in ability to bind methylated DNA, a 
minor impact of the R133C mutation on the secondary structure of the MBD was 
observed using circular dichroism (CD) (Ballestar et al, 2000) or by NMR 
spectroscopy with no evidence of unfolding or instability (Free et al, 2001). This 
issue was revisited using a combination of fluorescence spectroscopy and CD (Ghosh 
et al, 2008). By fluorescence spectroscopy, MeCP2R133C was partially unfolded, 
resulting in increased exposure of Trp104 to solvent and a reduction of emitted 
fluorescence. The Tm (temperature at which 50% of protein was unfolded) was 
lower for MeCP2R133C than wild type protein (38oC vs 44.5oC, respectively).  In 
addition, when wildtype MeCP2 bound to a 45 base pair segment of DNA from the 
BDNF promoter IV region, which was methylated at one CpG pair, its Tm increased 
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by 18.6oC, indicating an increase in stability induced by DNA binding. In contrast, 
the Tm of MeCP2R133C only increased by 10.7oC when bound to the same oligomer, 
suggesting lower affinity binding. Interestingly, the fluorescence emission spectra for 
wild type MBD and MBDR133C were identical, but with a small reduction in thermal 
stability (the Tm of MBDR133C was 3.4oC lower).  This was explained using CD, as 
the authors were able to distinguish the secondary structure of wildtype MBD and 
full-length protein. The CD spectra for R133C mutants were indistinguishable from 
wildtype equivalents, indicating minimal change in secondary structure and 
confirming earlier reports (Ballestar et al, 2000). When exposed to methylated DNA, 
however, there was no alteration in the CD spectrum for MBDR133C, as there was for 
the wild type MBD with a small increase in alpha helicity, indicating that the 
conformation of the mutant protein was not altered or stabilised by interaction with 
methylated DNA. These results suggest that (1) the secondary structure of the full-
length wildtype protein is different to that of the MBD fragment, (2) thermal 
instability of the R133C mutant is detectable using full-length protein, and (3) 
structural differences attributable to the R133C mutant are subtle, becoming apparent 
on binding to methylated DNA. 
 
Recently, Kucukkal et al modelled the DNA binding deficit of MBDR133C in silico 
using the previously determined X-ray structure (Ho et al et al, 2008) as a starting 
point (Kucukkal et al, 2015). They found that MBDR133C still bound to methylated 
DNA, but its interaction was significantly reduced. This was attributable to a 
reduction in hydrogen bonding with methylated DNA (both direct bonding via 
arginine 133, but also an indirect reduction of hydrogen bonding by arginine 111) 
and the loss of two salt bridges in the vicinity of the arginine fingers. A predicted 
model of mutant binding is shown in Figure 1.8.2. The consequence of the mutation 
on secondary structure was proposed to be a reduction in alpha helicity of the bound 





Figure 1.8.2 The structural impact of the R133C mutation 
 
(A) Predicted model of MBD binding to a methylated CpG pair. Arginine 111 and 133 make 
contact with the guanines and form hydrogen bonds with the methylated cytosines of the 
CpG pair. Arginine 111 forms a hydrogen bond with aspartic acid 121. 
(B) Predicted model of MBDR133C binding to a methylated CpG pair. The cysteine 133 
interaction with guanine is now dependent on water molecules and there is no bond with the 
methylated cytosine. 
Hydrogen bonds are indicated by dotted lines, methyl groups by green balls & water 
molecules by grey & orange balls. Adapted from Brown et al, unpublished. 
 
1.8.3 Binding to chromatin 
In vitro assessment indicated that the R133C mutation had little impact on the ability 
of MeCP2 to compact unmethylated nucleosomal arrays (Georgel et al, 2003) or 
methylated nucleosomal arrays: MeCP2R133C protected nucleosomes from 
micrococcal nuclease digestion, indicating a preserved ability to bind and compact 
chromatin (Nikitina et al, 2007).  
 
Chromatin association of R133C mutants has also been studied in cells. Kudo and 
colleagues transfected mouse fibroblast cells with EGFP-tagged MeCP2 and 
observed protein localisation to heterochromatic foci 48 hours later in fixed cells. 
Surprisingly, despite the previous literature indicating that the R133C mutation 
abolished specificity for methylated DNA, they observed a focal staining pattern for 
MeCP2R133CEGFP that was indistinguishable from wildtype (Kudo et al, 2003).  
 
Baubec and colleagues studied the binding of MeCP2R133C in ES cells using ChIP-
seq and published methylation maps (Baubec et al, 2013). The biotin-tagged MeCP2 
constructs were expressed from a known site in the mouse ES cell genome (in 
addition to endogenous MeCP2 expression) and could be immunoprecipitated using 
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streptavidin. The authors revealed that wildtype MeCP2 tracked mCpG density but 
this specificity was lost with MeCP2R133C. Mutant protein enrichment over wildtype 
protein enrichment was plotted against methylation density, so although it appears 
that MeCP2R133C had no specificity for methylated DNA, any small increase in 
enrichment may have been masked by a larger fold change in enrichment for the 
wildtype protein. In addition, the MeCP2R133C expressing ES cells had a normal 
pattern of localisation to heterochromatic foci by microscopy. An interpretation that 
consolidates the in vitro and structural R133C data would be that the mutant’s 
apparently normal pattern of localisation to heterochromatin may rely on preserved 
non-specific binding. 
 
The relative mobility of mutant protein on heterochromatic foci has been studied in 
cells by FRAP using murine fibroblasts transfected with EGFP-tagged MeCP2R133C. 
The residence half time over heterochromatin was reduced for MeCP2R133C at 12 
seconds compared to wild type protein (21 seconds), indicating reduced affinity for 
chromatin (Kumar et al, 2008). These figures were in agreement with a similar 
FRAP study using EGFP-tagged MeCP2 transfected into murine Mecp2-null 
fibroblasts (Schmiedeberg et al, 2009). In the second study the residence half time 
was approximately 22 seconds for wild type protein and approximately 15 seconds 
for MeCP2R133C. The advantage of the second study was that there was no competing 
endogenous MeCP2. Therefore by FRAP, there is a modest reduction in the affinity 
of EGFP-tagged MeCP2R133C for heterochromatin that would be compatible with the 
apparently normal pattern of localisation to foci seen in fixed cells. 
 
Agarwal and colleagues measured the ability to cluster chromatin as well as the 
association with heterochromatic foci using murine myoblasts transfected with 
EGFP-tagged MeCP2 constructs (Agarwal et al, 2011). They found a subtle but 
significant reduction in the relative amount of MeCP2R133CEGFP accumulated in the 
heterochromatic dots versus the nuclear background (3.6 vs 5 for wildtype). Then 
taking the mean number of foci as a proxy measure of heterochromatin clustering, 
they found that the clustering ability of MeCP2R133CEGFP was modestly impaired, with 
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a median number of 13 chromocentres per cell, compared to 11 with wild type 
MeCP2.  
 
Taken together, these results indicate that there are subtle reductions in MeCP2R133C 
localisation to and condensation of chromatin in some cellular assays that are not 
detected in vitro. 
1.8.4 Binding to hmC 
Mellen et al presented compelling data that human MeCP2(1-205)R133C binding to a 
multiply hydroxymethylated 120bp oligonucleotide probe from the BDNF promoter 
IV region was impaired by EMSA (Mellen et al, 2012). The authors made the case 
that this was a specific DNA binding impairment because an equivalent assay using a 
multiply methylated BDNF probe showed only a modest DNA binding impairment. 
They supported this data with surface plasmon resonance assays where biotinylated 
probes that were either unmethylated, methylated or hydroxymethylated were 
immobilised on parallel flow cells of a streptavidin-coated sensor chip. Exposure to 
full-length recombinant MeCP2 altered the steady state response of the flow cells. 
Binding curves were generated from the read-out following exposure to serial 
dilutions of recombinant protein. MeCP2R133C appeared to bind the 
hydroxymethylated probes non-specifically and had a maximum binding capacity of 
just 25% that of wild type protein. In contrast the maximum binding capacity for the 
methylated probes was 76% of the wild type value, which was not a statistically 
significant reduction. This differential result was at odds with the rest of the 
literature, which suggested a strong deficit in binding to methylated DNA. It was an 
intriguing finding: if MeCP2R133C lost only one of the binding capacities of MeCP2, 
then that could be the explanation for the resulting milder clinical picture of R133C 
Rett syndrome. 
1.8.5 Transcriptional repression 
The ability of MeCP2 to repress transcription has been measured using luciferase 
reporter constructs in Drosophila cells. The authors used two methylated promoters – 
one with a high level of transcriptional activity and one with a low level. They found 
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that MeCP2R133C could repress transcription with wildtype activity from both 
promoters (Kudo et al, 2003). 
1.9 Aims of this thesis 
The R133C mutation occurs in a critical region of MeCP2 that confers binding 
specificity yet results in a milder form of Rett syndrome in patients. The aim of this 
thesis is to create suitable models in which to study MeCP2R133C function to 
understand this paradoxical observation. The proposed models are (1) cultured 
neuronal cells and (2) a mouse. In this way, MeCP2 R133C function can be studied in 
cells and tissue relevant to Rett pathogenesis. Initially, it will be important to 
establish whether the R133C mutation results in a milder Rett-like phenotype in the 
male mouse in the absence of genetic heterogeneity and skewed XCI. The molecular 
defects of MeCP2R133C can then be investigated with particular attention to potential 
DNA binding deficits in order to resolve some of the inconsistencies reported in the 
literature. If DNA binding deficits are detected, the aim is to refine these as far as 
possible in terms of methylation status and sequence context using in vitro and in 
vivo techniques with the intention of understanding the relative importance of the 
different binding capacities of MeCP2. The overall aim is to determine the molecular 
basis of R133C Rett syndrome, thus advancing understanding of Rett pathogenesis 
and MeCP2 function. 
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2. Materials and Methods 
2.1 Cell culture 
2.1.1 Standard ES cell culture 
ES cells were grown at 37oC in 5% CO2 in sterile, tissue culture gelatinised plastic 
ware (Greiner). Standard ES cell medium comprised Glasgow minimum essential 
medium (Invitrogen) supplemented with 15% (v/v) fetal bovine serum (Hyclone), 
1mM sodium pyruvate, 50 µM β-mercaptoethanol, 2mM L-glutamine, non-essential 
amino acids (all Gibco) and recombinant human leukaemia inhibitory factor (a gift 
from J.Guy). Cells were passaged when around 80% confluent using Trypsin-EDTA 
(Gibco) in PBS. Sterile Dulbecco’s phosphate-buffered saline (PBS, Gibco) was used 
for cell washes. Cell number was estimated using a Scepter 2.0 Cell Counter 
(Millipore). 
2.1.2 ES cell targeting 
Wildtype ES cells were targeted with Mecp2 carrying the R133C mutation in order to 
establish a novel mouse line and differentiate mutant neuronal cells. A suitable 
targeting vector was kindly supplied by J.Guy (Lyst et al, 2013). It contained Mecp2 
exons 3 and 4 with the coding sequence of enhanced green fluorescent protein 
(EGFP) fused in frame to the end of Mecp2 exon 4 with a downstream neomycin 
resistance (NEO) cassette. Point mutation, R133C was introduced by C.Merusi using 
the QuikChangeII XL Site-Directed Mutagenesis Kit (Agilent Technologies). The 
vector was linearised at the 5’ end with SnabI (NEB). Gene targeting was performed 
on E14 TG2a ES cells, derived from the mouse 129/Ola substrain. ES cells (2 x 107) 
were transfected with 30µg linearised targeting vector in 600µl of HEPES buffered 
saline by electroporation (240V, 500µF, BioRad Gene Pulser), left for ten minutes on 
ice, then plated at 5×106 or 2.5x106 cells per 10cm dish on day zero. Cells were 
selected by culturing in standard ES medium supplemented with 350µg/ml G-418 
(Roche) from day one then 150 µg/ml G-418 from day three. Colonies were picked 
on day nine into a 96 well plate. On reaching confluence, cells were split into two 96 
well plates. One plate was frozen down in standard culture medium adjusted to 20% 
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(v/v) FBS, 5% (v/v) dimethyl sulfoxide (Sigma) and the other was used for 
screening. 
2.1.3 NEO cassette deletion 
A pCAGGS vector that expressed Cre recombinase (Cre) under the control of the 
CAG promoter was used for transfection. The expression vector (20µg) was 
resuspended in 800µl of HEPES buffered saline and 1x107 ES cells were transfected 
by electroporation (220V, 950µF, Biorad Gene Pulser). Cells were left for ten 
minutes at room temperature then resuspended in 18ml of standard ES medium and 
split equally between two 10cm dishes. Cells were fed the following day then split at 
low density to 1000 cells per 10cm dish in order to establish colonies derived from 
single ES subclones. After seven days in standard ES medium colonies were suitable 
for picking into a 96 well plate. They were immediately disaggregated and split into 
“master” and “selection” plates. The master plate was cultured in standard ES 
medium. The selection plate was grown on the following day in standard ES medium 
supplemented with 350µg/ml G-418 in order to reveal ES cell subclones that were 
now sensitive to the antibiotic and therefore had successfully had their floxed NEO 
cassette deleted by Cre. Such clones were expanded from the corresponding well of 
the “master” plate and used for neuronal differentiation. 
2.1.4 Neuronal differentiation 
ES cells were trypsinised and 4 x 106 cells were plated in 10cm bacterial dishes 
(Greiner) in embryoid body (EB) medium (standard ES cell medium with 10% (v/v) 
fetal bovine serum and no LIF). Medium was changed every two days. Four days 
after plating, new EB medium was supplemented with 5µM retinoic acid to 
encourage neuronal differentiation. Eight days after plating the EB’s contained 
neuronal precursor cells. They were washed in PBS and disaggregated with fresh 
trypsin solution (0.05% (w/v) trypsin (Sigma), 1mM EDTA in PBS). The reaction 
was quenched with 10ml of EB medium and cells were pelleted for five minutes at 
100 x g. The neuronal precursor cells were resuspended in N2 medium (advanced 
Dulbecco’s modified Eagle medium, nutrient mixture F12, N2 supplement, 
100units/ml penicillin and 100µg/ml streptomycin, (all Gibco)) and passed through a 
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40µm cell strainer (BD Falcon). Cells were counted, pelleted for five minutes at 100 
x g then resuspended in an appropriate volume of N2 medium to be plated at 1.5 x 
105 cells/cm2. This was designated day zero. Culture dishes were washed with sterile 
water (Corning) and pre-treated with 0.1mg/ml poly-DL-ornithine (Sigma) in 30mM 
boric acid pH 8.3 48 hours before plating neuronal precursors. The day before 
plating, dishes were washed three times in sterile water and treated with 2µg/ml 
laminin (Roche) in PBS. This was washed briefly with PBS prior to plating. On day 
one, medium was replaced with 1:1 N2:Neurobasal medium (Neurobasal medium, 
B27 supplement, 100units/ml penicillin and 100µg/ml streptomycin, Gibco). On day 
three, half the medium was removed and replaced with Neurobasal medium. Neurons 
were harvested on day six. 
2.2 The R133C-GFP mouse 
2.2.1 Generation of the R133C-GFP mouse line 
Correctly targeted ES cell clones with the NEO cassette still present were injected by 
J.Selfridge into blastocysts from C57BL/6J females 3.5 days after natural mating. 
Injections were performed in M2 medium (Sigma) with 10–15 ES cells being 
injected into each blastocyst before 6-12 were transferred to pseudopregnant 
recipient C57BL/6J females. Chimaeric pups were identified by agouti coat colour. 
On maturity, chimaeras were mated with C57BL/6J mice expressing Cre under the 
cytomegalovirus promoter to establish germline transmission and simultaneously 
delete the NEO cassette. Mice were then back-crossed for five generations onto a 
C57BL/6J genetic background (with the aid of C57BL/6J single nucleotide 
polymorphism analysis after four back-crosses). Unless otherwise stated, all mice 
used for biochemical analysis were 6 weeks of age. 
2.2.2 Mouse phenotypic scoring & growth 
Mice were weighed and scored for RTT on a weekly basis at the same time and in 
the same room. Scoring of symptoms was performed on the bench worktop and was 
done blind to the genotype of the mice. Six parameters were examined (activity, gait, 
hind-limb clasping, tremor, breathing and general condition) and given a score 
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between 0 and 2 (Guy et al, 2007; See Appendix 1). Given the slower and subtler 
development of the phenotype compared with Mecp2-null male mice, two 
intermediate scores (0.5 and 1.5) were utilised (Cheval et al, 2012). Animals scoring 
2 for tremor, breathing or general condition, or those having reached the severity 
limit of the experiment according to the Home Office License, were automatically 
culled. 
2.2.3 Behavioural analysis 
R133C-GFP male mice were subjected to a battery of four behavioural tests at 9-10 
weeks and 20-21 weeks. Female behavioural analysis was done at 1 year. Mice were 
assigned an animal unit number at birth so that they could be identified. Behavioural 
testing followed the chronological order of these numbers and so was random in 
relation to genotype. Firstly, mice underwent the elevated plus maze in order to 
assess anxiety level. Animals were placed individually in a cross-shaped maze 65cm 
above the floor with two open arms (20 x 8cm), two closed arms (20 x 8 x 25cm) and 
a central area (8 x 8cm). The experimenter left the room during trials, which were 15 
minutes long and conducted in uniform dim lighting. Mice were tracked using ANY-
maze software (Stoelting). The total time spent in open and closed arms along with 
the number of arm entries was recorded. If mice jumped from the maze during the 
trial, the trial was stopped and restarted a maximum of two times. If a mouse jumped 
from the apparatus three times, the data was discounted. 
 
Secondly, in order to assess motor strength and coordination, mice underwent the 
hanging wire test. Animals were suspended from a 1.5mm diameter wire, 35cm 
above the bench worktop. The latency to bring one hindpaw up to grasp the wire was 
timed. An average time was taken from three trials, with an inter-trial interval of 15 
minutes. Trials lasted for a maximum of 30 seconds. 
 
Thirdly, mice underwent the open field test to assess anxiety and locomotor activity. 
Animals were placed individually in the centre of a 50x50cm square arena in uniform 
dim lighting. The experimenter left the room for the trial of 20 minutes. Mice were 
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tracked using ANY-maze software. The total time spent in the centre, total distance 
travelled, mean speed and time spent immobile were recorded. 
 
Finally, to assess motor coordination and learning, mice underwent the accelerating 
rotatrod. Mice were trained to run on a 3cm diameter rod rotating at 4 revolutions per 
minute (RPM) on day one. If they fell, they were replaced on the rod over a 30 
second period. Following this, there were three experimental days. Each day, mice 
completed four 5-minute trials, separated by an hour. During the trials, the rod 
accelerated between 4RPM and 40RPM and latency to fall was recorded. 
2.3 DNA manipulation 
2.3.1 Genomic DNA extraction 
For screening of 96 well plates, ES cells were incubated in lysis buffer (100mM Tris 
HCl pH 8.5, 5mM EDTA, 0.2% (w/v) SDS, 200mM NaCl, 0.1mg/ml proteinase K) 
for 24 hours at 37oC. Following incubation, DNA was precipitated with 1 volume of 
isopropanol and retrieved by centrifugation. Pellets were washed in 70% (v/v) 
ethanol before being dissolved in 50µl TE (10mM Tris HCl, 1mM EDTA; pH 8). 
 
Otherwise, ES cells were pelleted by centrifugation, washed with PBS and incubated 
in lysis buffer (10mM Tris HCl pH 8, 400mM NaCl, 3mM EDTA, 1% (w/v) SDS, 
0.4mg/ml proteinase K) overnight at 37oC. The following day, 100µg/ml RNAseA 
was added for one hour at 37oC. Samples were briefly centrifuged and the 
supernatant was treated with phenol/chloroform/isoamyl alcohol (1:1). Following 
centrifugation, DNA was precipitated from the aqueous phase using 1 volume of 
isopropanol, pelleted by centrifugation and washed with 70% (v/v) ethanol, before 
being air-dried and dissolved in TE. 
 
Frozen mouse half brains were homogenised in phosphate buffered saline (140mM 
NaCl, 3mM KCl, 2mM KH2PO4, 10mM Na2HPO4, (PBS)) then genomic DNA was 
prepared using the Gentra Puregene Tissue Kit (Qiagen) according to manufacturer’s 
instructions. DNA was cleaned up by phenol/chloroform/isoamyl alcohol (1:1) 
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extraction. Following centrifugation, DNA was precipitated from the aqueous phase 
by adding 1/10th volume of 3M NaOAc pH 5.2 and 2.5 volumes of ice-cold ethanol, 
pelleted by centrifugation and washed in 70% (v/v) ethanol before being air-dried 
and dissolved in TE. 
2.3.2 Measurement of DNA concentration 
DNA concentration was measured at OD260nm and OD280nm on a Nanodrop-1000 
spectrophotometer (Thermo Scientific) and an automated concentration reading was 
calculated using Beer’s law: concentration (ng/µl) = (absorbance OD260nm x 
extinction coefficient dsDNA 50ng/µl/cm)/pathlength cm. Purity was determined by 
the OD260nm:OD280nm ratio. Values ≥1.8 indicated a lack of protein or phenol 
contaminants. 
2.3.3 Restriction digestion 
DNA was digested by restriction endonucleases according to manufacturer’s 
instructions (NEB). Typically, DNA was digested using 6 units of enzyme per µg 
DNA with corresponding dilution buffer and 100µg/ml bovine serum albumin (if 
appropriate) in 20µl reactions for 1-2 hours at 37oC.  
2.3.4 DNA electrophoresis 
DNA was loaded onto agarose gels using Orange G buffer (0.033% (w/v) orange G, 
2% (w/v) Ficoll, 20mM EDTA pH 8, 0.7% (w/v) SDS) and resolved by 
electrophoresis at 120 volts (Sub-cell system, Bio-Rad). Agarose gel concentration 
0.8-2% (w/v) and appropriate ladders in supplied loading buffer were selected 
(NEB/Bioline) depending on the size of DNA fragments to be resolved. Gels were 
prepared with Tris-acetate EDTA (40mM Tris-acetate, 1mM EDTA (TAE)) and 
0.5µg/ml ethidium bromide as an intercalating agent, so that DNA could later be 
visualised using UV light. 
2.3.5 Standard polymerase chain reaction (PCR) 
PCR was primarily used to screen ES cell colonies firstly for homologous 
recombination of the R133C-GFP targeting vector and secondly to check for absence 
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of the NEO cassette following NEO deletion; to amplify genomic DNA prior to 
Sanger sequencing; in bisulfite sequencing firstly to amplify selected genomic 
regions of interest from mouse brain bisulfite-treated genomic DNA then secondly to 
screen bacterial colonies for presence of the bisulfite-treated PCR product following 
transformation; and also to test qPCR primers. 
 
For homologous recombination screening, 1µl of genomic DNA was added to 0.625 
units of Go Taq Polymerase with 1x Green Go Taq buffer (Promega), 200µM 
deoxynucleotide triphosphates (Thermo Scientific) and 0.5µM primers in 25µl on 
ice. Cycling conditions comprised an initial 5-minute denaturation at 95oC, then 38 
cycles of 1-minute denaturation at 95oC, 1-minute annealing at 61oC and 2 minutes 
10 seconds of extension at 72oC. There was a final 5-minute extension at 72oC. 
 
For NEO cassette screening, approximately 100ng of genomic DNA was added to 
3mM MgCl2, 0.5µm primers, 200µM deoxynucleotide triphosphates, 1 x reaction 
buffer IV and 2.5 units of Red Hot Taq (Thermo Scientific) in 50µl reactions. 
Cycling conditions were a 5-minute denaturation at 94oC followed by 35 cycles of a 
30-second denaturation at 94oC, 45-second annealing at 64oC and 1 minute 30-
second extension at 72oC. There was a final elongation step of 5 minutes at 72oC. 
 
Bacterial colony PCR, qPCR primer screening and amplification of bisulfite-treated 
genomic DNA all employed 1x DreamTaq Green PCR mastermix (Thermo 
Scientific) and 0.25µM primers. PCR conditions were individualised for specific 
primer pair melting temperatures and size of desired PCR product. A temperature 
gradient was employed to determine optimal annealing temperatures for new primer 
pairs (G-storm thermal cycler). Cycle number was 40 for general purposes except 
bacterial colony PCR, which was 25 cycles. Denaturation conditions were 1 minute 
at 95oC initially and during cycles. There was also a final extension step at 72oC for 5 
minutes. 
 
PCR amplification of bisulfite-treated chromatin immunoprecipitated DNA utilised 
JumpStart REDTaq polymerase (Sigma Aldrich), which has a high tolerance for 
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uracil in the sequence to be amplified. The 50µl reactions contained less than 50ng of 
DNA, 1x JumpStart REDTaq buffer, 2.5 units of JumpStartREDTaq, 0.25µM 
primers and 200µM deoxynucleotide triphosphates. Cycling conditions were 1 
minute of denaturation at 94oC, then 40 cycles of 30-second denaturation at 94oC, 
30-second annealing at 60oC and 1-minute extension at 72oC, with a final 5-minute 
72oC elongation step. 
 
PCR products were usually analysed by agarose gel electrophoresis. 
2.3.6 Real-time quantitative PCR (qPCR) 
Real-time qPCR of cDNA was used to determine relative levels of mRNA transcripts 
in neurons differentiated in culture and male mouse whole brain or cerebellar tissue. 
SYBR green technology was used where the amount of amplified DNA is 
determined from the integration of the green fluorescent dye during the reaction. 
25ng (neurons) or 50ng (mouse brain or cerebellum) of template cDNA was 
combined with 0.25µM primers and 1x SensiMix SYBR & Fluorescein Master Mix 
(Bioline) in a 12.5µl reaction volume. Cycling reactions on a Roche Lightcycler were 
as follows: 5 minutes denaturation at 95oC then 45 cycles of 15-second denaturation 
at 95oC, 15-second annealing at 60oC and 20-second extension at 72oC (with a single 
acquisition at 522nm taken at the end of the extension phase). Melting curve analysis 
followed where the temperature was increased from 60oC to 95oC at a rate of 
0.11oC/second with continuous acquisitions. A single melting curve indicated the 
presence of one PCR product and absence of non-specific products that would 
interfere with quantification. Cycle threshold (Ct) values were determined for each 
sample by Roche lightcycler software using the second derivative maximum method. 
A standard curve was calculated for all primer pairs in every qPCR run using dilution 
of input material. An average Ct value for each dilution was plotted against a log 
transformation of an arbitrary number corresponding to the dilution factor. The slope 
of the standard curve was used to calculate the efficiency of the reaction (a slope 
between -3.6 and -3.3 indicated 90-100% efficiency). The standard curve equation: 
y= ax + b was used to transform the Ct values for samples by calculating a “real 
amount” = (Ct value – b)/a. This log of this real amount was then calculated, before 
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taking an average value from replicate wells for that sample (duplicate or triplicate). 
The Ct value was normalised to a housekeeping or control gene. The standard 
deviation was calculated from: √([standard deviation/average for gene of interest]2 + 
[standard deviation/average for housekeeper]2). 
 
Real time qPCR was also used to determine the relative abundance of genomic 
regions of interest in input DNA and chromatin immunoprecipitated DNA in neurons 
differentiated in culture and male mouse whole brain tissue. Under these 
circumstances, 2.5µl of template and 0.5µM primers were combined with 1x 
SensiMix SYBR & Fluorescein Master Mix (Bioline) in a 12.5µl reaction volume. 
Cycling reactions were as follows: 10-minute denaturation at 95oC, then 45 cycles of 
1-minute denaturation at 95oC, 15-second annealing at 60 or 62oC (depending on the 
primers) and a 20-second extension at 72oC. Melting curves and Ct values were 
calculated as above. 
2.3.7 Southern blot 
Southern blot was employed as a second screen for homologous recombination of the 
R133C-GFP targeting vector and also to check that the NEO cassette had been 
deleted from the targeted locus following exposure to Cre. For screening of 96 well 
plates, 25µl of genomic DNA was digested with 30 units of KpnI. Otherwise, 
approximately 15µg of ES cell DNA was digested with BamHI (for the 5´ end of the 
locus) or KpnI (for the 3´ end of the locus) in 40µl reactions. Digested DNA was 
resolved by electrophoresis at 1.5V/cm on a 0.8% (w/v) TAE agarose gel. The DNA 
was depurinated with 0.25M HCl for 15 minutes, rinsed with water then denatured in 
0.4M NaOH for 45 minutes. It was then transferred overnight by dry blot to a Zeta-
Probe GT Nylon Blotting Membrane (Bio-Rad), which had been pre-wet and 
incubated in NaOH for ten minutes. Blots were washed twice in 2xSSC (300mM 
NaCl, 30mM Na3C6H5O7, pH 7) before being blocked by modified Church & Gilbert 
hybridisation buffer (0.5M NaPi, 7% (w/v) SDS, 1mM EDTA, 10mg/ml BSA, 
50µg/ml herring sperm ssDNA (Sigma)) at 65oC for 30 minutes. For screening at the 
5’ end and 3’ end, DNA was probed with a 1.15-kb HindIII fragment or 1.1kb NcoI-
BamHI fragment, respectively. Approximately 30ng of probe was labelled with P32, 
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incorporated into cytosine nucleotides using the Megaprime DNA Labelling System 
(GE Healthcare) according to manufacturer’s instructions. Radiolabelled probes were 
added to 40ml hybridisation buffer and hybridised overnight at 65oC. Blots were 
washed in 3xSSC (450mM NaCl, 45mM Na3C6H5O7, pH 7) and 1xSSC (150mM 
NaCl, 15mM Na3C6H5O7, pH7) then remaining activity checked with a Geiger 
counter, before being visualised by phosphorimagery (Typhoon FLA 9500). 
2.3.8 Sequencing 
Approximately 50ng DNA corresponding to regions of interest was sequenced using 
2µl BigDye Terminator v3.1 ready reaction mix (Applied Biosystems) and 3.2 
picomoles of primer in 10µl reactions. Cycling conditions were: 1 minute of 
denaturation at 96oC, then 25 cycles of 10 seconds of denaturation at 96oC, 5 seconds 
for annealing at 50oC and 4 minutes of extension at 60oC. Sequencing was completed 
by the University of Edinburgh Genepool facility. 
2.3.9 Bisulfite sequencing 
Bisulfite sequencing was used to determine the methylation status of genomic 
regions used in chromatin immunoprecipitation (ChIP) and DNA that was 
immunoprecipitated with MeCP2 during ChIP in mouse brain.  
 
For genomic DNA, 2µg was bisulfite converted using the EpiTect Bisulfite Kit 
(Qiagen) according to manufacturer’s instructions. In brief, DNA was incubated at 
60oC and low pH (approximately 5) in the presence of sodium bisulfite to convert 
unmethylated cytosines to uracil, before being washed, desulfonated and purified. 
Approximately 50ng of converted DNA was amplified by PCR. The PCR product 
was gel analysed then bands of the correct size were cut out and purified using the 
Zymoclean Gel DNA Recovery Kit (Zymo Research), according to manufacturer’s 
instructions. Recovered product was blunted and ligated (in 3 molar excess) into the 
pJET1.2/blunt vector using the CloneJET PCR Cloning Kit (Thermo Scientific) 
according to manufacturer’s instructions. Competent DH5α E.coli (50µl) were 
transformed with 2.5µl of ligation reaction. For transformation, DNA was added to 
bacteria for 20 minutes on ice, heat-shocked at 42oC for 45 seconds, incubated on ice 
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for 2 minutes then grown in 0.9ml sterile Super Optimal broth with Catabolite 
repression (SOC) medium (20g/l bacto-tryptone, 5g/l bacto-yeast extract, 10mM 
NaCl, 2.5mM KCl, 10mM MgCl2, 10mM MgSO4, 20mM glucose, pH 7) at 37oC for 
1 hour. Cells were plated on Luria Bertani broth agar (10g/l bacto-tryptone, 5g/l 
bacto-yeast extract, 20mM NaCl, 20g/l bacto-agar, pH 7) with 50µg/ml ampicillin 
overnight at 37oC. Colonies containing inserts were identified by growth on the 
plates, as recircularised vector expressed a lethal restriction enzyme. Inserts were 
PCR amplified from single colonies using pJET1.2 specific primers. 5µl of PCR 
reaction was resolved by agarose gel electrophoresis and reactions containing cloned 
fragments corresponding to the correct size were treated with 5 units of Exonuclease 
I (NEB) and 5 units of Antarctic Phosphatase (NEB) for 15 minutes at 37oC. 
Enzymes were then heat inactivated at 80oC for 15 minutes, before 3µl of reactions 
were sequenced. Sequencing data was aligned using Lasergene Software version 
12.0.0 and data analysis performed with BiQ-Analyser software (Bock et al, 2005). 
 
The protocol above was followed for methylation analysis of input and ChIP DNA 
from the 1-minute formaldehyde cross-link conditions in adult male mouse brain 
with the following modifications: (1) DNA was concentrated using the Agencourt 
AMPure XP Purification system (Beckman Coulter) prior to bisulfite conversion, (2) 
approximately 120ng of DNA was bisulfite converted, (3) approximately 12ng of 
converted DNA was PCR amplified using site-specific primers and (4) 5µl of PCR 
product was gel analysed, but the rest was purified using MSB Spin PCRapace 
(STRATEC Molecular), prior to blunting and ligation into pJET1.2/blunt. 
2.4 RNA manipulation 
2.4.1 RNA extraction 
RNA was extracted from cells and tissues for the purposes of estimating relative 
mRNA transcript abundance by qPCR and microarrays. 
 
ES cells, corresponding neuronal precursors and neurons differentiated in culture 
were mixed thoroughly with Tri Reagent (Sigma) by pipetting at a ratio of 1 x 107 
 89 
cells: 1ml Tri Reagent. Frozen half brains were homogenised in 3ml Tri Reagent 
with the Ultra Turrax T25 for 15 seconds. After sitting at room temperature for 5 
minutes, 0.1ml of 1-bromo-3-chloropropane was added per ml of Tri Reagent, then 
samples were vortexed for 15 seconds before standing at room temperature for 15 
minutes. Samples were then centrifuged at 12,000g for 15 minutes at 4oC and the 
aqueous phase was transferred to new tubes. Due to excess fatty tissue in the aqueous 
phase, whole brain RNA was cleaned up by re-extraction with 1 volume of 
chloroform, followed by another centrifugation step. RNA was precipitated with 
0.5ml of isopropanol per ml of Tri Reagent: samples were mixed vigorously, left for 
10 minutes at room temperature, then centrifuged at 12,000g for 10 minutes at 4oC to 
pellet RNA. Pellets were washed with 75% (v/v) ethanol before being dissolved in 
nuclease free water (Ambion). 
 
RNA extracted from 6-week male mouse cerebella was homogenised in 1ml of Tri 
Reagent with the Ultra Turrax T25 and cleaned up following isolation with the 
RNeasy Mini Kit (Qiagen) according to manufacturer’s instructions. In brief, RNA 
was diluted in a buffer containing ethanol then bound to a silica-based membrane 
while contaminants and remaining genomic DNA were washed away. Molecules 
greater than 200 nucleotides in length were purified therefore there was enrichment 
for mRNA. 
2.4.2 Measurement of RNA concentration & integrity 
RNA concentration was measured at OD260nm and OD280nm on a Nanodrop-1000 
spectrophotometer (Thermo Scientific) and an automated concentration reading was 
calculated using Beer’s law with extinction coefficient for ssRNA 40ng/µl/cm. Purity 
was determined by the OD260nm:OD280nm ratio. Values ≥2.0 indicated a lack of protein 
or phenol contaminants. 
 
Quality of cerebellar RNA was verified on the Agilent 2100 Bioanalyser by on-chip 
gel electrophoresis. This system uses integration of fluorescent dye and generation of 
electropherograms to detect the size and quantity of the migrating species with 
reference to a standard RNA 6000 ladder (Ambion) and marker. The RNA integrity 
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number (RIN) (which took the entire electropherogram trace into account) indicated 
RNA quality. A RIN of ≥8 was deemed good quality. 
2.4.3 cDNA synthesis 
RNA intended for qPCR was DNAse treated using the DNA-free kit (Ambion) then 
500ng (cells differentiated in culture) or 1µg (mouse brain tissues) was reverse 
transcribed using the iScript cDNA Synthesis Kit (Biorad) in a reaction volume of 
20µl. Cycling conditions were 5 minutes at 25oC, 30 minutes at 42oC then 5 minutes 
at 85oC. Reactions containing everything except the iScript reverse transcriptase 
were included to control for potential contamination of DNA. Resulting cDNA was 
diluted in 100µl of nuclease free water (Ambion) and 5µl was used per reaction in 
qPCR. 
2.5 Protein manipulation  
2.5.1 Site directed mutagenesis 
A recombinant human MeCP2 (amino acids 1-205) expression vector was 
constructed with a C-terminal histidine tag using the bacterial expression plasmid, 
pET30b (Novagen) by Dr R Klose (Klose et al, 2004). MeCP2(1-205) expression 
was therefore under control of the T7 promoter. The R133C mutation was placed 
using the QuikChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies) 
as per manufacturer’s instructions. The PCR cycles included 6 minutes 10 seconds of 
elongation at 68oC. The mutated plasmid was isolated using the Qiagen Qiaprep Spin 
Miniprep kit. The presence of the R133C mutation was confirmed by sequencing. 
2.5.2 Expression of MeCP2(1-205) in E.coli 
BL21(DE3)pLysS E.coli were transformed with MeCP2(1-205) plasmids because the 
bacteria express T7 RNA polymerase from the lacUV5 promoter. Under basal 
conditions, this is minimised by the production of T7 lysozyme and lac repressor, but 
with the addition of isopropyl-β-D-thiogalactopyranoside (IPTG), expression can be 
strongly induced and reliably high transcription of MeCP2(1-205) was stimulated 
under control of the T7 promoter. 100µl of competent cells were transformed with 
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approximately 500ng of pet30bhMeCP2(1-205) and pet30bhMeCP2(1-205)R133C 
under the same conditions described in 2.3.9, then plated on LB with 15µg/ml 
kanamycin overnight at 37oC. Two scrapes of colonies were inoculated in 25ml LB 
medium (10g/l bacto-tryptone, 5g/l bacto-yeast extract, 20mM NaCl, pH 7) with 
50µg/ml kanamycin & 17µg/ml chloramphenicol and shaken overnight at 37oC. 
Cultures were inoculated in 500ml warm LB medium with 50µg/ml kanamycin & 
17µg/ml chloramphenicol and shaken at 37oC until the OD was 0.6-0.8 at 600nm. 
The addition of 1mM IPTG induced MeCP2 expression and cultures were transferred 
to 30oC for 3 hours. E.coli was pelleted by centrifugation at 6,700 x g, 4oC for 15 
minutes and stored at -80oC until use. 
2.5.3 Purification of MeCP2(1-205) 
Bacterial pellets were thawed on ice before being mashed in ice-cold lysis buffer 
(50mM NaH2PO4; 100mM NaCl; 10% glycerol; 30mM imidazole; 0.1% NP40; 2x 
protease inhibitor (complete EDTA free cocktail, Roche); pH 7.5) and passed 
through a 21G needle twice to break open cells. Following this, 750 units of 
benzonase were added before lysates were sonicated for 10 cycles of 30 seconds 
on/off, 30% amplitude on ice (Branson Digital Sonifier 450) to break down 
associated bacterial DNA. Sonicates were adjusted to 0.3M NaCl then spun down at 
31,000g, 4oC for 30 minutes. 
 
Chelating Sepharose Fast Flow beads (GE Healthcare) were washed in double 
distilled water then coated in nickel by rotating in 0.2M NiSO4 for 10 minutes. 
Coated beads were resuspended in 0.3M NaCl lysis buffer prior to use. Soluble 
protein was then precipitated from the sonication supernatant using its histidine tag 
by incubation with 0.5ml bead volume of nickel-coated beads for 1 hour at 4oC. 
Protein-bound beads were washed three times in ice-cold 0.3M NaCl lysis buffer to 
remove non-specific binding. Lysis buffer was prepared with 250mM imidazole, 
which would displace protein from the nickel-coated beads. Beads were resuspended 
in 0.5ml of this buffer for 1 minute on ice, spun down briefly and eluted protein was 
collected in five fractions. Eluted fractions were pooled, made up to 1mM EDTA, 
transferred to a Slide-A-Lyzer Dialysis Cassette 7K MWCO (Thermo Scientific) and 
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dialysed against HEPES buffer (20mM HEPES pH 7; 100mM NaCl; 1mM EDTA; 
5mM β-mercaptoethanol) overnight at 4oC in two steps. 
 
The protein underwent a further purification step by cation exchange 
chromatography using HiTRap SP Sepharose HP 1ml Columns (GE Healthcare). 
Protein bound to the negatively charged sulphopropyl coated agarose matrix was 
eluted with 0.7M NaCl in HEPES buffer. Protein concentration was measured and 
HEPES buffer was adjusted to 10% glycerol before snap freezing and storing 
suitably sized aliquots at -80oC. Protein purity was assessed using SDS PAGE after 
appropriate dilution and addition of loading buffer. 
2.5.4 Measurement of protein concentration 
Protein concentration was measured using a Bradford Assay. By this method, 
differential colour change of acidic Coomassie Brilliant Blue G-250 dye occurs in 
response to variable concentrations of protein, because protein binding to dye causes 
a shift in absorbance maximum from 465nm to 595nm. Bio-Rad protein assay dye 
reagent concentrate was diluted 1 in 5 in distilled, deionised water. Known quantities 
of bovine serum albumin (BSA) and known volumes of MeCP2 polypeptides were 
added to 1ml aliquots, vortexed briefly and left for 15 minutes at room temperature. 
OD was measured at 595nm and a standard curve was derived from BSA readings. 
Protein concentration was estimated from comparison to the resulting BSA standard 
curve. 
2.5.5 SDS-Polyacrylamide gel electrophoresis (PAGE) 
ES cell pellets were resuspended in ice-cold NE1 buffer (20mM HEPES pH 7.9, 
10mM KCl, 1mM MgCl2, 0.1% (v/v) Triton X-100, 20% (v/v) glycerol, 0.5mM 
DTT, complete protease inhibitor cocktail (Roche)) at a ratio of 8 x 104 cells per µl 
of NE1. Then 250 units of benzonase were added per 2 x 107 cells and samples were 
left for 15 minutes at room temperature before adding 1 volume of 2x SDS loading 
buffer (125mM Tris HCl pH 6.8, 20% (v/v) glycerol, 4% (w/v) SDS, 0.25% (w/v) 
bromophenol blue, 20mM DTT, 0.3M β-mercaptoethanol) to leave a final 
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concentration of 4 x 104 cells/µl. Samples were boiled for 3 minutes, spun briefly 
then 12.5µl was loaded onto a 4%-12% Run Blue SDS precast gel (Expedeon). 
 
For brain tissue, 6-week mice (adult) or postnatal day 0-2 (neonatal) were culled by 
cervical dislocation or decapitation, respectively. Brains were dissected, halved 
(adults) and snap frozen in isopentane on dry ice. They were stored at -80oC until 
use. Half adult or whole neonatal brains were dounce homogenised with 10 strokes 
in 750µl of ice-cold NE1 buffer. Then 750 units of benzonase were added for 15 
minutes at room temperature before adding 1 volume of 2x SDS loading buffer. 
After boiling for 3 minutes and a brief spin, 8µl was loaded onto 4%-12% Run Blue 
SDS precast gels (Expedeon). In the case of co-immunoprecipitation experiments, 
10µl of sample were loaded onto a 4-15% Mini-PROTEAN® TGX™ Gel (Biorad).  
 
Protein was resolved by electrophoresis at 120V for approximately 1 hour with 
PageRuler Prestained Protein Ladder (Thermo Scientific) in Rapid SDS Run Buffer 
(Expedeon). Co-immunoprecipitation gels were resolved in Tris-glycine SDS buffer 
(25mM Tris, 250mM glycine, 0.1% (w/v) SDS) at 270V for 30 minutes. 
2.5.6 Wet transfer of proteins to a membrane 
A Bio-rad mini trans-blot cell was used for wet transfer according to manufacturer’s 
instructions. The transfer cassette was assembled as follows: 0.2µm pore size 
nitrocellulose membrane (Biorad) was cut to size and soaked in water for 5 minutes 
then transfer buffer (25mM Tris, 192mM glycine) along with 3mm Whatman paper; 
two pieces of wet Whatman were placed in the cassette with air bubbles carefully 
removed by rolling; the membrane was added, followed by the protein gel after a 
rinse in transfer buffer and another two wet pieces of Whatman paper. The cassette 
was immersed in ice-cold transfer buffer and transferred at a constant current of 
400mA for 1 hour. Membranes were rinsed in Tris buffered saline (50mM Tris-HCl 
pH 8.0, 150mM NaCl (TBS)) briefly before western blotting. 
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2.5.7 Western blotting 
Membranes were blocked and agitated gently by rocking in 5% milk (w/v), 0.1% 
Tween-20 (v/v) in TBS (milk TBST) overnight at 4oC, or for one hour at room 
temperature. Primary antibodies were diluted in milk TBST as follows: anti-MeCP2 
1:1000 (mouse monoclonal, Sigma M6818), anti-Gamma tubulin 1:3000 (mouse 
monoclonal, Sigma T5326). They were incubated with the membrane for 4 hours at 
room temperature, or overnight at 4oC, with rocking agitation. The membranes were 
washed three times in 0.1% Tween-20 (v/v) in PBS (PBST) for 10 minutes. 
Secondary antibody was infra red dye-conjugated IgG (donkey anti-mouse 800, 
Licor 32212). It was diluted 1:10,000 in milk TBST and incubated with the 
membrane for 2 hours at room temperature. Following this, the blot was washed 
three times for 10 minutes in PBST and rinsed in PBS before imaging. 
 
For co-immunoprecipitation experiments, blocking solution contained 0.05% (v/v) 
Tween-20. Primary antibodies, anti-MeCP2 (mouse monoclonal, Sigma M6818), 
anti-HDAC3 (rabbit polyclonal, Santa Cruz Biotechnology SC-11417) and anti-
TBLR1 (rabbit polyclonal, Bethyl Laboratories A300 408A) were diluted in blocking 
solution at 1:1000. Secondary antibodies were horseradish peroxidase-conjugated.   
Anti-mouse or Anti-rabbit IgG (GE Healthcare NA931V or NA934V, respectively) 
was diluted 1:2000 in blocking solution. 
 
Standard western blots using infra red-conjugated secondary antibody were imaged 
using the Licor Odyssey Infrared Imager. Quantification of bands was performed 
using Image Studio Lite Software (Licor, version 2.1.10). For co-
immunoprecipitation experiments with HRP-conjugated secondary antibody, blots 
were treated with developing solution (100mM Tris HCl pH 8.8; 0.01% H2O2; 
1.5mM luminol; 0.25mM p-coumaric acid). The blot was dried, wrapped in saran 
and exposed to Hyperfilm ECL (Amersham Biosciences). 
2.5.8 Co-immunoprecipitation 
Frozen half brains from 6-week male mice were dounce homogenised with 10 
strokes in 1ml ice-cold NE1 buffer and pelleted at 800 x g for 5 minutes at 4oC. 
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Pellets were washed in NE1 then resuspended in 500µl NE1 with 375 units of 
benzonase for 10 minutes at room temperature. Samples were adjusted to 150mM 
NaCl and incubated at 4oC for 20 minutes. After centrifugation at 14,500 x g, 4oC for 
20 minutes, 30µl of supernatant was set aside from each sample for input. Equal 
volumes of supernatant were incubated with 5µl bead volume of anti-GFP antibody 
coupled to agarose beads (GFP-Trap_A, Chromotek) for 1 hour at 4oC in order to 
immunoprecipitate MeCP2EGFP and associated binding partners. Beads were then 
washed four times in 150mM NaCl NE1 to minimise non-specific 
immunoprecipitation, removing as much as possible from the beads following the 
final wash. All samples were then resuspended in 20µl of 2x SDS loading buffer 
(inputs in 30µl), boiled for 3 minutes, spun briefly and equal volumes were resolved 
by SDS PAGE. Following this, protein was transferred to nitrocellulose membranes 
and visualised by western blotting. 
2.6 Immunofluorescence 
Immunofluorescence was conducted to confirm expression of neuronal proteins in 
cells differentiated in culture and assess the pattern of MeCP2 association with 
heterochromatin in neurons differentiated in culture and mouse brain. 
2.6.1 Neurons differentiated in culture 
Neurons grown on coverslips were washed twice in PBS on day six before being 
fixed for 15 minutes with 3.7% (w/v) paraformaldehyde in PBS, pH 7.4. They were 
then washed three times with PBS, before being permeabilised for 15 minutes with 
0.1% (v/v) Triton X-100 in PBS then washed another three times in PBS. Coverslips 
were incubated for 20 minutes at room temperature in blocking solution (1.5% (v/v) 
goat serum (Sigma) in PBS). Primary antibodies were diluted in blocking solution as 
follows: anti-NeuN 1:300 (rabbit polyclonal, Millipore ABN78) and anti-
neurofilament 1:500 (mouse monoclonal, Covance SMI 311R) and applied for 1 
hour. Coverslips were washed three times in PBS then secondary antibodies were 
applied for 1 hour at a dilution of 1:400 in blocking solution (Alexa Fluor 594 goat 
anti-mouse IgG (Life A11032) and Alexa Fluor 633 goat anti-rabbit IgG (Life 
A21071)). Coverslips were washed with PBS then stained for 15 minutes with 
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1µg/ml DAPI, followed by another three PBS washes. Finally coverslips were 
mounted on slides using Prolong Gold Antifade Reagent (Molecular Probes). Slides 
were visualised on a Leica TCS SP5 Confocal Laser Scanning Microscope using 21-
slice z-stacks taken at 100x magnification, 8 bit resolution, with pixel size 512 x 512. 
Stacks were compressed using Image J software version 1.46. 
2.6.2 Cell dot quantification 
Intensity of DAPI fluorescence in neuronal nuclei was analysed with Image-Pro Plus 
Software version 7.0 using a macroinstruction programme written by D.Kelly. 
Firstly, nuclei were highlighted then could be selected manually in order to discount 
dead cells. The maximum intensity was defined across a field of cells by the brightest 
DAPI pixel. To be considered a “DAPI dot”, areas had to be 0.67 of this brightness 
and more than one pixel in area. The intensity of these “dot areas” was then 
measured on the corresponding GFP panel and compared to the average GFP 
intensity throughout the rest of the nucleus. These measurements were taken for 50 
cells per genotype. Dot prominence was calculated as the average GFP intensity of 
the dots/(the average GFP intensity of the dots + the average GFP intensity of the 
nuclear background) to give an estimate of how much MeCP2EGFP was located within 
the dot areas. 
2.6.3 Mouse brain 
Adult (6-12 week) mice were culled by cervical dislocation and rapidly perfused 
with 3.7% (w/v) paraformaldehyde in PBS, pH 7.4 injected into the left ventricle by 
J.Selfridge. The quality of the anti-MeCP2 signal appeared to be dependent on a 
rapid fix. Brains were then harvested and slowly fixed overnight in 
paraformaldehyde at 4oC. This solution was replaced with 30% (w/v) sucrose in PBS 
overnight to dehydrate the tissue. Following this step, brains were washed briefly in 
PBS then blotted dry, halved, snap frozen in isopentane cooled on dry ice and stored 
at -80oC until used. Sections were taken of 10µm thickness on the Leica CM 1900 
Cryostat and dried on slides at room temperature. Slides were rinsed in PBS then 
washed twice for 10 minutes in Coplin jars. Slices were permeabilised in 0.1% (v/v) 
Triton X-100 in PBS for 15 minutes, washed three times in PBS then blocked in 
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1.5% (v/v) goat serum in PBS for 1 hour at room temperature. Primary antibodies 
were diluted in this blocking solution as follows: anti-MeCP2 1:200 (rabbit 
monoclonal, 07_013 Millipore), anti-NeuN-Cy3 1:100 (mouse monoclonal, 
MAB377C3 Millipore). Sections were stained with primary antibodies overnight at 
4oC in a humidified chamber. Slides were washed in PBS three times then sections 
stained for 1 hour with secondary antibody at a dilution of 1:400 in blocking solution 
(Alexa Fluor 633, goat anti-rabbit IgG, Life A21071) if required. Finally, slides were 
washed for 10 minutes with PBS then sections stained for 10 minutes with 1µg/ml 
DAPI before two final 10-minute PBS washes. Coverslips were mounted on slides 
using Prolong Gold Antifade Reagent (Molecular Probes). Slides were visualised on 
a Leica TCS SP5 Confocal Laser Scanning Microscope using 21-slice z-stacks taken 
at 63x or 100x magnification, 12-bit resolution, with pixel size 512 x 512. Stacks 
were compressed using Image J software version 1.46. 
2.7 Chromatin extraction and immunoprecipitation 
Chromatin immunoprecipitation (ChIP) was performed in order to estimate binding 
of R133C-GFP relative to WT-GFP at selected regions in the genome with known 
methylation patterns. MeCP2EGFP was precipitated using an anti-GFP antibody 
mounted on agarose beads, GFP-Trap_A (Chromotek). 
2.7.1 Neurons differentiated in culture 
Day six neuronal cells were fixed with 360mM formaldehyde in PBS for 10 minutes 
at 37oC before quenching the cross-link with 125mM glycine in PBS for 5 minutes at 
room temperature, with gentle agitation. Dishes were washed twice with 5ml of ice-
cold PBS before cells were harvested by scraping. Neurons were pelleted by 
centrifugation at 350 x g, 4oC for 5 minutes then resuspended in WASH 1 (0.25% 
(v/v) Triton X-100, 10mM EDTA, 10mM EGTA, 10mM HEPES, protease inhibitor 
(complete EDTA free cocktail, Roche), 1µM PMSF). Samples were incubated for 10 
minutes on ice to allow swelling of cell membranes before centrifugation at 4oC. 
This was repeated with second wash, WASH 2 (200mM NaCl, 1mM EDTA, 10mM 
EGTA, 10mM HEPES, protease inhibitors, 1µM PMSF) in order to lyse the cell 
membrane, leaving nuclei in tact. The nuclear pellet was resuspended in lysis buffer 
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according to size (1% (w/v) SDS, 10mM EDTA, 50mM Tris HCl pH 8.1, protease 
inhibitors, 1µM PMSF) in order to lyse the nuclear membrane, resulting in a solution 
of cellular chromatin.  
 
Chromatin was sonicated for 15 cycles of 30 seconds on-off on high power using the 
Diagenode Biorupter Twin Sonicator in order to generate 250-400bp fragments. 
Debris was pelleted by centrifugation for 10 minutes at 4oC then the concentration of 
chromatin was measured. For ChIP, 50µg of chromatin was diluted 1 in 10 (170mM 
NaCl, 17mM Tris HCl pH 8.1, 1mM EDTA, 1.1% (v/v) Triton X-100, 0.01% (w/v) 
SDS) and 5µg was set aside for inputs. ChIP chromatin was pre-cleared for 1-2hours 
at 4oC with 30µl of blocked agarose beads (bab-20, Chromotek). Following removal 
of these beads by centrifugation at 4oC, 40µl of GFP-Trap_A slurry (washed in TE: 
10mM Tris HCl pH 8, 1mM EDTA) was incubated with the ChIP chromatin by 
rotation overnight at 4oC. 
 
Beads were washed for 4 minutes at 4oC in RIPA (150mM NaCl, 50mM Tris HCl 
pH 8.0, 0.1% (w/v) SDS, 0.5% (w/v) sodium deoxycholate, 1% (v/v) NP40), high 
salt buffer (500mM NaCl, 50mM Tris HCl pH 8.0, 0.1% (w/v) SDS, 1% (v/v) 
NP40), LiCl buffer (250mM LiCl, 50mM Tris HCl pH 8.0, 0.5% (w/v) sodium 
deoxycholate, 1% (v/v) NP40) followed by two TE washes. Between washes the 
beads were pelleted by centrifugation for 1 minute, 2,600 x g, 4oC. 
Immunocomplexes were eluted in 400µl of elution buffer (2% (w/v) SDS, 100mM 
Na2CO3, 10mM DTT), along with 200mM NaCl to reverse the cross-link. Elution 
buffer and NaCl was also added to inputs and samples were shaken overnight at 
65oC. DNA was extracted by adjusting to 10mM EDTA, 40mM Tris HCl pH 6.5, 
0.1µg/µl proteinase K for 1 hour at 55oC and removing proteins by phenol-
chloroform extraction. DNA was precipitated using NaOAc and ice-cold ethanol at -
20oC with 20µg glycogen as a carrier. DNA pellets were washed with 70% ethanol 
and dissolved in 200µl nuclease-free water. DNA from input samples was diluted 
1:20 (overall 1 in 200 dilution compared to ChIP samples) and 2.5µl was used for 
qPCR analysis. 
 99 
2.7.2 Whole mouse brain 
Frozen half brains (adult) or whole brains (neonate) were dounce homogenised with 
10 strokes in 1ml cold PBS. Cross-linking was either for 8 minutes at room 
temperature (standard), 1 minute at room temperature (short cross-link) or 1 minute 
straight from ice (stringent) with 355mM formaldehyde in PBS. Cross-link quench 
was either with 125mM glycine in PBS (standard) or 250mM glycine in PBS (short 
cross-link and stringent). The protocol was otherwise the same as for neuronal cells 
differentiated in culture with the following modifications: the chromatin was not pre-
cleared; ChIP samples were incubated with GFP-Trap_A for 1.5 hours at 4oC; and 
neonatal DNA was dissolved in 150µl nuclease-free water at the end of the protocol. 
2.7.3 ChIP-seq 
DNA libraries were prepared from the R133C-GFP short cross-link ChIP and input 
samples using the Nugen Ultralow Library System by S.Lagger. In brief, this 
involved ligation of unique barcoded adaptors onto the fragmented DNA and 
amplification by PCR. Libraries were sequenced at the Wellcome Trust Sanger 
Institute, Cambridge using Illumina Solexa high throughput paired end sequencing. 
The barcoded DNA was bound to complementary immobilised adapters on a flow 
cell. DNA was amplified generating clusters of identical amplicons, which were then 
sequenced. The unique barcoding meant that more than one sample could be 
processed in parallel in one flow cell lane. The sequencing data was analysed by 
S.Webb. MeCP2 ChIP summits (peaks of MeCP2 found in the ChIP sample 
compared to the input sample) were derived using the macs2 callpeaks algorithm 
with a minimum fold change of 1, maximum fold change of 30 and a p value cut off 
of 0.2. The maximum fold change meant that large counts were removed, as these 
tended to be artefacts, arising from the sequencing process. The ChIP summits were 
extended 4kb up- and downstream and divided into 20 nucleotide bins. Mean 
methylation density was calculated for CG and CA dinucleotides using a published 
bisulfite-seq data set from adult mouse frontal cortex (Lister et al, 2013). For each 
bin, the percentage methylation of individual cytosines (CG or CA) was summed and 
divided by 20. The mean bin methylation density was plotted for all summit regions. 
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2.8 Electrophoretic mobility shift assays (EMSA) 
EMSA’s were used to assess MeCP2(1-205) binding to methylation and 
hydroxymethylation in particular sequence contexts. Unphosphorylated single 
stranded oligonucleotides corresponding to the BDNF promoter region (plus 
complementary reverse strands) were obtained from Biocore and annealed by 
J.Connelly. In brief, oligonucleotides were resuspended in nuclease-free water, and 
600 picomoles of complementary pairs were boiled for 20 minutes in 150mM NaCl 
& 10mM Tris HCl pH 8. Tubes were allowed to cool slowly so that complimentary 
oligonucleotides annealed to form double-stranded probes. Probes were then radio-
labelled by adding 500ng to 2µl ATP gamma 32P, with 25 units of T4 polynucleotide 
kinase (PNK) and 1x polynucleotide kinase buffer (NEB). Reactions were incubated 
at 37oC for 30 minutes so that PNK could catalyse the transfer of phosphate from 
ATP to the probes. The radio-labelled probes were then extracted using the MinElute 
PCR Purification Kit (Qiagen), resuspended to a final concentration of 10ng/µl and 
stored at -20oC until used. 
 
Recombinant protein concentration was adjusted using ice-cold reaction buffer 
(0.1mg/ml BSA, 5% (v/v) glycerol, 0.1mM EDTA, 10mM Tris HCl pH 7.5, 150mM 
KCl) then added to 1µg polydeoxyadenylic-thymidylic acid competitor DNA 
(Sigma-Aldrich) and 1ng double-stranded 32P-labelled probe in reaction buffer with 
careful mixing. Reactions were incubated on ice for 20 minutes. Loading buffer was 
added (4% (v/v) glycerol, 2mM Tris HCl pH 7.5, 5mM NaCl, 0.0002% (w/v) 
Bromophenol Blue) and reactions were resolved by PAGE. EMSA gels were 10% 
(w/v) acrylamide:bis-acrylamide (29:1, Bio-rad), Tris Borate EDTA (45mM Tris-
borate, 1mM EDTA (TBE)), polymerised by ammonium persulphate with TEMED 
as a catalyst. Gels were self-poured using the Bio-rad Mini Protean-3 apparatus. 
Reactions were resolved by PAGE at 120V for 70 minutes in chilled TBE and 
visualised using phosphorimagery (Typhoon FLA 9500). Percentage of probe shifted 
was calculated using Image J software version 1.46. 
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2.9 Gene expression by microarray 
2.9.1 RNA library preparation and microarray 
RNA was prepared from 6-week male mouse cerebella and analysed as described in 
2.4.1 and 2.4.2. Libraries of copy RNA (cRNA) were prepared from 400ng using the 
Illumina Total Prep RNA Amplification Kit (Ambion). In brief, cDNA was prepared 
with reverse transcription using a T7 oligo(dT) primer, followed by second strand 
synthesis and degradation of remaining RNA using RNAse H. cDNA was column 
purified before undergoing in vitro transcription with T7 RNA Polymerase and 
biotin-nucleotide triphosphates to synthesize cRNA that was biotinylated. This 
biotinylated cRNA was column purified then sent to the Wellcome Trust Clinical 
Research Facility (WTCRF) in Edinburgh to be assessed for quality. The WTCRF 
staff then measured gene expression on MouseWG-6 v2 BeadChips (Illumina) using 
a direct hybridisation assay, where signal detection is dependent on streptavidin-Cy3. 
 
2.9.2 Analysis of microarray data 
Gene expression levels were analysed using the Bioconductor Limma package by 
S.Webb. Probes were removed from the analysis if they were detected in fewer than 
three samples and background correction, normalisation, transformation, differential 
expression analysis and annotation were performed on the remaining set following 
standard procedures (Ritchie et al, 2011). For genes with multiple probes, mean log 
fold changes were calculated. Genes were ordered by length based on the Ensembl 
GRCm39 release 79 annotations and divided into bins using a window of 400 genes 
and a sliding step of 80 genes. The mean log fold change was plotted against the 




Primers were resuspended in nuclease-free water (Ambion) at a concentration of 
100µM and stored at -20oC. 
 


































2.10.1 Real time qPCR of ChIP DNA 




Major Satellite*  GGCGAGAAAACTGAAAATCACG AGGTCCTTCAGTGTGCATTTC 
L1 LINE**  TTTGGGACACAATGAAAGCA CTGCCGTCTACTCCTCTTGG 
IAP Elements**   GAGATTGGACTTTTGACTTGT TGTGGCTTGCTCATAGATTAG 
BDNF  TTCGATTCACGCAGTTGTTC CTGAGCCAGTTACGTGACCA 
Cyp3a25  CAGGTTTGGGGTGTTGTGAA CTGCAGCTGTTGTGGGAG 
Cyp3a57  GTGCTGCTCTTACATGGCTG GTGGGGCTACAGTCTATGCT 
Cyp3a59  CCTGACTGGCTGCTCACTAT AGGCTGTGAACTATAGGAGCC 
Mad1|1  TGGTGAGACAGCCTTCTTCT GTGCCCCTCTGACCTCTG 
Egfl7  GCAGCTGGACCGAATTGATT TGCCCATCCCAGAAGAAGTT 
Olfr325  TCTTGGTTGCCTAGGAGACA GGTGGGTGTCAGAGAGTACC 
Cpa6  GCCAAGTACACCCTCTCCTT TTCTCTACAGGGTCCAGTGC 
Gata3  ACCCCTTTATTCCTCCGTGT CCAGGAGAGGGGTCGTTTAA 
 
*Skene et al, 2010 
**Brunmeir et al, 2010 
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2.10.2 Real time PCR of cDNA  





Cyclophillin A TCGAGCTCTGAGCACTGGAG CATTATGGCGTGTAAAGTCAC
CA 
   
Abhd1 TTGGCGTTGCTCTCTACTTG TCCAGGAAGGCCAGAAACT 
Aplf GGGGCAGACTGTGATAGGC AATGGCATGTCTTCTGGATACT
C 
Dag1 CTGCTGCTGCTCCCTTTC CCAGGCAGTGTTGAAAACCT 
Krt222 GCTCAGGCTGAACTCAAGGA GCCTGCAGGGAGTTCTCA 
Zfp428 GATGAAGACCTTTCCCCAGA GGGTCATCAGTGGTCTCCTCT 
Camk1d* CCTCTACCTGGTCATGCAACT TGTGTAAAACCCCTTCTCCACT 
Prkca* CTGGTGCTTGGGTTGAATG TAACTCCTGGGGCTGCAC 







Plekha5* ACAGGCTGTTAGTCCCCAGA GCCGTCTCAGCTTTATTAGCA 
Arhgap26* TGCACTTGCTTTTTGACAGG TTGGCAGGCGTACAAAGC 
Lrrc8d* CCAGGATGGAGGAGTGAAGT CGCAAGGGTAAACATTCCTG 
Ptprk* CATCAATGCTGCTCTTATGGAT GCAGTGGGTATTGTGTGACG 
Magi1* GGGAGGCTTGCTTCTACCTT TTCCGGAACACCTTGTGC 















*Gabel et al, 2015 
 
2.10.3 Bisulfite sequencing 




























BDNF TAGTTTTTAAGAGGAAAAGGGA AAAAAAACCAAAACAACCTC 
Bai3 













3. Construction of Mecp2R133C models 
3.1 Introduction 
Arginine 133 occupies a key position in the MBD of MeCP2, yet its mutation to 
cysteine results in a form of Rett syndrome that is at the milder end of the phenotypic 
spectrum (Leonard et al, 2003). Several laboratories have assessed the impact of the 
mutation on DNA binding. Findings have been variable, indicating that binding to 
methylated DNA is impaired (Ballestar et al, 2000) and in contrast, nearly 
indistinguishable from wildtype by alternative assays (Mellen et al, 2012). The 
degree of binding impairment has varied according to the protein species, fragment 
length, target probe and assay. No consistent conclusions can be drawn regarding the 
impact of this mutation on DNA binding from the previous literature.  
 
The explanation for this may lie in the choice of model system in which to study 
protein function. The R133C mutation in MeCP2 has only previously been studied in 
vitro or in non-neuronal cell types. ES cells and fibroblasts have been used in 
experimental paradigms where mutant protein was transfected or expressed from an 
artificial promoter at an alternative locus, on top of endogenous protein expression. 
Rett syndrome is a neuropsychiatric disorder and deletion of MeCP2 in the brain 
only is sufficient to cause RTT (Guy et al, 2001). MeCP2 is an abundant nuclear 
protein that binds methylated cytosines and is most highly expressed in neurons 
(Skene et al, 2010). It is appreciated that the methylome is quite unique in the mature 
nervous system, with a greater proportion of methylation occurring in a CAC context 
and a higher abundance of hmCpG than other tissues (Lister et al, 2013). Using more 
relevant model systems might yield more consistent conclusions regarding the 
impact of the R133C mutation on DNA binding, as well as other putative functions 
of MeCP2.  
 
ES cells can be differentiated into a homogeneous population of mature cells in 
culture (Bibel et al, 2004). If ES cells were targeted by homologous recombination 
with Mecp2 carrying the R133C mutation, they could be differentiated into a 
population of neuronal cells under defined culture conditions. Similar strategies have 
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been used previously with Mecp2-null ES cells (Li et al, 2013) and induced 
pluripotent ES cells from patient material (Marchetto et al, 2010). The major 
advantage is the clonal nature of the cells, thus eliminating the issue of potential cell 
type-specific effects obscured with the study of whole tissues (Sugino et al, 2014). 
MeCP2 would be abundantly expressed from the endogenous promoter with no 
competing alternative transfected species, in the context of a neuronal methylome. 
 
Mouse models of Mecp2 deficiency have been used extensively to study the impact 
of protein function in the whole organism, yielding interesting insights into the 
pathogenesis of Rett syndrome. For example, the seminal finding that replacement of 
the protein on an Mecp2-null background alleviates the Rett-like phenotype (RTT) in 
the mouse (Guy et al, 2007). The advantage of using a whole organism is that the 
interaction of the mutation and the phenotype can be studied. With mouse breeding 
protocols, it is possible to obtain a relatively homogeneous genetic background by 
backcrossing. This virtually eliminates confounding genetic variation when 
interpreting the impact of an individual mutation. In the mouse, unlike in patients, 
males with Rett syndrome survive into adulthood (Guy et al, 2001). In males, any 
manipulation of Mecp2 can be studied without the added complication of the 
individual’s pattern of XCI and its influence on phenotypic expression because there 
is no need for dosage reduction (Gibson et al, 2005). There are no existing mouse 
models of the R133C mutation. In this context, it would be possible to confirm 
whether the R133C mutation does result in a milder form of RTT than other Mecp2 
mouse models (Guy et al, 2001; Lyst et al, 2013), as is seen in patients (Cuddapah et 
al, 2014). This would yield important prognostic information for patients and provide 
a useful resource for trial of therapeutic interventions. 
 
The enhanced green fluorescent protein (EGFP) tag is widely used as a means of 
easily identifying a protein of interest due to its bright and reliable expression in 
comparison to wildtype GFP. There are obvious advantages to using the tag for 
microscopy in that fluorescence is stable, species-independent and there is no need to 
apply additional cofactors (Zhang et al, 1996). There are also reliable anti-EGFP 
antibodies commercially available, making immunoprecipitation of tagged proteins 
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in the context of chromatin, or in association with other protein complexes 
achievable. An Mecp2 targeting vector containing a C-terminal EGFP tag was 
selected for these reasons. 
 
The objective was to knock Mecp2R133C in to the endogenous locus in wildtype ES 
cells. The resultant protein would have a C-terminal EGFP tag and be expressed 
from the endogenous promoter. These targeted cells could be differentiated along the 
neuronal lineage or injected into blastocysts to create a homogeneous population of 
Mecp2R133C neuronal cells and an Mecp2R133C mouse model, respectively. Together, 
these would provide pertinent model systems in which to study the impact of the 
R133C mutation on MeCP2 function. 
3.2 Mecp2R133C targeting strategy 
The objective was to create ES cells that were targeted by homologous 
recombination with Mecp2 carrying the R133C mutation and a C-terminal EGFP tag. 
In this way, the effects of the mutation on the protein in neurons and mouse brain 
could be studied. A schematic of the desired protein with functional domains and 
putative AT hook motifs is shown in Figure 3.2. A suitable targeting construct 
created by J.Guy was available: a 7.2-kb plasmid subclone of mouse 129/Ola 
genomic DNA, including Mecp2 exon 3 and exon 4, had the coding sequence of 
EGFP fused in-frame to the end of the coding sequence of exon 4, followed by a 
LoxP-flanked neomycin resistance (NEO) cassette as a selectable marker (plus STOP 
codon), retaining the first 2 kb of the Mecp2 3′ untranslated region. The targeting 
construct is depicted in Figure 3.2, along with the wildtype locus. Point mutation 
R133C was introduced into the wildtype Mecp2EGFP targeting vector by C.Merusi. 
The C to T substitution engineered in codon 133, resulted in the R133C mutation, 
which was confirmed by Sanger sequencing (data not shown). The targeting vector 




Figure 3.2 Mecp2R133C targeting strategy 
 
(A) Schematic representation of MeCP2 protein resulting from ES cell targeting. Isoform e2 
is shown with a C-terminal EGFP tag. The major functional domains are shown: the 
methylated DNA binding domain (MBD) with position of the R133C missense mutation, the 
nuclear localisation signal (NLS) and the NCoR Interaction Domain (NID), along with three 
putative AT hooks.  
(B) Diagram depicting the targeting strategy by homologous recombination. Exons 2-4 (black 
boxes) and the 3’ untranslated region (UTR) of the endogenous Mecp2 locus are 
represented. The targeting vector is shown with the R133C mutation (R) in exon 4, C-
terminal EGFP coding sequence (green box) and floxed neomycin resistance cassette (fl 
NEO, grey box flanked by triangles) along with the targeted locus resulting from homologous 
recombination.  
3.3 Targeting of wildtype ES cells with Mecp2R133CEGFP (R133C-
GFP) 
After being linearised at the 5’ end by SnabI, wild type 129/Ola ES cells were 
electroporated and selected by culture in G-418 supplemented ES cell medium. 
Colonies that were resistant to the antibiotic were picked and screened by 
polymerase chain reaction (PCR), Southern blot and finally sequencing. PCR primers 
were designed that flanked the NEO cassette and the 3’ untranslated region, outwith 
the region that was included in the targeting vector (Figure 3.3A). The resulting PCR 
product of 2.2kb, should only be seen in ES cell clones correctly targeted by 
homologous recombination. A plate of colonies screened by PCR and resulting 2.2kb 




Figure 3.3 Successful targeting of wildtype ES cells with Mecp2R133CEGFP(R133C-GFP) 
 
(A) Maps of the wildtype and targeted loci are shown for reference including exons 2-4 (black 
boxes), EGFP tag (green box), floxed NEO cassette (grey box flanked by triangles) and 
R133C mutation (R). PCR primers (arrows), BamHI (B) and KpnI (K) restriction sites and 
Southern blot probes used to screen colonies are represented. 
(B) Screening by PCR showed correctly targeted clones. An ethidium bromide gel with the 
desired 2.2kb PCR product in 11% of picked colonies indicates homologous recombination. 
Positive control DNA is indicated (+). Clones A3 and B11, which were taken forward to make 
neurons and the mouse, are labelled in white lettering. 
(C) Clones A3 and B11 were screened for homologous recombination by Southern blot. 
Upper panel, screening at the 5’ end of the locus following BamHI digestion resulted in an 
8.8kb band at the targeted locus and a 10.8kb band at the wildtype (WT) locus. Lower panel, 
screening at the 3’ end of the locus following KpnI digestion resulted in an 8.5kb band at the 
targeted locus and a 4.6kb band at the wild type (WT) locus. 
 
Selected clones were then screened by Southern blot to check that the vector had 
been incorporated into the endogenous locus. Following digestion with BamHI, the 
5’ end of the locus was analysed. Digestion of the targeted locus would yield an 
8.8kb band in comparison to the 10.8kb band seen following digestion of the 
wildtype locus, due to the introduction of an additional BamHI site by the targeting 
construct (Figure 3.3A&C). Clones were also screened at the 3’ end following 
digestion with KpnI. The targeted locus yielded an 8.5kb band, whereas the wildtype 
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locus yielded a 4.6kb band. This was due to the introduction of the EGFP tag and 
floxed NEO cassette between KpnI restriction sites in the targeted locus (Figure 
3.3A&C).  Clones A3 and B11 were deemed correctly targeted following these two 
screening methods and so were also checked by Sanger sequencing (data not shown). 
The creation of two Mecp2R133CEGFP ES cell lines was confirmed. From here on in, 
the Mecp2R133CEGFP genotype will be referred to as R133C-GFP. 
3.4 Creation of an R133C-GFP mouse model. 
It was desirable to create a novel mouse line carrying the R133C mutation in order to 
study genotype-phenotype correlation and have access to mature brain tissue. Clone 
B11 was selected and injected into C57BL/6J mouse blastocysts by J.Selfridge. This 
was done prior to deletion of the NEO cassette so that cells had a lower passage 
number and spent less time in culture, thus reducing the opportunity to acquire 
additional random mutations of DNA. On average, 12 injected blastocysts were re-
implanted per female recipient, primed for pregnancy by being mated with sterile 
males. 
 
By using 129/Ola ES cells for targeting, it was apparent which resulting pups 
comprised a combination of the parent blastocyst cells and the targeted stem cells by 
nature of their mixed coat colour. Overall, from 9 surgeries, 11 chimaeras were 
generated. These chimaeras were test mated with C57BL/6J mice to establish 
whether the targeted cells had contributed to the germ line. The test breeding mice 
also expressed Cre recombinase under the cytomegalovirus (CMV) promoter, thus 
simultaneously excising the floxed NEO cassette from the endogenous locus. Germ 
line transmission was again apparent by the mixed (agouti) coat colour of the 
resulting pups. Mice were then back-crossed for a further four generations onto a 
C57BL/6J genetic background in order to minimise other sources of confounding 
genetic variation, before phenotypic analysis and harvesting of brain tissue. The 
injection strategy and breeding plan is depicted in Figure 3.4. The result was creation 
of a novel R133C-GFP mouse line on a C57BL/6J genetic background. Mutant pups 
were born at expected Mendelian ratios. 
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Figure 3.4 Creation of an R133C-GFP mouse model. 
 
The injection and breeding strategy for creation of the R133C-GFP mouse line is shown. 
First correctly targeted (green asterisk) male ES cells derived from the 129-Ola mouse strain 
were injected into 3.5 day old C57BL/6J blastocysts. Blastocysts were immediately re-
implanted into pseudo-pregnant females and successful integration into the developing 
embryo was determined by the birth of chimaeric pups. After one cross with C57BL/6J mice, 
it was apparent whether there was germ line transmission from chimaeras by the production 
of agouti pups. Mice were then back-crossed onto a C57/BL6J genetic background for 
further analysis. 
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3.5 Deletion of the NEO cassette from the R133C-GFP 
targeted locus 
Following the establishment of two ES cell clones correctly targeted with R133C-
GFP, it was necessary to delete the NEO resistance cassette from the targeted locus 
prior to neuronal differentiation, in order to avoid any undesirable effect it may have 
on protein expression or DNA binding. The appearance of the targeted locus 
following recombination is shown in Figure 3.5A, along with screening strategies. 
 
 
Figure 3.5 Deletion of the NEO Cassette from the R133C-GFP Targeted Locus 
 
(A) A map of the targeted locus is shown including exons 2-4 (black boxes), EGFP tag 
(green box), floxed NEO cassette (grey box flanked by triangles) and R133C mutation (R). 
PCR primers (arrows), KpnI (K) restriction sites and Southern blot probe used to screen 
colonies following recombination are represented. The targeted locus following exposure to 
Cre recombinase (+Cre) is shown with the remaining single LoxP site (triangle). 
(B) PCR screening for presence of the NEO cassette revealed a lack of 470bp product in the 
subclones of R133C-GFP ES cells transiently exposed to Cre. 
(C) Southern blot screening following KpnI digest showed that the probe bound a 5.5kb 
fragment in the subclones of R133C-GFP ES cells transiently exposed to Cre. Wildtype 
genomic DNA was probed for reference (WT). 
 
Targeted clones were transiently transfected with Cre plasmid by electroporation in 
order to excise the cassette. Post electroporation, cells were grown in normal ES cell 
medium at low density then colonies were picked and immediately split between two 
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plates, so that new sensitivity to G-418 could be assessed without killing the 
subclones. Sensitivity to G-418 indicated that the NEO cassette had been excised. 
Sensitive clones were screened by PCR: primers were within the NEO cassette and 
did not generate a 470bp product in correctly deleted subclones (Figure 3.5B). 
Secondly, clones were screened at the 3’ end of the locus by Southern blot following 
KpnI digest as described above. Subclones with the cassette deleted would now have 
a 5.5kb band using this method (Figure 3.5C). In this fashion, daughter subclones 
were established that did not carry the NEO resistance cassette. They were denoted 
by .1, for example A3.1 from A3. 
3.6 Differentiation of R133C-GFP ES cells into neuronal cells 
R133C-GFP ES cells were differentiated into neuronal cells in order to create a 
suitable model system in which to study the effects of the mutation on protein 
function. It was possible to differentiate wildtype (WT) ES cells and ES cells targeted 
with the wildtype Mecp2EGFP (which will be referred to as WT-GFP) in parallel for 
comparison. In this way, the effect of the EGFP tag and the R133C mutation could 
be determined. The differentiation strategy is shown in Figure 3.6A. R133C-GFP ES 
cells were cultured in embryoid body medium (which was essentially standard ES 
cell medium with no leukaemia inhibitory factor and lower fetal bovine serum 
content) in non-gelatinised dishes. This encouraged the pluripotent cells to form 
embryoid body aggregates (Figure 3.6A). The embryoid bodies were cultured in the 
presence of retinoic acid to encourage neuronal differentiation, before being 
disaggregated and plated in medium optimised for culture of post mitotic neurons in 
dishes coated with poly-DL-ornithine and laminin. This was gradually changed to 
neurobasal medium for culture of hippocampal and cortical neurons. This process 
took two weeks in total and was sensitive to variation in cell density and temperature. 
The neuronal cells were harvested on day six for further analysis. Day six cells 
stained positively for neurofilament, a major component of the cytoskeleton in 
neurons and NeuN, a marker of terminal neuronal differentiation, indicating that the 
process had been successful (Figure 3.6B). It was therefore possible to differentiate 






Figure 3.6 Differentiation of R133C-GFP ES Cells into Neuronal Cells 
 
(A) Schematic of the differentiation strategy to produce a homogeneous population of 
neuronal cells from R133C-GFP embryonic stem cells. Representative light microscopy 
images of embryoid bodies and neuronal precursor cells are shown. Neuronal cells were 
harvested six days after plating. EB, embryoid body. NP, neuronal precursor. 
(B) Confocal images of day six neuronal cells derived from WT, WT-GFP and R133C-GFP 
ES cells are shown. The neuronal cells were stained for neurofilament (red) and NeuN (pale 
green). 
 
3.7 MeCP2 level increases during neuronal differentiation 
MeCP2 expression increases with neuronal differentiation (Kishi et al, 2004). In 
keeping with this, the level of Mecp2 mRNA increased during the process of 
differentiation in the ES cell-derived neurons for all genotypes studied (Figure 3.7A). 
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The relative transcript level in ES cells and neuronal precursors was approximately 
15% and 50% of neuronal level, respectively when normalised to Cyclophilin A 
transcript levels. This was thought to be a suitable housekeeper for normalisation 
because the gene was highly expressed regardless of the stage of neuronal 
differentiation and the quantitative PCR cycle threshold values were similar and 
consistent across genotypes, suggesting that the expression of Cyclophilin A was not 
dependent on MeCP2 function or stage of differentiation. The increase in Mecp2 
mRNA transcript with neuronal differentiation was reflected in western blotting of 
MeCP2 protein from whole cell lysates (Figure 3.7B). For western blotting, Histone 
3 was selected as a loading control because protein expression was equal throughout 
differentiation and between genotypes (see Figure 3.7B). These observations 





Figure 3.7 MeCP2 level increases during neuronal differentiation  
 
(A) Graph depicting Mecp2 mRNA levels relative to Cyclophilin A through the process of 
neuronal differentiation for WT, WT-GFP and R133C-GFP cells. For each genotype mRNA 
level increased in the neuronal cells compared to earlier time points. Representative graph 
from one differentiation is shown. 
(B) Representative western blot of increasing MeCP2 level through the process of neuronal 
differentiation for wild type (W), WT-GFP (G) and R133C-GFP (R) cells. ES cells (ES), 
neuronal precursors (NP) and day six neuronal cells (neuronal) are shown. MeCP2 is 
indicated by < and MeCP2EGFP by <<. Histone 3 was the loading control. 
 
3.8 Discussion 
Previous studies on the impact of MeCP2R133C on DNA binding have not yielded 
consistent findings. The goal was to create two suitable model systems that were 
relevant to the pathogenesis of Rett syndrome, with the hypothesis that MeCP2 
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function would more accurately reflect function in vivo. The impact of the mutation 
could be analysed and this would lead to a greater understanding of its molecular 
consequences and why in patients, it results in expression of a milder phenotype 
(Cuddapah et al, 2014). 
3.8.1 Optimisation of targeting protocol 
The successful targeting reported was preceded by an unsuccessful attempt. There 
was no evidence of homologous recombination and on Southern blot screening it 
appeared that multiple copies of the targeting vector had been incorporated in 
concatemers. In order to rectify this, several steps were taken. Firstly, the targeting 
vector was linearised with SnabI at the 5’ end instead of SalI at the 3’ end, which had 
only created 2kb of homology. This resulted in an extra 1.1kb of homology upstream 
of exon 3, thus increasing the chance of homologous recombination. Secondly, ES 
cells were targeted when they were less confluent in the dish and therefore dividing 
rapidly. If the dish became confluent then it was reasoned that the chances of the 
cells entering a more stationary phase, with increased propensity to differentiate 
would be higher. Thirdly, the ratio of targeting vector:ES cells was reduced to 
decrease the likelihood of multiple integrants. Fourthly, the positive selection was 
modified such that the concentration of G-418 decreased over time. In this way, 
multiple vector integrants would not be selected for. Fifthly, the electroporator 
settings were modified to a slightly higher voltage, but lower charge as 
recommended by Millipore. Finally, the PCR screening was optimised: primers were 
redesigned and an alternative Taq polymerase was used. 
 
With all these steps taken, the next targeting attempt worked with an overall 
frequency of 6.25% when all picked colonies were taken into account. Unfortunately 
when targeted clones identified by PCR were screened by Southern blot and 
sequencing, evidence of mixed clones was apparent, that is, having both a band 
corresponding to the wildtype locus and the targeted locus on Southern blot. This 
reduced the number of R133C-GFP clones, but there were two clean ones 
manufactured: A3 and B11. Both clones were taken forward to differentiate into 
neuronal cells: clone B11 made the mouse model. 
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3.8.2 Inconsistencies in neuronal culture 
There are a number of advantages to having a homogeneous population of neuronal 
cells as a model system for studying MeCP2 function: higher levels of MeCP2 
expression than in other cell types; endogenous levels of MeCP2 expression from the 
nascent promoter; the ability to study the pathogenesis of Rett syndrome in the 
principal tissue affected by the disorder; an ability to detect effects that may be cell 
type-specific; and the ability to compare different genotypes of neurons that are 
differentiated in parallel. This is dependent on reproducibility and reliability of the 
protocol, so that differences between the individual cultures are not inadvertently 
attributed to differences between the genotypes. In fact, the neuronal cells varied in 
appearance between different cultures using the same clone. There were multiple 
steps to the protocol that appeared sensitive to subtle variation. For example, the rate 
at which the ES cells were growing at the start of the process, the quality of the poly-
DL-ornithine and laminin coating of the dishes the neurons were plated in, or 
variation in the temperature of the incubator (following completion of all neuronal 
experiments it was discovered that the incubator was nearly two degrees below the 
desired 37oC). This may have impacted on the reproducibility of the results from 
experiments using this model and this will be discussed further in Chapter 5. 
3.8.3 EGFP-tagging MeCP2 
The protein was EGFP-tagged for ease of identification by microscopy and for 
straightforward immunoprecipitation. There were additional Mecp2EGFP mouse lines 
available to which the R133C-GFP line could be compared. In this fashion, 
genotype-phenotype correlation could be studied. Western blotting of neuronal 
whole cell lysates gave an early indication that the MeCP2 expression may be higher 
with the EGFP-tagged protein in comparison to the untagged protein, which was an 
unanticipated observation. This will be discussed further in Chapter 5 with formal 
quantification. 
3.8.4 Summary 
In summary, R133C-GFP ES cell lines were manufactured. They could be 
differentiated into a population of neuronal cells and were used to create a novel 
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4. Phenotyping the R133C-GFP Mouse 
4.1 Introduction 
The R133C mutation consistently falls at the milder end of the spectrum when 
genotype is linked to phenotypic severity in patients, independent of patient age or 
geographical location of the study (Bebbington et al, 2008; Cuddapah et al, 2014). 
The significant limitation of these studies is that most groups have not measured the 
pattern of XCI in individuals participating in the study. In extreme circumstances, if 
patients with MECP2R133C tended to have skewed XCI, where the mutant allele was 
expressed in less than 20% of cells (and this reflected the XCI pattern in the brain), 
this could artificially make the phenotype seem less severe. Given that R133 
occupies a key position in the MBD of MeCP2 (Ho et al, 2008), the intuitive 
prediction would be that this mutation would be catastrophic to protein function and 
result in a severe form of Rett syndrome. It therefore becomes imperative to 
disentangle the effects of the potentially confounding pattern of XCI, in order to 
understand the molecular basis of the syndrome. 
 
This problem can be circumvented using the R133C-GFP mouse model. Mouse 
models have been used with huge success in the Rett syndrome field (Guy et al, 
2011). In contrast to humans, male Mecp2-null mice survive into adulthood. They 
display a constellation of signs that recapitulate the human Rett syndrome (Guy et al, 
2001). First they develop a stiff, uncoordinated, wide-based gait. This is followed by 
a reduction in mobility and a clasping together of their hindlimbs. Later on, they 
develop tremors and breathing difficulties before early mortality. Their growth is 
also affected: null mice are smaller than their wildtype littermates. A well-
established scoring system for measuring this phenotype exists (Guy et al, 2007; 
Appendix 1). Using the male mouse as a Rett syndrome model means that one can 
disregard the pattern of XCI because this does not take place when there is only one 
copy. MeCP2 function will be directly attributable to the genetically manipulated 
form. The male mouse therefore serves as an ideal platform to assess the severity of 
the R133C mutation in a whole organism. Using the scoring system, it is possible to 
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compare mouse lines and so the R133C-GFP line can be compared to other GFP-
tagged lines.  
 
Mice can also be phenotyped using behavioural tests. The elevated plus maze is a 
commonly used test to measure anxiety (Pellow et al, 1985). Mice are placed on a 
cross-shaped maze, elevated above the ground. Two of the maze arms are enclosed 
by high-sided walls and two are open. Wildtype mice find the unprotected open arms 
more anxiety provoking and will typically spend most of the trial in the safer closed 
arms. The open field test also measures anxiety as well as mobility (Prut & Belzung, 
2003). Mice are placed in an enclosed field. Wildtype mice typically spend most of 
their time during the trial against the walls of the enclosure – a phenomenon known 
as thigmotaxis. This is preferable to venturing in to the centre of the open field, 
which is more anxiety provoking. The hanging wire test assesses motor strength and 
coordination (Gomez et al, 1997). Mice are suspended from a thin wire above the 
bench by their forepaws. The time taken for the mouse to bring one hind paw up to 
grasp the wire is recorded over a number of spaced trials. The accelerating rotarod 
also assesses motor strength and coordination (Jones & Roberts, 1968). Mice learn to 
run on a rotating rod during a training session. Over subsequent days, mice run on 
the rod in separate trials. The latency for the mouse to fall from the rod as the 
rotation accelerates is recorded. These four tests have previously been used to 
phenotype mice modelling Rett syndrome mutations (Goffin et al, 2011; Lyst et al, 
2013; Heckman et al, 2014). They are suitable because Rett syndrome patients suffer 
from abnormal muscle tone and mobility, as well as intellectual disability and 
heightened anxiety (Smeets et al, 2011). Therefore it is necessary to establish 
whether these features are recapitulated in the R133C-GFP mouse.   
 
In order to determine whether an entity is mild, it is necessary to have appropriate 
comparators, which would be judged as more severe. Three other mouse strains serve 
this purpose: Mecp2EGFP (WT-GFP), Mecp2R306CEGFP (R306C-GFP) and 
Mecp2T158MEGFP (T158M-GFP). These lines were created by J.Guy, J.Selfridge & 
C.Merusi using the same targeting vector that was used to make R133C-GFP. The 
WT-GFP strain is simply wildtype Mecp2 with a C-terminal EGFP tag. The R306C-
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GFP strain additionally carries a missense mutation in the NID of Mecp2. Similar 
strains have previously been studied without the C-terminal EGFP tag (Lyst et al, 
2013) and when expressed from a transgene on an Mecp2-null background 
(Heckman et al, 2014). The R306C mutation accounts for approximately 5% of Rett 
syndrome cases (Christodoulou et al, 2003). Patients with this mutation have mild to 
moderate clinical severity (Colvin et al, 2004; Neul et al, 2008; Bebbington et al, 
2008; Cuddapah et al, 2014) and this was reflected in mouse phenotyping with an 
average survival of approximately 18 weeks. The T158M-GFP strain carries a 
missense mutation in the MBD of Mecp2. The T158M mutation is the most common 
Rett-causing mutation, accounting for nearly 9% of cases (Christodoulou et al, 
2003). Patients with this mutation have moderate to severe clinical severity (Colvin 
et al, 2004; Charman et al, 2005; Bebbington et al, 2008; Cuddapah et al, 2014). 
This is a novel mouse line, although mice with the T158A mutation have previously 
been reported and displayed an average survival of 16 weeks (Goffin et al, 2011). 
 
The hypothesis was that the R133C-GFP mouse would develop a Rett-like 
phenotype, but that this would be less severe than R306C-GFP and T158M-GFP 
mice, thus recapitulating and validating the patient genotype-phenotype correlation. 
The R133C-GFP mouse could then be used to study the molecular basis of Rett 
syndrome caused by the R133C mutation. The Rett-like phenotype displayed in the 
mouse will be referred to as “RTT” for brevity. When discussing phenotype in 
patients, “Rett syndrome” will be used. 
4.2 Phenotypic analysis of male mice 
It was not known whether the R133C-GFP mouse would develop RTT as the patient 
data suggests R133C would cause a milder syndrome and Rett syndrome appears to 
be milder in the mouse as males without Mecp2 survive into adulthood (Guy et al, 
2001). Mice were weighed and observed for emergence of RTT on a weekly basis at 
the same time and in the same room where possible. As is customary, mice were 
compared to their wildtype littermates, in order to minimise any impact that 
environmental factors might have on phenotypic observations. The observations 
 121 
were done blind to genotype. The mice were on a 96% C57BL/6J genetic 
background having been backcrossed for five generations. 
4.2.1 Growth 
R133C-GFP mice weighed significantly less than their wildtype littermates over the 
52-week period of observation, two-way repeated measures ANOVA F(1,21)=61.49, 
p<0.001 (Figure 4.2.1A). The absolute weight difference between the cohorts 
increased from 4.3g at 4 weeks to 11g by 52 weeks. There was an early flattening of 
the R133C-GFP growth curve, indicating an early stagnation in growth, which is also 
observed in human patients (Kerr & Engerström, 2001). 
 
 
Figure 4.2.1 Reduced weight of R133C-GFP mice in comparison to wildtype 
littermates. 
 
(A) Growth curves showing that R133C-GFP mice are significantly lighter than their wildtype 
(WT) littermates, n=10 & n=13, respectively. Mean±SEM plotted. ***p<0.001, two-way 
repeated measures ANOVA. 
(B) Back-crossing onto a C57BL/6J background reduces the weight of the mice. C57BL/6J 
contribution is indicated in brackets. WT(87.5%), n=10; R133C-GFP(87.5%), n=10; 
WT(75%), n=5-17; R133C-GFP(75%), n=5-9. Means±SEM plotted. 
 
Cohorts of R133C-GFP mice at earlier stages of back-crossing onto the C57BL/6J 
background were also observed: two and three back-crosses, equivalent to 
approximately 75% and 87.5% C57BL/6J contribution, respectively. The 96% 
C57BL/6J mice were lighter than 75% and 87.5% cohorts, indicating that the higher 
the contribution of C57BL/6J to the genetic makeup, the lighter the mouse. The 
effect was seen independently of Mecp2 genotype (Figure 4.2.1B). As seen in Figure 
4.2.1B, the variability in weight within the groups was greater for the 75% and 
87.5% cohorts. Mice were humanely culled if they lost 20% of their body weight. 
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4.2.2 Phenotypic scoring 
An established scoring system for mouse RTT exists (see Appendix 1). Mobility, 
gait, hindlimb clasping, tremor, breathing and general condition were observed and 
given a score from 0 (no symptom) to 2 (significant symptom) for each aspect with a 
maximum score of 12. Half scores were utilised as introduced previously (Cheval et 
al, 2012), given that the anticipated phenotype was subtle and the scoring system had 
been developed using mice null for Mecp2. Mice were humanely culled if they 




Figure 4.2.2 R133C-GFP mice develop RTT at 10-12 weeks of age. 
 
(A) R133C-GFP mice (n=10) develop progressive RTT at 10-12 weeks of age. Wildtype 
(WT, n=13) almost invariably score 0. Mean score±SEM plotted. 
(B) There is no consistent effect of back-crossing onto a C57BL/6J background on 
phenotypic score. C57BL/6J contribution is indicated in brackets. WT(87.5%), n=10; R133C-
GFP(87.5%), n=10; WT(75%), n=5-17; R133C-GFP(75%), n=5-9. 
 
R133C-GFP mice began to develop RTT between 10 and 12 weeks of age (Figure 
4.2.2A). Symptoms worsened with time, reaching a maximum mean score of 6.4 at 
50 weeks. Their wildtype littermates rarely displayed any symptoms that would be 
compatible with the disorder. R133C-GFP mice did not manifest any unusual or 
unanticipated symptoms that would indicate a unique phenotype associated with the 
mutation. Conversely, they did not have preservation of any particular measured 
faculty, although it was rare to observe breathing irregularity until a very late stage. 
The degree of backcross onto the C57BL/6J background did not have a consistent 
impact on the mean phenotypic score (Figure 4.2.2B). The R133C-GFP mice on the 
96% C57BL/6J background scored intermediately between those on the 75% and 
those on the 87.5% backgrounds. 
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4.2.3 Survival 
The R133C-GFP mice had a significantly reduced lifespan in comparison to their 
wildtype littermates (Figure 4.2.3A), with a median survival of 42 weeks. Mice were 
humanely culled when they reached the end point of the experiment. This 
corresponded to severe RTT that exceeded the severity limit of the Home Office 
License as detailed above. The reduced survival is analogous to the increased 
mortality seen in Rett patients (Freilinger et al, 2010). Survival of the wildtype mice 
was undetermined as only two mice died during the observation period of 52 weeks. 
These mice were humanely culled following injuries obtained during in-cage 
fighting. Both of these mice were from the same cage and were littermates. This in-
cage fighting was prominent and problematic feature of the earlier generation of 
R133C-GFP mice that had 87.5% C57BL/6J contribution. Several mice were culled 
because of fighting injuries (four wildtype mice and four R133C-GFP mice), to the 
extent that it was considered whether the mutation produced an aggression phenotype 
(Figure 4.2.3B). The male mice had been pooled into larger cages following weaning 
and so a decision was taken to keep later generations in cages with only their 
littermates. This, along with the extra contribution of C57BL/6J, seemed to eradicate 
the phenomenon. The survival of the more outbred R133C-GFP mice was also 
significantly reduced, relative to wildtype, despite the confounding factor of the 
aggression (Figure 4.2.3B). There was no significant difference in the survival of the 
R133C-GFP cohorts. The median survival for the R133C-GFP mice with 87.5% 
C57BL/6J contribution was 24 weeks. 
 
Given that the R133C-GFP mice displayed reduced body weight, an early stagnation 
in growth, reduced survival and RTT, it was considered that the novel mouse line 





Figure 4.2.3 Reduced survival of R133C-GFP mice 
 
(A) R133C-GFP mice (n=10) have significantly reduced survival compared to wildtype 
littermates (WT, n=13). 
(B) Back-crossing onto a C57BL/6J background does not significantly alter median survival 
in wildtype or R133C-GFP mice. Contribution of C57BL/6J is indicated in brackets. 
WT(87.5%), n=10. R133C-GFP(87.5%), n=10. WT only comparison p=0.13, R133C-GFP 
only comparison p=0.08. 
*p<0.05, **p<0.01, Log-rank Mantel Cox Test. 
 
4.3 Behavioural analysis of 9-10 week male mice 
Mice were further characterised using a battery of behavioural tests in order to more 
precisely describe their phenotype. Mice underwent the elevated plus maze, hanging 
wire test, open field test and accelerating rotarod. Behavioural testing was done at 
two time points: 9-10 weeks and 20-21 weeks (see 4.4) to represent pre-symptomatic 
and symptomatic stages. Separate cohorts of R133C-GFP mice and their wildtype 
littermates were used.  
4.3.1 Elevated plus maze 
First, the mice underwent the elevated plus maze to assess their level of anxiety. The 
trial was 15 minutes. As expected, the wildtype mice spent significantly more time in 
the closed arms of the maze than the open arms (643 seconds vs 91 seconds, Figure 
4.3.1A). This was also true of the R133C-GFP mice (459 seconds vs 208 seconds) 
although the difference between the mean times was smaller (552 seconds for 
wildtype vs 250 seconds for R133C-GFP mice). Compatible with this observation, 
the R133C-GFP mice spent significantly more time in the open arms than their 
wildtype littermates (208 seconds vs 91 seconds, respectively) and significantly less 
time in the closed arms (459 seconds vs 643 seconds, respectively). This was not a 
result of the R133C-GFP mice moving to an open arm and remaining there for the 
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duration of the test, as there was no significant difference in the number of times the 
R133C-GFP mice entered the closed arms compared to the wildtype mice (45±4 vs 




Figure 4.3.1 R133C-GFP mice display a mild reduction in anxiety on the elevated plus 
maze at 9 weeks. 
 
(A) Box plots of individual animal times showing that R133C-GFP mice (n=10) spent 
significantly more time in the open arms than their wildtype littermates (WT, n=13), though 
still showed a preference for closed arms. 
(B) Box plots of individual animal entries showing that the R133C-GFP mice entered the 
closed arms as many times as the wildtype mice.  
Cohort median, interquartile range, maximum and minimum represented. *p<0.05, 
***p<0.001, Kolmogorov-Smirnov Test. 
 
In summary, the R133C-GFP mice spent significantly more time in the anxiety-
provoking arms of the maze than their wildtype counterparts, although they still 
displayed a preference for the closed arms. This would indicate a marginally lower 
level of anxiety in the R133C-GFP mice. 
4.3.2 Hanging wire test 
Next, motor strength and coordination were assessed using the hanging wire test 
(Figure 4.3.2). The maximum time allowed per trial was 30 seconds. The R133C-
GFP mice took significantly longer than their wildtype littermates – almost double 
the time - to bring one hind paw up to grasp the wire when suspended over three 





Figure 4.3.2 R133C-GFP mice show impaired motor strength and coordination in the 
hanging wire test at 9 weeks. 
 
Box plots of mean individual latencies over three 30-second trials show that R133C-GFP 
mice (n=10) took significantly longer than wildtype (WT, n=13) mice to bring one hind paw to  
grasp the wire. Cohort median, interquartile range, maximum and minimum represented. 
*p<0.05, Kolmogorov-Smirnov Test. 
 
4.3.3 Open field test 
Thirdly, mice did the open field test to assess anxiety, as well as mobility in a single 
20-minute trial (Figure 4.3.3).  The R133C-GFP mice spent significantly more time 
than their wildtype littermates in the anxiety-provoking central area of the open field 
(42 seconds vs 23 seconds, respectively, Figure 4.3.3D). This was not the result of 
moving into the centre and staying there for the duration of the test, as there was no 
significant difference in the overall mean distance travelled (93m vs 93m), mean 
speed (0.077ms-1 vs 0.077ms-1) or time spent immobile (11 seconds vs 12 seconds) 
during the test for the R133C-GFP mice compared to their wildtype littermates 
(Figure 4.3.3A-C). The R133C-GFP mice seemed less perturbed by or less aware of 




Figure 4.3.3 R133C-GFP mice display reduced anxiety in the open field test at 9 weeks. 
 
(A) There was no significant difference in the distance travelled by the R133C-GFP (n=10) 
mice in comparison to their wildtype littermates (WT, n=13). 
(B) There was no significant difference in the mean speed of the R133C-GFP mice in 
comparison to their wildtype littermates. 
(C) The R133C-GFP mice did not spend significantly more time immobile in comparison to 
their wildtype littermates. 
(D) The R133C-GFP mice spent significantly more time in the centre of the field in 
comparison to wildtype littermates.  
Box plots of individual times. Cohort median, interquartile range, maximum and minimum 
represented. **p<0.01, Kolmogorov-Smirnov Test. 
 
4.3.4 The accelerating rotarod 
Finally, mice underwent the accelerating rotarod, another test of motor strength and 
coordination (Figure 4.3.4). Mice undertook four trials per day over three days: each 
trial was a maximum of five minutes. The R133C-GFP mice performed as well as 
their wildtype littermates on this test, across all three days (repeated measures two-
way ANOVA F(1,21)=0.21, p=0.65). On day one it took wildtype mice 56 seconds 
to fall from the rod and R133C-GFP mice 41 seconds on average. On day two 70 
seconds and 69 seconds, respectively and on day three, 77 seconds and 78 seconds, 
respectively. There was a significant difference in mean latency to fall over the 
different days of the test for both the genotypes as determined by repeated measures 
one-way ANOVA: wildtype animals (F(2,12)=10.76, p<0.001); R133C-GFP animals 
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(F(2,9)=18.95, p<0.001). A Tukey post-hoc test revealed a significantly higher mean 
latency to fall for wildtype animals on day two (+14.6 seconds 95%CI 2.8-26.3 
seconds, p<0.05) and day three (+21.4 seconds 95%CI 9.6-33.1 seconds, p<0.001) 
versus day one. Similarly there was a significantly higher mean latency to fall for 
R133C-GFP animals on day two (+27.2 seconds 95%CI 11.5-42.8 seconds, p<0.001) 
and day three (+36.3 seconds 95%CI 20.6-51.9 seconds, p<0.001) versus day one. 
Both genotypes therefore showed evidence of motor learning with significant 
improvement across the three days of testing. 
 
 
Figure 4.3.4 No significant motor impairment of 10-week R133C-GFP mice was 
detected on the accelerating rotarod. 
 
Scatterplot of accelerating rotarod performance across days. Individual means are plotted 
with the bar representing cohort mean. The R133C-GFP mice (n=10) performed as well as 
their wildtype littermates (WT, n=13) on all days of the test (two-way repeated measures 
ANOVA, p=0.65). Both genotypes showed evidence of motor learning across days. 
***p<0.001, one-way repeated measures ANOVA. 
 
In summary, at 9-10 weeks the R133C-GFP mice displayed signs of reduced anxiety 
level on two behavioural tests and motor impairment on one behavioural test. 
4.4 Behavioural analysis of 20-21 week male mice 
The battery of tests was repeated at 20-21 weeks, when the R133C-GFP mice were 
obviously symptomatic with RTT (average score 4.1) to gain an appreciation for the 
evolution of the phenotype over time. 
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4.4.1 Elevated plus maze 
Again, the wildtype mice showed a significant preference for the closed arms over 
the open arms of the elevated plus maze (652 seconds vs 89 seconds, Figure 4.4.1A). 
However, at this symptomatic time point, the R133C-GFP mice no longer showed a 
significant preference for the closed arms over the open arms, spending 414 seconds 
in the closed arms and 329 seconds in the open arms, on average. They spent 
significantly more time than the wildtype mice in the open arms (329 seconds vs 89 
seconds respectively) and significantly less time than the wildtype mice in the closed 
arms (414 seconds vs 652 seconds, respectively). Again, the R133C-GFP mice 
entered the closed arms as many times as the wildtype mice (30±4 vs 31±5 times) 
and so spending more time in the open arms was informed after sampling the whole 
area of the apparatus (Figure 4.4.1B). Therefore at a symptomatic stage of RTT, the 
R133C-GFP mice show evidence of reduced levels of anxiety, or awareness of 
potential danger and no longer show a significant preference for the safer, closed 




Figure 4.4.1 R133C-GFP 20-week mice display reduced anxiety in the elevated plus 
maze. 
 
(A) R133C-GFP (n=11) mice spent significantly more time in the open arms than their 
wildtype littermates (WT, n=9) and showed no significant preference for the closed arms. 
(B) The R133C-GFP mice entered the closed arms as many times as the wildtype mice.  
Box plots representing individual animal times or entries with cohort median, interquartile 




4.4.2 The hanging wire test 
At 20-21 weeks, the R133C-GFP mice took significantly longer to bring their hind 
paw up to clasp the wire in comparison to their wildtype littermates on the hanging 
wire test (27 seconds vs 10 seconds, respectively, Figure 4.4.2). There was 
deterioration in motor strength and coordination as the difference between the mean 
latencies had increased to 17 seconds from 9.2 seconds at 9-10 weeks. 
 
 
Figure 4.4.2 R133C-GFP mice show impaired motor coordination and strength on the 
hanging wire test at 20 weeks. 
 
The R133C-GFP mice (n=11) took significantly longer to bring one hind paw up to the grasp 
the wire than their wildtype littermates (WT, n=9). Box plot of individual latencies with cohort 
median, interquartile range, maximum and minimum represented. ***p<0.001, Kolmogorov-
Smirnov Test. 
 
4.4.3 The open field test 
In contrast to performance at 9-10 weeks, at 20-21 weeks the R133C-GFP mice did 
not spend significantly longer in the centre of the open field in comparison to 
wildtype littermates, although there was a trend towards this (74 seconds vs 44 
seconds, respectively, Figure 4.4.3D). Again, there was no significant difference 
found between the R133C-GFP mice and their wildtype littermates in the mean 
distance travelled (83m vs 66m), the mean speed (0.069ms-1 vs 0.055ms-1) or the 




Figure 4.4.3 R133C-GFP mice show a trend towards reduced anxiety in the open field 
at 20 weeks. 
 
(A) There was no significant difference in the distance travelled by the R133C-GFP (n=11) 
mice in comparison to their wildtype littermates (WT, n=9). 
(B) There was no significant difference in the mean speed of the R133C-GFP mice in 
comparison to their wildtype littermates. 
(C) The R133C-GFP mice did not spend significantly more time immobile in comparison to 
their wildtype littermates. 
(D) There was a trend towards the R133C-GFP mice spending more time in the centre of the 
field in comparison to wildtype littermates.  
Box plots of individual times. Cohort median, interquartile range, maximum and minimum 
represented. Kolmogorov-Smirnov Test. 
 
There was a trend towards the R133C-GFP mice spending more time immobile, 
which did not meet significance. On further inspection of individual’s performances 
the mice that spent the most time immobile were not the same individual animals that 
spent the longest times in the centre. Therefore the trend towards R133C-GFP mice 
spending more time in the centre cannot be explained by mice entering the centre and 
remaining immobile there for the duration. Although there was no significant 
difference in how the two genotypes performed in the open field, there was a trend 
towards the R133C-GFP mice spending more time in the centre, which would be 
compatible with a reduced level of anxiety or awareness of danger. 
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4.4.4 The accelerating rotarod. 
Finally the 20-21 week mice underwent the accelerating rotarod test as a second 
motor paradigm (Figure 4.4.4). Again, there was no significant difference in the 
performance of the R133C-GFP mice compared to their wildtype littermates on this 
test, across all three days (repeated measures two-way ANOVA F(1,18)=0.14, 
p=0.72) although there was a trend towards the R133C-GFP mice falling off earlier. 
On day one it took wildtype mice 46 seconds to fall from the rod and R133C-GFP 
mice 55 seconds; on day two, 75 seconds and 68 seconds, respectively; and on day 
three, 93 seconds and 78 seconds, respectively. Again, there was a significant 
difference in mean latency to fall for the different days of the test for both the 
genotypes as determined by repeated measures one-way ANOVA: wildtype (F(2,8) = 
19.57, p<0.001); R133C-GFP (F(2,10) = 5.76, p<0.05). A Tukey post-hoc test 
revealed a significantly higher mean latency to fall for wildtype animals on day two 
(+29.1 seconds 95%CI 9.5-48.8 seconds, p<0.01) and day three (+47.2 seconds 
95%CI 27.5-66.8 seconds, p<0.001) versus day one. There was no significant 
increase in the mean latency to fall for R133C-GFP animals on day two (+13.0 
seconds 95%CI -4.3-30.3 seconds) versus day one, however there was for day three 
(+23.1 seconds 95%CI 5.8-40.4 seconds, p<0.01) versus day one. Both genotypes 
therefore showed evidence of motor learning with significant improvement across 
the three days of testing. 
 
Together, the behavioural analysis of the R133C-GFP males both at pre-symptomatic 
and symptomatic stages would suggest that the animals are less anxious (or cautious) 
than wildtype littermates and display a mild level of motor impairment that worsens 





Figure 4.4.4 No significant motor impairment of R133C-GFP mice was detected on the 
accelerating rotarod at 21 weeks. 
 
Scatterplot of accelerating rotarod performance across days. Individual mean latencies are 
plotted with the bar representing cohort mean. The R133C-GFP mice (n=11) performed as 
well as their wildtype littermates (WT, n=9) on all days of the test (repeated measures two-
way ANOVA, p=0.72) and both genotypes showed evidence of motor learning across time 
*p<0.05, ***p<0.001, repeated measures one-way ANOVA. 
 
4.5 Phenotypic analysis of female mice 
Rett syndrome primarily affects girls, as boys carrying mutations in MECP2 
typically die in early infancy (Schüle et al, 2008). It follows that the true model of 
Rett syndrome would be the heterozygous female mouse. Mecp2+/R133CEGFP females 
(which will be referred to as +/R133C-GFP) were weighed and observed for the 
development of RTT on a monthly basis, under the same conditions as the male mice 
described above (Figure 4.5). The larger interval between observations was 
determined on the premise that the phenotypic development would be very gradual 
and there would be little change on a weekly basis. The observed females were 96% 
C57BL/6J. 
 
There was no significant difference in the weight of the +/R133C-GFP females 
compared to wildtype littermates at any time point across the 50-week observation 
period (Figure 4.5A). The +/R133C-GFP females began to develop RTT at around 
11 months, with a mean phenotypic score of 2.9 by 50 weeks, which was the last 
point of observation (Figure 4.5B). None of the +/R133C-GFP females died during 
the observation period (Figure 4.5C) however one wildtype mouse was humanely 
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culled for health reasons unrelated to RTT. Therefore the +/R133C-GFP females 
displayed very mild RTT, with normal weight and survival. 
 
 
Figure 4.5 Phenotypic analysis of female +/R133C-GFP mice reveals mild RTT by 46 
weeks. 
 
(A) There was no significant difference in the mean weight of the +/R133C-GFP mice (n=10) 
compared to their wildtype littermates (WT, n=10), p=0.07, repeated measures two-way 
ANOVA. Mean±SEM plotted 
(B) The +/R133C-GFP mice began to develop mild RTT at 11 months. Mean±SEM plotted. 
(C) The survival of the +/R133C-GFP  mice was indistinguishable from their wildtype 
littermates, p=0.32, Log-rank Mantel Cox test. 
 
4.6 Behavioural analysis of female mice 
A cohort of +/R133C-GFP females underwent the same battery of behavioural tests 
as male mice. It was decided to test females at one year of age, given the late-onset 
phenotype. Behavioural testing was done in females that had been back-crossed three 
times on to a C57BL/6J background: some of these females were still Cre positive 
following directed breeding to excise the NEO cassette that was introduced by the 
targeted ES cells. 
4.6.1 The elevated plus maze. 
Anxiety level was assessed on the elevated plus maze (Figure 4.6.1). Both the 
+/R133C-GFP females and their wildtype littermates spent significantly more time 
in the closed arms than the open arms of the maze:  +/R133C-GFP (628 seconds vs 
127 seconds); wildtype (629 seconds vs 128 seconds). There was no significant 
difference in the mean time spent in the open arms between the two genotypes 
(Figure 4.6.1A). There was a trend towards the +/R133C-GFP females entering the 
open and the closed arms more times than their wildtype littermates: open (15±6 vs 
5±2); closed (20±5 vs 7±1), though this did not reach significance (Figure 4.6.1B). 
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Therefore the +/R133C-GFP performance was indistinguishable from wildtype on 




Figure 4.6.1 Equivalent performance of +/R133C-GFP mice and their wild type 
littermates on the elevated plus maze at 1 year. 
 
(A) Both +/R133C-GFP mice (n=8) and their wildtype littermates (WT, n=8) spent 
significantly less time in the open arms than the closed arms of the maze. 
(B) There was no significant difference in the mean number of times the +/R133C-GFP mice 
entered the open or the closed arms when compared to wildtype littermates.  
Box plots of individual times or entries with cohort median, interquartile range, maximum and 
minimum represented. Kolmogorov-Smirnov Test. 
 
4.6.2 The hanging wire test. 
Next, the mice underwent the hanging wire test to look at motor coordination and 
strength. There was no significant difference in the average latency to bring one hind 
paw up to clasp the wire between the two genotypes: +/R133C-GFP, 19 seconds; 
wildtype, 21 seconds (Figure 4.6.2) and so there was no discernible difference in 
motor ability. 
4.6.3 The open field test 
The open field test did not reveal any significant differences in performance between 
the two groups (Figure 4.6.3), with both spending comparable time in the centre of 
the field (wildtype, 36 seconds; +/R133C-GFP, 45 seconds). This result echoed that 
of the elevated plus maze in finding no detectible difference in anxiety level between 
the +/R133C-GFP and wildtype mice. 
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Figure 4.6.2 Equivalent performance on the hanging wire test for +/R133C-GFP mice 
and their wildtype littermates at 1 year. 
 
There was no significant difference in the mean latency to bring one hind paw to the wire 
between the genotypes. +/R133C-GFP mice (n=8); wildtype (WT, n=8). Box plots of 
individual means with cohort median, interquartile range, maximum and minimum 





Figure 4.6.3 Equivalent performance in the open field test for +/R133C-GFP mice and 
their wildtype littermates at 1 year. 
 
(A) There was no significant difference in the distance travelled by the +/R133C-GFP mice 
(n=8) in comparison to their wildtype littermates (WT, n=8). 
(B) There was no significant difference in the mean speed of the +/R133C-GFP mice in 
comparison to their wildtype littermates. 
(C) The +/R133C-GFP mice did not spend significantly more time immobile in comparison to 
their wildtype littermates. 
(D) There was no significant difference in the time the +/R133C-GFP mice spent in the 
centre of the field in comparison to wildtype littermates.  
Box plots of individual times. Cohort median, interquartile range, maximum and minimum 
represented. Kolmogorov-Smirnov Test. 
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4.6.4 The accelerating rotarod. 
Finally, the females undertook the second motor test, the accelerating rotarod (Figure 
4.6.4). The +/R133C-GFP mice performed as well as their wildtype littermates on 
this test, on all three days (repeated measures two-way ANOVA F(1,14)=0.02, 
p=0.90). On day one it took wildtype mice 26 seconds to fall from the rod and 
R133C-GFP mice 21 seconds; on day two, 43 seconds and 39 seconds, respectively; 
and on day three, 49 seconds and 55 seconds, respectively. Again, there was a 
significant difference in mean latency to fall across days of testing for both the 
genotypes as determined by repeated measures one-way ANOVA: wildtype (F(2,7) = 
10.64, p<0.01); +/R133C-GFP (F(2,7) = 18.46, p<0.001). A Tukey post-hoc test 
revealed a significantly higher mean latency to fall for wildtype animals on day two 
(+17.0 seconds 95%CI 3.6-30.4 seconds, p<0.05) and day three (+22.7 seconds 
95%CI 9.3-36.1 seconds, p<0.01) versus day one. There was also a significant 
increase in the mean latency to fall for +/R133C-GFP animals on day two (+18.0 
seconds 95%CI 3.3-32.8 seconds, p<0.05) and day three (+34.2 seconds 95%CI 
19.4-48.9 seconds, p<0.001) versus day one. Both genotypes therefore showed 




Figure 4.6.4 Equivalent performance on the accelerating rotarod for +/R133C-GFP 
mice and their wildtype littermates at 1 year. 
 
Scatterplot of accelerating rotarod performance across days. Individual mean latencies to fall 
are plotted with the bar representing cohort mean. The +/R133C-GFP mice (n=8) performed 
as well as their wildtype littermates (WT, n=8) on all days of the test (repeated measures 
two-way ANOVA, p=0.90) and both genotypes showed evidence of motor learning across 
time **p<0.01, ***p<0.001, repeated measures one-way ANOVA. 
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To conclude, the +/R133C-GFP mice do not reveal signs of altered anxiety level or 
motor impairment on behavioural testing at one year of age. 
4.7 Comparison with the EGFP-tagged allelic series 
In order to answer the question of whether the R133C mutation results in a milder 
Rett phenotype the severity was placed in the context of WT-GFP, R306C-GFP, 
T158M-GFP and Mecp2-null phenotypic data that was gathered by other 
experimenters (J.Guy, J.Selfridge and D.De Souza). According to patient studies, the 
R306C and T158M mutations both result in Rett syndrome that is phenotypically 
more severe than that caused by the R133C mutation (Colvin et al, 2004; Bebbington 
et al, 2008; Cuddapah et al, 2014). The EGFP-tagged lines together comprised an 
“allelic series”. All comparator lines were on a 94% C57BL/6J background, 
equivalent to four backcrosses. The hypothesis was that when data was collated, 
male mice from these lines would fall in order, from least to most severe: WT-GFP, 
R133C-GFP, R306C-GFP, T158M-GFP then Mecp2-null. 
4.7.1 Phenotypic analysis  
Figure 4.7.1 depicts the collated weekly weights (A) and phenotypic scores (B) of all 
the aforementioned mouse lines. Overall survival is shown in (C).  The animals fell 
into the expected pattern of severity in terms of weight, score and survival. The WT-
GFP mice weighed the most, then R133C-GFP and R306C-GFP fell together, 
followed by T158M-GFP, whose growth curve was similar to the Mecp2-null mice. 
The average phenotypic score at week ten was 0 for WT-GFP, 1.4 for R133C-GFP, 
2.8 for R306C-GFP, 5.4 for T158M-GFP and 6.8 for the Mecp2-null mice. The 
median survival was undefined for WT-GFP (as no mice died during the observation 
period), 42 weeks for R133C-GFP, 30 weeks for R306C-GFP, 13 weeks for T158M-




Figure 4.7.1 Phenotypic analysis reveals that the GFP-tagged allelic series 
recapitulates the spectrum of severity seen in patients.   
 
(A) Graph showing that the GFP-tagged allelic series recapitulates the spectrum of severity 
observed in patients in terms of growth. The crucifix symbol indicates that there were no 
more surviving animals in the cohort. Mice were invariably culled due to severity of RTT 
symptoms. Mean±SEM plotted. 
(B) Graph showing that the GFP-tagged allelic series recapitulates the spectrum of severity 
observed in patients in terms of RTT score. Mean±SEM plotted. 
(C) The R133C-GFP mice have the longest mean survival of the allelic series. Survival was 
significantly reduced for all mutants in comparison to WT-GFP. **p<0.01, ***p<0.001, Log-
rank Mantel Cox Test. 
WT-GFP, n=8; R133C-GFP, n=10; R306C-GFP, n=11; T158M-GFP, n=11; Mecp2-null, 
n=12-24. Data from JS, JG & DD added to R133C-GFP. 
 
4.7.2 Behavioural analysis  
The R133C-GFP behavioural data was placed in the context of allelic series data 
gathered by J.Selfridge at 8-10 weeks (a time point when T158M-GFP mice were 
able to participate). Given that individual mutants were compared to corresponding 
wildtype littermates, the extra C57BL/6J back-cross in the R133C-GFP line was 




Figure 4.7.2 Behavioural analysis of the GFP-tagged allelic series recapitulates the 
spectrum of severity seen in patients.  
 
(A) Box plots showing that all allelic series mutants spent significantly more time in the open 
arms of the elevated plus maze than their wildtype littermates. WT-GFP performed as 
wildtype (WT), p>0.99. 
(B) Box plots showing that all cohorts of GFP-tagged mice took longer than their wildtype 
littermates on average to bring one hind paw to the wire in the hanging wire test. 
(C) Scatterplots of individual mean latencies to fall from the accelerating rotarod (dots) and 
cohort means (lines). Only the WT-GFP and R133C-GFP performed as well as their wildtype 
littermates over all three test days.  
WT-GFP n=9, WT n=10. R133C-GFP, n=10, WT n=13. R306C-GFP n=10-11, WT n=9. 
T158M-GFP n=7, WT n=6. Box plots of individual times. Cohort median, interquartile range, 
maximum and minimum represented. *p<0.05, **p<0.01, ***p<0.001 Kolmogorov-Smirnov 
Test. 
Data from JS added to R133C-GFP. 
 
All of the mutant mice spent significantly longer in the open arms than their wildtype 
littermates, indicating a reduction in anxiety or awareness of danger. Only the 
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T158M-GFP mice lost a preference for the closed arms over the open arms (384 
seconds vs 302 seconds, data not shown). This would suggest that T158M-GFP was 
the most severely impaired in this trial, in keeping with the working hypothesis. 
 
All of the mice, including the WT-GFP strain took significantly longer than their 
wildtype littermates to bring one hind paw up to grasp the wire in the hanging wire 
test (Figure 4.7.2B). However, the absolute difference in the mean times between the 
mutants and their corresponding wildtype littermates differentiated the genotypes: 
WT-GFP 5.1 seconds; R133C-GFP 9.2 seconds; R306C-GFP 18.9 seconds; and 
T158M-GFP 14.4 seconds. This result indicated that R133C-GFP was the least 
impaired of the allelic series lines on this test.  
 
The accelerating rotarod test also supported the phenotypic severity hypothesis. 
Figure 4.7.2C shows that only WT-GFP and R133C-GFP performed as well as their 
wildtype littermates with no significant difference in the average latency to fall from 
the rod on any of the three test days. In contrast both the R306C-GFP and T158M-
GFP mice fell significantly earlier than their wildtype littermates by day three of the 
motor paradigm, indicating impairment in motor coordination and ability.  
 
In summary, from comparison with phenotypic and behavioural data from two other 
GFP-tagged missense mutant mouse lines, it can be concluded that the R133C-GFP 
mouse line has milder RTT. Therefore on a homogeneous genetic background with 
no possibility of skewing of XCI, the R133C mutation does result in a form of Rett 
syndrome that is less severe, in concordance with the patient studies. 
4.8 Discussion 
The objective of this chapter was to test the hypothesis that the R133C mutation in 
MECP2 would result a milder form of Rett syndrome when the mutation was present 
on a homogeneous genetic background with no possibility of skewed XCI. In order 
to achieve this, the phenotype of the novel R133C-GFP mouse line was determined, 
before comparing this to other mouse models of Rett syndrome. 
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4.8.1 R133C-GFP mice as a model for human Rett syndrome 
R133C-GFP mice were weighed and observed on a weekly basis for the 
development of RTT. The benefit of back-crossing onto an almost pure C57BL/6J 
genetic background was seen with the increased weight and variability in weight in 
the more outbred cohorts as well as significant aggression in the males, resulting in 
the early death of many mice in the experimental group. It is desirable that mice 
belonging to one experimental cohort differ only in the variable that is being 
measured and so introducing external variability from the degree of 129/Ola genetic 
background would act as a confounder of the experiment. However, from analysis of 
R133C-GFP mice at different degrees of back-cross, it was noted that there was little 
impact on the average phenotypic score. This is notable and interesting because it 
echoes what it seen in the patient population: with wide genetic diversity, patients 
carrying the R133C mutation still cluster together at one end of the spectrum of 
severity (Leonard et al, 2003). 
4.8.2 Subjective phenotypic scoring does not reveal preserved 
capacities 
The phenotypic scoring system is well established in the Rett research field (Guy et 
al, 2007; Appendix 1). Assessing six aspects of mouse appearance and behaviour, it 
encapsulates the key features of RTT. Although the mice were scored blind to 
genotype, as mice aged and became unwell, it became obvious which ones carried 
the mutation when observed next to their larger, healthier wildtype littermates. This 
compromised the blinding process. Another limitation to the scoring system is that 
there is an element of subjectivity in assigning a score to a particular symptom: one 
must judge the degree to which a mouse is impaired by a particular aspect of the 
phenotype. Inter-rater reliability has not been demonstrated where a second 
independent assessor’s judgment of individual animals’ phenotypic severity would 
consistently correlate well with the first’s. This makes recording of weight, survival 
and behavioural analysis particularly important to include as more objective 
measures of phenotypic severity. There was no obvious preservation or loss of a 
specific capacity that would point to unique R133C Rett pathogenesis. Speech, hand 
use and ambulation are more often preserved in patients with R133C Rett 
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(Yamashita et al, 2001; Leonard et al, 2003). Two of these three features are difficult 
to assess in the mouse. 
4.8.3 Progressive behavioural deficit in R133C-GFP mice 
R133C-GFP mice underwent a battery of behavioural tests that measured motor and 
emotional function at a relatively pre-symptomatic age (9-10 weeks) and a 
symptomatic age (20-21 weeks). The pre-symptomatic age was chosen because RTT 
had not manifested in all of the R133C-GFP mice at this age and it would be possible 
to compare results to analyses done on other mouse lines at the same stage of 
development. The symptomatic age was chosen because all of the R133C-GFP mice 
were scoring for RTT by this time point. It was interesting that the motor impairment 
in the R133C-GFP mice at both time points was only detectable by the hanging wire 
test and not the accelerating rotarod. There are two possible explanations for this. 
Firstly, the tests measure different motor function: the hanging wire is a test of 
strength as well as coordination; the accelerating rotarod is a test of motor 
coordination as well as endurance, requiring adequate respiratory function. It could 
be that the R133C-GFP mice only have a deficit in motor ability that is specific to the 
hanging wire test, for example strength or hypertonicity. A second possible 
explanation is that the ability to complete the hanging wire test is affected by the 
presence of one of the core RTT symptoms in the mice – the hindlimb clasp. Once a 
mouse is suspended from the wire by its forepaws, if it clasps the hindlimbs together 
and cannot unclasp them during the 30-second trial, it will have no opportunity to 
bring its hind paws to the wire. Overall the behavioural testing showed evidence of a 
mild motor impairment on the hanging wire test and a deficit in the elevated plus 
maze and open field test in the R133C-GFP mice.  
 
The elevated plus maze and open field tests have been extensively validated as 
assays of rodent anxiety, where animal performance is sensitive to anxiolytic 
medication (Pellow et al, 1985; Prut & Belzung, 2003). Therefore abnormalities 
detected in the R133C-GFP cohorts appeared to be characterized by a lack of 
wildtype anxiety about threatening environmental circumstances, spending 
significantly more time in the open arms of the elevated plus maze, or the centre of 
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the open field. This result seems incompatible with the heightened levels of anxiety 
seen in Rett syndrome patients (Smeets et al, 2011) although this has been reported 
previously in other Mecp2 deficient mice, including female heterozygotes (Kerr et al, 
2008; Samaco et al, 2008; Goffin et al, 2011; Samaco et al, 2012; Yasui et al, 2014). 
It is likely that the genetic background of the mice contributes to the particular 
anxiety phenotype (Crawley et al, 1997) as increased anxiety has also been reported 
in Rett models (Shahbazian et al, 2002; Heckman et al, 2014). Alternatively (or 
additively) it may relate to the particular Mecp2 mutation. Two other factors may 
account for this apparent reduction in anxiety found on these two behavioural tests. 
Firstly, Rett patients are also moderately to severely intellectually disabled, however, 
and perhaps this mouse behaviour does not represent a calmer animal, but an animal 
that is less able to cognitively appraise its environment and act accordingly, a 
function that would be reliant on the frontal cortex as well as the limbic system. This 
would be a different quality to the muscle memory, training and motor learning 
displayed in the accelerating rotarod, which is perhaps more reliant on peripheral 
muscle, cerebellar and respiratory function. Further cognitive testing of the cohorts, 
for example using an object recognition test, may help to clarify whether this was a 
contributory factor. Secondly, the phenomenon of thigmotaxis, where a rodent 
remains close to the walls of tunnels in their natural habitat, or the walls of the 
testing apparatus, is dependent on vision and use of the whiskers and therefore 
adequate sensory capabilities. As sensory function was not tested in this study, it 
cannot be said conclusively that the R133C-GFP mice spent more time in the 
anxiety-provoking regions of the apparatus due to reduced anxiety and not impaired 
sensory function. 
 
There was subtle progression in the behavioural phenotype between the pre-
symptomatic and symptomatic age points. At 20-21 weeks R133C-GFP mice no 
longer spent significantly more time in the closed arms than the open arms of the 
elevated plus maze, indicating reduced anxiety or reduced appreciation of hazardous 
environmental cues. In addition, their performance deteriorated, relative to wildtype 
littermates, on the hanging wire test and there was a non-significant trend towards 
poorer performance on the accelerating rotarod. Although the symptomatic mice did 
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not spend significantly more time in the centre of the open field than their wildtype 
littermates, there was a strong trend towards this outcome. These observations help 
to validate the use of the behavioural paradigms as a correlate of progressive 
phenotypic severity. Moreover they are suggestive of increased sensitivity compared 
to simple observation as clear behavioural deficits were found at a relatively “pre-
symptomatic” stage. The assumption was made that testing two separate cohorts of 
R133C-GFP mice and their wildtype littermates at the two time points was 
preferable to using the same cohort of mice in a longitudinal study design. This was 
because the mice would not have had the opportunity to learn, or acclimatise to the 
testing apparatus, which would appear less anxiety-provoking on the second 
presentation, thus potentially confounding the results of the elevated plus maze and 
the open field tests. Additionally, the mice may have achieved artificially loner times 
on the accelerating rotarod and reducedimprovement across days of testing due to 
retained motor learning from the experimental run at 9-10 weeks. On the contrary, 
the possibility that the second cohort of R133C-GFP mice and their wildtype 
littermates (tested at 20-21 weeks) were different in some unaccounted for way to the 
initial cohort (tested at 9-10 weeks) cannot be excluded. A longitudinal behavioural 
study design would therefore complement the behavioural, phenotypic scoring, 
growth and survival data from this study in concluding that there was progression in 
the behavioural phenotype of the R133C-GFP mice. 
4.8.4 Possible confounders of +/R133C-GFP behavioural analysis 
There was no discernible behavioural phenotype in the +/R133C-GFP mice – 
arguably the true model of Rett syndrome. The females began to phenotypically 
score at around eleven months and the behavioural testing was done at one year (due 
to time constraints), so perhaps this was too early to detect a significant difference 
from the wildtype littermates. Should the females have been tested at 1.5 or 2 years, 
for example, given the progressive nature of the RTT phenotype, a behavioural 
deficit may have been more obvious in the +/R133C-GFP mice. The behavioural 
cohort was more outbred than the scoring cohort (87.5% C57BL/6J) and the 
+/R133C-GFP, but not the wildtype, experimental group contained Cre positive 
mice (5 of 8), due to low availability of females of a suitable age. This was a remnant 
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of breeding with the C57BL/6J CMV-Cre deleter line, in order to remove the NEO 
cassette from the targeted Mecp2 locus. It was not anticipated that Cre positivity 
would affect the behavioural performance. It may have acted as a confounder 
because it appeared that the Cre positive mice were more active than the Cre 
negative mice. Mice were monitored by tracking software during the elevated plus 
maze and open field trials. Maps of mouse activity showed that the Cre positive 
individuals travelled greater distances during the trials. In addition Cre positive mice 
were jumpy and hyperactive in the cage environment and when being handled. From 
analysis of individual animal’s performances, this increased activity did not seem to 
impact on the decision to spend more time in the safer areas of the apparatus, 
although this is difficult to conclude with any certainty. It would be interesting to 
repeat the behavioural analysis in a group of females on a pure C57BL/6J 
background in the absence of Cre to see if the same results are achieved. 
4.8.5 The R133C mutation produces a milder Rett-like phenotype 
than R306C or T158M 
Once the R133C-GFP mouse phenotype was known, it was possible to compare the 
observational and behavioural data to that of other GFP-tagged mutant mouse lines 
to determine if the R133C mutation resulted in the least severe phenotype of the 
allelic series. Here the WT-GFP line was employed to control for the presence of the 
GFP tag in the mutants as a potential confounder of any difference from their 
wildtype littermates. This was a useful exercise, as although the WT-GFP mice did 
not weigh significantly less, have higher phenotypic scores, or reduced survival 
compared to their wildtype littermates (data not shown), they were impaired on the 
hanging wire test. Therefore determining the difference between wildtype and mutant 
mean latencies to bring one hind paw to the wire was useful as an alternative read-
out of phenotypic severity. Despite this, the WT-GFP mice performed as well as their 
wildtype littermates on all other behavioural paradigms. The overwhelming 
conclusion therefore is that the WT-GFP mice do not have an overt phenotype and so 
can be used as a proxy wildtype comparator for the allelic series. There was some 
evidence that they had mild overexpression of MeCP2, which may be related to the 
detected motor deficit as mice also display neurological phenotypes with 
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overexpression of MeCP2 (Collins et al, 2004). This is discussed in more detail in 
Chapter 5. 
4.8.6 Summary 
Weight, average phenotypic score, survival and behavioural data all pointed 
convincingly towards the R133C-GFP mouse having the least severe phenotype of 
the allelic series. Therefore the R133C-GFP mouse nicely recapitulates human Rett 
syndrome caused by the R133C mutation and lends extra weight to conclusions from 
the patient studies (Leonard et al, 2003; Bebbington et al, 2008; Cuddapah et al, 
2014). This supports important prognostic information for families of affected 
patients, at the point of diagnosis of Rett syndrome. Although Rett syndrome caused 
by the R133C mutation is still a severe and debilitating illness, the possibility of 
preservation of some faculties is hugely encouraging for affected families. 
Additionally, the mouse line will provide a useful resource for study of therapeutic 
strategies as well as a vehicle for determining the molecular basis of MECP2R133C 





5. The Molecular Basis of Rett Syndrome Caused by 
the R133C Mutation 
5.1 Introduction 
Previous chapters have described creation of models in which to study MeCP2 
function and verification that within a model organism, the R133C mutation in 
Mecp2 produces a mild Rett-like phenotype, as is observed in Rett syndrome patients 
(Leonard et al, 2003). The goal of this chapter is to determine the specific deficits in 
MeCP2 function that are caused by the R133C mutation and their biological 
consequences. In other words, what is the molecular basis of MECP2R133C Rett 
syndrome? 
 
The bridge model, which was conceived from observing the distribution of Rett-
causing mutations, hypothesises that the critical function of MeCP2 is to connect the 
NCoR complex with methylated DNA in preventing Rett syndrome (Lyst & Bird, 
2015). MeCP2 works as a transcriptional repressor according to this model. The 
complexity of this theory increases when it is considered that in the unique neuronal 
methylome (Lister et al, 2013), MeCP2 binds to mCpG across the whole genome 
(Skene et al, 2010) but also binds to methylation and hydroxymethylation in a non-
CG context, about which very little is known (Guo et al, 2014; Gabel et al, 2015; 
Chen et al, 2015). It is possible that the capacity of MeCP2 to bind to different 
sequences and signalling moieties represents different biological functions of the 
protein. Support for this comes from the observation that in brain, although mCA 
content of long genes seems to relate to MeCP2 regulation (Gabel et al, 2015), genes 
that are downregulated in the absence of Mecp2 are also rich in mCH (Chen et al, 
2015). Furthermore, mCA in the neuronal genome has been associated with 
transcriptional repression (Xie et al, 2012; Guo et al, 2014), whereas mCA in the ES 
cell genome has not (Lister et al, 2009; Ziller et al, 2011). MeCP2 binding to 
methylation marks in different cellular contexts may result in alternative biological 
outcomes, perhaps dependent on the pool of binding partners in a particular cell type 
at a particular developmental stage. 
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Examining the specific deficits in MeCP2 function caused by Rett mutations will 
shed some light on these issues. The R133C mutation is well placed to disentangle 
the binding capacities of MeCP2 because it occurs in a key position of the MBD (Ho 
et al, 2008), yet results in a milder syndrome in humans (Cuddapah et al, 2014) and 
mice. One hypothesis is that the R133C mutation abolishes all of the protein’s 
binding capacities because the mutation lies in a key position in the MBD. Therefore 
the mutation no longer connects the NCoR complex to DNA and the result is Rett 
syndrome. This theory does not explain the reduced severity of R133C Rett. An 
alternative hypothesis is that the R133C mutation loses one of the binding capacities 
in particular and, for this reason, results in a milder form of Rett syndrome. The 
biological consequences of the second hypothesis might illuminate any differential 
effects of binding to mCpG versus mCA. For example, a unique gene expression 
profile in tissue derived from the R133C-GFP mouse.  
 
Previous studies have shown on one hand that MeCP2R133C binding to mCG is 
significantly impaired (Ballestar et al, 2000) and on the other hand that MeCP2R133C 
binding to mCG is near wildtype, but there is a specific impairment in binding to 
hmC in the context of DNA probes (Mellen et al, 2012). These conflicting findings 
have been replicated in cell culture experiments analysing localisation to heavily 
methylated heterochromatin, indicating both that binding is indistinguishable from 
wildtype (Kudo et al, 2003) and that it is modestly defective (Kumar et al, 2008; 
Schmeideberg et al, 2009; Agarwal et al, 2011). The only prior ChIP study of 
MeCP2R133C suggested a complete loss of binding selectivity for mCG (Baubec et al, 
2013). MeCP2R133C binding to mCH has not previously been investigated. 
 
In order to resolve these discrepancies and test the two hypotheses above, 
MeCP2R133C binding was analysed by confocal microscopy and ChIP in neuronal 
cells and mouse brain and by EMSA in vitro. ChIP regions included the BDNF 
promoter site, which has previously been shown to be an endogenous target of 
MeCP2 (Chen et al, 2003) and three classes of heavily methylated repetitive DNA: 
(1) highly abundant major satellite DNA, which constitutes almost half of murine 
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mCpG (Horz & Altenburger, 1981); (2) L1 long interspersed repetitive elements (L1 
LINE), which are integrated throughout the murine genome with truncated versions 
of the full-length consensus sequence being represented hundreds of thousands of 
times (Boyle et al, 1990; Brunmeir et al, 2010); (3) Intracisternal A-particle (IAP) 
elements, which are related to retroviruses and transpose into new genomic sites 
through reverse transcription of an RNA intermediate. They are represented around 
1000 times in the mouse genome (Barbot et al, 2002). MeCP2 binding has been 
shown to all three classes of repetitive DNA (Muotri et al, 2010; Skene et al, 2010; 
Chen et al, 2015). In addition, gene expression was investigated using microarrays in 
R133C-GFP cerebellum. These investigations were conducted with the purpose of 
determining the molecular basis of R133C Rett syndrome. 
5.2 Investigation of hypotheses that do not relate to DNA 
Binding 
5.2.1 R133C-GFP expression in neurons 
Lack of sufficient protein would be an obvious molecular cause of disease and so it 
was crucial to rule this out in the first instance. R133C-GFP mRNA and protein 
levels were measured in the neuronal cells and adult male mouse brain tissue using 
reverse transcription qPCR and western blot, respectively. Wildtype and WT-GFP 
cells and brain tissue were included for comparison: for the brain tissue, the wildtype 
samples were littermates of the R133C-GFP mice.  
 
The relative level of Mecp2 mRNA in the WT-GFP cells was 152% that of the 
wildtype neuronal cells (Figure 5.2.1A).  Interestingly, the presence of the R133C 
mutation reduced the level of Mecp2 mRNA, so that it was not significantly different 
from that in the wildtype cells (96%). This made R133C-GFP mRNA approximately 
63% of the measured level in WT-GFP cells. Although the level of MeCP2 protein 
appeared greatly increased by around four times in the WT-GFP neuronal cells, 
relative to wildtype, the difference did not reach significance due to variability 
between individual replicates (Figure 5.2.1B). The level of protein in the R133C-
GFP cells also appeared increased by around 1.6 times relative to wildtype cells, but 
 151 
this did not stand up to statistical testing, again due to variability in the results from 
replicate neuronal cultures. Comparing the two EGFP-tagged cell lines, the level of 
protein in R133C-GFP cells was 59% that in WT-GFP cells. Therefore from analysis 
of the neuronal cells, EGFP-tagging MeCP2 increased the level of the mRNA 
transcript by around 1.5 times, but having the R133C mutation on top abolished this 
effect. The Mecp2 mRNA level in R133C-GFP cells was around 60% of WT-GFP 
mRNA. There was a trend towards the same phenomenon in MeCP2 protein levels, 




Figure 5.2.1 R133C-GFP neuronal cells have reduced Mecp2 mRNA and a trend 
towards reduced MeCP2 expression in comparison to WT-GFP cells. 
 
(A) Graph showing that Mecp2 mRNA level is reduced in R133C-GFP neuronal cells relative 
to WT-GFP, but not wildtype (WT) cells. n=4, mean±SEM plotted, one-way ANOVA followed 
by Tukey’s multiple comparison post-hoc testing, ***p<0.001. 
(B) Left: representative western blot. Right: quantification of western blotting showing a trend 
towards reduced protein expression in R133C-GFP, relative to WT-GFP neuronal cells. n=3, 
mean±SEM plotted, one-way ANOVA, p=0.15. << MeCP2EGFP, < MeCP2, GT gamma 
tubulin.  
5.2.2 R133C-GFP expression in mouse brain 
The level of Mecp2 mRNA was also significantly increased in the WT-GFP male 
mouse brain, relative to wildtype (Figure 5.2.2A). WT-GFP brains had 152% the 
Mecp2 mRNA level found in wildtype brains, which was exactly the same increase 
found in the neuronal cell model. Again, the presence of the R133C mutation in 
addition reduced this back to a similar level found in wildtype brain (89%). The level 
of Mecp2 mRNA in R133C-GFP brain was therefore approximately 60% of that 
found in WT-GFP brain. These data were reflected in quantitative western blotting of 
whole brain lysates (Figure 5.2.2B). The level of MeCP2 in the WT-GFP brain was 
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163% the level in wildtype brain. Again, with the R133C mutation, the MeCP2 
protein level dropped back to 93% of the level in wildtype brain. This means that the 
MeCP2 protein level in the R133C-GFP brain was 57% of that in WT-GFP brain. 
The relative mRNA and protein levels found in the neuronal cell model therefore 
support the relative levels found in using the whole brain tissue. To conclude, the 
R133C mutation reduces Mecp2 mRNA and protein levels by approximately 40% in 
vitro and in vivo. 
 
 
Figure 5.2.2 Mecp2 mRNA and protein expression is reduced by 40% in adult male 
R133C-GFP mouse brain, relative to WT-GFP. 
 
(A) Graph showing that Mecp2 mRNA level is reduced in R133C-GFP mouse brain relative 
to WT-GFP, but not wildtype (WT) brain. n=4, mean±SEM plotted, one-way ANOVA followed 
by Tukey’s multiple comparison post-hoc testing, **p<0.01.. 
(B) Left: representative western blot for mouse brain. Right: quantification of western blotting, 
showing a reduction in MeCP2 expression in R133C-GFP brain, relative to WT-GFP. n=3, 
mean±SEM plotted, one-way ANOVA followed by Tukey’s multiple comparison post-hoc 
testing, ***p<0.001. << MeCP2EGFP, < MeCP2, GT gamma tubulin. 
 
5.2.3 WT-GFP expression in the GFP-tagged allelic series 
These findings were placed in the context of data from the comparator mouse lines, 
comprising the EGFP-tagged “allelic series”, which was quantified by J.Selfridge. 
With reference to Figure 5.2.3A, it can be seen that all the other EGFP-tagged 
mutants had significantly increased Mecp2 mRNA, relative to their own wildtype 
littermates. However, figure 5.2.3B shows that the relative protein abundance does 
not reflect this pattern in brain. R306C-GFP protein was increased by 146% relative 
to wildtype, but T158M-GFP protein levels were only 50% of wildtype. Placing this 
in the context of protein abundance, R306C-GFP, R133C-GFP and T158M-GFP are 
90%, 57% and 31%, respectively of WT-GFP. Therefore it is likely that reduced 
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protein abundance of MeCP2T158M contributes to the severity of Rett syndrome and 
may be the first indication of the reason that MECP2R133C, another MBD mutant, 
produces a milder syndrome in patients. It is unlikely that protein abundance 
contributes to the MECP2R306C phenotype. 
 
 
Figure 5.2.3 MeCP2 protein expression in adult male mouse brain partially explains 
the severity spectrum in the EGFP-tagged allelic series. 
 
(A) Graph showing that Mecp2 mRNA is significantly increased in GFP-tagged mouse lines, 
other than R133C-GFP, relative to their wildtype littermates. WT-GFP (n=9); R133C-GFP 
(n=4); R306C-GFP (n=3); T158M-GFP (n=3), mean ±SD plotted. 
(B) Quantification of western blotting showing a significant reduction in T158M-GFP protein 
in mouse brain, relative to wildtype. WT (n=6); WT-GFP (n=6); R133C-GFP (n=3); R306C-
GFP (n=4); T158M-GFP (n=6), mean±SEM plotted. 
**p<0.01, ***p<0.001, unpaired t-test. Data from JS added for WT-GFP, R306C-GFP & 
T158M-GFP. 
 
5.2.4 R133C-GFP association with the NCoR complex 
Another important cause of Rett syndrome, according to the bridge model, is failure 
to associate with the NCoR transcriptional repressor complex (Figure 5.2.4A; Lyst & 
Bird, 2015). This is thought to be the molecular mechanism of Rett syndrome caused 
by MECP2R306C (Lyst et al, 2013). It was important to rule this out as a contributory 
factor in the pathogenesis of Rett syndrome caused by MECP2R133C. Co-
immunoprecipitation experiments were done using whole brain lysates in order to 
check for association of MeCP2 with NCoR complex components, transducin β-like 
protein 1 related protein 1 (TBLR1) and histone deacetylase 3 (HDAC3) in vivo. 
MeCP2 was pulled down by virtue of its EGFP tag using an anti-GFP antibody and 
so in this experiment, the wildtype littermates acted as a negative control for the 
MeCP2 pull down, given that the protein was untagged. Association with NCoR 
components was detected using western blot of immunoprecipitates and the GFP-pull 
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down was checked with a C-terminal anti-MeCP2 antibody. R306C-GFP brains were 
included as a negative control for NCoR association. 
 
Figure 5.2.4 R133C-GFP associates with NCoR 
 
(A) Simple cartoon depiction of the NCoR complex components in association with MeCP2, 
which, in turn, is making contact with DNA. GPS2, G protein pathway suppressor 2. 
(B) Co-immunoprecipitation of MeCP2 and NCoR components in whole cell lysates from 
adult male mouse brain. MeCP2 was immunoprecipitated using an anti-GFP antibody and 
MeCP2-bound NCoR components were assayed using western blots. R133C-GFP 




With reference to Figure 5.2.4B, it can be seen that there was a protein of between 70 
and 100 kDa in the wildtype input lane of the MeCP2 blot, representing untagged 
MeCP2. The presence of TBLR1 (55-70 kDa) and HDAC3 (<55 kDa) was also 
detected. The wildtype immunoprecipitate (IP) lane was clear of all these proteins, 
indicating the specificity of the GFP pull-down. The WT-GFP input lane revealed a 
protein of between 100 and 130 kDa in the MeCP2 blot, which was the EGFP-tagged 
MeCP2. From scrutiny of all the EGFP-tagged protein input lanes, further evidence 
of the protein expression levels calculated in the preceding section could be seen: the 
band in the WT-GFP input lane was the darkest, followed by R306C-GFP, R133C-
GFP then T158M-GFP. There was an enrichment of WT-GFP in the IP lane along 
with a band representing protein degradation (MeCP2 without the EGFP tag) and a 
non-specific band migrating at a smaller size. The presence of TBLR1 and HDAC3 
could be seen in the WT-GFP IP lane, indicating that WT-GFP associated with these 
proteins in mouse brain. The same pattern is seen in the R133C-GFP co-IP, 
 155 
indicating that MeCP2 with the R133C mutation still associates with NCoR 
components and therefore failure to interact with NCoR is not the cause of Rett 
syndrome in this model. The R306C-GFP IP lane was free of NCoR components, 
reproducing the data that this mutant protein does not associate with NCoR in vivo 
(Lyst et al, 2013). There was evidence that T158M-GFP also associated with NCoR 
from the co-IP. To summarise, the two MECP2 missense mutants that are located in 
the MBD, R133C and T158M, still associated with NCoR in vivo and so it is unlikely 
that failure to associate with this complex plays a role in the pathogenesis of their 
resulting Rett syndromes. 
5.3 R133C-GFP association with chromatin by microscopy 
The abundance of R133C-GFP was not reduced to a degree that would account for 
RTT in the mice as absolute protein levels were equivalent to untagged wildtype 
protein and the mutant protein still associated with NCoR components in vivo. 
Therefore, according to the bridge model, the pathogenesis should involve a deficit 
in DNA binding, which would be predicted, given the location of the mutation in the 
MBD of MECP2. Association with heterochromatin was investigated in the neuronal 
cell model and adult mouse brain using confocal microscopy. 
5.3.1 Verification of EGFP signal 
Figure 5.3.1 demonstrates the specificity of the EGFP signal for MeCP2 in adult 
male mouse hippocampus. In fixed sections, the neurons of the CA1 region of the 
hippocampus were stained with NeuN and their nuclei with DAPI. The characteristic 
heterochromatic dots of the murine cell nucleus can be seen with the DAPI stain. 
MeCP2 typically associates with these heterochromatic dots, as they represent a 
substantial fraction of mCG in the mouse genome (Horz & Altenburger, 1981). 
Mecp2-null, wildtype and WT-GFP brains were compared to demonstrate (1) the 
lack of EGFP staining in the Mecp2-null and wildtype brains, (2) the presence of the 
MeCP2 signal in wildtype and WT-GFP brains using a C-terminal anti-MeCP2 
antibody and (3) that this MeCP2 staining corresponds to the EGFP staining in the 
WT-GFP brains. Therefore EGFP signal is specific, representing MeCP2 with the 
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EGFP tag and the tagged protein displays the expected punctate pattern of 




Figure 5.3.1 Verification that the GFP signal in tagged lines corresponds to MeCP2. 
 
Sections of male mouse adult hippocampus were stained for NeuN (red), DAPI (blue) and 
MeCP2 (white) and visualised by confocal microscopy. Mecp2-null (null), wildtype (WT) and 
WT-GFP brains are shown to demonstrate the normal pattern of MeCP2 localisation to 
heterochromatic foci and that the GFP signal (green) in the WT-GFP brains is specific to 
MeCP2. Scale bar represents 20µm. 
 
5.3.2 Reduced association of R133C-GFP with chromatin in 
neurons 
R133C-GFP binding was analysed in the neuronal cells, differentiated from ES cells 
in culture, in comparison to the EGFP-tagged allelic series mutants (Figure 5.3.2A). 
Cells stained for NeuN, indicating that they were post-differentiation neuronal cells. 
R133C-GFP binding appeared to be abnormal when the protein was viewed by 
confocal microscopy using its EGFP tag (Figure 5.3.2A). In contrast to WT-GFP and 
R306C-GFP, the protein did not clearly correspond to the heterochromatic foci, 
visualised using the DAPI panel. This was also apparent in the DAPI/GFP merge 
panel, where DAPI dots with no corresponding GFP signal can be seen. The R133C-
GFP protein appeared to be diffusely spread throughout the nucleus, with no clear 
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confinement to the dots. This was also apparent, to a greater degree, in the T158M-
GFP cells, where it was difficult to appreciate discernible dots in the GFP panel.  
 
Figure 5.3.2 Abnormal localisation of R133C-GFP to heterochromatic dots in neuronal 
cells. 
 
(A) Representative confocal microscopy images of WT-GFP, R133C-GFP, R306C-GFP and 
T158M-GFP neuronal cells. Localisation to heterochromatic foci was abnormal in the MBD 
mutants but not in R306C-GFP. NeuN (red), DAPI (blue), MeCP2EGFP (green). Scale bar 
10µm. 
(B) Graph showing quantification of MeCP2EGFP localisation to heterochromatic foci. A 
significantly lower proportion of MeCP2EGFP is bound to dots in the MBD mutants. 
Mean±SEM plotted. *p<0.05, **p<0.01, ***p<0.001 unpaired t-test. 
 
 
The GFP signal was quantified for fifty cells of each genotype from compressed z-
stack images. The proportion of GFP in DAPI dots was calculated as follows: 
individual cell nuclei were identified using Image Studio Software and verified 
manually; DAPI dot areas were identified by the software within each nucleus; the 
average GFP intensity within the DAPI dot defined areas was measured (a); the 
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average GFP intensity outwith the dot areas but within the nucleus was measured (b); 
the proportion of GFP in the dot areas was calculated as a/(a+b). This method 
controlled for overall MeCP2 expression variance between the genotypes. Using this 
technique, the proportion of MeCP2 in the nucleus that was located in the dots could 
be plotted and compared between the genotypes (Figure 5.3.2B). The R306C-GFP 
cells had a greater proportion of MeCP2 located in the dots than WT-GFP (0.62 vs 
0.60). The two MBD mutant cell lines R133C-GFP and T158M-GFP had a lower 
proportion of MeCP2 located in the dots than WT-GFP (0.58 and 0.54 vs 0.60, 
respectively). This result was compatible with the imaging data and indicated that 
although the MBD mutant proteins still bound to heterochromatin, proportionately 
less of the total nuclear protein fraction was located there i.e. more protein was 
spread, presumably unbound, throughout the nucleus. The degree to which the 
protein was able to bind to the heterochromatic foci also reflected the severity of the 
Rett syndrome phenotype: R133C-GFP was localised to a greater degree than 
T158M-GFP and produced a milder phenotype. Therefore this suggests that 
heterochromatin localisation could be a proxy measure of phenotypic severity for 
Rett mutations in the MBD. 
5.3.3 Reduced association of R133C-GFP with chromatin in male 
mouse brain  
Confocal microscopy of fixed sagittal sections of adult male mouse brain was 
performed in order to ascertain what the localisation pattern of R133C-GFP was in 
vivo (Figure 5.3.3). All images were initially taken with the same confocal settings, 
however due to the lower levels of MeCP2EGFP expression in the mutant brains 
(Figure 5.2.3B), it was difficult to see the protein localisation. For clarity, a second 
set of images was taken where the GFP signal was optimised for each mutant 
individually. This was done by applying a look-up table (LUT) to an image of the 
CA1 region of the hippocampus. In LUT, blue pixels denote over-saturation of the 
image and green pixels denote zero. Photon multiplier tube gain was kept constant 
and laser power was adjusted until one or two pixels were blue and as few pixels as 
possible were green. These settings were saved and used for all subsequent images 
for that genotype. 
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R133C-GFP localisation was viewed in the CA1 region, CA3 region and dentate 
gyrus of the hippocampus and cortical neurons in the approximate region of the 
motor cortex (Figure 5.3.3A-D, respectively). Figure 5.3.3A shows the classic 
binding pattern of MeCP2 with tight localisation to heterochromatic dots in the WT-
GFP hippocampus, CA1. This pattern was echoed in the R306C-GFP images. 
However, evidence of a more mixed punctate and diffuse binding pattern can be seen 
in R133C-GFP and T158M-GFP brains, indicating abnormal binding to DNA 
(represented in schematic GFP panel to the right of images). This is more clearly 
displayed in the lower panel of Figure 5.3.3A, taken with individual GFP settings for 
each genotype. Furthermore, in the DAPI/GFP merge panel on the GFP-optimised 
set of images, there is evidence of R133C-GFP and T158M-GFP binding in small 
foci outwith the DAPI dot regions (indicated more clearly in zoom images). These 
observations were made in all regions studied. Interestingly, in the cortical images 
(Figure 5.3.3D), there was evidence of reduced nuclear and soma size in the T158M-









Figure 5.3.3 Abnormal localisation of R133C-GFP to heterochromatic dots in male 
mouse brain. 
 
Confocal microscopy of male mouse brain revealed abnormalities of MeCP2EGFP localisation 
to heterochromatic foci in the MBD mutants but not of R306C-GFP in the CA1 region (A), 
CA3 region (B) & dentate gyrus (C) of the hippocampus and in motor cortex (D). Observed 
localisation pattern is indicated by a schematic GFP panel to the right of the images. 
Additionally, R133C-GFP and T158M-GFP localise to foci that do not correspond to DAPI 
dots. This is highlighted with white arrows in zoom images of circled cells in (A) & (B). 
Fixed sagittal brain sections (10µm) were stained for NeuN (red) and DAPI (blue). 
MeCP2EGFP (green). Upper panels were taken with the same confocal settings. In lower 
panels, GFP settings were optimised (opt) for each genotype to make binding pattern more 
visible. (A-C) scale bar represents 20µm; (D) scale bar represents 10µm, GFP optimised 
images only, white dotted lines indicate cells that were captured in their entirety by z-stacks. 
 
5.3.4 Reduced association of R133C-GFP with chromatin in 
female mouse brain  
The abnormal localisation of R133C-GFP is seen more easily in the images 
optimised for reduced protein abundance. To rule out the possibility that the diffuse 
binding pattern is an artefact of increasing the GFP laser intensity, a double mutant 
female mouse was created by crossing +/R133C-GFP mice with WT-GFP mice: WT-
GFP/R133C-GFP. These mice expressed either wildtype protein with an EGFP tag 
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or R133C protein with an EGFP tag: the exact proportion of either was subject to the 
pattern of XCI. The binding of both proteins was therefore captured using the same 
confocal settings in the same image. Figure 5.3.4A shows control images taken from 
female mice heterozygous for Mecp2EGFP (+/WT-GFP and +/R133C-GFP) prepared 




Figure 5.3.4 Abnormal localisation of MeCP2EGFP in approximately 50% of cells in the 
WT-GFP/R133C-GFP mouse brain.  
 
(A) Upper panel, CA1 region of hippocampus from +/WT-GFP brain shows EGFP expression 
in approximately 50% of the cells with punctate binding. Lower panel, CA3 region of 
hippocampus from +/R133C-GFP brain shows EGFP expression in approximately 50% of 
the cells with mixed punctate and diffuse binding. 
(B) Images of CA1, CA3 and motor cortex from the WT-GFP/R133C-GFP brain. All cells now 
express EGFP: there is an abnormal pattern of localisation to heterochromatic foci in 
approximately 50% of neuronal nuclei. 
Fixed sagittal sections were stained for NeuN (red), DAPI (blue) and MeCP2 (white). 




The +/WT-GFP image (Figure 5.3.4A, upper panel) taken from the CA1 area of the 
hippocampus shows all of the neuronal nuclei in the NeuN, DAPI and anti-MeCP2 
panels, but only half of the nuclei are visible in the GFP panel, indicating cells 
expressing WT-GFP from the active X chromosome. A typical punctate binding 
pattern can be seen in these nuclei. The pattern of XCI is also apparent in the 
DAPI/GFP merge panel, where the cells expressing wildtype MeCP2 only have blue 
DAPI dots. In contrast, the +/R133C-GFP image (Figure 5.3.4A, lower panel) from 
the CA3 area of the hippocampus again shows all the neuronal nuclei in the NeuN 
and DAPI panels and only some of the nuclei in the GFP panel, indicating cells 
expressing R133C-GFP from the active X chromosome, but this time the cells 
expressing the mutant protein, don’t stain with the anti-MeCP2 antibody and the 
binding pattern is a mixture of punctate and diffuse. This is reaffirmed in the images 
taken from the double mutant WT-GFP/R133C-GFP across all brain areas (Figure 
5.3.4B). All nuclei in the CA1 and CA3 regions of the hippocampus are stained with 
NeuN and DAPI, but only some (the WT-GFP expressing cells) stain with the anti-
MeCP2 antibody. The GFP panel in these images shows a mixed population of cells: 
some with clear punctate binding where MeCP2EGFP is bound to heterochromatic foci 
and some with a mixed punctate and diffuse binding pattern. The background nuclear 
GFP intensity in these mixed pattern cells appears equivalent to the background GFP 
intensity in the punctate cells, but the foci are less intensely stained. The protein 
displays lower affinity for the heavily methylated dot regions. The lack of anti-
MeCP2 staining in these cells also helps to identify them as the likely cells 
expressing R133C-GFP. The lack of anti-MeCP2 staining in the mutant cells was 
unexpected (see discussion). 
 
In summary, investigating R133C-GFP association with chromatin by confocal 
microscopy revealed that the mutant protein had a subtly abnormal pattern of 
localisation to heterochromatic foci in neuronal cells differentiated in culture and in 
the adult male and female mouse brain. This is in contrast to previous literature 
suggesting an indistinguishable binding pattern for MeCP2R133C using transfection of 
recombinant protein in non-neuronal cells (Kudo et al, 2003). These findings indicate 
that MeCP2R133C association with heavily methylated chromatin is impaired. 
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5.4 R133C-GFP association with chromatin by ChIP 
R133C-GFP binding to chromatin is impaired as measured by confocal microscopy. 
This DNA binding impairment can be further defined using ChIP where the amount 
of DNA, corresponding to specific genomic regions, that is pulled down by R133C-
GFP can be measured by qPCR. From this one can infer the strength of the protein’s 
association with the different regions.  
5.4.1 Verification of methylation status of target regions 
Four known MeCP2 binding sites were selected as ChIP regions in order to compare 
R133C-GFP binding to WT-GFP: major satellite DNA, L1 LINE and IAP elements 
(as methylated repetitive DNA) and the BDNF promoter region (as relatively 
unmethylated, CpG island-associated DNA). The methylation status of these regions 
in mouse brain was confirmed by bisulfite sequencing. Sodium bisulfite treatment of 
DNA converts all unmethylated cytosines to uracil, leaving methylated cytosines in 
tact. Regions of interest can be amplified by PCR using this bisulfite converted 
DNA, followed by sequencing. The methylation pattern of the original genomic 
DNA in this region can be inferred from any remaining cytosines in the sequenced 
PCR amplicon (Frommer et al, 1992).  
 
Given that MeCP2 binds to methylated DNA, it is possible that the methylation 
pattern of the underlying DNA could change in the absence of MeCP2: is one of the 
functions of MeCP2 to maintain genomic methylation patterns? It follows that if 
there is reduced association with DNA in R133C-GFP brain, the underlying 
methylation status of the DNA might alter. For this reason, bisulfite sequencing was 






Figure 5.4.1 Bisulfite sequencing of ChIP regions confirms methylation status in 
mouse brain. 
 
Bisulfite sequencing of repetitive elements and the BDNF promoter region in whole brain 
confirms that they are largely methylated and unmethylated, respectively. A map and 
bisulfite sequencing data are shown for each region. The black bar indicates genomic DNA 
with vertical black ticks representing CpG sites. Primers for qPCR are indicated as arrows 
and the location of the bisulfite amplicon by the grey bar. A scale bar is indicated. The 
methylation status of each CpG is represented by the circles: open are unmethylated; black 
filled are methylated; a dash indicates missing data. Each line represents a single clone. 
WT-GFP results are shown and were representative of wildtype and R133C-GFP 
sequencing. 
 
Figure 5.4.1 shows the results of the bisulfite sequencing over major satellite, L1 
LINE, IAP elements and the BDNF promoter for WT-GFP genomic DNA, along 
with the location of the bisulfite PCR amplicon. It can be seen that the bisulfite PCR 
amplicons correspond to the region amplified by qPCR following ChIP. Therefore 
the pattern of methylation was likely to be representative of the region bound by 
MeCP2 in the subsequent ChIP experiments. There were no major differences in the 
methylation pattern of the four regions between genotypes (wildtype and R133C-
GFP data not shown). Major satellite DNA was heavily methylated in wildtype, WT-
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GFP and R133C-GFP genomic DNA from whole brain (90%, 90% & 92% 
respectively); L1 LINEs were moderately methylated (67%, 63% & 72%); IAP 
elements were heavily methylated (98%, 96% & 80%); and the BDNF promoter 
region was largely unmethylated (3%, 5% & 8%). Therefore (1) it is unlikely that 
DNA methylation patterns change in the absence of MeCP2 binding and (2) these 
genomic regions could be considered representative of “methylated” and 
“unmethylated” DNA for all three genotypes for the purpose of ChIP analysis. 
5.4.2 Reduced binding of R133C-GFP in cultured neurons 
ChIP was performed to estimate R133C-GFP binding to major satellites, L1 LINEs 
and the BDNF promoter in neurons differentiated in culture. MeCP2 was 
immunoprecipitated using an anti-GFP antibody and so in this experiment WT-GFP 
cells and wildtype cells acted as positive and negative controls, respectively. The 
DNA immunoprecipitated by MeCP2 was expressed as a percentage of input DNA. 
Figure 5.4.2 shows that R133C-GFP pulled down 0.14% of the input DNA at major 
satellites. This was lower in comparison to WT-GFP (0.71%) but did not reach 
significance.  For L1 LINEs, R133C-GFP pulled down a significantly lower 
percentage of the input (0.10%) in comparison to WT-GFP (0.32%). Finally, at the 
BDNF promoter site, R133C-GFP also pulled down a significantly lower percentage 
of the input (0.09%) in comparison to WT-GFP (0.24%). This would equate to 
approximately 20%, 31% and 38% of WT-GFP binding at major satellites, L1 LINEs 
and the BDNF promoter site, respectively. This data must be interpreted with the 
consideration that background protein abundance is only 60% of WT-GFP in the 
R133C-GFP cells. In summary, in the neuronal cells, there is evidence of a reduction 
in R133C-GFP association with both methylated and unmethylated genomic sites in 





Figure 5.4.2 R133C-GFP binding to chromatin is significantly reduced, relative to WT-
GFP by GFP ChIP. 
 
Graph depicting significantly lower percentage of input DNA pulled down by R133C-GFP at 
L1 LINEs (LINE) and the BDNF promoter in comparison to WT-GFP in neuronal cells. n=3. 
Mean % input±SEM plotted. *p<0.05, **p<0.01, ns, p=0.05, unpaired t-test. 
 
5.4.3 Reduced binding of R133C-GFP in mouse brain 
The ChIP was repeated using the same regions plus IAP elements as another example 
of methylated repetitive DNA, in adult male mouse brain (Figure 5.4.3A). Relative to 
WT-GFP, there was a trend towards reduced R133C-GFP binding at major satellites 
(0.63% vs 0.19%), L1 LINEs (0.23% vs 0.11%), IAP elements (0.30% vs 0.13%) 
and the BDNF promoter (0.23% vs 0.11%). These relative reductions in percentage 
input did not stand up to statistical testing because the percentage of input DNA that 
was pulled down for both genotypes varied between replicate experiments (see 
discussion). In fact, the R133C-GFP percentage input expressed as a percentage of 
WT-GFP signal was quite consistent between replicates. Nevertheless, the results 
supported the findings in neuronal cells in that R133C-GFP binding was reduced 
relative to WT-GFP binding at methylated and unmethylated sites in the genome. 
R133C-GFP binding was approximately 30%, 48%, 43% and 48% of WT-GFP 
binding at major satellites, L1 LINEs, IAP elements and the BDNF promoter, 
respectively.  
 
With the knowledge that the R133C mutation reduced MeCP2 protein abundance by 
around 40%, it was observed that the ChIP results could simply reflect protein 
abundance and not a deficit in DNA binding. FRAP data revealed that MeCP2EGFP 
dissociates from methylated DNA every 22 seconds and MeCP2R133CEGFP every 15 
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seconds (Schmiedeberg et al, 2009). Therefore in the eight minute ChIP cross-
linking period, increasing amounts of MeCP2 would continue to bind to DNA. This 
might cloud the picture of relative binding of the two genotypes, as ambient nuclear 
protein could continue to associate until all binding sites are occupied and the 
readout reflected protein abundance instead of binding capacity (Poorey et al, 2013). 
The ChIP protocol was modified in order to address this issue, firstly by reducing the 
cross-linking time from eight minutes to one minute and secondly, by reducing the 
cross-linking temperature: samples were cross-linked straight from ice instead of 
being allowed to acclimatise to room temperature. 
 
The results achieved following modification of the ChIP protocol are shown in 
Figure 5.4.3: shortening the cross-linking period (B) and lowering the cross-linking 
temperature (C). S.Lagger contributed replicate data to (B). Shortening the cross-
linking time to one minute had little impact on the relative reduction in R133C-GFP 
binding. At major satellites mutant protein pulled down 0.62% of the input DNA, 
which was significantly lower than WT-GFP (1.31%) and represented 47% of 
binding. At L1 LINEs mutant protein pulled down 0.41% of the input DNA, which 
was significantly lower than WT-GFP (0.89%) and represented 46% of binding. At 
IAP elements mutant protein pulled down 0.56% of the input DNA, which was 
significantly lower than WT-GFP (1.20%) and represented 47% of binding. Finally, 
at the BDNF promoter, mutant protein pulled down 0.39% of the input DNA, which 
was significantly lower than WT-GFP (0.66%) and represented 59% of binding. 




Figure 5.4.3 Increasing the stringency of GFP ChIP exposed a binding deficit in 
R133C-GFP at repetitive DNA and the BDNF promoter. 
 
(A) Graph showing trend for reduced binding of R133C-GFP to major satellites, L1 LINEs, 
IAP elements and the BDNF promoter, relative to WT-GFP in mouse brain by GFP ChIP, 
n=3, p values for non-significant comparisons are detaied in adjacent table. 
(B) Graph showing significant reduction in binding for R133C-GFP to methylated and 
unmethylated genomic regions relative to WT-GFP with 1 minute cross-link, n=3-4.  
(C) Reducing the cross-linking temperature revealed a marked reduction in R133C-GFP 
binding at all ChIP regions, relative to WT-GFP, n=4. 
Wildtype (WT). Mean % input±SEM plotted. *p<0.05, ** p<0.01, ***p<0.001, unpaired t-test. 
 
 
Lowering the cross-linking temperature in addition to shortening the cross-linking 
time (Figure 5.4.3C) yielded different results. At major satellites mutant protein 
pulled down 0.14% of the input DNA, which was significantly lower than WT-GFP 
(0.99%) and represented 14% of binding. At L1 LINEs mutant protein pulled down 
0.08% of the input DNA, which was significantly lower than WT-GFP (0.54%) and 
represented 15% of binding. At IAP elements mutant protein pulled down 0.11% of 
the input DNA, which was significantly lower than WT-GFP (0.72%) and 
represented 15% of binding. Finally, at the BDNF promoter, mutant protein pulled 
down 0.09% of the input DNA, which was significantly lower than WT-GFP 
(0.38%) and represented 24% of binding. These more stringent conditions appeared 
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to expose a deficit in binding to DNA in the mutant protein (relative to WT-GFP) 
that did not track protein abundance and had not been appreciable previously. It 
approximated to a 6-7 fold reduction in binding at methylated sites and a 4 fold 
reduction at the unmethylated site. This reduction was a combination of reduced 
protein abundance and chromatin binding, as would be the case in patients with the 
R133C mutation. 
5.4.4 ChIP supports the phenotypic severity spectrum in the GFP-
tagged allelic series 
These results were placed in the context of the EGFP-tagged allelic series for 
comparison (Figure 5.4.4). The R306C-GFP and T158M-GFP ChIP experiments 
were done in parallel under the stringent conditions with lower cross-linking 
temperature. S.Lagger contributed one replicate. The hypothesis was that the amount 
of R133C-GFP bound to the four regions (as inferred from the percentage of input 
DNA measured by real time qPCR) would be greater than T158M-GFP. The reason 
was firstly, because R133C-GFP is more abundant than T158M-GFP and secondly, 
the DNA binding deficit was predicted to be less severe for R133C-GFP because, by 
confocal microscopy, the localisation to heterochromatic foci appeared to be more 
deranged in the T158M-GFP brain. The converse was predicted for R306C-GFP, 
which was more abundant, had a normal pattern of localisation by microscopy and 
carried a mutation in the domain of Mecp2 that binds to the NCoR complex (Lyst et 
al, 2013).  
 
Compared to WT-GFP pulling down 0.99% of input at major satellite DNA, the 
percentage input pulled down by all the mutants was lower: R133C-GFP (0.14%); 
R306C-GFP (0.38%); and T158M-GFP (0.07%). This equated with 14%, 38% and 
7% of WT-GFP binding, respectively. At L1 LINEs, WT-GFP pulled down 0.54%, 
which was more than R133C-GFP (0.08%), R306C-GFP (0.19%) and T158M-GFP 
(0.05%). This was the equivalent of 15%, 35% and 9% of WT-GFP binding, 
respectively. Relative to the percentage of input DNA pulled down by WT-GFP at 
IAP elements (0.72%), the percentage bound by the mutants was lower: R133C-GFP 
(0.11%), R306C-GFP (0.24%) and T158M-GFP (0.05%). This corresponded to 15%, 
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33% and 7% of WT-GFP binding, respectively. The final region assessed was the 
BDNF promoter: compared to 0.38% for WT-GFP, again, all the mutants bound a 
lower percentage of their input DNA: R133C-GFP (0.09%), R306C-GFP (0.16%) 
and T158M-GFP (0.05%). This equated with 24%, 42% and 13% of WT-GFP 
binding, respectively. Therefore it was observed that the amount of R133C-GFP 
bound to these specific genomic regions under stringent conditions was intermediate 
between R306C-GFP and T158M-GFP. This was compatible with the hypothesis 
stated above. The non-significant trend towards reduced R306C-GFP binding at all 
ChIP regions, relative to WT-GFP was in line with a previous report that showed 
significantly reduced DNA binding relative to WT-GFP (Heckman et al, 2014). 
 
Figure 5.4.4 Significantly reduced binding of GFP-tagged MBD mutants, relative to 
WT-GFP at all ChIP regions. 
 
Graph displaying GFP ChIP under stringent conditions for the EGFP-tagged allelic series at 
major satellite DNA, L1 LINEs, IAP elements and the BDNF promoter region in male mouse 
brain. Significantly less of the MBD mutant protein (R133C-GFP and T158M-GFP) is bound 
to all four sites, relative to WT-GFP. Wildtype (WT). n=3-4. Mean % input±SEM plotted. 
*p<0.05, unpaired t-test. 
 
In summary, GFP ChIP revealed that R133C-GFP binding to heavily methylated 
repetitive DNA and an unmethylated site is reduced relative to WT-GFP in both 
neuronal cells and the male mouse brain. Under standard ChIP conditions in mouse 
brain, the reduction in binding was 2-3 fold, whereas under more stringent 
conditions, the reduction was 6-7 fold at methylated sites and 4 fold at the 
unmethylated BDNF promoter region. Placing this in the context of the EGFP-tagged 
allelic series, significantly less of the two MBD mutants, R133C-GFP and T158M-
GFP, was bound at all assayed sites. This result was consistent with the confocal 
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microscopy findings that showed an abnormal pattern of localisation in these two 
mutants. In both cases, the deficit in R133C-GFP binding seemed to be less severe, 
in keeping with the decreased severity of the Rett syndrome phenotype in patients 
carrying this mutation. The objective was to further refine the DNA binding deficit to 
place it in the context of known MeCP2 binding capacities. 
5.5 Mecp2R133C binding in vitro by EMSA. 
Thus far, it has been shown that R133C-GFP does not associate perfectly with 
heterochromatic foci and significantly less R133C-GFP was bound to methylated 
repetitive DNA and an unmethylated site, relative to WT-GFP. These in vivo 
experiments have the limitation that they are influenced by the reduced protein 
abundance of MeCP2R133C. It has previously been suggested that MeCP2R133C loses 
binding specifically to hmC (Mellen et al, 2012), however this does not seem 
compatible with the results presented so far. The goal was to answer the question of 
whether MeCP2R133C has a sequence-specific DNA binding deficit, where only a 
subset of MeCP2 binding sites are affected. 
 
EMSAs were employed as an experimental tool to answer this question. In this assay, 
protein binding to specific radio-labelled oligonucleotide probes can be 
quantitatively determined. It is possible to modify these oligonucleotides to be 
methylated or hydroxymethylated and so MeCP2R133C binding to hydroxymethylated 
DNA could be investigated. Although it has been reported in the literature that 
MeCP2 binds to hmCpG in vitro (Mellen et al, 2012; Spruijt et al, 2013), this has 
since been disproved in vivo (Gabel et al, 2015; Chen et al, 2015) in agreement with 
earlier in vitro data (Valinuck et al, 2004; Hashimoto et al, 2012) and unpublished 
work from Professor Bird’s lab: in fact MeCP2 only binds with high affinity to 
hmCA (Gabel et al, 2015). Additionally, J.Connelly found that MeCP2 binds with 
greatest affinity to methylation or hydroxymethylation in a CAC context 
(unpublished data). mCAC is overwhelmingly the most abundant form of mCH in 
the adult brain (Lister et al, 2013) and it has recently been shown that MeCP2 binds 
to mCA in vivo (Gabel et al, 2015). For these reasons, it was decided to investigate 
MeCP2R133C binding to methylation in a CG and CAC context and 
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hydroxymethylation in a CAC context, as these are the principal binding sites of 
MeCP2 in vivo. J.Connelly’s investigation of MeCP2 binding employed a 58-mer 
corresponding to a region of intron 3 of the BDNF locus. This probe contained a 
single central CpG site that could be altered in sequence context or methylation. The 





Figure 5.5.1 In vitro investigation of DNA binding by EMSA. 
 
(A) The 58mer double stranded oligonucleotide from the BDNF promoter IV region used in 
EMSA’s with a single central CpG site indicated in red. This site could be methylated or 
hydroxymethylated in a CpG or CAC context. 
(B) Schematic representation of MeCP2 protein isoform e2. The major functional domains 
are shown: the methylated DNA binding domain (MBD) with position of the R133C missense 
mutation, the nuclear localisation signal (NLS) and the NCoR Interaction Domain (NID), 
along with three putative AT hooks. For comparison, the (1-205) polypeptide used in EMSA 
experiments is represented. 
(C) SDS-PAGE showing MeCP2(1-205) (WT) and MeCP2(1-205)R133C (R133C). The 
polypeptide was expressed in E.coli then purified by two steps. There is only one major 
migrating species between 35 and 40 kilodaltons with no evidence of polypeptide 
degradation. 
 
5.5.1 Expression & purification of MeCP2(1-205) 
The 1-205 fragment of human MeCP2 was employed for ease of purification and use 
in the EMSA. This fragment contains the N-terminal portion of the protein as well as 
the MBD and the first AT hook of MeCP2 (Figure 5.5.1B). A suitable recombinant 
polypeptide expression vector containing the 1-205 fragment with a C-terminal 
histidine tag was available in the lab. The R133C mutation was engineered by site-
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directed mutagenesis. Recombinant polypeptide was expressed in E.coli then purified 
in two steps. Firstly, it was extracted from bacterial cell lysates by its histidine tag 
using nickel-coated sepharose beads. Secondly, the polypeptide was eluted from a 
sulphopropyl sepharose column by cation exchange. This two-step process resulted 
in minimal degradation. An example of the recombinant polypeptide used in the 
EMSAs is shown in Figure 5.5.1C. There was only one major migrating species 
corresponding to MeCP2(1-205). 
5.5.2 Wildtype MeCP2(1-205)R133C binding to mCpG 
MeCP2(1-205)R133C binding to the BDNF probe that was singly methylated at the 
central CpG, relative to MeCP2(1-205), is shown in Figure 5.5.2. Polypeptide 
concentration was decreased while the concentration of competitor DNA and radio-
labelled probe were kept constant. The percentage of probe shifted was quantified 
using Image J software and plotted on a binding curve. Interestingly, MeCP2(1-
205)R133C binding to a single mCpG dyad was indistinguishable from MeCP2(1-205) 
binding. For example, at the highest polypeptide concentration MeCP2(1-205)R133C 
shifted 66% of the probe and MeCP2(1-205) shifted 64%. 
5.5.3 Reduced MeCP2(1-205)R133C binding to mCAC 
In contrast, when binding to mCAC was measured, MeCP2(1-205)R133C was easily 
distinguishable from MeCP2(1-205) (Figure 5.5.3). At the maximum polypeptide 
concentration measured, MeCP2(1-205)R133C shifted significantly less of the 
oligonucleotide probe compared to MeCP2(1-205) (27% vs 43%). The same was true 






Figure 5.5.2 MeCP2(1-205)R133C binding to mCpG is indistinguishable from wildtype. 
 
(A) Representative gel showing mCpG probe bound and shifted by polypeptide (<) in 
comparison to free probe (<<) for decreasing concentrations (triangle) of MeCP2(1-205) 
(WT) and MeCP2(1-205)R133C (R133C). - no protein. 
(B) Quantification graph of EMSAs (n=3) showing that the percentage of mCpG probe 




Figure 5.5.3 MeCP2(1-205)R133C binding to mCAC is reduced relative to wildtype. 
 
(A) Representative gel showing mCAC probe bound and shifted by polypeptide (<) in 
comparison to free probe (<<) for decreasing concentrations (triangle) of MeCP2(1-205) 
(WT) and MeCP2(1-205)R133C (R133C). - no protein. 
(B) Quantification graph of EMSAs (n=3) showing that the percentage of mCAC probe 
shifted was significantly reduced for MeCP2(1-205)R133C. Mean percentage of probe shifted 
is plotted±SEM. *p<0.05, ** p<0.01, unpaired t-test. 
 
5.5.4 Reduced MeCP2(1-205)R133C binding to hmCAC  
This differential binding was also apparent with the hmCAC probe (Figure 5.5.4). 
MeCP2(1-205)R133C shifted significantly less of the oligonucleotide probe at all 
concentrations except the maximum (28% vs 40%), although there was a trend 
towards this. There was negligible binding of MeCP2(1-205) and MeCP2(1-




Figure 5.5.4 MeCP2(1-205)R133C binding to hmCAC is reduced relative to wildtype. 
 
(A) Representative gel showing hmCAC probe bound and shifted by polypeptide (<) in 
comparison to free probe (<<) for decreasing concentrations (triangle) of MeCP2(1-205) 
(WT) and MeCP2(1-205)R133C(R133C). - no protein. 
(B) Quantification graph of EMSAs (n=3) showing that the percentage of hmCAC probe 
shifted was significantly reduced for MeCP2(1-205)R133C at all but the highest measured 
protein concentrations. Mean percentage of probe shifted is plotted±SEM. *p<0.05, ** 
p<0.01, unpaired t-test. 
 
Therefore measuring MeCP2(1-205)R133C DNA binding using EMSAs revealed a 
specific deficit where the mutant polypeptide had reduced binding to methylation and 
hydroxymethylation in a CAC sequence context, relative to wildtype. In contrast the 
binding to methylation in a CpG context was indistinguishable from wildtype. 
5.5.5 Reduced MeCP2(77-167) binding to mCpG 
Although this result was intriguing, an identical experiment by J.Connelly using a 
smaller fragment of MeCP2(77-167), corresponding to the MBD, yielded different 
results (Figure 5.5.5). He found that the MeCP2(77-167)R133C polypeptide had 
virtually no binding to the mCpG probe (2% shift vs 68% wildtype shift). This raised 
the question of whether the specific binding deficit to CAC (hydroxy)methylation 
was an artefact of using a particular fragment of MeCP2 in this in vitro technique. 
The objective was now to investigate the possibility of a specific loss of binding to 




Figure 5.5.5 MeCP2(77-167)R133C binding to mCpG is virtually abolished. 
 
(A) Representative gel showing mCpG probe bound and shifted by polypeptide (<) in 
comparison to free probe (<<) for decreasing concentrations (triangle) of MeCP2(77-167) 
(WT) and MeCP2(77-167)R133C (R133C). - no protein. 
(B) Quantification graph of EMSA’s (n=3) showing that the percentage of mCpG probe 
shifted was significantly reduced for MeCP2(77-167)R133C at higher polypeptide 
concentrations tested. Mean percentage of probe shifted is plotted±SEM. ** p<0.01, 
unpaired t-test. 
Data reproduced with permission from J.Connelly. 
 
5.6 R133C-GFP binding to mCAC in vivo 
The idea that the reduced severity in Rett syndrome caused by the R133C mutation 
could be attributable to a loss of one of the specific binding capacities of MeCP2 was 
fascinating. The goal was to search for evidence in the mouse brain that would 
corroborate the in vitro findings. There were three main approaches to this: (1) 
repetition of the GFP ChIP experiment described above in tissue with low levels of 
mCH; (2) GFP ChIP in new areas of the genome enriched for mCpG over mCAC 
(and vice versa); and (3) bisulfite sequencing of ChIP DNA. The focus was on 
detecting differences in binding to mCpG sequences and mCAC sequences and not 
on binding to hmCAC sequences. The reason was that the level of hmCAC is very 
low by current estimates (Lister et al, 2013) and so associated MeCP2 binding is 
unlikely to be biologically significant. 
5.6.1 ChIP in low mCH tissue 
Repeating the GFP ChIP on repetitive sequences and the BDNF promoter region in a 
tissue with low levels of mCH was the first strategy employed. The hypothesis was 
that the percentage input pulled down by R133C-GFP would increase relative to the 
WT-GFP signal when there was only mCpG to bind to. Most adult peripheral tissues 
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have low levels of mCH (Guo et al, 2014). The liver was selected for GFP ChIP 
initially. Unfortunately the low level of MeCP2 expression in the liver meant that the 
EGFP-tagged wildtype protein was barely detectable over the background negative 
control signal (data not shown). Another strategy was to use neonatal brain tissue. 
Levels of mCH don’t increase until mice are a couple of weeks old (Lister et al, 
2013), so brains were harvested at postnatal day 0-2 and used for GFP ChIP.  
 
Importantly, at this age the reduction in R133C-GFP expression, relative to WT-
GFP, was also 40%, as found in both the neuronal cell model and the adult mouse 
brain, and so the ChIP would be comparable (Figure 5.6.1A). R133C-GFP 
expression was 259% untagged wildtype levels, whereas WT-GFP was 446% of 
untagged wildtype levels by quantitative western blot (Figure 5.6.1A). The GFP 
ChIP revealed that R133C-GFP pulled down 0.29% of the input at major satellites, 
compared to 0.28% for WT-GFP (Figure 5.6.1B). At L1 LINEs, it was 0.14% and 
0.15% for R133C-GFP and WT-GFP, respectively. At IAP elements, the percentage 
of input DNA pulled down was 0.20% and 0.18% for R133C-GFP and WT-GFP, 
respectively. Finally, at the BDNF promoter, R133C-GFP pulled down 0.12%, 
compared to 0.12% for WT-GFP. There were no significant differences in the 
percentage of input DNA pulled down by R133C-GFP and WT-GFP at any of 
regions assayed. This was compatible with the hypothesis that the R133C-GFP ChIP 
signal would increase relative to WT-GFP in the neonatal brain in the absence of 
mCH, if R133C-GFP had a specific deficit in binding to mCAC. Although this 
appeared convincing, there was no significant difference in ChIP signal between the 
positive control (WT-GFP brain) and the negative control (wildtype brain). The 
variability of the results was high. Furthermore, the overall percentage input was 
low. These three points indicate that the abundance of WT-GFP was too low at this 







Figure 5.6.1 GFP ChIP in the male neonatal brain is compatible with a specific deficit 
in R133C-GFP binding to methylation in a CH context. 
 
(A) Left, western blot of MeCP2 (<) and MeCP2EGFP (<<) expression in wildtype (WT), WT-
GFP and R133C-GFP neonatal brain. GT, Gamma tubulin. Right, graph showing a 
significant decrease in R133C-GFP abundance relative to WT-GFP, n=3. Mean % WT 
level±SEM plotted. ** p<0.01, ***p<0.001, one-way ANOVA with Tukey’s multiple 
comparisons test. 
(B) There was no significant difference in the % input pulled down by R133C-GFP and WT-
GFP by GFP ChIP in neonatal brain, n=3-4. Mean % input±SEM plotted. Unpaired t-test, p 
values for non-significant comparisons are detailed in adjacent table. 
 
 
5.6.2 No change in R133C-GFP ChIP signal at mCAC rich sites 
The second strategy to investigate a specific deficit in R133C-GFP binding was to 
perform ChIP at selected sites in the genome that were enriched for mCpG and 
depleted of mCAC, “mCpG rich” sites or conversely, enriched for mCAC and 
depleted of mCpG “mCAC rich” sites. The Cytochrome p450 gene locus is a good 
example of a mCpG rich region in brain. Cytochrome p450 proteins are enzymes that 
utilise a haem cofactor in the metabolism of endogenous and exogenous chemicals 
(Danielson, 2002). They are highly expressed in the liver where they are essential for 
drug metabolism. In brain, the locus is coated in a blanket of CpG methylation, but 
contains regions where CH methylation and hydroxymethylation are virtually absent 
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(Figure 5.6.2A). Three of the cytochrome p450 genes – Cyp3a25, Cyp3a57 and 
Cyp3a59 were selected for ChIP. The mCAC rich sites were found by G.Schweikert. 
Regions of the genome were ranked by level of mCpG, mCAC and hmCpG (taking 
into account percentage methylation and number of sites) and outlier regions were 
chosen that were particularly enriched for mCAC and not mCpG (or 
hydroxymethylation). These regions were the Epidermal Growth Factor like domain 
7 (Egfl7) gene, Olfactory Receptor 325 (Olfr325) gene and Mitotic arrest deficient 
1|1 (Mad1|1) gene. Two regions that were devoid of methylation were included as 
controls: the Carboxypeptidase A6 (Cpa6) gene and Trans-acting T cell Specific 
Transcription Factor (Gata3) gene.  
 
The selected regions are represented in Figure 5.6.2B, where they are plotted for 
mCAC and mCpG level. These levels represent the region spanned by the real time 
qPCR primers (approximately 190bp), as well as the 5’ and 3’ flanking 150bp. This 
was to exclude the possibility that the methylation context was significantly different 
over neighbouring regions of the genome, which could also be immunoprecipitated 
by chromatin fragments of MeCP2EGFP, averaging 300bp in size. 
 
 
The hypothesis was that there would be less of a reduction in the R133C-GFP ChIP 
signal relative to the WT-GFP signal at the mCpG rich sites, but not the mCAC rich 
sites if there was a specific deficit in R133C-GFP binding to mCAC. Figure 5.6.2C 
shows the results. The real time qPCR primers were run on the same ChIP DNA that 
was derived from the GFP ChIP under the stringent conditions in Figure 5.4.3C.  
Starting with the mCpG rich sites, the percentage of input DNA for WT-GFP at 
Cyp3a25 was 0.70%. This was significantly higher than the percentage of input DNA 
for R133C-GFP (0.11%). At the second methyl-CG rich site, Cyp3a57, WT-GFP 
pulled down a significantly higher percentage of the input DNA than R133C-GFP 
(0.56% vs 0.11%). For the third methyl-CG rich site, Cyp3a59 the picture was the 
same with WT-GFP pulling down a significantly higher percentage of the input DNA 
than R133C-GFP again (0.64% vs 0.11%). So for the mCpG rich sites, Cyp3a25, 
Cyp3a57 and Cyp3a59, the percentage of WT-GFP ChIP signal for R133C-GFP was 
16%, 20% and 17%, respectively. These figures are similar to the percentage of WT-
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GFP signal for the mutant protein at repetitive elements and the BDNF promoter 




Figure 5.6.2 GFP-ChIP at mCAC regions in male mouse brain does not support the 
hypothesis that R133C-GFP has a specific DNA binding deficit. 
 
(A) Schematic of (hydroxy)methylation context of representative Cytochrome p450 gene 
locus, Cyp3a25. Produced with permission from S.Lagger’s unpublished TAB-seq data in 
sorted neurons, glia and liver for comparison. The site is devoid of mCAC and hmCpG in 
brain. 
(B) Plot of methylation level for selected mCpG rich (circles), mCAC rich (triangles) and 
control regions (squares). Level represents 190bp plus flanking 150bp up and downstream. 
(C) Graph of GFP ChIP showing that there is no sequence or methylation dependence on 
the relative percentage input for R133C-GFP compared to WT-GFP, n=4. Mean % 
input±SEM plotted. *p<0.05, ** p<0.01, unpaired t-test. 
 
Moving on to the mCAC rich sites, the percentage of input DNA for WT-GFP 
immunoprecipitated at Egfl7 was 0.48% (Figure 5.6.2C). This was significantly 
higher than the percentage of input DNA for R133C-GFP (0.10%). At the second 
mCAC rich site, Olfr325, WT-GFP pulled down a significantly higher percentage of 
the input DNA than R133C-GFP (0.57% vs 0.12%). For the third mCAC rich site, 
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Mad1|1 the picture was the same with WT-GFP pulling down a significantly higher 
percentage of the input DNA than R133C-GFP again (0.55% vs 0.11%). So for the 
mCAC rich sites, Egfl7, Olfr325 and Mad1|1, the percentage of WT-GFP ChIP 
signal for R133C-GFP was 21%, 21% and 20%, respectively. These results were 
almost identical to those for the mCpG rich sites described above. There was no 
relative reduction in R133C-GFP binding over the mCAC rich sites, compared to the 
mCpG rich sites. Further to this, the R133C-GFP signal at the control regions, Gata3 
and Cpa6, was a very similar percentage of the WT-GFP ChIP signal. At the first of 
the two sites with no cytosine methylation, Gata3, R133C-GFP pulled down 0.09% 
of the input, which was significantly less than WT-GFP (0.38%) and represented 
24% of the ChIP signal. At the second site, Cpa6 R133C-GFP also pulled down a 
significantly lower percentage of the input compared to WT-GFP (0.11% vs 0.52%). 
This was approximately 21% of the EGFP-tagged wildtype signal. 
 
To summarise, the R133C-GFP percentage of input DNA relative to that pulled 
down by WT-GFP was constant across all the sites, including the control regions 
with no methylation. Therefore, by this strategy of performing ChIP at specific sites 
in the genome, enriched for methylation in one sequence context over another, there 
was no evidence to support the hypothesis that R133C-GFP binding to mCAC was 
specifically impaired. 
5.6.3 R133C-GFP ChIP DNA is enriched for mCpG but not mCAC 
The third strategy to test the specific binding deficit hypothesis was to do bisulfite 
sequencing on DNA immunoprecipitated by R133C-GFP. Using this method, the 
reduced relative abundance of the mutant protein would be less contributory to the 
experiment. By comparing immunoprecipitated DNA to input DNA, the bisulfite 
sequencing would reveal whether (1) the DNA bound by WT-GFP was enriched for 
mCpG (which would be the prediction for a methyl CpG binding protein), (2) if the 
DNA bound by WT-GFP was enriched for mCAC (a recently reported phenomenon) 
and (3) if the DNA bound by R133C-GFP was enriched for mCpG but not for mCAC 
(as the specific binding deficit hypothesis would predict). 
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Two genomic sites were chosen from a recent publication, which showed that 
MeCP2 binds to mCH (Guo et al, 2014). One of these sites contained a CpG pair 
every 28bp with a low level of baseline methylation: the Fibroblast Growth Factor B 
(Fgf1b) gene. The second site contained a CAC sequence every 63bp with a low 
level of baseline methylation: the Brain Specific Angiogenesis Inhibitor 3 (Bai3) 
gene. WT-GFP and R133C-GFP GFP ChIP and input DNA were concentrated, 
treated with sodium bisulfite, then PCR amplified at these two regions. The PCR 
product was transformed into E.coli and the resulting colonies were screened for 
presence of the PCR insert then sequenced to reveal the methylation pattern. The 
location of the bisulfite amplicons is shown in Figure 5.6.3. 
 
Figure 5.6.3A shows the results of the bisulfite sequencing of the MeCP2EGFP-
immunoprecipitated DNA from the Fgf1b locus. The proportion of mCpG in the 
input DNA was similar for WT-GFP and R133C-GFP brain (22% and 15%, 
respectively). The DNA immunoprecipitated by WT-GFP was significantly enriched 
for mCpG in comparison to the input DNA (44% vs 22%, respectively) as would be 
expected for a methyl CpG binding protein. Similarly, the DNA immunoprecipitated 
by R133C-GFP was significantly enriched for mCpG in comparison to the input 
(40% vs 15%, respectively). Therefore, independent of protein abundance, R133C-
GFP showed evidence of binding to mCpG in vivo, with a comparable enrichment to 





Figure 5.6.3 Bisulfite sequencing of ChIP DNA supports a specific deficit in binding to 
mCAC for R133C-GFP. 
 
(A) Bisulfite sequencing of DNA immunoprecipitated by WT-GFP and R133C-GFP at the 
Fgf1b locus is significantly enriched for mCpG over input. 
(B) Bisulfite sequencing of DNA immunoprecipitated by WT-GFP but not R133C-GFP at the 
Bai3 locus is significantly enriched for mCAC over input. 
Maps of the regions are shown with scale bars (solid scale) and location of the bisulfite 
amplicons. Bisulfite sequencing is shown with scale bars (dashed scale): the methylation 
status of each site is represented by circles: black open are unmethylated CpG; black filled 
are mCpG; red open are unmethylated CAC; red filled are mCAC. Each line represents a 
single clone. Graphs represent proportion of methylated residues at both loci. In, input.         
* p<0.05, *** p<0.001, Fisher’s exact test. 
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Figure 5.6.3B shows the results of the bisulfite sequencing of the MeCP2EGFP-
immunoprecipitated DNA from the Bai3 locus. The proportion of mCAC in the input 
DNA was similar for WT-GFP and R133C-GFP brain (17% and 19%, respectively). 
The DNA immunoprecipitated by WT-GFP was significantly enriched for mCAC in 
comparison to the input DNA, which was compatible with the recent finding that 
MeCP2 binds mCA (Gabel et al, 2015). The proportion of mCAC in the Bai3 
amplicon was 34% in the DNA pulled down by WT-GFP. In contrast, the DNA 
immunoprecipitated by R133C-GFP was not significantly enriched for mCAC in 
comparison to the input. The proportion of mCAC in the DNA pulled down by 
R133C-GFP was 21%. Therefore, independent of protein abundance, R133C-GFP 
showed evidence of a deficit in binding to mCAC in vivo, in comparison to WT-
GFP, with no enrichment for this modification in immunoprecipitated DNA over 
input DNA. 
 
Taken together, these results provide in vivo evidence that there is a specific deficit 
in R133C-GFP binding to methylation in a CAC context. This supports the 
hypothesis generated by the EMSA DNA-binding assay in vitro.  
 
5.6.4 R133C-GFP ChIP-seq is inconclusive 
The results of bisulfite sequencing ChIP DNA at individual loci suggested that it was 
possible to detect a specific reduction in R133C-GFP affinity for mCAC. The next 
logical step was to look for this pattern genome wide. R133C-GFP ChIP and input 
samples from whole brain were taken for library preparation by S.Lagger in parallel 
with ChIPs and inputs for sorted neurons and glia. High throughput sequencing was 
performed at the Wellcome Trust Sanger Institute, Cambridge and data was analysed 
and combined with published bisulfite-seq data for frontal cortical neurons (Lister et 
al, 2013) by S.Webb. Peaks of R133C-GFP binding over input were identified and 
the methylation density with sequence context was plotted over 8 kilobases centred 
around this peak (averaged over 20 nucleotide bins). mCA density was considered to 
capture all potential mCAH binding, however mCAC will be overrepresented as it is 
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the most abundant form of mCA in the brain (S.Lagger, unpublished). With reference 
to Figure 5.6.4A, it can be seen that in neurons and glia, WT-GFP bound at regions 
of increased mCpG and mCA. Contrary to expectation, R133C-GFP also bound at 
regions of mCA, but not mCpG. However, if just the top 30,000 peaks are considered 
(when peaks are ranked by confidence, or p value) the opposite pattern is seen, with a 
comparable mCpG density at peaks of R133C-GFP and WT-GFP in neurons but 
reduced mCA density at R133C-GFP peaks compared to WT-GFP peaks in neurons 
and glia (Figure 5.6.4B). These results are inconsistent. Furthermore, there does not 
appear to be increased mCpG density at regions of WT-GFP binding in the top 





Figure 5.6.4 Inconclusive results from R133C-GFP ChIP-seq in whole brain. 
 
(A) Plots of mean methylation density at all identified peaks of MeCP2EGFP binding in R133C-
GFP whole brain and WT-GFP sorted neurons and glia. R133C-GFP appears to bind at 
regions of similar mCA density but reduced mCpG density, in comparison to WT-GFP in 
neurons and glia. 
(B) In contrast, the same plots of just the top 30,000 summits show the opposite pattern with 
R133C-GFP binding at regions of similar mCpG density but reduced mCA density, in 
comparison to WT-GFP in neurons and glia. There was no increase in mCpG density at 
peaks of WT-GFP binding in neurons. 
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5.7 Gene expression in R133C-GFP cerebellum 
The biological consequence of losing one of the binding capacities of MeCP2 is not 
clear, as the function of MeCP2 is poorly understood. Many groups have investigated 
gene expression in the context of MeCP2 deficiency by gene expression microarrays 
(Tudor et al, 2002; Jordan et al, 2007; Urdinguio et al, 2008; Charhour et al, 2008; 
Ben Shachar et al, 2009; Samaco et al, 2012). The result appeared to be many small 
changes in gene expression - some genes were upregulated, some were 
downregulated. This was unexpected from the loss of a proposed transcriptional 
repressor. Until recently, there was no unifying feature of the genes that were 
upregulated in the absence of Mecp2. Within the last year, it was reported that in 
MeCP2 deficiency, there is an upregulation of long (>100kb) genes and that this was 
dependent on binding to mCA (Sugino et al, 2015; Gabel et al, 2015, Chen et al, 
2015). So, if a long gene has a high level of mCA, it is more likely to be upregulated 
in the absence of MeCP2. If MeCP2R133C only loses the capacity to bind to mCA(C), 
then the hypothesis would be that the upregulation of long genes would be 
exaggerated by this mutation. 
 
This was investigated with gene expression microarrays using cerebellar tissue from 
WT-GFP and R133C-GFP adult male mice. Wildtype and Mecp2-null mice were 
included for comparison. The cerebellum was selected as firstly, it is an accessible 
region; secondly, it is made predominantly of one cell type – granule cells and so this 
would largely control for cell type-specific effects; and thirdly, cerebellar 
dysfunction is relevant to the motor aspects of the Rett syndrome phenotype. Adult 
mice were culled at six weeks in order to be able to use Mecp2-null controls, which 
were still alive at this time point, and in effort to capture primary effects of Rett 
syndrome, prior to symptom onset in R133C-GFP mice. Total RNA was extracted 
from three cerebella for each genotype. Reverse transcription using an oligo(dT) 
primer generated cDNA, the second cDNA strand was synthesised and then RNA 
libraries were transcribed in vitro. This in vitro transcription involved biotinylation 
of the RNA, so it could then directly hybridise with streptavidin-Cy3 and be detected 
following association with Illumina microarray probes. 
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5.7.1 Handful of significantly altered genes 
Figure 5.7.1 shows the results of the gene expression microarray analysis. This data 
was analysed by S.Webb using the Bioconductor Limma package. Figure 5.7.1A 
shows principal component analysis of the gene expression. This form of analysis 
defines the two greatest sources of variation within the samples, assigns them a 
numerical value and plots each individual data set according to these sources of 
variation. In this way, it can be determined whether the animals cluster by genotype, 
microarray chip or relatedness (some of the mice included in this study were 
littermates). The mice did not cluster by genotype or by relatedness. The WT-GFP 
mice seemed to be outliers according to the principal component analysis. This was 
an indication that the pattern of gene expression in these animals contributed the 
greatest source of variation in the experiment. 
 
A second way of analysing variation in the data set was to create a heatmap of 
Euclidean distances between animals’ expression values across all probes, followed 
by hierarchical clustering to look for patterns of similarity. The distance between the 
values is indicated by colour with paler colour indicating larger distance and 
dissimilarity. An example is shown in Figure 5.7.1B where the genotype of the 
samples has been considered. This analysis indicates that the animals do not cluster 
according to genotype, although the R133C-GFP animals seem to cluster with the 
Mecp2-null animals and the six wildtype animals (untagged and EGFP-tagged) 
cluster together. Similar plots were generated indicating that the animals did not 
cluster by litter or by the particular microarray chip used to analyse their RNA (data 
not shown). 
 
These two plots combined would have revealed whether the R133C-GFP mouse had 
a unique pattern of gene expression, causing individual animals with this genotype to 
cluster together, appearing distinct from the other genotypes. There was no evidence 





Figure 5.7.1 Microarray analysis of cerebellar gene expression in R133C-GFP 
compared to WT-GFP mice revealed only two genes that were significantly altered. 
 
(A) PCA plot of variance in gene expression in wildtype (W1-3), Mecp2-null (N1-3), WT-GFP 
(G1-3) & R133C-GFP (R1-3) cerebella shows no clustering by genotype and that WT-GFP 
animals were outliers when the two leading source of variance were considered. 
(B) Heatmap of Euclidean distance between samples shows that wildtype (tagged and 
untagged) mice clustered together and Mecp2-null and R133C-GFP mice clustered together. 
Paler shades indicate greater distance between samples. 
(C) Volcano plot of WT-GFP & R133C-GFP comparison shows hundreds of subtly up- and 
downregulated genes, with very few significant changes. Red line indicates p<0.1; grey line 
indicates the cut-off for changes arising by chance; black dots are individual genes. 
(D) Graphs showing relative transcript level in five of six significantly altered genes from (C) 
by qPCR of cerebellar cDNA. Only downregulation of Abhd1 & Aplf was validated. Mean fold 
change relative to Cyclophilin A±SD plotted. Arrows indicate direction of expected change in 
R133C-GFP indicated by microarray. * p<0.05, *** p<0.001, unpaired t-test.  
 
Volcano plots were used to obtain an impression of the overall pattern of gene 
expression change between the genotypes. This type of plot shows the relative 
change in expression of individual genes with a direct comparison of two genotypes 
(the fold change) and the confidence held in those changes (the log odds), where zero 
on the y-axis represents a 50:50 chance of expression change. A representative plot is 
 192 
shown in Figure 5.7.1C comparing WT-GFP with R133C-GFP data. This plot shows 
that the expression level of hundreds of genes is different between the WT-GFP and 
R133C-GFP mice. Genes are both up and down-regulated in the R133C-GFP 
compared to the WT-GFP mice. The fold changes in gene expression were small and 
only a handful of these changes met statistical significance. 
 
There were only six genes that showed significantly (p<0.05) altered expression 
between the WT-GFP and R133C-GFP animals: Abhd1, Krt222, Mybpc3, Dag1, Aplf 
and Zfp428. Only two of five tested were validated by qPCR (one primer pair did not 
work; qPCR kindly run by S.Lagger). These were Aprataxin and Polynucleotide 
Kinase-like factor (Aplf), encoding a protein involved in DNA double strand break 
repair (Iles et al, 2007) and Lung alpha/beta hydrolase domain gene 1 (Abhd1), 
encoding a protein containing an alpha/beta hydrolase catalytic domain, widely 
involved in enzymatic reactions (Edgar & Polak, 2002). Both genes were 
downregulated in R133C-GFP animals (Figure 5.7.1D). 
5.7.2 Small upregulation of long genes 
The data was analysed for changes in expression of long genes to find out if there 
was an exaggerated effect in the R133C-GFP cerebellum, in accordance with the 
hypothesis that there was a specific deficit in MeCP2R133C binding to CA(C) 
methylation and that this binding capacity was the basis of MeCP2 regulation of long 
genes (Gabel et al, 2015). Figure 5.7.2A plots fold change in gene expression against 
gene length for the R133C-GFP/WT-GFP comparison. There was a small 
upregulation of long genes (>100kb) in the R133C-GFP cerebellum relative to WT-
GFP. The magnitude of this change, however was less than 1.1-fold. There also 
appeared to be a downregulation of short genes (<10kb) and so there was a clear 
length-dependent relationship in the perturbation of gene expression in the R133C-
GFP mouse. 
 
Figure 5.7.2B shows the Mecp2-null/wildtype comparison and the R133C-
GFP/wildtype comparison on the same graph. Here R133C-GFP data is being 
compared to untagged wildtype MeCP2, so any potential effects of EGFP-tagging 
the protein are not being controlled for, however, the overall protein abundance 
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should be comparable in the two genotypes so this reveals the sole effect of the 
R133C mutation. Surprisingly, the Mecp2-null cerebellum showed minor 
upregulation of long gene expression in this experiment. Furthermore, there was little 
evidence of a length-dependent change in gene expression in the R133C-GFP 
cerebellum with this comparison. There was still a small degree of downregulation of 
short (<10kb) genes, but no upregulation of long genes. The explanation for this was 
apparent in the WT-GFP/wildtype comparison. Ideally, the gene expression pattern 
of these two controls would be indistinguishable. In fact, there is a clear length-
dependent relationship, showing a small downregulation of long genes (Figure 
5.7.2C). This may be due to the relative overexpression of tagged MeCP2 (Figure 
5.2.2). Therefore the relative upregulation seen in R133C-GFP cerebellum is 
attributable to the derangement in the WT-GFP gene expression, relative to wildtype. 
Cytosine methylation was plotted against gene length using S.Lagger’s unpublished 
mouse cerebellar bisulfite-SEQ data. In order that this analysis remained consistent 
with previously published data (Gabel et al, 2015), mCA level and not mCAC level 
was plotted. However, mCAC will be overrepresented in this plot, given that mCAC 
is the major form of mCA in the brain (Guo et al, 2014), representing approximately 
50% of mCAH (S.Lagger, unpublished data). Additionally, the function of the lower 
affinity binding of MeCP2 to mCAT (J.Connelly, unpublished data) has not been 
explored and will be captured by this analysis. It can be seen in Figure 5.7.2D that 
mean mCA level and mCA density increase with gene length, but only mean mCpG 
level increases with gene length: mCpG density actually peaks in genes of average 
length. Therefore the deregulated genes correspond to those with both high and low 




Figure 5.7.2 Subtle length-dependent change in gene expression in R133C-GFP 
cerebellum, relative to WT-GFP. 
 
(A) Graph plotting mean log2 fold change against gene length reveals a small downregulation 
of short genes and a small upregulation of long genes in the R133C-GFP cerebellum, 
compared to WT-GFP, n=3. 
(B) Graph plotting mean log2 fold change against gene length for Mecp2-null (null, n=3) and 
R133C-GFP compared to wildtype (WT, n=3). There was subtle evidence of length-
dependent gene expression changes in Mecp2-null cerebellum. There appeared to be a 
small downregulation of short genes in R133C-GFP cerebellum. 
(C) Graph plotting mean log2 fold change against gene length for WT-GFP compared to 
wildtype. There was evidence of length-dependent gene expression changes in WT-GFP 
cerebellum with downregulation of long genes and upregulation of short genes. 
(D) Graph plotting methylation sequence context in relation to gene length shows that only 
mCA and not mCpG density increases with length. Curve height is not to scale. Reproduced 
by S.Webb with permission from S.Lagger (unpublished data). 
 
5.7.3 qPCR does not validate upregulation of selected long genes 
A subset of long genes (>100kb) that are consistently upregulated in Mecp2 knock-
out models and downregulated in Mecp2 overexpression models was recently 
identified (Gabel et al, 2015). Real-time qPCR was performed to estimate the 
expression of ten of these genes in the cerebellum of the same Mecp2-null, wildtype, 
WT-GFP and R133C-GFP mice in order to validate the length-dependent 




Figure 5.7.3 qPCR does not validate the upregulation of long genes seen in R133C-
GFP cerebellum, relative to WT-GFP. 
 
Graph of relative transcript levels in a subset of long genes that are consistently deregulated 
in Rett syndrome models. There was a trend towards increased relative transcript levels in 
Mecp2-null (null) and R133C-GFP cerebellum relative to wildtype (WT), but WT-GFP 
transcripts appeared to be more abundant than R133C-GFP for the majority of the long 
genes. Relative transcript levels were calculated by normalising qPCR signal to three control 
genes, Ubp1, Rufy3 and Nr3c1. Relative transcript levels are plotted as mean fold change 
over wildtype±SD.  
 
Relative transcript levels and fold-changes were calculated by normalising the real 
time qPCR signal for each sample to three genes from a set of control genes that do 
not show evidence of altered expression in Mecp2 knock-out or over-expression 
models, but are also long (Gabel et al, 2015). The real-time qPCR did not show any 
significant differences in the relative transcript levels of the subset of long genes 
between the four genotypes. There was notable variation in levels between replicate 
animals within each genotype. This was in keeping with the microarray data. There 
was a trend towards higher relative transcript levels in the Mecp2-null and R133C-
GFP cerebellum, in comparison to the wildtype cerebellum. This was also consistent 
with the microarray data. However, in six of the genes (PrkCa, Plekha5, Arhgap, 
CamK1d, Lrrc8d, Tiam1) there was a trend towards higher relative transcript levels 
in WT-GFP cerebellum relative to R133C-GFP. This was the opposite pattern to that 
seen in the gene expression microarray. 
 
In summary, there was variability between R133C-GFP and WT-GFP replicates in 
the microarray analysis so only six gene expression changes were statistically 
significant overall. Just two of these were validated by qPCR. There was some 
evidence of a length-dependent change in gene expression in the R133C-GFP 
cerebellum. However, the changes were very small (less than 1.1 fold 
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downregulation of short genes and upregulation of long genes) and may have been 
attributable to mild overexpression of MeCP2 in WT-GFP cerebellum driving gene 
expression changes in the opposite direction. In addition, qPCR did not completely 
validate the microarray findings – although there was a trend towards higher relative 
transcript levels for long genes in Mecp2-null and R133C-GFP cerebellum relative to 
wildtype, there was a trend towards the relative transcript levels in WT-GFP 
cerebellum being higher than R133C-GFP in six of ten tested genes. 
5.8 Discussion 
The goal of this chapter was to investigate the molecular basis of Rett syndrome 
caused by the R133C mutation in order to explain why this results in a milder 
variant. As the mutation lies within the MBD of MECP2, the prediction was that 
MeCP2R133C would have a DNA binding deficit. It is now known that MeCP2 can 
bind to methylated cytosines, both in a CG, as well as a CA, context (Guo et al, 
2014; Gabel et al, 2015). Furthermore, MeCP2 can bind to hmCA (Gabel et al, 
2015). One hypothesis is that R133C Rett syndrome might be less severe because 
only some of the binding capacities of MeCP2 are impaired i.e. there is a specific 
deficit in DNA binding, rather than a general loss of binding to all sequences that 
MeCP2 recognises. This hypothesis was investigated using a combination of protein 
binding assays in vitro, a neuronal cell model and the R133C-GFP mouse.  
5.8.1 Reduced protein abundance contributes to R133C Rett 
syndrome 
The initial objective was to rule out alternative causes of Rett syndrome that would 
not result from an impairment of DNA binding. The first alternative considered was 
a lack of sufficient protein, affecting all proposed functions of MeCP2.  
 
During investigation of relative mRNA level and protein abundance, it was 
discovered that EGFP-tagging MeCP2 was of consequence. The protein abundance 
was increased by around 1.5 times in the neuronal cell model and the mouse brain. 
This can only be an estimate due to the different rate of transfer of proteins of 
different size from a protein gel onto a nitrocellulose membrane for western blotting, 
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so it is difficult to accurately compare abundance. However, mRNA levels were 
increased by the same factor; gradient protein gels were employed to facilitate equal 
transfer of the differently sized proteins; and the increased protein abundance of WT-
GFP was also supported by confocal microscopy, so there was reasonable confidence 
in the result. The molecular explanation is unclear - it is unlikely that the EGFP tag 
resulted in more frequent initiation of transcription or an increased rate of elongation 
of the transcript. It is possible that disruption of the 3’ untranslated region in MeCP2 
increased the stability of the transcript, the result being that more protein is 
subsequently translated. It is known that the different lengths of MECP2 transcript 
have different relative abundance throughout development (Coy et al, 1999). In 
support of this, it was observed that WT-GFP was markedly more abundant than 
wildtype protein in neonatal brain tissue (4.5-fold) and cultured neuronal cells (4-
fold). The observation of increased abundance of WT-GFP flagged the importance of 
including it as a control in all subsequent molecular experiments. Notably, although 
producing a subtle increase in protein abundance, EGFP-tagging the protein did not 
result in RTT in the mouse (see chapter 4).  
 
Western blots of cultured neuronal cell lysates revealed different relative protein 
abundances with each differentiation. The quantifications derived from the blots 
were variable and no significant differences could be found as a result. This was for 
two reasons. Firstly, there was variation in the neuronal differentiation between 
genotypes, between clones and between dishes. It was later discovered that this was 
likely due to fluctuation in the temperature of the incubator, but inadvertent variation 
at each point in the differentiation protocol would have a similar effect. For example 
an inaccurate automated cell count at the time of plating the neuronal precursors 
would result in cells that were less dense, grew less profusely, showed early signs 
that connecting axons were disintegrating and presumably expressed less MeCP2. 
Secondly, this variation of input material could not be corrected for. It has previously 
been shown that MeCP2 deficient neuronal cells in culture have lower levels of RNA 
(Li et al, 2013). When estimating MeCP2 mRNA levels in this study, total RNA was 
quantified then a set amount was reverse transcribed to use in real time qPCR. The 
number of input cells was not taken into account. The protein lysate preparation had 
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to rely on a cell count prior to making a pellet of cells, which would often include 
dead cells in the final read-out. Although there was variability in the quantification of 
MeCP2 abundance derived from western blots of neuronal cell lysates, calculating 
the average from independent differentiations with different mutant ES cell clones 
yielded very similar results to those from mouse brain and so the results were 
considered supportive of conclusions drawn. 
 
Interestingly, the abundance of MeCP2 mRNA and protein was reduced by 
approximately 40% in both the R133C-GFP neuronal cells and the R133C-GFP 
mouse, relative to the WT-GFP. This relative reduction in MeCP2 level should not 
be enough to cause RTT on its own, as a mouse with a floxed Mecp2 gene and 
approximately 60% MeCP2 protein abundance, did not display full RTT, but had 
mild motor impairment and a normal lifespan (Samaco et al, 2008). Furthermore, 
there was no absolute reduction in MeCP2 abundance when comparing R133C-GFP 
to wildtype littermates, given that the additive result of the EGFP tag and the 
mutation was an endogenous MeCP2 level. It follows that the protein abundance 
would not fully account for the mouse phenotype. However, the relative reduction in 
ambient MeCP2 in the nucleus would amplify the effects of any other deficit in 
protein function caused by the R133C mutation when compared to the WT-GFP 
control.  
 
Comparing the R133C-GFP mRNA level and protein abundance in adult mouse 
brain to WT-GFP and the other EGFP-tagged missense mutants, R306C-GFP and 
T158M-GFP was useful. The instability of MeCP2 when the threonine 158 residue is 
mutated has previously been reported (Goffin et al, 2011) and was recapitulated in 
this study where, despite equivalent T158M-GFP transcript levels, protein abundance 
was approximately 30% of WT-GFP. It is not clear why R133C did not cause protein 
instability: the abundance of R133C-GFP correlated with the relative mRNA 
transcript level. One possibility is that protein that is not associated with DNA is 
more likely to be degraded indicating that MeCP2T158M has a weaker association with 
DNA. Another linked possibility, supported by structural data is that the degree of 
misfolding of MeCP2 is greater in the presence of the T158M mutation than the 
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R133C mutation, which leads to early degradation (Ghosh et al, 2008). The protein 
abundance data provided an initial explanation for the reduced phenotypic severity of 
R133C Rett syndrome – at least in relation to T158M Rett syndrome. This 
observation may be applicable to other mutations in the MBD that result in Rett 
syndrome. Protein abundance was not significantly reduced in the R306C-GFP brain 
and previous literature suggests that R306C Rett syndrome is caused by a lack of 
association with the NCoR complex (Lyst et al, 2013) so this trend did not seem 
applicable to Rett-causing mutations outwith the MBD. 
 
In conclusion, MeCP2 abundance is reduced by approximately 40% in the adult brain 
in the presence of the R133C mutation and this will contribute to the Rett phenotype. 
5.8.2 MeCP2R133C associates with NCoR 
The second alternative hypothesis for the molecular mechanism of R133C Rett 
syndrome was failure to perform functions of MeCP2 other than DNA binding. The 
bridge model of MeCP2 function was conceived from the observation that Rett-
causing missense mutations cluster over the MBD and the NID of the MECP2 gene, 
whereas neutral variants in the population lie outwith these regions. Therefore the 
hypothesis would be that failure to bind DNA or the NCoR complex is sufficient to 
cause Rett syndrome (Lyst & Bird, 2015). Using an anti-GFP antibody in adult 
mouse brain, R133C-GFP immunoprecipitated HDAC3 and TBLR1 (both 
components of the NCoR complex), confirming an association in vivo and ruling this 
out as contributory to R133C Rett syndrome.  
5.8.3 The subnuclear localisation of MeCP2R133C is abnormal 
Having investigated these alternative causes of Rett syndrome, the objective was to 
establish whether there was evidence that R133C-GFP had a DNA binding deficit at 
all, as previous studies have indicated a wildtype pattern of subnuclear localisation 
(Kudo et al, 2003). To answer this question, R133C-GFP association with 
heterochromatin was visualised in mouse brain by confocal microscopy. This section 
discusses the microscopy findings along with technical challenges. 
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Notably, the pattern of WT-GFP localisation was indistinguishable from wildtype by 
confocal microscopy, as has previously been observed (Kudo et al, 2003; 
Schmiedeberg et al, 2009). There was an abnormal pattern of R133C-GFP 
subnuclear localisation in adult male mice across four separate brain regions: the 
CA1 area of the hippocampus, CA3 region of the hippocampus, the dentate gyrus 
and the motor cortex. There was a similar appearance in the cerebellum (data not 
shown). In contrast to EGFP-tagged wildtype protein, R133C-GFP did not appear 
tightly associated with heterochromatic foci: the protein was also diffusely spread 
throughout the nucleus. Despite there being 40% less protein than in the WT-GFP 
brain, the intensity of the background nuclear staining in R133C-GFP brain was 
grossly equivalent. In other words, the mutant protein appeared to be distributed 
throughout the nucleus to a greater degree than the EGFP-tagged wildtype protein. In 
addition to this, there were ectopic R133C-GFP dots that did not correspond to DAPI 
dots visible in several brain regions, raising the possibility that the protein bound 
non-specifically elsewhere in the genome, or displayed less functional ability to 
cluster chromatin, as has previously been suggested in cell culture experiments 
(Agarwal et al, 2011). These findings contradicted previous literature reporting a 
wildtype pattern of localisation with this mutation (Kudo et al, 2003) but were in 
accordance with studies that have suggested a mildly reduced association with 
heterochromatin (Kumar et al, 2008; Schmiedeberg et al, 2009; Agarwal et al, 2011). 
 
Observing this pattern was challenging, given the reduced abundance of R133C-
GFP. It was difficult to elucidate the binding pattern when confocal settings were 
optimised to WT-GFP brains because of the markedly reduced intensity of the 
R133C-GFP cells. When the confocal settings were optimised for the R133C-GFP 
brain, the abnormal localisation could be attributed to an artefact of “over-exposing” 
the image. This potential criticism was negotiated in two ways. Firstly, two sets of 
images were shown for each region – one set taken at the universal settings and one 
set taken at the individual settings for comparison. The same criteria were applied to 
optimise the settings for all genotypes. A look up table was employed to detect and 
minimise overexposure of the field. In this way, the sections were exposed to 
approximately the same degree. The second solution was to breed a double WT-
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GFP/R133C-GFP female mutant, which would express either the wildtype EGFP-
tagged protein or the mutant EGFP-tagged protein in any one cell (with the 
assumption that there were no non-cell-autonomous effects on localisation of 
protein). It was then possible to see the neighbouring cells in the same image, using 
the same, compromised settings. Indeed the double mutant appeared to have 
approximately 50% of neurons with punctate localisation and 50% with mixed 
punctate and diffuse localisation. It cannot be said with certainty that the “mixed” 
cells corresponded to the R133C-GFP expressing cells, however the lack of co-
staining with the anti-MeCP2 antibody supported this conclusion. 
 
It is not clear why the C-terminal anti-MeCP2 antibody did not stain R133C-GFP. It 
is conceivable that this staining was dependent on protein abundance. This 
phenomenon was also seen in the T158M-GFP brain (data not shown) and the 
staining less accurately reflected the EGFP signal in regions of the WT-GFP brain 
with lower levels of MeCP2 expression, for example the motor cortex (data not 
shown). As MeCP2 is a relatively unfolded protein, it is also possible that any 
conformational change in the MBD mutants (in combination with the EGFP tag) 
inhibited antibody binding. This may have been exacerbated by the long period of 
fixation used for the tissue preparation where the protein fixes internally as well as to 
DNA. 
 
The abnormal localisation was corroborated by confocal microscopy of the 
differentiated neuronal cells. Furthermore, it was possible to quantify the altered 
distribution of protein, given that the cultured cells grew in a monolayer. The 
quantification supported the visual interpretation of the microscopy. There was a 
significantly lower proportion of R133C-GFP within the DAPI dot regions than WT-
GFP. There were important limitations to the method used for quantification. Firstly 
heterochromatic dots were defined on the DAPI panel. The DAPI panel had to be 
utilised because of varying levels of WT-GFP expression in the different genotypes, 
so defining dots using EGFP intensity thresholds was problematic: one threshold 
would not fit all. To be a dot area, a region’s DAPI intensity had to be at least 0.67 of 
the pixel with the greatest DAPI intensity in the field of cells (following removal of 
 202 
dead cells), and had to be at least two pixels in size. There is a possibility that some 
dots were missed by this technique, by setting limits of DAPI brightness and size. In 
contrast, there may have been some areas defined as dots that were not, in areas of 
increased DAPI staining and overexposure for example, or in fields where the 
brightest DAPI dots were of relatively low intensity. Nevertheless, by using the 
DAPI panel to define the dot areas, it made the GFP intensity calculations relatively 
straightforward and independent of the overall protein abundance. The average GFP 
intensity in the dot region was divided by the sum of the average dot and average 
background intensity, to give a measure of protein distribution, or dot prominence. 
This method may have counted ectopic GFP dot areas as “background” and so if, as 
the brain microscopy suggested, the MBD mutant protein formed new loci outwith 
the heterochromatic foci, this may have artificially increased the GFP nuclear 
background intensity and therefore reduced the dot prominence. However, as this 
would still have represented an abnormal pattern of localisation, it is appropriate that 
it would result in a reduction of the “dot prominence” measure. One further 
limitation was that, because of the technical difficulties in running the macro on the 
GFP panel, the quantification was done on fifty cells per genotype from one 
differentiation instead of the originally planned, three differentiations. Therefore, it 
cannot be said definitively that the genotypes had a statistically significant difference 
in the prominence of their heterochromatic dots without further quantification. 
 
The quantification agreed with a previous report using transfected EGFP-tagged 
MeCP2 in murine myoblasts (Agarwal 2011), which also found a statistically 
significant reduction in the accumulation of EGFP-tagged human MeCP2R133C at 
chromocentres. Agarwal and colleagues found a greater ratio of protein accumulated 
in dots than that found in this study (3.6 for EGFPMeCP2R133C, 5 for EGFPMeCP2). 
However, to calculate their figure they took a simple ratio of mean GFP intensity 
from four chromocentre areas divided by the mean GFP intensity from four 
nucleoplasm areas in each cell. They did not take a proportion, by placing the total 
mean GFP intensity in the denominator. This was repeated for only ten cells from at 
least two transfections. Given the limitation introduced from using fewer cells and 
 203 
fewer dots, in addition to taking a ratio, rather than a proportion, it is possible that the 
measure of accumulation was an overestimate in their study.  
 
In order to determine the impact of the defect in association with heterochromatin on 
phenotypic severity, T158M-GFP and R306C-GFP brains were included for 
comparison. R306C-GFP appeared to have a normal punctate pattern of localisation 
despite having a slightly lower abundance than WT-GFP, which didn’t alter in 
appearance under the optimised GFP settings, thus supporting the conclusion that the 
abnormal pattern of localisation in R133C-GFP brain was not an artefact of 
technique. Protein appeared more diffusely spread throughout the nucleus in the 
T158M-GFP brains, suggesting that in addition to reduced relative protein 
abundance, the T158M mutation impairs DNA binding to a greater degree. This 
would be a second reason for the milder phenotype in R133C Rett syndrome. 
Although not formally measured, it was noted that cortical neuronal nuclei in the 
T158M-GFP brain appeared smaller than those in the other genotypes. Soma size is 
reduced in Rett syndrome patients (Bauman et al, 1995). The T158M-GFP RTT 
would have been more advanced at the age mice were culled for the experiment, so 
perhaps this phenomenon would have been observed at an older age in the other 
mutant mice and reflects progression of disease. 
 
To conclude, R133C-GFP did not localise normally to heterochromatic foci in 
cultured neurons or adult brain, indicating impairment in association with chromatin. 
5.8.4 MeCP2R133C binding to methylated and unmethylated 
genomic regions is defective. 
There was an indication that binding to heterochromatin was impaired in the R133C-
GFP cultured neuronal cells and brain and so this was followed up with ChIP 
experiments using an anti-GFP antibody to further refine this binding deficit. The 
following section discusses the necessary modification of experimental technique in 
order to delineate the binding defects. 
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Although heterochromatin association implies binding to mCpG, it is likely to 
represent a degree of non-specific binding also as the punctate binding pattern of 
MeCP2 was shown to be unperturbed in ES cells devoid of methylation (Baubec et 
al, 2013). The mCpG status of selected ChIP regions – major satellite DNA, 
L1LINEs, IAP elements and the BDNF promoter - was confirmed by bisulfite 
sequencing in adult mouse brain. It is accepted that there is likely to be variation in 
the level of methylation of selected repeat elements, occurring throughout the 
genome, which may not have been captured by the limited number of clones 
analysed. However, bisulfite sequencing of wildtype, WT-GFP and R133C-GFP 
genomic DNA yielded relatively consistent results, with varying degrees of MeCP2 
expression, indicating that the general pattern of DNA methylation does not change 
with altered abundance of MeCP2. These sites were taken to represent high 
(repetitive DNA) and low (BDNF) levels of methylation. The pattern of mCpG was 
likely to have been the same in the relatively immature cultured neuronal cells, as 
mCpG is established early on in the developing embryo (Bird et al, 2002). 
 
Both the cultured neuronal cell and brain ChIP revealed evidence of reduced binding 
to heavily methylated repetitive sequences and the relatively unmethylated BDNF 
promoter region with R133C-GFP. The interpretation of the ChIP was difficult 
because of the reduced abundance of R133C-GFP. It was not known how a 40% 
reduction in protein abundance would ultimately affect the ChIP signal and it 
appeared that the ChIP signal in the R133C-GFP brain relative to WT-GFP could 
have been attributable to the reduced background protein level without any 
superimposed DNA binding deficit (30% at major satellites; 48% at L1 LINE’s; 43% 
at IAP elements; and 48% at the BDNF promoter). The second challenge was 
presented by variation in percentage input between experiments, which impacted on 
the ability to detect significant differences between genotypes, even though the 
R133C-GFP percentage of WT-GFP signal remained consistent. This variation may 
have been the result of using different anti-GFP antibody aliquots between 
experiments. Both of these challenges were addressed by refining the ChIP protocol. 
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Both the original neuronal and brain ChIP used long cross-linking periods (greater 
than seven minutes) and it was hypothesised that this time was far in excess of the 
DNA on-off time for WT-GFP, estimated as approximately 20 seconds from two 
FRAP experiments (Kumar et al, 2008; Schmiedeberg et al, 2009). Therefore it was 
possible that MeCP2EGFP continued to accumulate on DNA during the crosslinking 
period to reach a point of saturation that correlated with overall protein abundance 
(Poorey et al, 2013). The ideal scenario when estimating the relative DNA binding of 
proteins would be to achieve an instantaneous snap shot of protein association with 
DNA, which could be approximated by reducing the cross-linking period. For 
handling samples, one minute was considered the shortest possible time that would 
be practically possible. Care was also taken to fully quench the formaldehyde by 
increasing the volume and concentration of the glycine, so that an excess molar ratio 
was achieved. Repeating the ChIP with a one-minute cross-link made little difference 
to the read-out. However, when the temperature of the one-minute cross-link was 
also reduced, the ChIP signal for R133C-GFP decreased relative to WT-GFP. Instead 
of the 2-3 fold reduction at tested sites, R133C-GFP ChIP signal was reduced by 6-7 
fold at repetitive sequences and 4 fold at the unmethylated site, relative to WT-GFP.  
 
With refinement of the protocol, the greater relative reduction in R133C-GFP 
binding at methylated regions was compatible with a loss of binding specificity, as 
suggested by structural studies (Ghosh et al, 2008; Kucukkal et al, 2015) and a 
previous ChIP-seq study in ES cells (Baubec et al, 2013). Additionally, with 
attention to using the same anti-GFP aliquot for experimental replicates, percentage 
input achieved was more consistent and statistical differences could be detected. The 
total percentage input did decrease slightly with the most stringent ChIP conditions, 
which would be expected if potential binding sites were not saturated during the 
cross-linking period, as discussed above. It is not possible to conclude that the 
stringent conditions reflect protein binding in vivo because the stringency may 
simply exaggerate the difference in protein abundance, rather than capturing the 
instantaneous DNA binding picture, as desired. However, it must be noted that in 
patients with the R133C mutation, cells expressing this protein will have both 
reduced abundance and a DNA binding deficit. So although the goal of the ChIP 
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experiments was to define the DNA binding deficit, with both factors operating, the 
result reflects the natural pathogenesis of Rett syndrome. Furthermore MeCP2R133C 
DNA binding deficits have been found by ChIP previously in ES cells (Baubec et al, 
2013) and in a cellular immunoprecipitation assay with transfected EGFP-tagged 
protein (S.Lagger, unpublished data), where there was no suggestion of reduced 
protein abundance. Therefore these results are in keeping with previous literature for 
MeCP2R133C, suggesting impairment in binding to methylated DNA by ChIP. 
Additionally, impairment in binding to relatively unmethylated chromatin is 
suggested, which contradicts a previous in vitro study (Georgel et al, 2003). 
 
Interestingly, by placing the R133C-GFP ChIP data in the context of the EGFP-
tagged allelic series, there was an apparent binding deficit with R306C-GFP in all 
four regions tested, which did not reach statistical significance. This was not 
predicted, although one previous report suggested that MeCP2R306C DNA binding 
may also be impaired by ChIP and EMSA, due to the disruption in a basic patch of 
amino acids (Heckman et al, 2014). This would place into question the assumption 
that Rett syndrome caused by this mutation is purely the result of a lack of 
association with the NCoR complex (Lyst et al, 2013). Less T158M-GFP than 
R133C-GFP appeared bound to all four regions, which was consistent with the 
reduced protein abundance and the appearance of the T158M-GFP brain by confocal 
microscopy. It was also compatible with the increased severity of the T158M Rett 
phenotype. 
 
To conclude, R133C-GFP binding was reduced by approximately 6-7-fold at heavily 
methylated genomic regions and 4-fold at a relatively unmethylated site under 
stringent ChIP conditions in comparison to WT-GFP. This suggests a differential 
defect in specific and non-specific association with chromatin-associated DNA, with 
the former affected to a greater degree. 
5.8.5 MeCP2R133C does not specifically lose binding to hmC 
It was desirable to refine this binding deficit further in order to explain the reduced 
severity of R133C Rett syndrome (Leonard et al, 2003) and shed light on the major 
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functions of MeCP2. For this reason, the sequence context and type of cytosine 
modification was investigated as a previous study had suggested that MeCP2R133C 
lost binding to hmC, whereas binding to mC was relatively preserved (Mellen et al, 
2012) and this could explain the distinguishable phenotype. 
 
EMSAs were done using the (1-205) fragment of MeCP2 with or without the R133C 
mutation to address the question of any specific deficit in MeCP2R133C binding. This 
in vitro technique had the advantage that binding to individual moieties could be 
studied in isolation with equal peptide concentrations. A probe taken from the BDNF 
locus was used, to recapitulate endogenous binding and was modified at a single 
cytosine in order to delineate the specific sequence and methylation context of the 
binding deficit. Interestingly, there appeared to be no binding deficit to a mCpG 
probe, but a specific deficit in binding to methyl- or hmCAC probes with the 
MeCP2(1-205)R133C peptide. This explained the conclusion drawn by Mellen et al, as 
the probe used in their study contained methylation in a CpG and CA context, and so 
MeCP2R133C binding to these probes when methylated would have appeared 
modestly reduced. However, given that MeCP2 doesn’t bind to hmCpG (Gabel et al, 
2015; Chen et al, 2015), in the hydroxymethylated probe, the reduced MeCP2R133C 
binding to hmCA would have been readily apparent. The results presented here 
contradict the claim that MeCP2R133C specifically loses binding to hmC. 
 
The apparent wildtype binding of MeCP2(1-205)R133C to the mCpG probe seemed at 
odds with the previous literature, which found mCpG binding to be virtually 
abolished by MeCP2R133C in Southwestern assays and by EMSA (Ballestar et al, 
2000; Yusufzai et al, 2000; Free et al, 2001; Galvão & Thomas, 2005). A conflicting 
result was also found in our laboratory using a shorter fragment of MeCP2 in exactly 
the same assay: MeCP2(77-167)R133C binding to a singly methylated CpG dyad was 
abolished. How can these disparate findings be resolved? As a relatively unstructured 
protein, it is possible that MeCP2 folds in different ways depending on the length of 
the peptide fragment. Some support for this comes from one study that found an 
enhancement of MeCP2 binding to DNA probes with the addition of the N-terminus 
to the MBD, suggesting some sort of inter-domain stabilisation, or allosteric coupling 
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(Ghosh et al, 2010). Additionally, structural studies suggest quite distinctive CD 
spectra for the MBD of MeCP2, compared to the full-length protein (Ghosh et al, 
2008). Notably, the only study to reach a similar conclusion that mC binding was 
near wildtype also made use of the (1-205) fragment of MeCP2 (Mellen et al, 2012), 
suggesting that this polypeptide may have unique binding characteristics. 
 
To conclude, MeCP2R133C does not specifically lose binding to hmC as previously 
suggested. The binding characteristics of MeCP2 polypeptides in vitro are dependent 
on the length of the fragment used. 
5.8.6 A mCAC binding deficit contributes to the molecular basis 
of R133C Rett syndrome 
The previous section ruled out specific hmC binding deficits using in vitro 
techniques, but this analysis uncovered a potential defect in MeCP2R133C binding to 
mCAC and hmCAC, specifically. It was unclear whether the evidence of a particular 
deficit in (h)mCAC binding was relevant in vivo, as previous studies have not 
addressed binding to mCH with MeCP2R133C. Here, it has been demonstrated that by 
ChIP, R133C-GFP showed reduced affinity for heavily methylated repetitive DNA, 
presenting a significant majority of mCpG sites in the mouse genome (Horz & 
Altenburger, 1981). A loss of specificity for mCpG has also been demonstrated by 
ChIP in ES cells (Baubec et al, 2013). Therefore it is unlikely that full-length protein 
retains wildtype binding for mCpG in vivo. However, the ChIP experiments were 
confounded by reduced R133C-GFP abundance and the ChIP-seq in ES cells showed 
a reduction in specificity by plotting MeCP2R133C/MeCP2, so any smaller preference 
for mCpG may have been masked by a larger wildtype affinity, or higher abundance 
of protein expressed from the transgene. Loss, or impairment of one of the binding 
capacities of MeCP2 would be a compelling hypothesis to explain the milder nature 
of R133C Rett syndrome. The focus was then to determine whether there was any 
evidence of a specific, or disproportionate DNA binding deficit to mCAC in vivo and 
this is the topic of the following discussion. At this point, the investigation of 
hmCAC was concluded as these sites represent less than 2% of hmC by current 
estimates and so, are unlikely to be biologically significant (Lister et al, 2013). 
 209 
 
The hypothesis was that MeCP2R133C binding was more impaired to mCAC than 
mCpG. This was investigated initially using ChIP in mouse brain. According to this 
hypothesis, in neonatal brain tissue, with negligible mCAC, R133C-GFP ChIP signal 
would be less reduced relative to WT-GFP ChIP signal, in comparison to the same 
ChIP assay in adult tissue. Importantly, R133C-GFP abundance was also 40% less 
than WT-GFP at this stage. The hypothesis was correct, however neither the WT-
GFP nor the R133C-GFP signal was significantly different from the negative control 
– wildtype brain with no EGFP tag. This was probably because the absolute protein 
abundance was low at this developmental stage. Furthermore, it’s possible that there 
wasn’t much mCAC in the repetitive sequences used in the ChIP assay in the adult 
brain. So a difference may have been difficult to detect in these particular regions.  
 
Specific genomic loci enriched for mCpG or mCAC were then selected for GFP 
ChIP to see if the ChIP signal in R133C-GFP adult brain at the mCpG enriched sites 
would be higher than at the mCAC enriched sites, relative to WT-GFP. The results 
provided no evidence that this was the case, with an almost identical relative 
percentage input across all sites immunoprecipitated, including the control regions 
with no methylation. It was notable that the percentage of input DNA that was pulled 
down was slightly higher at the mCpG rich sites than at the mCAC rich sites in WT-
GFP brain, indicating that these were higher affinity binding sites. This was in 
agreement with the EMSA findings where the percentage of mCpG probe shifted at 
the highest concentration of wildtype MeCP2(1-205) (64%) was higher than the 
percentage of mCAC shifted (43%). The lack of discrimination of R133C-GFP 
between the mCG-rich and mCAC-rich sites could have occurred for a number of 
reasons: firstly, the ChIP may not have been a sensitive enough assay to detect a 
distinctive binding pattern, especially with the reduced protein abundance; secondly, 
the sites may not have been equivalently enriched for the two signalling moieties – 
the mCAC sites had a lower “level” of enrichment (approximately 2) than the mCpG 
sites (approximately 8); thirdly, MeCP2 binding at the selected sites might have been 
at a low level, making it different to detect relative differences; fourthly, analysis of 
the methylation context in some of the mCpG-rich sites in a separate published 
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bisulfite-seq data set (Lister et al, 2013) following this experiment revealed that there 
were appreciable amounts of mCAC at this locus, at least in frontal cortex; finally, 
the hypothesis may have been incorrect. 
 
To resolve the issue of lower protein abundance in R133C-GFP brain overshadowing 
any specific deficit in binding to mCAC, DNA that had already been 
immunoprecipitated by the protein was bisulfite-sequenced at two known MeCP2 
binding sites: Fgfb (with several CpG’s) and Bai3 (with several CAC’s) (Guo et al, 
2014). Although both the WT-GFP and R133C-GFP immunoprecipitated DNA were 
enriched for mCpG over their respective input DNA at the Fgfb locus, only the WT-
GFP immunoprecipitated DNA was enriched for mCAC over the corresponding 
input DNA at the Bai3 locus. This finding was supportive of a specific deficit in 
mCAC binding.  
 
An important limitation of this experiment was that it was not possible to calculate a 
non-conversion rate for the mCAC rich site (Bai3) bisulfite sequencing experiment 
due to the nature of conventional bisulfite sequencing protocols that use cytosines 
outwith a CpG context to calculate non-conversion rate following the bisulfite 
treatment (i.e. if a non-CpG cytosine remained a C, it was considered to have not 
been converted, rather than methylated). Given that the protocol was identical to that 
used for all of the bisulfite sequencing, which had achieved conversion rates of over 
95%, it is unlikely that a significant majority of detected mCAC represented non-
conversion. However, it would be important to repeat this experiment with a control 
probe, methylated in a known sequence context to have a definitive measure of non-
conversion. With this limitation in mind, the experiment was supportive of the 
hypothesis that there was a greater deficit in R133C-GFP binding to mCAC, which 
presents a lower affinity endogenous binding site. Although inconclusive, the 
R133C-GFP ChIP-seq lent some support to the hypothesis – at least in the protein 
peaks identified with the highest confidence. It was unexpected that there appeared to 
be no increase in mCpG at WT-GFP binding sites in the sorted neurons. This may be 
because there was a notable AT-bias in the sequenced DNA following library 
preparation (S.Lagger, unpublished communication) and so the sites with the highest 
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mCpG content may not have been represented. Another possibility is that the 
published data set of frontal cortical neuron methylation that was used to plot the 
mean methylation density may not be representative of all regions of the brain, so the 
ChIP binding profiles may not match adequately. There is evidence to suggest that 
gene regulation by MeCP2 can be cell type-specific (Sugino et al, 2014). Therefore, 
this data must be interpreted with caution and it would be important to repeat this 
experiment with matching bisulfite sequencing data. 
 
Taken together, the western blotting, confocal microscopy, ChIP, EMSA, and 
bisulfite sequencing data would suggest that the molecular basis of R133C Rett 
syndrome is a combination of a modest reduction in protein abundance and reduced 
affinity to both of the major binding sites of MeCP2: methylation in a CpG and CAC 
context, with the latter probably abolished. Non-specific binding and binding to a 
third moiety, hmCAC may also be reduced, although the biological significance of 
this is unknown. 
5.8.7 Do deregulated long genes cause Rett syndrome? 
There is recent evidence suggesting that repression of long genes by MeCP2 is 
dependent on binding to mCA, which in the brain occurs predominantly in a CAC 
context (Xie et al, 2012; Guo et al, 2014; Gabel et al, 2015; Lister et al, 2013). The 
prediction from this was that the long gene effect would be prominent in the R133C-
GFP brain with little to no mCAC binding. To investigate this prediction and 
determine what the biological consequences of R133C Rett syndrome were, gene 
expression in adult mouse cerebellum was measured with microarrays in triplicate 
for six week-old R133C-GFP, WT-GFP, wildtype and Mecp2-null mice. This final 
section discusses the limited evidence from these experiments that deregulation of 
long genes causes Rett syndrome. 
 
Microarray data did not display clustering with genotype, indicating (1) significant 
variability between the genotype replicates and (2) lack of a distinct pattern of gene 
expression with the R133C mutation. The expression of thousands of genes in the 
R133C mutant was altered to a small degree, both by up- and downregulation, in 
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comparison to the WT-GFP control, which was consistent with previous similar 
studies (Jordan et al, 2007; Urdinguio et al, 2008; Ben-Shachar et al, 2009), but there 
were only six significant changes in expression of individual genes (two of which 
were later validated by qPCR). Additionally, this handful of significantly altered 
genes was not the same as those found with the wildtype and Mecp2-null 
comparison. However, it was possible to observe an upregulation of long genes 
(>200kb) and down-regulation of short genes (<10kb) in R133C-GFP compared to 
WT-GFP cerebellum. This was not validated by real time qPCR and was 
significantly reduced in the R133C-GFP and wildtype comparison, indicating that 
most of the effect was attributable to a downregulation of long genes (and vice versa) 
in the WT-GFP cerebellum. This was compatible with the mild MeCP2 
overexpression in this mouse and the observation that the WT-GFP samples appeared 
to be outliers according to principal component analysis and heat-mapping.  
 
The relative fold changes detected in gene expression were small. Microarray 
analysis assumes that the overall level of transcription in the samples is the same, 
which appeared to be the case. Total RNA was isolated from half cerebella and 
normalised to total genomic DNA for all four genotypes and no significant 
differences were found (data not shown). Therefore the subtle upregulation of long 
genes in the mutant and Mecp2-null cerebella was not underestimated by reduced 
total RNA in these brains. Following the experiment, it emerged that the cerebellum 
had the smallest degree of long gene upregulation in Mecp2-null mice in comparison 
to other brain regions (Gabel et al, 2015), so it was not the optimal platform in which 
to detect effects specific to a loss in mCA(C) binding. Although the cerebellum is 
mostly comprised of granule cells, there are other cell types and cell type-specific 
gene expression changes may have been masked by analysing the whole tissue 
(Mellen et al, 2012; Sugino et al, 2014). It would be useful to repeat this experiment 
with a greater number of replicates, in several different brain regions and/or neuronal 
subtypes.  
 
With these limitations in mind, importantly, these data may challenge the hypothesis 
that upregulation of long genes causes Rett syndrome. The magnitude of 
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downregulation in the WT-GFP and wildtype comparison was to the same degree as 
the magnitude of upregulation in the R133C-GFP and WT-GFP comparison and the 
WT-GFP mice did not show evidence of progressive neurological impairment 
previously reported in mouse models of Mecp2 overexpression (Collins et al, 2004). 
In fact, the mice were overtly wildtype. This magnitude was greater than the 
magnitude of upregulation of long genes seen in the Mecp2-null and wildtype 
comparison. Additionally, the R133C-GFP cerebellum showed virtually no 
upregulation of long genes relative to untagged wildtype and the mice did have 
obvious RTT. It may be important that the cerebellum was harvested prior to 
manifestation of R133C RTT, but this would only suggest that upregulation of long 
genes represents a secondary effect, rather than primary effect of the disease. Perhaps 
lending weight to this argument was the observation of Gabel et al, that the 
upregulation of long genes worsened as Rett syndrome progressed (Gabel et al, 
2015).  
 
The obvious downregulation of genes less than 10kb in length in R133C-GFP 
cerebellum, although also apparent in the study by Gabel and colleagues in other Rett 
models, has not been widely discussed. One of the features that the short and long 
genes have in common is low mCpG density, suggesting that in the neuronal 
methylome, high density mCpG sites are not critically regulated by MeCP2 or on the 
contrary, that there are additional mechanisms safeguarding their regulation. There 
has been criticism of the claim that long genes are overrepresented in autism with the 
counter argument that this relationship is a product of the methods of mutation 
discovery (Shohat & Shifman, 2014). With further tissue and methylation-specific 
analysis, it will be interesting to see if shorter genes become relevant in the 
pathogenesis of Rett syndrome in the future. This study does not present convincing 





Rett syndrome is a debilitating and progressive neuropsychiatric disorder caused by 
mutation in MECP2. Studies in mice and cells have suggested that Rett is a disorder 
of synaptogenesis and neuronal maintenance, in that it can be largely reversed 
following onset with restoration of lifelong MeCP2 expression in all brain cells. The 
onset of Rett syndrome coincides with maturation of the unique 
(hydroxy)methylation landscape of the brain (with expansion of mCH and hmCpG), 
increasing expression of MeCP2 and formation of synapses, suggesting the three are 
critically linked. MeCP2 is well placed to interpret this new repertoire of cytosine 
modification. The function of MeCP2 is not clearly elucidated, but undoubtedly 
involves linking methylation of DNA to remodelling of chromatin and at least in 
part, repression of transcription. The functional mechanisms are undetermined, but it 
has recently been proposed that MeCP2 binding to mCA in the brain results in the 
specific transcriptional repression of long genes. Regulation of MeCP2 by 
phosphorylation, coincident with neuronal firing, would implicate the protein in 
accurate interpretation of incoming sensory stimuli and translation into targeted gene 
expression. These actions would be essential for synaptogenesis and cognitive 
function and together, this forms an attractive hypothesis. 
 
In order to further understand the specific functions of MeCP2 and their relevance to 
Rett syndrome, the field must progress to the study of specific Rett-causing 
mutations. In patients, classical Rett runs a stereotyped course but there is significant 
clinical heterogeneity. Despite this, it is apparent that there is a spectrum of 
phenotypic severity associated with different mutations. The reasons for this are 
uncertain. This work focused on the missense mutation, R133C, which is common, 
occurs in a key position of the MBD and results in a milder syndrome in patients. A 
novel mouse model of the R133C was created. With comparison to other mouse lines 
it was confirmed that the R133C mutation results in a milder Rett-like phenotype in 
the male in the absence of potentially confounding patterns of XCI. The molecular 
basis was the result of a modest reduction of protein abundance and reduced 
association with heterochromatin. This was a combination of decreased binding to 
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relatively unmethylated regions and repetitive DNA rich in mCpG, with the latter 
affected to a greater degree and only becoming apparent under stringent experimental 
conditions. There was evidence to suggest that binding to mCAC was more markedly 
impaired than binding to mCpG, both in vitro and in vivo. This work also 
contradicted a previous claim that the R133C mutation results in a specific deficit in 
binding to hmC (Mellen et al, 2012). The consequences of the R133C mutation in 
terms of gene expression require further investigation: results were variable and there 
was a subtle upregulation of long genes in the cerebellum. However this was largely 
the result of a downregulation of genes in the EGFP-tagged wildtype control 
cerebellum. This result questions the pathological relevance of deregulation of long 
genes in Rett models. Perhaps the pattern of long gene upregulation is a red herring 
and simply represents a final common pathway in brain tissue that is “sick” from a 
variety of causes, akin to the early stages of apoptosis or atrophy. There may be 
alternative cellular mechanisms to protect the expression of genes with dense CpG 
methylation, for example and the role of aberrant short gene expression has not been 
investigated. 
 
This study and others suggest that phenotypic severity in Rett syndrome results from 
the degree to which key functions of MeCP2 are impaired, producing additive 
compound effects. R133C Rett may be less severe because protein expression and 
non-specific binding are only modestly reduced, mCAC binding is (potentially) 
abolished, but a degree of mCpG binding is retained. Transcriptional repression 
(Kudo et al, 2003), association with NCoR and (possibly) protein regulation by 
phosphorylation are preserved. In comparison, protein abundance and association 
with heterochromatin are reduced to a greater degree with MeCP2T158M (Kumar et al, 
2008; Schmiedeberg et al, 2009). The R306C mutation abolishes association with 
NCoR (Lyst et al, 2013), but may also reduce DNA binding to a modest degree 
(Heckman et al, 2013) and disrupt regulation by phosphorylation (Ebert et al, 2013).  
6.1 Future directions 
Specifically, it would be useful to study gene expression in the context of 
MeCP2R133C in other brain regions or particular cell types on a larger scale. An RNA-
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seq study may be useful in this respect, in order to delineate isoform-specific changes 
that are lost in microarray analysis. In combination with methylation maps 
corresponding to these brain regions and MeCP2R133C ChIP-seq, this data could 
precisely define the binding profile of the protein and the impact on gene expression. 
The R133C-GFP mouse will be a useful tool for trialling therapeutic strategies, to 
investigate mutation-specific responses to treatments, allowing a personalised 
approach to Rett syndrome management. Functional impairment conferred by Rett 
mutations outwith the MBD and NID for example C-terminal deletions, A2V, P225R 
and P322L require further investigation and may highlight the importance of other 
protein domains, functions or forms of regulation in Rett pathogenesis, for example 
chromatin compaction, phosphorylation or non-specific association with DNA. 
 
More generally, it will be fascinating to further delineate MeCP2 binding profiles in 
vivo and determine how this mechanistically leads to derangement of gene 
expression. The lack of deregulation of genes that are dense in mCpG is surprising, 
and further manipulation of methylation marks at different developmental stages, 
along with further classification of genes in terms of methylation content in specific 
cell types, may help to pinpoint MeCP2 transcriptional repression. The deregulation 
of short genes observed in several Rett models requires further investigation.  
 
It is certainly an exciting time for epigenetics research in this complex field of 
neurodevelopment and the autistic spectrum. The discipline is edging closer to a 
complete understanding of Rett pathogenesis, with the ultimate goal of achieving 
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Abstract
Rett syndrome is caused by mutations in the X-linked MECP2 gene, which encodes a chromosomal protein that binds to
methylated DNA. Mouse models mirror the human disorder and therefore allow investigation of phenotypes at a molecular
level. We describe an Mecp2 allelic series representing the three most common missense Rett syndrome (RTT) mutations,
including first reports of Mecp2[R133C] and Mecp2[T158M] knock-in mice, in addition to Mecp2[R306C] mutant mice. Together
these three alleles comprise∼25%of all RTTmutations in humans, but they vary significantly in average severity. This spectrum
ismimicked in themousemodels; R133C being least severe, T158Mmost severe and R306C of intermediate severity. Both R133C
andT158Mmutations cause compound phenotypes at themolecular level, combining compromisedDNAbindingwith reduced
stability, the destabilizing effect of T158M being more severe. Our findings contradict the hypothesis that the R133C mutation
exclusively abolishes binding to hydroxymethylated DNA, as interactions with DNA containing methyl-CG, methyl-CA and
hydroxymethyl-CA are all reduced in vivo.We find thatMeCP2[T158M] is significantly less stable thanMeCP2[R133C], whichmay
account for the divergent clinical impact of the mutations. Overall, this allelic series recapitulates human RTT severity, reveals
compound molecular aetiologies and provides a valuable resource in the search for personalized therapeutic interventions.
Introduction
Mutations in the X-linked MECP2 gene are implicated in several
human disorders characterized by developmental delay and
intellectual disability, including Rett syndrome (RTT) (1) and
MECP2 duplication syndrome (2). RTT is a conditionwith postnatal
onset that predominantly affects girls, as males fail to survive be-
yond infancy. Animalmodels haveproveduseful for improving our
understanding of MeCP2 function and for explaining in molecular
terms the origin of the RTT phenotype. The first mouse models
were simple loss-of-function alleles caused by gross deletion
of most of the coding sequence (3,4), but knock-in mutations cor-
responding to specific RTT-causing mutations (5,6) offer the op-
portunity for deeper understanding. Of particular interest are
missense RTT mutations leading to the substitution of a single
amino acid, as these pinpoint critical regions of the protein that
cannot be deduced from frameshift and nonsense mutations, or
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mutations that affect splicing (7). Importantly, human and mouse
MeCP2 arehighlyhomologous proteins, being∼95% identical at the
aminoacid level across∼500 amino acids. This stringent functional
conservation over evolutionary timemakes it likely thatmutations
in themouse geneprovide appropriatemodels for determining the
molecular aetiology of the human disorders.
In this study, we generated knock-in mice for the three most
common RTT missense mutations: T158M, R306C and R133C,
which together account for ∼25% of all RTT cases. The most fre-
quent of all RTT mutations is T158M (∼12% of cases), followed by
R306C (∼9%) and R133C (∼5%) (8). Two of the three mutations
(T158M and R133C) localize to the methyl-CpG binding domain
(9), and previous in vitro studies suggest that both can adversely
affect DNA binding (10–12). The R306Cmutation is locatedwithin
the recently defined NCoR/SMRT Interaction Domain (NID) (13).
This mutation, like others close by, prevents MeCP2 from in-
teracting with the NCoR/SMRT corepressor complex and inhi-
bits transcriptional repression in cell-based assays. Although all
three mutations result in ‘classical’ RTT symptoms, there is a
clear difference between them when clinical severity rating
scales frommany patients are analysed (8,14). T158M is more se-
vere than R306C on average. Least severe of the most frequent
RTT mutations is R133C, which is more often associated with
preservation of walking and/or speech (8). We sought to explain
this clinical spectrum in molecular terms.
The R133Cmutationhas not previously beenmodelled inmice,
but it has been proposed that its milder phenotype is due to reten-
tion of binding to 5-methylcytosine accompanied by loss of bind-
ing to hydroxymethylcytosine (hmC) (15). Mice with the T158A
RTTmutation were characterized (6), but themuchmore common
T158M RTT allele has not yet been reported. The R306C mutation
has been shown to cause Rett-like phenotypes in knock-in mice
(13), and mice bearing an integrated mutant transgene have been
comprehensively phenotyped (16). Here, we focus on the compara-
tive phenotypes caused by these threemutants atmolecular, cyto-
genetic and behavioural levels. This was achieved by comparing
lines of male mice expressing MeCP2 variants from the endogen-
ous Mecp2 locus as fusions with the reporter protein enhanced
green fluorescent protein (EGFP), including wild type (WT). We
find that these RTT mutations recapitulate the severity spectrum
of human RTT, and they offer a molecular explanation for this
phenotypic range. In particular, the R133Cmutant proteinhas a re-
duced affinity for all known MeCP2 target sequences, including
methyl-CG (mCG) and is significantly reduced in abundance. We
conclude that the RTT-like phenotype cannot be exclusively attrib-
utable to loss of hmC binding by this mutant protein as previously
proposed (15). The greater severity of the T158M mutation is ex-
plained by more extreme destabilization of the protein, coupled
with reduced affinity for modified DNA. This finding mirrors that
reported previously for a less frequent allele, T158A, affecting the
same amino acid (6). R306C, which has lost the ability to interact
with the NCoR/SMRT co-repressor, persists atWT levels and large-
ly retainsWT chromatin binding characteristics. ThisMecp2 allelic
series allows resolution of the compound phenotypes underlying
these causes of RTT. In addition, the studysupports available prog-
nostic information regarding Rett syndrome and provides a re-
source in the search for individualized therapeutic approaches.
Results
WT MeCP2-GFP mice are essentially phenotypically WT
We generated an allelic series in which endogenous Mecp2 or
mutant Mecp2 genes were fused in frame with EGFP at their
C-termini (Fig. 1A; Supplementary Material, Fig. S1). Mice expres-
sing knock-in WT MeCP2-EGFP fusion genes have been reported
(13,17), but without extensive characterization. We initially
looked for phenotypic defects due to the fusion of WT MeCP2
with EGFP by monitoring male mice at the molecular and
whole organism levels. Analysis of hemizygous males has the
advantage that phenotypic severity is not influenced by the pat-
tern of X chromosome inactivation, and so severity of individual
mutations can be assessed in an unbiased fashion. Quantitative
polymerase chain reaction (PCR) andwestern blots indicated that
bothmRNA and protein products of theMecp2-GFP gene (WT-GFP)
were expressed in brain, though at somewhat higher levels than
the endogenous Mecp2 gene (WT) (Fig. 1B and C). Quantitative
western blots suggested that the level of WT-GFP is ∼1.6-fold
higher than in untagged WT littermates. At the whole organism
level, we analysed cohorts of WT-GFP mice back-crossed for four
generations to give a genetic background that is ∼94% C57BL/6J.
WT-GFP knock-in mice were fertile and showed normal survival
but tended to be smaller than WT littermates (Fig. 1D and E). Co-
horts were monitored using a phenotypic scoring methodology
that records breathing, tremor, gait, hindlimb clasping, mobility
and general condition (18). This series of observational tests
has the advantage that it is not affected by learning and can
therefore be performedweekly over long periods, giving reprodu-
cible results. Using this method,WT-GFPmice showed no signifi-
cant phenotypic deterioration compared with WT littermates
(Fig. 1F), reinforcing the view that, despite the presence of the
EGFP tag, they are essentially WT.
To search for neurological phenotypes inmore detail, we sub-
jectedWT-GFPmice to a series of motor coordination and behav-
ioural tests (Fig. 1G–I). Performance on the elevated plus maze
was indistinguishable from WT and on the accelerating rotarod
was also not significantly different from WT littermates. The
hanging-wire test showed a weak but reproducible reduction in
the ability to engage hindlimbs with the wire. We noted in add-
ition that there was a trend towards a mild reduction in weight
and a trend towards defective rotarod performance, but neither
achieved significance. These very weak phenotypic effects may
be attributable to the over-expression of MeCP2-GFP relative to
untagged protein. Taking the findings together, however, we con-
clude that the addition of the C-terminal EGFP epitope and the
moderate over-expression of the protein have minimal pheno-
typic consequences by these assays.
Allelic series of RTT missense mutations recapitulates
severity in humans
Using the same knock-in technology, we generated the following
mouse lines: Mecp2[T158M]EGFP, Mecp2[R306C]EGFP and Mecp2
[R133C]EGFP, referred to as T158M-GFP, R306C-GFP and R133C-
GFP, respectively. Both MeCP2 isoforms, which differ only at
their extreme N-termini, are affected by the knock-in. Each line
was back-crossed to obtain a predominantly C57BL/6J genetic
background equivalent to that of the WT-GFP mice (94%). Each
of themutants gave rise tomales that exhibited overt phenotypic
defects from ∼6 weeks of age (see below), but their survival pro-
files were very different (Fig. 2A). T158M-GFP male survival was
slightly prolonged comparedwithMecp2-nullmice fromprevious
analyses (18) (median survival 13weeks comparedwith 9weeks),
whereas R306C-GFP males survived significantly longer (median
= 30 weeks). R133C-GFP males were most mildly affected, with a
median survival of 42 weeks.
Phenotypic scoring of T158M-GFP, R306C-GFP and R133C-GFP
mice matched survival curves and provided detail regarding
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progression (Fig. 2B). T158M-GFP male mice acquired a range of
phenotypic traits rapidly over a few weeks, whereas R306C-GFP
mice, after an initially rapid onset, remained phenotypically rela-
tively stable until 33weeks, at which timephenotypes of survivors
became more severe. Interestingly, this late inflection point coin-
cides with an age identified previously as being particularly sensi-
tive to MeCP2 deficiency (19). R133C-GFP males showed a more
gradual build-up of phenotypic defects compared with either
R306C-GFP or T158M-GFP. Weight profiles revealed that all themu-
tantswere lighter thanWT-GFPanimals of equivalent age (Fig. 2C).
Cohorts of the allelic series underwentmotorcoordinationandbe-
havioural testing at 8–10 weeks of age at which time T158M-GFP,
R306C-GFPandR133C-GFPmice scored5.4, 2.8 and1.4, respectively,
using the observational scoring method (see Fig. 2B). None of the
mutants performed as well as their correspondingWT littermates
on the hanging wire and elevated plus maze (Fig. 3A and C).
T158M-GFP and R306C-GFP were also significantly compromised
as assayed by the 3-day accelerating rotarod-learning paradigm
(Fig. 3E), but R133C-GFP mice showed no detectable defects
compared with WT in this test.
Figure 1.WT-GFPmice showminimal overt phenotype. (A) Schematic representation ofMeCP2with an EGFP tag.Missensemutations analysed in this study (T158M, R133C
and R306C) are shown in relation to the MBD and NID. (B) Levels (mean ± SD) of Mecp2 transcripts in WT-GFP mouse brain (n = 9) compared with WT littermates (n = 9),
expressed relative to Cyclophilin A transcript (CycA). (C) Representative western blot and quantification comparing MeCP2 protein abundance in WT-GFP mouse brain
(double arrow-head, n = 6) versus WT littermates (single arrow-head, n = 6). Gamma tubulin (GT) served as an internal control. Mean ± SEM plotted. (D) The Kaplan–
Meyer plots showing survival of WT-GFP mice (n = 8) compared with their WT littermates (n = 8) and Mecp2-null mice [Ref. (18)] (n = 24). (E) Growth curve showing
average weight of WT-GFP mice (n = 8) compared with their WT littermates (n = 8). Using repeated measures ANOVA, the difference was consistent and significant
(P < 0.001) over time, but at any single time point, the difference was not significant. (F) Phenotypic scoring (see the text) of WT-GFP or WT mice. For comparison,
Mecp2-null scoring is shown. (G–I) WT-GFP mice (n = 9) and their WT littermates (n = 10) were compared using three behavioural tests: (G) the hanging-wire test, (H) the
elevated plus maze, and (I) the accelerating rotarod showing individual mean latencies (dots) and cohort mean latency (line) for each of three days of trials. Statistical
analysis took all trials into account. Statistical tests were unpaired two-tailed t-test (B, C and E) and the Kolmogorov–Smirnov test (G–I). All behavioural paradigms
were conducted on animals aged 8–10 weeks, and biochemical analyses were conducted using tissues from adults aged 6–12 weeks. Asterisks denote the following P
values: *P < 0.05, **P < 0.01 and ***P < 0.001.
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In these analyses, WT littermates lacked the GFP tag on en-
dogenous MeCP2, but as shown in Figure 1, the presence of this
tag has minimal phenotypic consequences. We confirmed that
the presence of C-terminal GFP was not contributing to pheno-
type by comparing the performance of mutant-GFP mice with
age-matched WT-GFP mice in the same tests (Fig. 3B, D and F).
Comparison between litters of different lines in this way is less
well controlled, as illustrated by the variability of WT test scores
in Figure 3A and C. Nevertheless, we observed that both R133C
and R306C mice performed significantly less well than WT-GFP
in the hanging-wire and rotarod tests, while performance of
T158M mice in both elevated plus maze and rotarod was signifi-
cantly inferior. In cases where differences between mutant and
WT-GFP mice did not reach statistical significance (R133C and
R306C in the elevated plus maze, and T158M on the hanging-
wire test), the data showed trends towards defective performance
that matched those detected in the comparison with littermates.
The behavioural analyses therefore confirm phenotypic scoring
and survival data in showing that the Rett missense mutations
are responsible for the observed phenotypes.
Heterozygous females show RTT-like phenotypes
Rett syndrome affects females who are heterozygous for these
MECP2 mutations and consequently mosaic for expression of WT
ormutant alleles, due to X-chromosome inactivation. Inmice, het-
erozygotes for the null allele showa delayed-onset phenotype that
is usually detectable between 4 and 12 months of age. We com-
pared phenotypic scores of heterozygotes for each mutation over
∼12 months. WT-GFP female heterozygotes were not scored in
this fashion as they invariably displayed no signs of disease up to
at least 1 year. All had RTT-like symptoms, with R133C-GFP and
R306C-GFP being less severe than T158M-GFP (Supplementary Ma-
terial, Fig. S2). In this respect, also thephenotypes of these frequent
RTT mutations in mice reflect the spectrum of human severity.
MeCP2 R133C-GFP and T158M-GFP show reductions in
both abundance and chromatin binding in neurons
The matching spectrum of severity between humans and mice
with respect to T158M-GFP, R306C-GFP and R133C-GFP mutations
provides validation that the mouse models are an appropriate
system to investigate the mechanism by which these mutations
cause RTT in humans. We used cell biological and biochemical
techniques to understand the reasons for compromised MeCP2
function. At the level of mRNA, expression of the Mecp2-GFP
knock-in alleles in brain was somewhat elevated compared
with the native Mecp2 gene, except in the case of R133C-GFP
(Fig. 4A). In agreement with the mRNA analysis, WT-GFP and
R306C-GFP proteins were 1.5-fold more abundant than native
MeCP2 in the brain, with the expression of R306C-GFP modestly
reduced relative to WT-GFP (Fig. 4B). In contrast, R133C-GFP pro-
tein was reduced to ∼55%, and T158M-GFP was present at only
∼30% of WT-GFP by western blotting (Fig. 4B and Supplementary
Material, Fig. S3A) and fluorescence-activated cell sorting
(Supplementary Material, Fig. S3B). Abundance was therefore
equivalent to approximately 95 and 50% of untagged MeCP2 for
R133C-GFP and T158M-GFP, respectively. Reduced stability of
T158A, a distinct allele of T158, was reported previously (6), mak-
ing it likely that this is an intrinsic property of MeCP2 lacking the
hydrogen-bonding capability of threonine at this position (20). To
determinewhether themore subtle reduction in R133C-GFP seen
in the brains is specific to this particular mouse line or is a repro-
ducible property of the mutant protein, we analysed embryonic
stem cell-derived neurons in culture using an independent
knock-in clone. Again R133C-GFP was present at approximately
half the level ofWT-GFP, suggesting that themutation itself is re-
sponsible for the deficiency, probably due to compromised RNA
or protein stability (Supplementary Material, Fig. S3C). This rela-
tionship was also seen with an alternative WT-GFP clone (data
not shown).
Figure 2. The Mecp2-GFP allelic series mimics the clinical severity of equivalent human mutations. (A) The Kaplan–Meyer plots showing reduced survival of T158M-GFP
(red), R306C-GFP (blue) and R133C-GFP (green) mutants in comparison with WT-GFP (dark grey) and Mecp2-null (light grey) mice (18). Statistical significance is denoted as
follows: *P < 0.05, **P < 0.01 and ***P < 0.001 (Mantel-Cox test) and calculated in comparison with the WT-GFP mice. (B) Graph showing average phenotypic score for each
cohort over time. (C) Graph showing averageweight over time. Cohorts comprisedWT-GFP (n = 8), R133C-GFP (n = 10), R306C-GFP (n = 11), T158M-GFP (n = 11) andMecp2-null
mice (n = 12–24). A cross indicates that all mice in the cohort had been culled by this time point due to severity of the RTT-like phenotype.
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Taking advantage of GFP immunofluorescence, we examined
localization of the different MeCP2 variants in hippocampal sec-
tions of hemizygous male mouse brains (Fig. 4C). The intensities
of nuclear EGFP immunofluorescence in brain sections con-
firmed qualitatively that in comparison with WT-GFP protein,
R306C-GFP expression was similar, R133C-GFP expression was
moderately reduced and T158M-GFP was severely reduced
in the brain. We focussed on sub-nuclear localization of the
MeCP2 variants, as about half of all 5-methylcytosine in the
mouse genome is concentrated in pericentromeric foci due to
the abundance and CG richness of mouse satellite DNA se-
quences. Native MeCP2 localized to pericentromeric foci in a
DNA methylation-dependent manner (21) as did WT-GFP and
R306C-GFP fusion proteins. R133C-GFP and T158M-GFP, however,
Figure 3. Behavioural analysis of the Mecp2-GFP allelic series indicates that R133C-GFP mice are less severely affected than R306C-GFP and T158M-GFP. Mutant males and
WT male littermates underwent behavioural analysis as in Figure 1. (A) Hanging-wire test, (C) elevated plus maze and (E) accelerating rotarod. R133C-GFP (n = 10, green)
plus WT littermates (n = 13, grey); R306C-GFP (n = 10–11, blue) plus WT littermates (n = 9, grey); T158M-GFP (n = 7, red) plus WT littermates (n = 6, grey). B, D and F show
comparisons between mutant males and WT-GFP males in the same series of tests. (E and F) Graphs showing mean time to descent for individuals (dots) and cohorts
(lines) for each trial day. Statistical analysis took all trials into account, and significance is denoted as follows: *P < 0.05, **P < 0.01 and ***P < 0.001 (Kolmogorov–Smirnov
test). All behavioural paradigms were conducted on animals aged 8–10 weeks.
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showed a more diffuse distribution throughout the nucleoplasm
coupled with reduced heterochromatic localization. Diffuse
nuclear staining in comparison with WT-GFP and R306C-GFP
mutant proteins was more apparent at higher confocal laser in-
tensity, which showed background nuclear EGFP fluorescence
in addition to heterochromatic localization (Supplementary Ma-
terial, Fig. S3D). This effect was more severe for T158M-GFP than
for R133C-GFP. An equivalent patternwas also seen in embryonic
stem cell-derived neurons in culture (Supplementary Material,
Fig. S3E). The results suggest compromised binding to mCG sites
by both these mutants, as explored below.
Compromised binding of MeCP2[R133C] and MeCP2
[T158M] to modified DNA in vivo and in vitro
Published evidence regarding the DNA binding affinity of R133C
protein is inconsistent. South-western (10,22) and EMSA
(10,11,22,23) analyses revealed reduced binding of R133C to
Figure 4.R133C-GFPandT158M-GFPare less abundant thanWT-GFPandhave an abnormal pattern of sub-nuclear localization. (A) Graph showing level ofMecp2 transcript
normalized to Cyclophilin A in mutant male mouse brains relative to WT littermates (mean ± SD). WT-GFP, n = 9; R133C-GFP, n = 4; R306C-GFP, n = 3; T158M-GFP, n = 3. (B)
Quantification of western blots showing levels of WT-GFP, R306C-GFP, R133C-GFP and T158M-GFP protein in male mouse brain, relative to WT (mean ± SEM). GT
served as an internal control; WT, n = 6; WT-GFP, n = 6; R133C-GFP, n = 3; R306C-GFP, n = 4; T158M-GFP, n = 6. (C) Representative images of the CA1 region of the
hippocampus in adult male mice from the allelic series. Slices were imaged using the same confocal settings. Immunofluorescence was performed with DAPI (blue)
and anti-NeuN (red). MeCP2 was imaged by virtue of its EGFP tag. R133C-GFP and T158M-GFP show mixed punctate and diffuse sub-nuclear localization. Scale
bar = 20 μm. Statistical significance is denoted as follows: *P < 0.05, **P < 0.01 and ***P < 0.001 (two-tailed unpaired t-test). All biochemical analyses were conducted using
tissues from adults aged 6–12 weeks.
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methylated DNA. Expression of R133C protein from an integrated
transgene in embryonic stem cells also revealed reduced specifi-
city formethylatedDNA (24). On the other hand, surface plasmon
resonance indicated that the affinity ofMeCP2 for CG-methylated
DNA is unaffected by the R133C mutation, whereas binding to
hydroxymethylated DNA is greatly reduced (15). In a transfection
assay, over-expressed R133C-GFP localized normally to hetero-
chromatin (12,24,25), although the mobility in a FRAP assay was
somewhat increased, compatible with a modest reduction in
affinity for DNA (25,26). In view of the somewhat variable obser-
vations, we repeated EMSAs using either the methylated DNA
binding domain (MBD) alone (amino acids 77–167) or a larger
N-terminal fragment ofMeCP2 (amino acids 1–205). Interestingly,
these two polypeptides showed very different DNA binding affin-
ities when carrying the R133C mutation. The 77–167 fragment of
R133C, which corresponds to the MBD alone, lost the ability to
form a stable complex with methylated DNA, whereas 1–205
[R133C] was essentially WT by an equivalent assay (Fig. 5A and
Figure 5. Defective binding of MeCP2[R133C] and T158M to modified DNA in vitro and in vivo. Representative gels and quantification of EMSAs measuring MeCP2 peptide
binding tomCG probes using (A) aa77-167 or (B) aa1-205 fragments ofMeCP2with (green) or without (grey) the R133Cmutation. Mean percentage of probe shifted ± SEM is
plotted from three replicated experiments. Triangle represents decreasing peptide concentration; –, no peptide. Statistical significance is denoted as: *P < 0.05,
**P < 0.01 and ***P < 0.001 (unpaired two-tailed t-test). (C) ChIP oligonucleotide duplex probes containing symmetrical mCG or hmCG, or asymmetrical mCA or hmCA
sites or both mCA and mCG sites together. Control DNA lacks all modifications. (D–G) Results of five independent transient transfection experiments followed by ChIP
of MeCP2-associated probe oligonucleotide fragments. Cells transiently expressed WT-GFP, R133C-GFP, T158M-GFP and R306C-GFP, respectively. Mean % input ± SD
plotted (n≥ 3).
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B). These opposing findings with a common probe and under the
same conditions recapitulate the spectrum of in vivo and in vitro
findings in the literature for this mutant, and they leave open
the question of whether this defect has any impact on chromatin
association in living cells.
To address this issue,weused acellularassay inwhich the vari-
ous forms of MeCP2 are over-expressed transiently at equivalent
levels in the presence of double-stranded oligonucleotides bearing
specific modifications of cytosine (S. Lagger et al., manuscript in
preparation). Themethodhas the advantage that it detects binding
of full-lengthprotein in living cellswhile allowing themodification
status of the target DNA to be precisely defined. In this way, we
could test binding not only to mCG, but also to methyl-CA (mCA)
and hydroxymethyl-CA (hmCA), which are all implicated as target
sequences for MeCP2 (27). Double-stranded oligonucleotides con-
taining either three symmetrically methylated mCGs, three
hmCGs or both mCA and mCGmodifications (Fig. 5C) were transi-
ently transfected intohumanembryonic kidney (HEK293) cells that
transiently expressedWTMeCP2-GFP (WT-GFP) ormutantMeCP2-
GFP from plasmid constructs. Unmodified oligonucleotides of the
same sequence served as controls. Recovery of the target DNA by
immunoprecipitation with anti-MeCP2 antibodies was monitored
by quantitative PCR (qPCR). The results showed preferential bind-
ing of WT-GFP protein to DNA containing mCA, mCG and, less ef-
ficiently, hmCA compared with non-methylated DNA, confirming
the specificity of themethod (Fig. 5D). R306C-GFP, whosemissense
mutation is outside the DNA binding domain bound tomethylated
DNA indistinguishably from WT (Fig. 5G). Mutant R133C-GFP and
T158M-GFP proteins, in contrast, showed greatly impaired binding
toallmodifiedoligonucleotides (Fig. 5E and F). Importantly, protein
expression levels were closely similar between experiments (Sup-
plementary Material, Fig. S4), and therefore the effects of the
mutation on protein stability as seen in mouse brain do not affect
these results. Of particular note, the R133C mutation significantly
compromises the interaction between MeCP2 and all modified oli-
gonucleotides in vivo, including mCG.
To examine the effects of mutations on MeCP2 binding in the
native genome in vivo, we quantitatively analysed R133C-GFP and
T158M-GFP binding in mouse brain by ChIP-qPCR using an anti-
EGFP antibody. For comparison, we also analysed WT-GFP and
R306C-GFP mutant proteins. The results showed that recovery
ofmouse satellite DNA, LINE1 elements, intracisternal A particles
and the gene for brain-derived neurotrophic factor (Bdnf ) from
cross-linked brain chromatin by R133C-GFP was reduced to
∼45–60% of the WT-GFP level, whereas T158M-GFP was 5–10%
ofWT-GFP (Fig. 6A). Binding of R306C-GFP proteinwas not signifi-
cantly different from WT-GFP. We were concerned that reduced
binding of the two MBD mutants might reflect their low abun-
dance rather than an effect on binding affinities per se. We there-
fore increased the stringency of cross-linking by reducing the
fixation temperature on ice. Under these conditions, ChIP of the
R133C-GFP protein was reduced to ∼15% of the WT-GFP level,
which is significantly greater than the reduction in protein abun-
dance of ∼50%. It was noticeable that under these stringent con-
ditions binding by R306C-GFPwas also compromised, as reported
by others (16), although this was not seen using our standard
cross-linking protocol (Fig. 6B). The ChIP results, together with
the in vitro data, transfection experiments and immunofluores-
cence, suggest that both T158M-GFP and R133C-GFP mutant pro-
teins have a significantly reduced affinity for chromatin.
AsMeCP2 is proposed to bind to bothmCA- andhmC-contain-
ing DNA (16,27), we considered the possibility that the reduced
ChIP signal from R133C-GFP brain may be due to compromised
binding to these sequences rather than to mCG. To test this, we
Figure 6. Chromatin immunoprecipitation reveals abnormal binding of R133C-GFP to mCG-rich repetitive sequences and genes in mouse brain. (A) ChIP-qPCR of WT-
MeCP2 (lacking a GFP tag) and knocked-in WT-GFP, R133C-GFP, R306C-GFP and T158M-GFP in the adult male mouse brain. Primers amplify, respectively, major
satellite, LINE and IAP transposable elements and the Bdnf gene locus. The antibody was against GFP and therefore does not precipitate untagged WT MeCP2 (n≥ 3).
(B) Similar assay to (A) but with a lower and therefore more stringent cross-linking temperature (n = 4). (C) Column plot showing binding of R133C-GFP at the mCG-rich
cytochrome p450 locus by GFP ChIP (n = 3). (D) The same assay as (C) but using a more stringent cross-linking temperature. Plots are expressed as %WT-GFP value. Error
bars represent ± SEM, and statistical significance is denoted as: *P < 0.05, **P < 0.01 and ***P < 0.001 (unpaired, two-tailed t-test). Each replicate experiment used tissue froma
separate animal. (E) Schematic of the Cyp3a57 locus depicting cytosinemethylation context. All biochemical analyseswere conducted using tissues from adults aged 6–12
weeks.
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probed immunoprecipitates for non-repetitive DNA sequences
that contain mCG, but very low levels of mCA and hmCG. The
∼900 kb cytochrome P450 gene locus, which is transcriptionally
silent in the brain, meets this requirement as whole-genome bi-
sulphite and TAB sequencing show a high level of CG methyla-
tion (28), while the other proposed MeCP2 binding sites, hmC
and mCH, are rare (Fig. 6E). Three of the genes from this locus,
Cyp3a25, Cyp3a57 and Cyp3a59 represented this pattern of
methylation and were selected for ChIP analysis. Again, recovery
of these sequences by ChIP was reduced in R133C-GFP brain ex-
tracts, reinforcing the conclusion that mCG binding by R133C-
GFP is significantly compromised (Fig. 6C and D).
Modestly increased expression of long genes in the
cerebellum of R133C-GFP mice
Previous studies have detected subtle changes in gene expression
in the brains of mice that are Mecp2-null or carry RTT mutations
(29). We compared gene expression in cerebellums of R133C-GFP
and WT-GFP mice using expression microarrays, along with WT
and Mecp2-null mice for reference. The results initially showed
statistically significant differences at six individual loci in
R133C-GFP cerebellum compared with WT-GFP, namely Abhd1,
Aplf, Dag1, Zfp428 (all down-regulated), Mybpc3 and Krt222
(up-regulated), but only two of these were reproduced by qPCR.
In one case, the effect was very small. In the other case (Abhd1),
the R133C-GFP expression was unchanged relative to WT or null
comparators. In fact, the variance in expression was attributable
to differences between WT-GFP cerebellum and the other tested
tissues (Supplementary Material, Fig. S5A). We explored the
data further by binning genes according to length to replicate re-
cent studies showing that long genes are disproportionately up-
regulated in Mecp2 mutant brains (27,30). The results showed a
small but sustained length-dependent increase in expression of
longer genes in R133C-GFP versus WT-GFP cerebellum (Supple-
mentary Material, Fig. S5B). In this study, the up-regulation of
long genes was modest in the Mecp2-null versus WT cerebellum,
which was in agreement with previous similar analyses of this
brain region (27).
Discussion
MeCP2 is identical between human and mouse throughout the
greatmajority of its sequence, suggesting that almost all residues
of the protein are essential for full function. Despite long-range
conservation of the primary sequence across evolution, the dis-
tribution of missense mutations causing RTT is highly non-ran-
dom (13). Most missense mutations are concentrated in the MBD
and NID domains, disrupting the interaction with DNA and
NCoR/SMRT, respectively (7). All of the most common RTTmuta-
tions, including nonsense truncations, potentially involve C to T
transitions at CG sites and are therefore most likely caused by 5-
methylcytosine deamination coupled with failure of repair (31).
Their high frequency of occurrence therefore reflects elevated
mutability. The most common missense mutation is T158M,
which disrupts hydrogen-bonding integral to maintaining the
configuration of an ASX turn (Asp156–Phe157–Thr158) and fol-
lowing STmotif (Thr158–Val159–Thr160–Gly161) in the C-termin-
al region of the MBD. This has been shown to destabilize MBD
structure and reduce affinity for methylated DNA (20). Next
most frequent is R306C, which is located in the NID and prevents
the interaction of MeCP2 with the NCoR/SMRT co-repressor com-
plexes (13). Least severe on average of the common RTT muta-
tions is R133C, which mutates an arginine residue that in the
X-ray structure makes hydrogen bond contact with one of the
guanines in the symmetrical CG dyad (20). Individuals with this
mutation more frequently retain some speech and the ability to
walk (8,14). We found that phenotypic severity in mice matches
the respective clinical severity of these mutations in humans,
suggesting that the molecular basis of the resulting disorders is
the same in the two species.
The effects onDNAbinding ofMeCP2[T158M] toDNAare some-
what inconsistently reported in the literature. Previous in vitro stud-
ies of full-length T158M protein showed either mild (10) or severe
(22) impairment of mCG binding by South-western assay. EMSA
analysis, using the MBD fragment, also revealed ambiguous find-
ings. Reduced binding to methylated DNA (10,20,23) was seen in
some instances but not others (11). Some of these discrepancies
may be attributed to the positions of N- and C-terminal affinity
purification tags (23). In vivo analysis ofmurine fibroblasts over-ex-
pressing full-length MeCP2[T158M] indicated defective binding to
heterochromatic foci, and FRAP analysis showed greater mobility
of MeCP2[T158M] compared with WT protein, indicating a less
stable associationwith chromatin (25,26). Most published evidence
therefore supportstheview that theT158Mmutation compromises
binding betweenMeCP2 andmethylatedDNA.OurChIP data based
on transient transfection of cultured cells and brain confirm this
defect in chromatin binding. These findings agreewith an analysis
of a different Mecp2 allelic variant involving the same amino acid,
T158A (6).
Molecular and cell biological assays allowed us to critically as-
sess a recent hypothetical explanation for the milder phenotype
in R133C-GFP mice. It was proposed that MeCP2[R133C] retains
WT levels of binding to mCG in vitro, but has specifically lost
the ability to interact with hydroxymethylated DNA (15). Our
findings place this hypothesis in doubt as several lines of evi-
dence show that mCG binding by MeCP2 is significantly compro-
mised by this mutation: (i) immunofluorescence analysis in
differentiated cultured neurons and in hippocampal sections
showed diffuse nuclear staining with reduced localization to
densely methylated heterochromatic foci; (ii) MBD DNA binding
in vitrowas defective by EMSA, in agreement with most previous
reports (though a longer fragment of MeCP2 displayed normal
binding); (iii) a cellular assay showed that full-length R133C-GFP
binding to mCG was greatly reduced; and (iv) ChIP analysis of
genomic regions where mCG was the only detectable modifica-
tion showed greatly reduced binding by the mutant protein in
the brain. The brain ChIP data are particularly compelling, as
mouse satellite sequences and a gene cluster, both of which
lack hmC andmCH, showed impaired binding in vivo. In addition
to this loss of mCG binding, transfection experiments showed a
significant reduction in MeCP2[R133C] binding to the alternative
canonical binding sites mCA and hmCA.
Despite occupying a key position in the MBD of MeCP2, the
R133C mutation results in a milder RTT phenotype and displays
residual mCG binding. These observations can be reconciled by
modelling the MeCP2–DNA interaction at a molecular level
(Fig. 7). The X-ray structure shows that two arginines, R133 and
R111, form equivalent hydrogen bonds with the two guanine
residues located on opposite strands at the self-complementary
dinucleotide sequence 5′CG (20) and also interact with 5-methyl-
cytosine (Fig. 7A). Replacement of R111 by glycine causes RTT, as
expected if DNA binding is severely disrupted. Substitution of
R133 by cysteine might be expected to have an equally severe ef-
fect, but in fact residual DNA binding persists. A notable differ-
ence between R111 and R133 is that the side chain of the
former adopts an all-trans extended configuration and its side-
chain amino group is held in this position by aspartic acid 121
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via a hydrogen bond ‘clip’. Loss of this interaction probably has
structural consequences for the MBD as a whole. In contrast,
the R133 side chain is relatively untethered, forming a single
salt bridge with the carboxylate group of glutamate at position
137 (20). Replacement of R133 by the compact cysteine residue
is unlikely to impact the integrity of the MBD, but due to loss of
interactions with mC and G will reduce specificity. By placing a
hypothetical water molecule in the major groove, it is possible
to generate hydrogen bonding with G (Fig. 7B), which may ac-
count for the retention of weak DNA binding. We and others
have previously reported that WT MeCP2 fails to interact with
hmCG in vitro (27,32–34). As hmCG is by far the most abundant
setting for hmC in the brain (28), it is unclearwhichhmCmoieties
might be targeted in vivo. Further work may be needed to define
the full range of DNA binding specificities for both WT and mu-
tant forms of MeCP2.
The R306C mutation occurs outside the MBD of MeCP2 and
has no obvious effect on its stability, but may weakly affect chro-
matin binding (see also (16)). DNA binding impairment of this
protein domain has not been characterized biochemically and
was not detected in our cellular assay with full-length protein.
It is possible that it is indirect, due for example to differences in
extraction or altered association with partners. Further work is
needed to address this issue. The two MBD mutations T158M
and R133C, however, display both compromised stability and
weaker DNAbinding. Therefore, it is unlikely that a reduced affin-
ity for chromatin alone underlies their clinical effects. In both
cases, MeCP2 abundance was found to be lower than WT-GFP
in knock-in mouse lines and when independent knock-in ESCs
were differentiated into neurons in culture. R133C-GFP exhibited
a less pronounced reduction in abundance (∼55%) in mice
comparedwith T158M-GFP (∼30%).We conclude that the reduced
abundance of T158M-GFP and R133C-GFP proteins is an intrinsic
property conferred on the protein by the respective mutations.
We speculate that the differing average severity associated with
these two mutations is primarily due to their contrasting abun-
dance. If both mutant proteins were present at the WT level,
through pharmacological stabilization or over-expression, we
speculate that they would exhibit similar pathologies at the
milder end of the RTT spectrum.
The introduction of specific RTT mutations into mice con-
firms the value of this model system in studying the molecular
basis of this condition. Generalizations are starting to emerge—
for example, three missense mutations (T158A, T158M and
R133C) have now been found to destabilize the protein and al-
most certainly make a significant contribution to the phenotype
(this work and reference (6)). It is likely that the high abundance
ofMeCP2 in neurons is dependent to some extent on stability and
the highly conserved amino acid sequence may serve to insure
this. A measure of protein stability derived from gene ablation
studies in adult mice suggested that MeCP2 has a half-life of ∼2
weeks in the brain (19), which is longer than average. A second
generalization fromstudies ofmissensemutations is that disrup-
tion of the interactions between MeCP2 and DNA (R133C, T158M,
T158A) or between MeCP2 and NCoR (R306C) is associated with
RTT (13). It will be of interest to discover ifmodelling of additional
RTTmutations in mice adds to this list of molecular causes. This
information is likely to be essential in the search for rational
therapeutic approaches to mutation-specific aetiologies under-
lying this condition.
Materials and Methods
Knock-in of Mecp2 alleles
Targeting vectors to create EGFP-tagged alleles for WT Mecp2,
Mecp2R133C, Mecp2T158M and Mecp2R306C were constructed
using a 7.2-kb plasmid subclone of mouse 129/Ola genomic DNA
(3), including Mecp2 exons 3 and 4 (Supplementary Material,
Fig. S1). The coding sequence of EGFP was fused in-frame to the
end of the coding sequence of Mecp2 in exon 4 followed by a loxP-
flanked NeoStop cassette as a selectable marker, retaining the
first 1.8 kb of theMecp2 3′UTR as the 3′ homology arm. Pointmuta-
tions R133C, T158MandR306Cwere introduced into theWTMecp2-
EGFP targeting vector using the QuikChange II XL Site-Directed
Mutagenesis Kit (Agilent Technologies). Linearized constructs
were electroporated into 129/Ola E14 TG2amouse ES cells and cor-
rectly targeted clones identified by PCR screening and Southern
blotting (Supplementary Material, Fig. S1). Mice were generated
fromES cells by standard procedures (3). The loxP-flanked selection
cassette was either removed in vitro for ES cell differentiation into
neurons by electroporation of targeted clones with pCAGGS-Cre
plasmid, or in vivo by test mating chimeras with the CMV-Cre del-
eter strain. Mice have been submitted to Jackson Laboratories
T158M-GFP: JAX Stock No. 26762 B6.Cg-Mecp2tm4.1Bird/J, R133C-GFP:
JAX Stock No. 26848 B6.Cg-Mecp2tm6.1Bird/J and R306C-GFP:JAX
Stock No. 26847 B6.Cg-Mecp2tm5.1Bird/J.
RNA extraction and qPCR
Frozenhalf brainswere homogenized in Tri Reagent (Sigma) using
the Ultra-Turrax T25. RNAwas extracted according to the manu-
facturer’s instructions. RNA was DNase I treated (DNA-free kit,
Ambion) and then reverse transcribed (iScript cDNA Synthesis
Kit, Bio-Rad) according to the manufacturer’s instructions. Fifty
Figure 7. Predictivemodelling ofMeCP2MBDbinding tomethylatedDNA reveals a
loss of specificity with the R133Cmutation. (A) Predictedmodel of MBD binding to
amethylated CpG pair. Arginine 111 and 133make contact with the guanines and
form hydrogen bonds with the methylcytosines of the CpG pair. Arginine 111
forms a hydrogen bond ‘clip’ with aspartic acid 121. (B) Predicted model of MBD
[R133C] binding to a methylated CpG pair. The cysteine 133 interaction with
guanine is now dependent on water molecules, and there is no significant
interaction with the methylcytosine. (A and B) Hydrogen bonds are indicated by
dotted lines, methyl groups by green balls, and water molecules by grey and
orange balls.
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nanograms of cDNAwas amplified inqPCRusing SensiMix SYBR&
Fluorescein Master Mix (Bioline) with the following primers:
Me2Ex3/4 FWD ACCTTGCCTGAAGGTTGGAC, REV GCAATCAA
TTCTACTTTAGAGCGAAAA; CypA FWD TCGAGCTCTGAGCACTG
GAG and REV CATTATGGCGTGTAAAGTCACCA. Mecp2 mRNA
was normalized to Cyclophilin A housekeeping gene expression.
EGFP mutants were compared with WT littermates.
Protein extraction and western blot
One frozen half brain was homogenized in ice-cold NE1 buffer
[20 m Hepes pH 7.9, 10 m KCl, 1 m MgCl2, 0.1% Triton X-100,
20% glycerol, 0.5 mDTT, protease inhibitor (complete EDTA free
cocktail, Roche)] before adding 750 units of benzonase for 15 min
at room temperature then an equal volume of 2× SDS loading buf-
fer (0.125 M Tris pH 6.8, 20% glycerol, 4% SDS, 0.25% bromophenol
blue, 20 mDTT, 0.3 M β-mercaptoethanol). Sampleswere boiled
for 3 min before loading equal volumes on a 4–12% Run Blue
SDS precast gel (Expedeon). Gels were transferred to a 0.2-μm
nitrocellulose membrane (Bio-Rad) and then blocked for 1 h (5%
milk, 1× TBS, 0.1% Tween) before applying anti-Mecp2 1:1000
(Sigma M6818) or anti-γ-tubulin 1:3000 (Sigma T5326) overnight
at 4°C, followed by IRDye 800CW donkey anti-mouse IgG
1:10 000 (LiCor) for 2 h at RT after washing. Membranes were im-
aged using the Odyssey Infrared Imager (LiCor) and quantified
using Image Studio Lite Software (LiCor).
Phenotypic analysis
Mice tested were of fourth or fifth generation back-crossed to
C57Bl/6J (N4 or N5). Scoring of symptoms and behavioural ana-
lyses were all performed blind to the genotype. Six parameters
were examined at the same time each week (activity, gait, hind-
limb clasping, tremor, breathing and general condition) and
given a score between 0 and 2, as previously described (19). Ani-
mals that scored 2 for tremor, breathing or general condition, or
which had lost 20% of their body weight had reached the severity
limit of the experiment according to the HomeOffice License and
were humanely culled. Mice were also weighed weekly. Behav-
ioural analysis was done between 8 and 10 weeks in the order
(1) elevated plus maze, (2) hanging wire and then (3) accelerating
rotarod. For details of behavioural assays, see (19). In brief, for ele-
vated plusmaze,micewere placed in a cross-shapedmaze 65 cm
above the floorwith 2 open arms (20 × 8 cm), 2 closed arms (20 × 8
× 25 cm) and a central area (8 × 8 cm) in uniform dim lighting.
Time spent in open arms of the maze was visualized using
ANY-maze software (Stoelting). For the hanging wire, time
taken to bring one hind paw to a 1.5 mm diameter wire, 35 cm
above the bench, after mice were suspended by forepaws was re-
corded for up to 30 s over 3 trials, inter-trial interval 15 min. For
the accelerating rotarod, mice had one habituation training day
then time taken to fall from a 3 cm diameter rotating rod, accel-
erating between 4 and 40 RPM over 5 min was recorded. Mice had
4 trials per day (inter-trial interval 1 h) over 3 days.
Immunofluorescence
Mice were perfused with 3.7% paraformaldehyde in PBS, pH 7.4,
then immersion fixed overnight. The brains were then dehy-
drated in 30% sucrose for 24 h, washed briefly in PBS, blotted
dry, halved and snap frozen in isopentane cooled on dry ice.
The brains were sectioned at 10 μm (Leica CM 1900 Cryostat)
and mounted. Slides were washed in PBS, permeabilized in
0.1% Triton X-100 for 15 min, washed, blocked for 1 h at RT in
1.5% normal goat serum, stained with anti-NeuN-Cy3 1:100
(MAB377C3 Millipore) overnight at 4°C then finally, washed,
stained with 1 μg/ml DAPI and washed again. Slides were
mounted in Prolong Gold Antifade Reagent (Molecular Probes).
The brains were visualized on a LeicaSP5 Confocal Laser Scan-
ning Microscope. For clarity, a set of images were taken where
the EGFP signal was optimized for each genotype individually.
A look-up table (LUT) was applied to hippocampal CA1 images,
where blue pixels denoted over-saturation and green pixels de-
noted zero. Photonmultiplier tube (PMT) gain was kept constant,
and laser power was adjusted until one or two pixels were blue
and as few pixels as possible were green. These settings were
saved and used for all subsequent images for that genotype.
Electrophoretic mobility shift assays
Recombinant MeCP2 protein expression vectors were constructed
with a C-terminal histidine tag in the bacterial expression plasmid
pET30b (Novagen). The R133C pointmutationwas introduced into
the WT plasmid using QuikChange II XL Site-Directed Mutagen-
esis Kit (Agilent Technologies) as per the manufacturer’s instruc-
tions. BL21(DE3)pLysS competent cells were transformed, and a
scrape of colonies was inoculated in a starter culture overnight,
then into 500 mlwarmLB (50 μg/ml kanamycin; 17 μg/ml chloram-
phenicol) and shaken at 37°C. Cultures were induced with 1 m
IPTG when the OD was 0.6–0.8 at 600 nm and then grown at 30°C
for 3 h. Pellets were mashed in ice-cold lysis buffer [50 m
NaH2PO4, 100 m NaCl, 10% glycerol, 30 m imidazole, 0.1%
NP40, protease inhibitor (complete EDTA free cocktail, Roche),
pH 7.5] and passed through a 21G needle prior to adding 750
units of benzonase then being sonicated 30 s on/off for 10 cycles
(Branson Digital Sonifier). Samples were adjusted to 0.3 M NaCl,
and then after centrifugation, 0.5 ml bead volume NiSO4-coated
ChelatingSepharose Fast Flowbeads (GEHealthcare) in lysis buffer
was added to lysates for 1 h at 4°C. Beads were washed 3 times in
lysis buffer before MeCP2 polypeptides were eluted with 250 m
imidazole lysis buffer in 5 fractions. Eluted fractions were pooled,
adjusted to 1 m EDTA and then dialysed [Slide-A-Lyzer Dialysis
Cassette 7 K MWCO (Thermo Scientific)] overnight at 4°C in 0.1 M
HEPES buffer (20 m HEPES pH7; 100 m NaCl; 1 m EDTA;
5 m β-mercaptoethanol). The polypeptides underwent a second
purification stepandwere eluted fromaHiTrapSPHP1 mlColumn
(GE Healthcare) using a 0.7 M NaCl HEPES buffer. An oligonucleo-
tide probe from the mouse Bdnf promoter region 5′ AAGCATG
CAATGCCCTGGAACGGAATTCTTCTAATAAAAGATGTATCATTTTA
AATGC 3′ (Biocore), plus complementary reverse strand, was
methylated or unmethylated at the central CG indicated in bold
italics. Five hundred nanograms of probe was radio-labelled
using T4 polynucleotide kinase (NEB) and purified (MinElute PCR
Purification Kit, Qiagen) according to the manufacturer’s instruc-
tions. One nanogram probe and 1 μg poly deoxyadenylic-thy-
midylic acid competitor DNA (Sigma-Aldrich) were added to
polypeptide in reaction buffer (5% glycerol, 0.1 m EDTA, 10 m
TrisHClpH7.5, 150 mKCl, 0.1 mg/mlBSA) on ice for 20 min. Sam-
ples were run at 120 V for 70min on a 10% acrylamide tris borate
EDTA gel (0.075% APS, 0.00125% TEMED) in chilled TBE. The gels
were exposed overnight and imaged using the Typhoon FLA
9500 scanner (GE Healthcare). Percentage shift was calculated
using Image J software.
Cellular immunoprecipitation
Using Lipofectamine 2000 (Life technologies), 1.5 × 106HEK 293 FT
cells were transfected over night with 0.5 μg of MeCP2 WT or
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R133C, T158M and R306C mutants tagged with EGFP, according to
the manufacturer’s instructions. After assessment of transfection
efficiency, the medium was changed and cells were transfected
withannealedunmodifiedormethylatedoligonucleotides (100 nM)
final concentration using TransIT Oligofect reagent (Mirus) for 4 h.
Cells werewashedwith PBS and harvested by trypsinisation. In the
next step, cells were cross-linked with 1% formaldehyde for 5 min
at room temperature and quenched by the addition of glycine to a
final concentration of 0.125 M for 5 min. At this stage, cell pellets
could be flash frozen in liquid nitrogen and stored at −80°C or
directly used for DNA–protein complex isolation and consecutive
IP. Oligonucleotide sequence: 5′ ATGCTAATTAACCCTCACTAAA
GGGAACTCGAGACATCGGAGAATTCACATCACCGGTGAATCAGTGC
TACCCGCAAGTGCACTGGATCCACTGGCCGTCGTTTTACAA 3′. The
transfected fragment consisted of an artificial sequence (49% GC
content) flanked by T3 andM13-20 primer binding sites for unique
amplification. Primer sequences are underlined. Differentially
methylated CGs are highlighted in bold. Soluble chromatin prepar-
ation and chromatin immunoprecipitation assays were carried out
as described previously with modifications. In short, chromatin
was sonicated using a Twin Bioruptor (Diagenode) 30 s on/off for
15 cycles. Equal amounts of chromatin were used for IP with 5 μg
MeCP2 M6818 antibody (Sigma) and incubated overnight. Protein–
antibody complexes were bound to magnetic protein G beads
(Life technologies) for 4–5 handwashedwithstandard IPwashbuf-
fers for 10 min at 4°C. The cross-link was reversed by addition of
0.05 volume of 4 M NaCl over night at 65°C. After proteinase K di-
gestion, DNAwas recovered byphenol–chloroform–isoamylalcohol
extraction and dissolved in 200 μl H2O. Real-time PCR of ChIP DNA
and corresponding input DNAwas performedusing T3 andM13-20
primers.
Brain chromatin immunoprecipitation
Frozen half brains were Dounce homogenized in 1 ml PBS and
then fixed in 1% formaldehyde for 1 min at room temperature
or 60 s after being on ice (stringent ChIP) before quenching with
250 m glycine. Chromatin immunoprecipitation assays were
carried out as described previously with modifications. In short,
chromatinwas sonicated using aTwin Bioruptor (Diagenode) 30 s
on/off for 15 cycles. Equal amounts of chromatin were used for IP
with 40 μl GFP-Trap_A beads (Chromotek) and rotated for 1.5 h at
4°C. Protein–antibody complexes were washed with standard IP
wash buffers for 4 min at 4°C. The cross-link was reversed by
addition of 0.05 volume of 4 M NaCl overnight at 65°C. After
proteinase K digestion, DNA was recovered by phenol–chloro-
form–isoamylalcohol extraction and dissolved in 200 μl H2O.
Real-time PCR of ChIP DNA and corresponding input DNA was
performed using specific primers. Major Satellite FWD GGC
GAGAAAACTGAAAATCACG, REVAGGTCCTTCAGTGTGCATTTC;
LINE1 Elements FWD TTTGGGACACAATGAAAGCA, REV CTGCC
GTCTACTCCTCTTGG; IAP FWD GAGATTGGACTTTTGACTTGT,
REV TGTGGCTTGCTCATAGATTAG; Bdnf FWD TTCGATTCACG
CAGTTGTTC, REV CTGAGCCAGTTACGTGACCA; Cyp3a25 FWD
CAGGTTTGGGGTGTTGTGAA, REV CTGCAGCTGTTGTGGGAG;
Cyp3a57 FWD GTGCTGCTCTTACATGGCTG, REV GTGGGGCTA
CAGTCTATGCT; Cyp3a59 FWD CCTGACTGGCTGCTCACTAT, REV
AGGCTGTGAACTATAGGAGCC.
Statistics
Behavioural data were analysed using the Kolmogorov–Smirnov
test with the Benjamini and Hochberg method of correction for
false discoverywithmultiple testing. Survival datawere analysed
using theMantel-Cox test. Biochemical datawere analysed using
two-tailed, unpaired t-tests.
Study approval
Mice were maintained under standard conditions and in accord-
ance with UK Home Office regulations and licenses.
Supplementary Material
Supplementary Material is available at HMG online.
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